

THE NEW YORK ACADEMY OF SCIENCES

(Founded in 1917)

BOARD OF TRUSTEES

BORIS PREGEL *Chairman of the Board*

<i>Class of 1969</i>	<i>Class of 1970-1981</i>	<i>Class of 1982-1992</i>
GORDON Y DILLARD	HARDY F TAYLOR	W STUART THOMPSON
HENRY C BRECH	<i>Class of 1960-1969</i>	
	DEAN RUSH	LOWELL C WADMOND

M J KOPAC *President of the Academy*

HILARY KOPROWSKI *Past President* BORIS PREGEL *Past President*
EUNICE THOMAS MINER *Executive Director*

SCIENTIFIC COUNCIL, 1960

President M J KOPAC

President Elect FREDERICK Y WHELOUT

EMERSON DAY <i>Vice-President</i>	THEODORE SHFELDORSH <i>Vice-President</i>
<i>Recording Secretary</i>	<i>Corresponding Secretary</i>
KARL MARAMOROSCH	CHARLES W MUSHETT

Elected Councilors

1959-1960

DAVID A KARLOFSKY	GUSTAV J MARTIN
WAYNE W UMBREIT	JOHN E VANCL

1959-1961

JOHN E DEITRICK	CHARLES W MUSHETT
ROBERT A MORISON	F L TATUM

1960-1969

JOHN JOSEPH LYNN JR	MORRIS SCHAFFER
---------------------	-----------------

Executive Director EUNICE THOMAS MINER

SECTION OF BIOLOGICAL AND MEDICAL SCIENCES

ROBERT L KROC <i>Chairman</i>	CHARLES MORACK <i>Vice-Chairman</i>
-------------------------------	-------------------------------------

DIVISION OF ANTHROPOLOGY

DOROTHY L KEUR <i>Chairman</i>	ETHEL BOISELAIN LESEER <i>Vice-Chairman</i>
--------------------------------	---

DIVISION OF INSTRUMENTATION

ANDRES FERRARI <i>Chairman</i>	WALTER E TOLLES <i>Vice-Chairman</i>
--------------------------------	--------------------------------------

DIVISION OF MICROBIOLOGY

KARL MARAMOROSCH <i>Chairman</i>	EMANUEL GRUNBERG <i>Vice-Chairman</i>
----------------------------------	---------------------------------------

DIVISION OF PSYCHOLOGY

GREGORY RAZRAN <i>Chairman</i>	LOUIS W MAY <i>Vice-Chairman</i>
--------------------------------	----------------------------------

SECTION OF CHEMICAL SCIENCES

FREDERICK R EIRICH <i>Chairman</i>	EVERETT S WALLIS <i>Vice-Chairman</i>
------------------------------------	---------------------------------------

DIVISION OF BIOCHEMISTRY

JAMES B ALLISON <i>Chairman</i>	RAYMOND L GARNER <i>Vice-Chairman</i>
---------------------------------	---------------------------------------

SECTION OF GEOLOGICAL SCIENCES

R W FAIRBRIDGE *Chairman*

DIVISION OF OCEANOGRAPHY AND METEOROLOGY

CHARLES KNUDSEN <i>Chairman</i>	JAMES K MCGUIRE <i>Vice-Chairman</i>
---------------------------------	--------------------------------------

DIVISION OF ENGINEERING

JACOB FELD <i>Chairman</i>	JOSEPH F SKELLY <i>Vice-Chairman</i>
----------------------------	--------------------------------------

Past Presidents

HILARY KOPROWSKI BORIS PREGEL

The Sections and the Divisions hold meetings regularly one evening each month during the academic year October to May inclusive. All meetings are held at the building of The New York Academy of Science, 2 East Sixty-third Street, New York 21, New York. Conferences are also held at irregular intervals at times announced by special programs.

August 27, 1960

Managing Editor
FRANKLIN N. FURNE

Associate Editor
LEONAR W. WHITE

SECOND CONFERENCE ON MEDICAL MYCOLOGY*

Conference Chairman and Consulting Editor
CHRISTOPHER W. FEMMONS

CONTENTS

Introduction	By KARL MARAMOROSCH	3
Part I. General New and Experimental Mycoses		
Subcutaneous Phycomycosis: A New Disease Found in Indonesia	By LIP HIAN JOE AND NJO INJO TJOEI LAG	4
Growth Characteristics of the Fungi of Chromoblastomycosis	By MARGARITA SILVA	17
Geographical Distribution and Prevalence of the Dermatophytes	By LINDRO AJELLO	30
The Effects of Cortisone in Experimental Fungus Infections	By DONALD B. LORRIA AND HARRY G. BROWNE	39
The Pathogenesis of Epidermal Histoplasmosis	By J. SCHWARTZ, G. L. BAUM AND H. FLOYD	47
Part II. Epidemiology, Biochemistry and Physiology		
The Occurrence of <i>Candida</i> and other Yeasts in the Intestinal Tracts of Animals	By N. VAN COTT	59
Epidemiology of the Dermatophytoses: Sources of Infection, Modes of Transmission and Epidemiology	By LUCILLE K. CROOK	69
Natural and Experimental Epidemiology of Histoplasmosis	By HOWARD W. LARSEN	78
<i>Emmonia coccinea</i> Sp. n. and <i>Albugomyces</i> (Haplomyces) in Mammals	By C. W. FEMMONS AND W. E. JELLISON	91
Studies on the Growth and Metabolism of <i>Coccidioides immitis</i>	By C. F. T. W. LANTS AND CARL L. FRACKEL	102
Approaches to the Physiology of <i>Coccidioides immitis</i>	By DEMOSTRANTIS PAPADOGIANIS AND CHRISTOPHER W. FEMMONS	109
Mechanisms of Action of Antibiotics	By S. C. BRADLEY AND I. A. JONES	122

* This series of papers is the result of a *Second Conference on Medical Mycology* held by The New York Academy of Sciences on January 11 and 12, 1960. The conference and its publications were supported in part by Grant 7-30497 from the National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.

Part III Immunology of Mycoses

Some Aspects of the Mode of Action of Polyene Antifungal Antibiotics	By E. DROUJET L. HIRTH AND G. LEBELRIER	134
Virulence and Growth Rates of <i>Cryptococcus neoformans</i> in Mice	By H. F. HASEN CLEVER AND WILLIAM O. MITCHELL	156
The Accuracy of Serologic Methods in Diagnosis	By CHARLOTTE C. CAMPBELL	163
The Question of Immunity in Ringworm Infections	By LORRAINE FRIEDMAN AND V. J. DERBES	178
Capsular Reactions of <i>Cryptococcus neoformans</i>	By E. EDWARD EVANS	184
Antigens of <i>Blastomyces</i>	By STANLEY MARCUS GILBERT A. HILL AND RALPH A. KNIGHT	193

Part IV Therapy

Experience with Amphotericin B	By JOHN H. SEABURY AND HARRY E. DISCONE	202
The Treatment of Systemic Fungus Infections with Amphotericin B	By VICTOR D. NEWCOMER, THOMAS H. STERNBERG, EDWIN T. WRIGHT, RONALD M. REISNER, CARL G. McNALL AND LLOYD J. SORESENSEN	221
The Treatment of Systemic Mycoses with Orally Administered Itraconazole: Preliminary Report	By VICTOR D. NEWCOMER, THOMAS H. STERNBERG, EDWIN T. WRIGHT, RONALD M. REISNER, CARL G. McNALL, AND LLOYD J. SORESENSEN	240
Griseofulvin	By FRANK J. KOTH, JR.	247
Griseofulvin in Deep Mycoses	By A. GONZÁLEZ OCHOA	254
Nystatin	By ELIZABETH L. HAZEN AND RACHEL BROWN	258
Tenacetin	By ASHTON I. WELSH	267
Analysis of Amphotericin Treatment Failures in Systemic Fungal Disease	By JOHN P. LITZ AND VINCENT T. ANDRIOLE	277

INTRODUCTION

Karl Maramba

The Rockefeller Institute, New York 1

On September 6, 1950, The New York Academy of Sciences published a monograph entitled *Medical Mycology*. At that time interest in this field was growing steadily. Nearly ten years have passed and there is no question that during that period the field of mycology has expanded and gained in importance. Impressive advances have been made not only in the basic fields of epidemiology, immunology, biochemistry, and physiology but also, more recently in therapy. These contributions, which in some cases were documented in the literature and in others were only discussed when investigators met privately, have prompted this publication.

Many eminent scientists from Indonesia, Mexico, Portugal, France, and many parts of the United States are contributors to this monograph. The list of contributors reads like a Who's Who in *Medical Mycology*. Chester W. Emmons, with the aid of his committee, planned a well balanced publication. Emphasis was put on the fundamental aspects of the field. For example, the importance of phycomycetes in physiological studies on coccidioides and studies on immunology and serology are presented. The newer advances in therapy also are not neglected although an attempt has been made to present them in a concise and critical form.

Tribute should be paid to one scientist who with his usual modesty remained in the background, but who made all the preparations and laid the groundwork for the conference on which this monograph is based. I mean Dr. Grunberg of the Division of Mycology of The New York Academy of Sciences, who have tried to organize an international conference of such proportions can think how many difficulties and problems are involved in an undertaking of this kind. In this great task Grunberg was aided and supported by Chester W. Emmons.

The past ten years have seen impressive progress in medical mycology. I am sure that this monograph will contribute significantly to the field of experimental and clinical medicine not only by providing new and valuable information but also by stimulating new and fruitful developments.

Reference

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES 1949 50 10 1209-1209

Part I. General, New, and Experimental Mycoses

SUBCUTANEOUS PHYCOMYCOSIS. A NEW DISEASE FOUND IN INDONESIA

Lie Kian Joe and Njo Injo Tjoet Eng

*Department of Parasitology and General Pathology, School of Medicine University of Indonesia,
Jakarta, Indonesia*

Subcutaneous phycomycosis is a localized eosinophilic granuloma caused by a phycomyceete that invades primarily the fat layer of the subcutaneous tissue. Three isolations of a *Basidiobolus* species and one of an unidentified phycomyceete have been made in Indonesia.

Five cases of subcutaneous phycomycosis have been found in Indonesia, and one case was observed recently in London, England, by W St C Symmers in a Dutch girl who had come from Indonesia. Spontaneous healing took place after varying periods of time.

The name phycomycosis is used to designate a fungus infection caused by a member of the phycomyceetes. Its use was proposed in a previous paper (Lie Kian Joe *et al*, 1959) in order to avoid the more restricted connotations of mucormycosis, while the name of coccidioidomycosis is to be retained. The name phycomycosis includes infections caused by *Mucor*, *Absidia*, *Rhizopus*, *Basidiobolus*, and similar phycomyceetes. The term is useful, too, for mycoses in which no culture was obtained, but in which sections of involved tissues revealed the presence of a fungus with a morphology usually associated with a phycomyceete.

Clinical Characteristics

The disease has been observed only in children varying in age from four to thirteen years. The infection begins as a movable subcutaneous nodule that gradually increases in size by peripheral growth to attain extensive proportions covering a large area of the body (FIGURES 1, 2, and 3). The swelling is painless and, when fully developed, may be 3 to 4 cm thick. The border with the healthy tissue is demarcated sharply. The surface of the swelling is smooth or it may show superficial lobation or nodules. Its consistency is firm, but there may be small, scattered soft areas. The skin covering the swelling is usually normal but, when the swelling is extensive, the skin is edematous and bluish red in color. In one case the skin was pruritic, scaly, and covered with secondary infections from excoriation (FIGURE 2).

The swelling is usually not adherent to the superficial fascia. The edge of the swelling often can be lifted somewhat from the underlying layer. It forms a firm, thick sheet of tissue lying between the corium of the skin and the superficial fascia. When surgically removed, it is easily loosened from the overlying and underlying tissue.

The swelling grows slowly. Growth may be restricted only to one or two areas of the swelling, and growth is often periodic. The swelling may progress at one edge while regressing at the opposite edge.

The duration of the disease may be from several months to more than four years. In long lasting cases the size of the lesion may be considerable. Spontaneous healing has been observed in four cases. One case died from other causes and in the most recent case the lesion is regressing after administration of oral potassium iodide.

There is apparently no site of predilection for the lesion. With the exception of one case where three lesions began simultaneously on the scrotum, right thigh and left buttock, the lesions are solitary but extend to cover large areas. One patient had an extensive lesion that started as a small nodule on the thorax. This extended gradually to both axillae, both upper arms and the upper part




FIGURE 1 Swelling of the entire right upper arm and shoulder in a girl aged 7 years. Scars on the dorsal part of the upper arm and near the axilla are from biopsies (case 3).

FIGURE 2 Swelling of the entire right thigh and buttock in a boy aged 8 years (case 4). The skin covering the swelling shows secondary infection.

FIGURE 3 Swelling on the right scrotum (arrows) of 1 month duration in a boy aged 5 years (case 5).

of the abdomen. While these lesions were regressing the swelling extended gradually to the buttocks, crossing the flanks before spontaneous healing occurred.

TABLE 1 shows the pertinent data of the cases observed.

Lymphogenous and hematogenous spread of the disease apparently do not occur. The regional lymph glands are not enlarged unless there is secondary bacterial infection.

The general condition of the patient is usually good. Fever was observed in only one patient who had a secondary infection of the lesion. The blood sedimentation rate was high in two of four patients examined. There was increased blood eosinophilia in two of four patients studied. In one of these two cases it was not known whether worm infection was present, but the other case was apparently free from worm parasites and no other cause for the eosinophilia could be found.

TABLE 1
SUBCUTANEOUS PHYLLOMYCOSIS

Case no	Author	Age	Sex	Location of lesion	Duration of disease	Isolation of fungus	Outcome of disease
1	Lie Kian Joe <i>et al</i> (1956)	4	M	Left pectoral region	9 months	<i>Basidiobolus ranarum</i> (?)	Spontaneous recovery
2	Lie Kian Joe <i>et al</i> (1956)	8	M	Thorax axillae upper arms abdomen flanks, buttocks	More than 4 years	—	Spontaneous recovery
3	Lie Kian Joe <i>et al</i> (1960)	7	F	Right upper arm and shoulder	1½ years	Unidentified phycete	Spontaneous recovery
4	Tio <i>et al</i> (1960)	8	M	Entire right thigh and buttock	1 year	<i>Basidiobolus</i> sp	Regressing under potassium iodide treatment
5	Tio <i>et al</i> (1960)	5	M	Scrotum right thigh, left buttock	1 month	<i>Basidiobolus</i> sp from lesions on thigh and scrotum	Died from other cause
6	Symmers (1960)	13	F	Interscapular region	More than 9 months	—	Spontaneous recovery

Histopathology

The swelling consists of granulomatous tissue. This granulomatous tissue replaces the subcutaneous fat tissue. Remnants of fat cells may be found within the pathological tissue. Cross and longitudinal sections of large branching hyphae with infrequent septations are seen within the granulomatous tissue. The diameter of the hyphae generally varies from $8\ \mu$ to $12\ \mu$. The hyphae occasionally may be smaller, from $5\ \mu$ in width, or swollen to $22\ \mu$ (FIGURE 13). The walls are dark blue in color in the hematoxylin and eosin-stained slides.




FIGURE 4 Granulomatous tissue in the subcutaneous fat. Cellular infiltration consists of eosinophils and histiocytes. Hypha (arrow) shows a narrow layer of eosinophilic granular necrosis (case 1). Hematoxylin and eosin stain. $\times 340$

FIGURE 5 Cross section of a hypha (arrow) found in an offshoot of the granulomatous tissue between fat cells. Note the narrow layer of eosinophilic granular necrosis surrounding the empty thin-walled hypha (case 4). Hematoxylin and eosin stain. $\times 570$

They are often thin and not easily seen but occasionally they may be thick, as is often the case in the large swollen hyphae. Most of the hyphae are empty (FIGURES 5, 6, 8 and 11), probably because of extreme shrinkage of the vacuolated cytoplasm or because the contents have fallen out during the process of staining. Some contain a light purple or light blue staining granular cytoplasm (FIGURE 4). The swollen hyphae occasionally contain dark staining, coarse, granular contents (FIGURE 13). Usually the hyphae have a regular shape, often they do not show protrusions of the wall in longitudinal sections, and usually they are round or oval in cross section. Fragmented, distorted or collapsed hyphae are also seen. These and the swollen ones are probably dead or degenerating hyphae. Branching is seldom seen. Hyphae are usually not numerous in the biopsy specimens, whether taken from the center or from the



FIGURE 6 Longitudinal section of a branching hypha causing a relatively broad area of eosinophilic granular necrosis. Note the thin wall of the almost empty hypha. Cellular infiltration consists of histiocytes and eosinophils (case 1). Hematoxylin and eosin stain $\times 504$.



FIGURE 7 Longitudinal section of a hypha with septa. Note eosinophilic granular necrosis. Cellular infiltration consists of histiocytes and eosinophils (case 3). Hematoxylin and eosin stain $\times 468$.




FIGURE 8 Large area of eosinophilic, granular necrosis around empty hyphae (arrow) within aggregations of histiocytes (case 3). Hematoxylin and eosin stain $\times 112$.



FIGURE 9 Branching hypha with thin walls surrounded by epithelioid histiocytes. Note palisading of histiocytes and eosinophilic, granular necrosis along the hypha (case 3). Hematoxylin and eosin stain $\times 340$.





FIGURE 10 Fragment of hypha phagocytosed by a multinucleated giant cell. Note absence of eosinophilic granular necrosis (case 2). Hematoxylin and eosin stain. $\times 504$.

FIGURE 11 Empty hypha (arrow) with a thick wall surrounded by epithelioid histiocytes and multinucleated giant cells. Marked eosinophilic granular necrosis with beginning of abscess formation. Proliferation of histiocytes (case 3). Hematoxylin and eosin slide. $\times 340$.



FIGURE 12 Microabscess containing eosinophils, neutrophils, and a thick-walled hypha. Absence of eosinophilic granular necrosis around the hypha (case 1). Hematoxylin and eosin stain. $\times 259$.

FIGURE 13 Swollen hypha with coarse granular content and thick wall found in a microabscess. Note absence of eosinophilic granular necrosis (case 2). Hematoxylin and eosin stain. $\times 570$.

peripheral part of the lesion. Usually only a few hyphae are found in each slide. In some biopsy specimens no hyphae have been found. The hyphae usually occur singly, not in groups.

The granulomatous reaction accompanying these hyphae is characterized by the presence of numerous eosinophils, histiocytes, pseudotubercles with foreign body giant cells, a number of small abscesses, and small necrotic areas. In addition, fibroblasts and fibrous tissue may be present.

A characteristic feature of the granulomatous tissue is the presence of numerous eosinophils. These cells are found throughout the whole pathologic tissue. In certain areas they are present in such large numbers that the area is stained red in hematoxylin- and eosin stained slides. There is a tendency for the eosinophils to accumulate about the hyphae, but actually they are found everywhere in the pathologic tissue.

The most characteristic feature of the granulomatous tissue is the presence of a peculiar tissue necrosis occurring around the hyphae. The necrotic tissue stains red in the hematoxylin- and eosin stained slides, and it has a smudgy, granular appearance. We call this eosinophilic granular necrosis. This type of necrosis is unique, since it is not found in other mycotic infections.

The necrotic layer surrounding the hyphae is usually not broad, varying in width from $3\ \mu$ to $15\ \mu$ (FIGURES 4 and 5). Sometimes necrosis may be more marked, resulting in a broader eosinophilic, granular zone (FIGURE 6). Occasionally, necrosis is so marked that relatively large areas surrounding the hyphae are stained red (FIGURE 8). However, not all hyphae are surrounded by necrotic tissue. Hyphae not associated with necrosis are often distorted or fragmented or swollen. They are probably dead or degenerated, and are found frequently within foreign body giant cells or in microabscesses. Apparently, active hyphae cause necrosis, and dead or inactive hyphae do not. It is assumed, therefore, that this peculiar necrosis is caused by specific metabolic products from the hyphae.

The extent of the necrosis depends probably not only on the amount of the metabolic products found, but also on many other factors such as the speed with which the metabolic products diffuse into the tissue, the speed with which the body gets rid of them, the resistance of the tissue involved, and other unknown factors. Relatively large areas of necrosis have been found within aggregations of epithelioid histiocytes and in areas with cellular infiltration. Apparently, only narrow ring necrosis is seen in fibrous tissue. In one case, invasion of the fungus into the muscle tissue occurred, resulting in widespread hyalin degeneration and leading to necrosis of the muscle fibers (Lie Kian Joe *et al.*, 1960). Despite this, the fungus did not grow deeper into the muscles but remained superficial in a localized area. No eosinophilic, granular necrosis is found in the muscle fibers.

Microabscesses contain neutrophils and eosinophils. In some, neutrophils predominate, in others, eosinophils and occasionally pure eosinophilic abscesses are seen. Microabscesses often contain a hypha (FIGURE 12). Many of these hyphae are probably dead, but hyphae showing an eosinophilic layer of necrosis may also be found within microabscesses. These microabscesses are usually not numerous. They are found frequently within aggregations of epithelioid histiocytes resulting in suppurating pseudotubercles (FIGURES 11 and 14).

They are also found in other areas of the granulomatous tissue, but apparently they are not present in fibrous tissue. The microabscesses are formed by supuration of the larger necrotic areas. Partly supplicated necrotic areas or remnants of the necrotic material at the periphery of the abscesses are often seen.

Palisading of histiocytes around hyphae, necrotic areas, and microabscesses is seen and is characteristic (FIGURES 9, 11 and 14). Multinucleated giant cells may contain fragments of hyphae (FIGURE 10). They may also contain eosinophilic granular material that is, apparently, phagocytosed necrotic tissue.

In certain areas of the granulomatous tissue, cellular infiltration predominates; in others, pseudotubercles and multinucleated giant cells, and in still




FIGURE 14 Eosinophilic granular necrosis showing suppurative palisading of histiocytes (case 3). Hematoxylin and eosin stain. $\times 170$

other areas, fibroblasts and fibrous tissue. The latter tissue reaction is probably a manifestation of the healing process that may be found next to active granulomatous tissue. In far advanced healed lesions only fibrous tissue is seen.

Hyphae are found chiefly in active granulomatous tissue. They are seldom found in areas with fibroblasts and fibrous tissue. They are never found outside the granulomatous tissue. There is no tendency for the hyphae to grow into the blood vessels, which usually show no abnormalities except that many of them are dilated.

The periphery of the granulomatous tissue is well separated from the healthy fat tissue. In many places offshoots of the granulomatous tissue extend between the fat cells into the healthy tissue. These offshoots consist of infiltration with histiocytes and eosinophils. Apparently, these offshoots are the routes by which the metabolic products of the fungus are carried away from the lesion. In the narrow offshoots no hyphae have been found, but in the broader ones hyphae may be seen (FIGURE 4).

The corium of the skin shows only infiltration with round cells and often a number of eosinophils in the hair follicles around sebaceous glands around the sweat glands and around the blood vessels. Hair follicles and sebaceous glands may become atrophic. In certain areas invasion of the lower part of the corium by granulomatous tissue and hyphae is seen. The epithelium is intact unless secondary bacterial infection is present. Parakeratotic areas may be seen in the epithelium covering the lesion.

Isolation of the Fungus

A fungus was isolated from four cases. From three cases a *Basidiobolus* species was cultured. The fungus obtained from the first case was identified as *Basidiobolus ranarum* (Emmons *et al.* 1957). Drechsler (1958) who studied this strain is of the opinion that it differs from *B. ranarum* as described by Eidam.

The two most recent isolations of *Basidiobolus* are being studied currently. Another phycomycete was isolated from one patient, but it could not be identified since spores did not develop and the strain soon died.

The genus *Basidiobolus* belongs to the family Entomophthoraceae a saprophytic fungus of the intestinal tract of insectivorous animals. It has been found in Indonesia in the gastrointestinal contents from frogs (*Bufo melanostictus*) toads (*Rana cancrivora*), gekkoes (*Gekko gekko* and *Hemidactylus renalis*) and chameleons (*Calotes jubatus*). These animals are believed to acquire their infections from insects that feed on the animals' excrements and are in turn eaten by the animals (Levisohn 1927).

Discussion

Subcutaneous phycomycosis is a characteristic disease entity. Its chief clinical feature a localized painless subcutaneous swelling that grows gradually to attain extensive proportions and is covered by the intact skin is so typical that one would suspect the disease from clinical examination only.

The histological picture of the lesion is also typical. It shows a granulomatous reaction characterized by the presence of numerous eosinophils and smudgy eosinophilic granular tissue necrosis around the hyphae. The eosinophilic granular necrosis is unique and is not found in other mycotic infections.

Marked tissue eosinophilia is also a characteristic feature and is rarely found in fungus infections. It was found in man once in a case of phycomycosis of the stomach wall associated with the presence of a large ulcer (Lie Huan Joe and Njo Injo Tjoer Eng 1956). However no eosinophilic granular necrosis around the hyphae was found in this case. Moreover the histopathology and the morphology of the fungus were quite unlike the appearance in subcutaneous phycomycosis.

Marked tissue eosinophilia was also described by Christiansen (1929) in pigs that showed infection with *Rhizopus* and *Asidia* but here again there was no eosinophilic granular necrosis of the tissue while the clinical picture of the disease was different from that of subcutaneous phycomycosis.

Histiocytes are found in large numbers in association with eosinophils. In certain areas eosinophils predominate in others histiocytes. These two kinds

of cells, along with eosinophilic granular necrosis, form the basic histological change in this disease. These changes are probably caused by specific metabolic products of the fungus. The concentration of these metabolic products probably influences the occurrence of necrosis or cellular infiltration. Around the hyphae the concentration is high, and necrosis is the result, further away, cellular infiltration occurs. Palisading of histiocytes around hyphae, necrotic areas, or microabscesses is not infrequent and is characteristic. It is marked in case 3 of TABLE I. Pseudotubercles and giant cells develop from the histiocytes, while the relatively large necrotic areas may suppurate and become microabscesses. Later fibroblasts and fibrous tissue are formed.

Spread of the fungus into the peripheral tissue occurs along offshoots of the granulomatous tissue. These offshoots are assumed to be the routes through which the metabolic products of the fungus drain away from the lesion. As the hyphae grow into the offshoots, these become broader in advance of the hyphae.

The growth of the lesion is periodic and slow. There is probably marked inhibition of the fungal growth in the tissue as compared with rapid growth in culture. The growth of the fungus in the tissue is probably associated with destruction of fat cells since the lesion is located chiefly in the layer of the subcutaneous fat. The lower part of the corium where there is no fat tissue, is affected only occasionally. In one case there was invasion of the fungus into the muscle tissue, causing widespread hyalin degeneration and necrosis of the muscles. Despite this the fungus did not grow deeply into the muscle tissue, but remained localized.

Branching of the hyphae in the tissue is seldom found. Therefore, hyphae are usually not numerous, they occur singly, not in groups. This is a marked contrast with the abundant growth of hyphae found in infections with *Rhizopus* and similar phycomycetes.

Hyphae often have a thin wall that makes them inconspicuous in the hematoxylin and eosin stained slides. In addition, they are often empty, which makes recognition difficult when they are cut transversely. The ring of eosinophilic granular necrosis surrounding many of the hyphae is extremely useful for locating them. This eosinophilic, granular ring stands out clearly and can be seen under low power magnification. When observed under high power, the thin dark blue wall of the often empty hypha can be seen attached to the inner surface of the eosinophilic ring.

The hyphae are not distributed evenly throughout the whole pathological tissue. In some biopsy specimens, hyphae are readily found, in others they are difficult to find. However, the presence of eosinophilic granulomatous tissue is a good clue to follow in making a serious attempt to find them.

Hyphae are stained red with the periodic acid Schiff stain, red violet with the Gridley modification, and black with Gomori's silver methanamine stain. However hyphae with a thin wall often are stained faintly with the periodic acid Schiff stain and with the Gridley method, while the Gomori method gives better results. These staining techniques, however, are not advantageous over the ordinary hematoxylin and eosin stain for detecting hyphae, since the eosinophilic, granular necrosis surrounding many of the hyphae is a good indi-

cator for locating hyphae. Isolation is sometimes easy, sometimes more difficult, depending probably on the presence or absence of hyphae in the tissue used for culture.

Basidiobolus infection has been described once in a man (Casagrandi, 1931) in whom zygospores were found on the surface of a gastric ulcer. This report was not convincing, and cultures were not made. Overeem (1915) reported isolating *B. ranarum* from fungus granules found in an abscess on the leg of a horse in Java, Indonesia.

Histological comparison of the cases from which *Basidiobolus* was isolated and the case from which an unidentified phycomycete was obtained revealed the following differences:

Hyphae were more numerous in the case with the unidentified fungus. Consequently, there was more eosinophilic, granular tissue necrosis and more marked giant cell formation. Palisading of histiocytes was also more marked. In addition, there was invasion of the superficial fascia and underlying muscle tissue by the fungus in this case. Until more cases are available it is difficult to evaluate the significance of these differences. Probably much depends on the area where the biopsy is taken, as well as on the stage of development of the lesion.

Administration of potassium iodide in one case still under observation has been followed by a marked regression of the lesion. This patient failed to respond to mycostatin, penicillin, chloromycetin, tetracycline, and griseofulvin. Penicillin was given to two other patients without clinical response.

We have tried to infect cats, dogs, rats, mice, and hamsters by inoculating the fungus into the subcutaneous tissue, but with negative results.

The mode of infection in man is not known. One would assume that infection occurs through introduction of the fungus into the skin by trauma. However, in all cases no history of a trauma at the site of the first lesion could be obtained. Moreover, if infection took place through traumatic introduction of the fungus, one would expect the lesion to be located more frequently in parts of the body such as the feet or hands which are exposed most often to trauma.

Cases of phycomycosis affecting organs other than the subcutaneous tissue and probably caused by other members of the phycomycetes have been reported in different countries. A few cases reported before 1943 in the German and French literature were summarized by Gregory *et al.* (1943). Most of these were of pulmonary infection while cases affecting the ears and gastric wall were also reported. Infections of the nose and skin were quite uncommon, and the central nervous system was affected least. Generalized dissemination of the fungus was observed once.

Since 1943 reports of phycomycosis have increased in frequency. The disease has been reported chiefly from the United States, but has also been found in Canada, England, and Australia. Baker (1957) summarized the literature between 1943 and 1957. Since Baker's publication many other cases have been reported. The disease as observed since 1943 has the following features. It takes mainly cerebral and also pulmonary forms and rarely, intestinal, ocular, and disseminated forms. The cerebral disease is usually associated with orbital and paranasal sinus infection. It occurs at all ages. It is acute rather than

chronic and is usually fatal, although recovery in a few patients has been observed. The disease usually is found as a complication of other diseases, of which uncontrolled diabetes is the commonest, but other diseases such as leukemia, multiple myeloma, Hodgkin's disease, fatal burns, uremia, cirrhosis, and diarrhea are also antecedent conditions. Cortisone, corticotropin, anti-leukemic chemical agents, and antibiotics may also be predisposing factors (Baker, 1957). Growth of the fungus in the tissue is abundant. Its spread is unique in that it has a great tendency to invade massively the tough arterial and venous walls, causing thrombosis that results in widespread necrosis of the tissue. Cellular infiltration and abscess formation are seen. This cellular reaction consists chiefly of neutrophils and macrophages. It is believed that this cellular reaction is provoked by tissue necrosis, since hyphae are often found within the tissue without causing cellular infiltration. Eosinophils were not reported to be a part of the tissue reaction, while multinucleated giant cells were rare and were reported in only one case (Baker, 1956). The fungus was isolated from three cases, and was found to belong to the genus *Rhizopus* (Harris, 1955; Bauer *et al.*, 1955; Baker, 1957).

Phycomycosis affecting organs other than the subcutaneous tissue has been found twice in Indonesia. One case presented an infection of the stomach wall (Lie Kian Joe and Njo Injo Tjoer Eng 1956). The fungus that was not cultured did not grow into the blood vessels. The patient recovered after partial gastrectomy. The second case presented a fatal infection of the central nervous system associated with orbital infection and uncontrolled diabetes mellitus (Lie Kian Joe *et al.*, 1960). The fungus, which was not isolated, grew abundantly and did invade blood vessels, but not massively. A few eosinophils were seen in granulomatous tissue which, in association with abscesses, consisted of epithelioid histiocytes and multinucleated giant cells.

Subcutaneous phycomycosis is unique in that it differs in many respects from phycomycosis affecting the other organs. These differences are:

(1) Subcutaneous phycomycosis has been found only in children. There is probably an age disposition, although we can not be sure until more cases are available for study.

(2) There are no known predisposing factors. The disease occurs in healthy children, and there has been no association of it with the use of antibiotics or other drugs.

(3) The disease is chronic, lasting for many months or many years without markedly affecting the general condition of the patient.

(4) The infection heals spontaneously.

(5) The disease produces an eosinophilic granulomatous tissue reaction.

(6) The fungus causes a peculiar smudgy, eosinophilic, granular necrosis of the surrounding tissue not found in other mycotic infections.

(7) The fungus has no tendency to grow into the blood vessels.

(8) The fungus grows slowly in tissue, and usually hyphae occur singly.

(9) Three strains of a *Basidiobolus* species and an unidentified phycomycete have been isolated.

We do not know why spontaneous healing occurred in one case more than 4 years after the disease started and, in another, after 9 months. This is a matter of balance between the defending host and the invading parasite, about which

we know nothing. However, we can assume that spontaneous healing may also occur a short time after infection when the lesion is still small. It may well be that such cases occur without recognition; their diagnosis is extremely difficult, since they do not show symptoms.

Subcutaneous phycormycosis has not been found in other countries. The patient observed by W. St. C. Symmers in London, England, had probably acquired the infection in Indonesia. It is possible that the disease is not restricted to Indonesia alone, since the fungus is found in many areas of the world.

Acknowledgment

We are grateful to Carlyn Halde for valuable assistance in the preparation of this paper and to W. St. C. Symmers, Department of Pathology, University of London, London, England, for having given permission to quote his case before publication.

References

- BAKER R. D. 1936 Pulmonary mucormycosis. *Am. J. Pathol.* 32: 237-313.
 BAKER R. D. 1937 Mucormycosis—A new disease? *J. Am. Med. Assoc.* 103: 805-808.
 BAUER H. L., AJELLO E., ADAMS & U. HERNANDEZ. 1955 Cerebral mucormycosis: Pathogenesis of the disease. *Am. J. Med.* 18: 822-831.
 CASAGRANDE C. 1931 Sur la présence de *Basidiobolus* dans l'homme. *Boll. soc. intern. sez. microbiol. ital.* 3: 399-400.
 CHRISTIANSEN M. 1929 Mucormykose beim Schwein. *Arch. path. Anat. u. Physiol. Virchow* 273: 829-858.
 DRECHSLER C. 1938 Formation of sporangia from conidia and hyphae segments in an Indonesian *Basidiobolus*. *Am. J. Botany* 45: 632-638.
 EMMONS C. W., LIE KIAN JOE, NJO INJO TJOEI ENG, A. POHAN, S. KERTOPATI & A. VAN DER MEULEN. 1957 *Basidiobolus* and *Cercospora* from human infections. *Mycologia* 49: 1-10.
 GREGORY J. E., A. GOLDEN & M. HAYMAKER. 1943 Mucormycosis of the central nervous system. Report of three cases. *Bull. Johns Hopkins Hosp.* 73: 405-419.
 HARRIS J. S. 1933 Mucormycosis. Report of a case. *Pediatrics* 16: 857-867.
 LEVISOHN I. 1927 Beitrag zur Entwicklungsgeschichte und Biologie von *Basidiobolus ranarum* Eidam. *Jahrb. wiss. Botan.* 66: 513-555.
 LIE KIAN JOE & NJO INJO TJOEI ENG. 1936 A case of mycosis of the stomach caused by a phycormycete. *Doc. Med. Geogr. Trop.* 8: 249-252.
 LIE KIAN JOE, NJO INJO TJOEI ENG, A. IOHAN II, VAN DER MEULEN & C. W. EMMONS. 1956 *Basidiobolus ranarum* as a cause of subcutaneous mycosis in Indonesia. *Arch. Dermatol. Syphilol.* 74: 378-383.
 LIE KIAN JOE, NJO INJO TJOEI ENG, SUTOMO TJOKRONEGORO, S. J. SCHAAPSMAN & C. W. EMMONS. 1959 Phycormycosis of the central nervous system associated with diabetes mellitus in Indonesia. *Am. J. Clin. Pathol.* 32: 62-70.
 LIE KIAN JOE, NJO INJO TJOEI ENG, SUTOMO TJOKRONEGORO & C. W. EMMONS. Phycormycosis (mucormycosis) in Indonesia. Description of a case affecting the subcutaneous tissue. *Am. J. Trop. Med. Hyg.* In press.
 SYMMERS W. ST. C. *Brit. Med. J.* To be published.
 TIO T. H., NJO INJO TJOEI ENG & LIE KIAN JOE. Two new cases of subcutaneous phycormycosis found in Indonesia. In preparation.
 VAN OVEREEM C. 1925 Beiträge zur Pilzflora von Niederländisch-Indien. 10. Über ein merkwürdiges Vorkommen von *Basidiobolus ranarum* Eidam. *Bull. Jardin Bot. Buitenzorg* 7: 423-431.

GROWTH CHARACTERISTICS OF THE FUNGI OF CHROMOBLASTOMYCOSIS*

Margarita Silva

Department of Dermatology College of Physicians and Surgeons, Columbia University,
New York N Y

It is well known that five species of imperfect, dematiaceous fungi are now recognized as causing chromoblastomycosis. These are *Phialophora terrucosa*, *Cladosporium carrionii* and three species of controversial genetic position that some of us prefer to place in the separate genus, *Fonsecaea*¹⁶, namely *Fungi pedrosi*, *F. compacta* and *F. dermatitidis*. These five species sporulate by three distinct methods of conidial production: the *Cladosporium*, the pseudo *Acrotheca*, and the *Phialophora* types. Since the three types of sporulation can occur simultaneously in various combinations and proportions, depending on the individual isolate and conditions of culture, it frequently takes a specialist to identify these pathogens.

This paper does not repeat the criteria on which final identification is based nor the arguments in favor of one or another of the proposed taxonomic treatments for this group; rather, it attempts to collate the criteria, some old, some new, that the nonspecialist may find helpful in making an initial differentiation between the fungi of chromoblastomycosis and related saprophytes and pathogens. This initial differentiation is necessary. For one thing, various species of *Cladosporium* are frequently introduced as air contaminants into cultures of clinical specimens. Such contaminants can no longer be discarded if they lack *Phialophora* or pseudo *Acrotheca* types of sporulation: the discovery of an undisputed *Cladosporium* (*C. carrionii*) as a frequent and widespread agent of chromoblastomycosis calls for other means of identification. Another need for differentiation springs from the confusing resemblance of *P. jeaneismei*, one of the causes of mycetoma, to the colony and microscopic morphology of the fungi of chromoblastomycosis. The resemblance has led to erroneous identification of this fungus and confusion in clinical diagnosis. Distinction between these two diseases is important if only for guiding therapy: the cutaneous localization of chromoblastomycosis makes it amenable to plastic surgery, in maduromycosis on the contrary, plastic surgery is inapplicable since there the fungus invades subcutaneous tissue, muscle, cartilage, and bone. Finally, it would also be helpful if a similar means of preliminary distinction could be found between *P. terrucosa* and the saprophytic phialophoras that attack wood. Although not yet reported as contaminants, conceivably such could happen.

Evaluation of Previously Proposed Diagnostic Criteria

Sporulating pattern. Since the fungi of chromoblastomycosis are yet to be rescued from the category of Fungi imperfecti, their asexual sporulation, as in all these form genera, is still the only legitimate basis for their identification. As mentioned earlier, however, the correct evaluation of their complicated

* The work described in this paper was supported in part by Research Grant No. II 299 (C7) from the Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.

we know nothing. However, we can assume that spontaneous healing may also occur a short time after infection when the lesion is still small. It may well be that such cases occur without recognition; their diagnosis is extremely difficult, since they do not show symptoms.

Subcutaneous phycomycosis has not been found in other countries. The patient observed by W. St. C. Symmers in London, England, had probably acquired the infection in Indonesia. It is possible that the disease is not restricted to Indonesia alone, since the fungus is found in many areas of the world.

Acknowledgment

We are grateful to Carlyn Hilde for valuable assistance in the preparation of this paper and to W. St. C. Symmers, Department of Pathology, University of London, London, England, for having given permission to quote his case before publication.

References

- BAKER, R. D. 1936. Pulmonary mucormycosis. *Am. J. Pathol.* 32: 287-313.
- BAKFR, E. D. 1957. Mucormycosis—A new disease? *J. Am. Med. Assoc.* 163: 805-808.
- BAUER, H., L. AJELLO, E. ADAMS & U. HERNANDEZ. 1955. Cerebral mucormycosis: Pathogenesis of the disease. *Am. J. Med.* 18: 822-831.
- CASAGRANDE, C. 1931. Sur la présence de *Basidiobolus* dans l'homme. *Boll. soc. intern. sez. microbiol. ital.* 3: 399-400.
- CHRISTIANSEN, M. 1929. Mucormykose beim Schwein. *Arch. path. Anat. u. Physiol. Virchow.* 273: 829-858.
- DRECHSLER, C. 1938. Formation of sporangia from conidia and hyphae segments in an Indonesian *Basidiobolus*. *Am. J. Botany* 45: 632-638.
- EMMONS, C. W., LIE KIAN JOE, NJO INJO TJOEI ENG, A. POHAY, S. KERTOPATI & A. VAN DER MEULEN. 1957. *Basidiobolus* and *Cercospora* from human infections. *Mycologia* 49: 1-10.
- GREGORY, J. E., A. GOLDEN & M. HAYMAKER. 1943. Mucormycosis of the central nervous system. Report of three cases. *Bull. Johns Hopkins Hosp.* 73: 405-419.
- HARRIS, J. S. 1955. Mucormycosis. Report of a case. *Pediatrics* 16: 857-867.
- LEVISION, I. 1927. Beitrag zur Entwicklungsgeschichte und Biologie von *Basidiobolus ranarum* Eidam. *Jahrb. wiss. Botan.* 66: 513-555.
- LIE KIAN JOE & NJO INJO TJOEI ENG. 1936. A case of mycosis of the stomach caused by a phycomycete. *Doc. Med. Geogr. Trop.* 8: 249-252.
- LIE KIAN JOE, NJO INJO TJOEI ENG, A. POHAY, H. VAN DER MEULEN & C. W. EMMONS. 1956. *Basidiobolus ranarum* as a cause of subcutaneous mycosis in Indonesia. *Arch. Dermatol. Syphilol.* 74: 378-383.
- LIE KIAN JOE, NJO INJO TJOEI ENG, SUTOMO TJOKRONEGORO, S. J. SCHAAFSMA & C. W. EMMONS. 1959. Phycomycosis of the central nervous system associated with diabetes mellitus in Indonesia. *Am. J. Clin. Pathol.* 32: 62-70.
- LIE KIAN JOE, NJO INJO TJOEI ENG, SUTOMO TJOKRONEGORO & C. W. EMMONS. Phycomycosis (mucormycosis) in Indonesia. Description of a case affecting the subcutaneous tissue. *Am. J. Trop. Med. Hyg.* In press.
- SYMMERS, W. St. C. *Brit. Med. J.* To be published.
- TIO, T. H., NJO INJO TJOEI ENG & LIE KIAN JOE. Two new cases of subcutaneous phycomycosis found in Indonesia. In preparation.
- VAN OVEREEM, C. 1925. Beiträge zur Pilzflora von Niederländisch Indien. 10. Über ein merkwürdiges Vorkommen von *Basidiobolus ranarum* Eidam. *Bull. Jardin Bot. Houtenzorg.* 7: 423-431.

GROWTH CHARACTERISTICS OF THE FUNGI OF CHROMOBLASTOMYCOSIS*

Margarita Silva

Department of Dermatology College of Physicians and Surgeons Columbia University
New York N. Y.

It is well-known that five species of imperfect, dematiaceous fungi are now recognized as causing chromoblastomycosis. These are *Phialophora terrucosa*, *Cladosporium carrionii* and three species of controversial generic position that some of us prefer to place in the separate genus, *Fonsecaea*¹⁶, namely *Fungi pedrosoi*, *F. compacta*, and *F. dermatitidis*. These five species sporulate by three distinct methods of conidial production: the *Cladosporium*, the pseudo-*Acrotheca*, and the *Phialophora* types. Since the three types of sporulation can occur simultaneously in various combinations and proportions, depending on the individual isolate and conditions of culture, it frequently takes a specialist to identify these pathogens.

This paper does not repeat the criteria on which final identification is based nor the arguments in favor of one or another of the proposed taxonomic treatments for this group; rather, it attempts to collate the criteria, some old, some new, that the nonspecialist may find helpful in making an initial differentiation between the fungi of chromoblastomycosis and related saprophytes and pathogens. This initial differentiation is necessary. For one thing, various species of *Cladosporium* are frequently introduced as air contaminants into cultures of clinical specimens. Such contaminants can no longer be discarded if they lack *Phialophora* or pseudo-*Acrotheca* types of sporulation: the discovery of an undisputed *Cladosporium* (*C. carrionii*) as a frequent and widespread agent of chromoblastomycosis calls for other means of identification. Another need for differentiation springs from the confusing resemblance of *P. jeaneusei*, one of the causes of mycetoma, to the colony and microscopic morphology of the fungi of chromoblastomycosis. The resemblance has led to erroneous identification of this fungus and confusion in clinical diagnosis. Distinction between these two diseases is important if only for guiding therapy: the cutaneous localization of chromoblastomycosis makes it amenable to plastic surgery, in maduromycosis, on the contrary, plastic surgery is inapplicable since there the fungus invades subcutaneous tissue, muscle, cartilage, and bone. Finally, it would also be helpful if a similar means of preliminary distinction could be found between *P. terrucosa* and the saprophytic phialophoras that attack wood. Although not yet reported as contaminants, conceivably such could happen.

Evaluation of Previously Proposed Diagnostic Criteria

Sporulating pattern: Since the fungi of chromoblastomycosis are yet to be rescued from the category of Fungi imperfecti, their asexual sporulation, as in all these form genera, is still the only legitimate basis for their identification. As mentioned earlier, however, the correct evaluation of their complicated

* The work described in this paper was supported in part by Research Grant No. E-299 (C7) from the Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.

pattern of conidial production requires experience and time-consuming observation. For further details on this criterion, Carrión,⁴ Emmons,² Conant,¹⁰ and Trejos²² may be consulted.

Serological reactions A review of the serological reactions employed before 1947 to distinguish these fungi has been published.^{4,7} The most pertinent of these were the observations of Martin *et al*¹⁴ and of Conant and Martin,⁹ who showed serological cross reactivity among the fungi of chromoblastomycosis but not between them and *C. sphaerospermum* (Jageroni). Later, in 1958, Seeliger¹⁵ reported that he and Trejos had found *P. jeaniselmei* antisera inactive against alcohol precipitated culture filtrates of the fungi of chromoblastomycosis. Although serological criteria can be very useful taxonomically, here again a specialized laboratory is essential.

Hyphal fusions The occurrence of hyphal fusions among the fungi of chromoblastomycosis was first reported by Trejos²² in *C. carrionii*. Although Ridley¹⁷ failed in her attempt to repeat this observation, Taschdjian²³ found intraspecific but not interspecific fusions when she tested 2 isolates each of *C. carrionii*, *F. pedrosoi*, *F. compacta*, *F. dermatitidis*, and *P. verrucosa*. This observation suggests another possible means of distinguishing between these species, but unless confirmed cytologically or by analysis of progeny, this method is not universally accepted as a criterion for the identification of species.

Enzymatic reactions Work with the enzymatic reactions of the fungi of chromoblastomycosis was reviewed in 1947 by Carrión and Silva,⁷ who concluded that previous tests were "too few and conflicting to permit conclusions." It was not until Montemayor's study of 1949⁸ that enzymatic reactions were proposed as a means of differentiating between the pathogens and related saprophytes. Proteolytic enzymes, that is, those liquefying Loeffler's coagulated serum medium or gelatin, and those peptonizing milk, were absent in the pathogens but present and very active in two saprophytic cladosporia used as controls.

This criterion has also been used by Trejos²² in describing *C. carrionii* as a new species, by Ridley¹⁷ in screening for pathogenic cladosporia among fourteen thermophilic isolates from soil and vegetable substrata in Australia.

Optimal temperature Montemayor¹³ had reported an optimal temperature of 20 to 25° C for 2 saprophytic cladosporia, of 29 to 30° C for 3 isolates of *P. jeaniselmei*, and of 37° C for 6 isolates from chromoblastomycosis. Silva,¹⁰ on the other hand, found the optimum temperature in the latter group to range between 25 and 35° C. Further observations were indicated.

Experimental inoculations Since the fungi of chromoblastomycosis are of very low infectivity for laboratory animals,^{7,10} animal inoculation has not been a practical criterion for pathogenicity. However, effective inoculation of three human volunteers was convincingly reported by Ridley¹⁷ as one of the criteria for identifying as *C. carrionii*, two isolates she had obtained from fence posts in Australia. Although useful in Ridley's experience and that of certain other investigators, inoculation of humans is not the most popular or the safest method of identifying fungi.

Search for Simpler Criteria

The above mentioned criteria, useful as they are in the hands of the specialist, are not only time consuming but require materials not generally available in laboratories devoted to isolation of fungi from clinical specimens. Therefore, there is still need for additional criteria that could be employed at least in the primary differentiation between the fungi of chromoblastomycosis and related saprophytes or pathogens.

My experience with these fungi has suggested that the rate of growth at 25° C, the ability to grow at or above 30° C, tolerance to cycloheximide, and growth stimulation by vitamins and dimorphism might be useful criteria for this preliminary differentiation.

Materials and Methods

To verify this impression a study was conducted with 83 isolates from the combined stock collections of Carrón, Benham, and myself. Of these, 64 were from chromoblastomycosis and included 47 of *Fonsecaea pedrosoi*, 4 of *F. compacta* (2 clinical isolates and their variants), 1 of *F. dermatitidis*, 5 of *C. carrionii*, 5 of *P. terrucosa* and 2 of "*Torula poikilospora*" (Takahashi). Eleven were related pathogens from other diseases and included 6 of *P. jeanselmei* and 2 of *C. gougeroti*†. The remaining isolates were saprophytes or plant parasites and included 6 *Cladosporium* sp., and 1 each of *P. richardsiae*, *P. obscura*, *Pullularia pullulans*, *C. elatum* and *C. sphaerospermum* (langeronii) (see TABLE 1).

The techniques employed in this study were the conventional ones: pin point inoculations were made in the center of cotton plugged agar slants and growth was measured as colony diameter after three weeks incubation on the various media and at the temperatures studied.

Growth rates were measured on 3 routine isolation media: Sabouraud's glucose agar obtained in dehydrated form* but with the agar concentration raised by us to 2 per cent, a similar medium designated as "home made" Sabouraud's in which Bactopeptone was substituted for the Neopeptone of the commercial preparation (both these media contained 4 per cent glucose, 1 per cent peptone, and 2 per cent agar, final pH of 5.5), and a third medium containing cycloheximide (BBL's Mycosel Phytone, 1 per cent, glucose, 1 per cent, agar, 1.5 per cent, cycloheximide, 0.4 per cent, chloramphenicol, 0.05 per cent).

To determine the dimorphic morphology, Cystine Heart Hemoglobin† (CHH) agar slants in screw cap tubes were inoculated by smearing the entire surface of the medium with inoculum contained in a wire loop or sterile cotton swab. Inocula were obtained from either a Sabouraud slant or a previous transfer on the cystine medium. Three successive transfers (T_1 , T_2 , and T_3) were made at intervals of 1 week on the cystine media. After 1 week's and again after 3 weeks' incubation of each of these subcultures at 37° C, their

* From Difco Laboratories Inc. Detroit, Mich.

† Difco.

micro-copic morphology was examined by means of teased mounts and the degree of conversion to the parasitic growth phase recorded

To determine the effect on growth of inorganic versus organic nitrogen substrates, agar slants of a mineral-base medium were prepared according to

TABLE I
ORIGIN OF CERTAIN ISOLATES STUDIED*

-
- (1) Pathogens resembling the fungi of chromoblastomycosis
- (a) *Phialophora jeanselmei*
- 563 Isolate obtained from the *Centraalbureau voor Schimmelcultures* (CBS) Baarn, Holland, in 1949, labeled as *Phialophora jeanselmei* (Langeron) Emmons L P, Negrom
- 565 1 Isolate recovered in 1943 from case of mycetoma of the hand seen by G M Lewis and M E Hopper (their No 43 505)
- 565 2 Isolate from second case of mycetoma seen in 1949 by Lewis and Hopper (their No 49-491)
- 579 Isolate received in 1946 from C W Emmons (his No 8724)
- 580 Isolate received in 1946 from Emmons (his No 8727)
- 625 Isolate recovered in 1941 from same patient as isolate 565 1, both described by Lewis and Hopper as *F. pedrosus typicus*²⁴
- (b) *Cladosporium gougerotii*
- 590 Isolate from case seen by L S Suter, Kennedy Hospital Memphis Tenn (his No 1792), and described by Young and Ulrich as *Sporotrichum gougerotii*²¹
- 1012 Isolate received from R Sabouraud's collection in 1929 labeled as *Sporotrichum gougerotii* Mille Zelande
- (2) Saprophytes resembling the fungi of chromoblastomycosis
- (a) *Phialophoras*
- 656 *Phialophora obscura* isolated from wood pulp in Sweden and received from L W White (United States Quartermaster Culture Collection No QM 268)
- 657 *Phialophora richardsiae* isolated from wood pulp in Sweden and received from the same source as above (QM 263)
- (b) *Cladosporia*
- 593 *Cladosporium sphaerospermum* (*Hormodendrum langeroni*) (No 377 in A L Carrion's collection isolate included in studies by Emmons 1936)²²
- 600 *Cladosporium* (*Hormodendrum*) *elatum* (No 385 in Carrion's collection, isolate included in studies by Emmons, 1936)²²
- 603 *Cladosporium* sp Isolate believed to be a contaminant received from C Calero (Panama Canal Zone) in 1945
- 604 *Cladosporium* sp isolated from leaves, 1935, labeled as saprophyte in Carrion's collection (his No 389)
- 650 *Cladosporium* sp Isolate received from W H Weston in 1944 and labeled as Bouganville, ■ C 22 (a)
- 651 *Cladosporium* sp Isolate received from Weston in 1944 and labeled Mold from carbathiazole
- 697 *Cladosporium* sp Isolate received from E L Hazen in 1959, as a "saprophytic *Cladosporium*" (No 4893 in the collection from the New York State Health Department, Division of Laboratories and Research Albany, N Y)
- 698 *Cladosporium* sp Isolate received in 1959 from L Ajello, believed to be a contaminant (C D C No My-374 59)
-

* List includes only those isolates from genera or species that failed to show uniform behavior (see *Results and Discussion*)

Georg and Camp,¹² to contain 4 per cent glucose, 0.01 per cent $MgSO_4 \cdot 7H_2O$, 0.18 per cent KH_2PO_4 (anhydrous), and 2 per cent agar* (not purified). Four modifications of this medium were prepared by adding (1) 0.15 per cent ammonium nitrate, (2) 0.15 per cent ammonium nitrate plus vitamin supplement, (3) 0.25 per cent casein hydrolysate, and (4) 0.25 per cent casein plus vitamin

supplement. The casein hydrolysate was obtained as 10 per cent sterile solution,* the vitamin supplement was that previously employed²¹ according to Arêa Leao and Cury¹ thiamine HCl, riboflavin, pyridoxine HCl, nicotinic acid, Ca pantothenate, 500 µg/l of each, inositol, 10,000 µg/l, biotin, 5 µg/l. Incubation was at 25° C.




FIGURE 1 Rates of growth of the fungi of chromoblastomycosis and of related saprophytes and pathogens. Total number of isolates examined of each species is shown in parenthesis; rates shown represent arithmetic average.


Results

Growth on routine isolation media. FIGURES 1 and 2 summarize the rates of growth obtained on Sabouraud's glucose agar (with Bactopeptone versus Neopeptone) calculated from the colony diameters after 3 weeks' incubation at 25 and at 30° C. The same illustrations also show the growth rates on the medium containing cycloheximide (Mycosel†), after three week's incubation at

* From Nutritional Biochemicals Co, Cleveland, Ohio

† Baltimore Biological Laboratories, Baltimore, Md


25 and at 37° C. All the isolates listed under *Materials and Methods* were employed in these measurements, except that on the cycloheximide media at 37° C, only 18 isolates were employed 2 each of *I. pedrosoi*, *I. compacta*, *P. terrucosa*, *C. carrionii* and *C. gougerotii*, 1 each of *I. dermatitidis*, *P. obscura*



CLADOSPORIUM CARRIONI

Key to culture media and temp

- Sabouraud glucose agar at 25° C. (neopeptone)
- ▨ Sabouraud glucose agar at 30° C. (neopeptone)
- Sabouraud glucose agar at 25° C. (bactopeptone)
- ▤ Sabouraud glucose agar at 30° C. (bactopeptone)
- ▥ Mycosel (cycloheximide) at 25° C.
- ▧ Mycosel (cycloheximide) at 37° C.



SAPROPHYTIC CLADOSPORIA

FIGURE 2 Comparison of rates of growth of five isolates each of *Cladosporium carrionii* and saprophytic cladosporia

P. richardsiae, *C. sphaerospermum* (langeronii), *C. elatum*, *P. fulvulaus*, and 2 of *P. jeaneusei*

It will be seen that practically all isolates grew better at 25° than at 30° C, the exceptions being *C. elatum*, *C. sphaerospermum* (langeronii) and isolate No 669 of *C. carrionii* (from E. H. Detrick, Brisbane, Australia). The more rapid growth rate at 25° C than at 30° C was particularly noticeable in the 5 saprophytic cladosporia shown in FIGURE 2 and in *P. obscura* (FIGURE 1).

Another notable observation was the superiority of Bactopeptone over

Neopeptone as a substrate for growth. Although the bar diagrams show this difference in growth rates calculated at the end of a three week period the difference was even more marked at the end of the first week of growth (FIGURE 3). Bactopeptone promoted a more rapid initiation of growth as well as larger colonies than Neopeptone.

Growth on cycloheximide media at 25° C was remarkably good even for saprophytes; here again there were some exceptions namely *P. jeanselmes*, *P. obscura* and *P. richardsiae*. Growth was absent on this medium in practically




FIGURE 3. Ster colonies of three of the fungi of chromoblastomycosis after one week of growth at 25° C on Sabouraud's glucose agar made with Neopeptone (left) and with Bactopeptone (right).

all those cultures incubated at 37° C (exception *F. dermatidis*), but this can not be attributed to greater toxicity of cycloheximide at this temperature. Another test, read too late to be included in the bar diagrams, revealed that none of the isolates that failed to grow on cycloheximide media at 37° C was able to grow at this temperature during a three week period on the home made Sabouraud's (Bactopeptone). *F. dermatidis* however grew on both these media although slowly attaining a diameter of 6 mm in 3 weeks.

Growth and morphology on Cystine Heart Hemoglobin agar at 37° C. On this medium 85 isolates were studied by the method described above. Growth here was graded as follows: ++++ represented confluent growth covering the entire surface of the agar; +++ confluent growth limited to an area ranging from one half to three fourths the agar surface; ++ several discrete colonies of at least 2 mm in diameter; + few colonies of only about 1 mm

in diameter, \pm , colonies hardly larger than particles of inoculum. That some growth had occurred even in the last category was verified by microscopic examination. Of the 85 isolates, the growth of 41 was + + + +, 10, + + +, 8, + +, 18, +, and 8, \pm . Among the isolates that were able to grow on this medium at 37° C. were included the 17 that had failed to grow on Sabouraud's Bactopeptone agar at this same temperature.

The degree of conversion to the parasitic phase was disappointing, even though a progressive change took place from a glossy-velvety growth to a dull mealy surface texture with variable numbers of chlamydo-spores. In no case,

TABLE 2

RESPONSE OF VARIOUS ISOLATES TO B-COMPLEX VITAMINS AND/OR ORGANIC NITROGEN*

Isolate No	Classification	Stimulation by B-complex vitamins	Stimulation by organic nitrogen
597, 607	<i>Fonsecaea pedrosi</i>	+	0
553, 589	<i>Fonsecaea compacta</i>	+	0
614	<i>Fonsecaea dermatitidis</i>	+	0
624, 669	<i>Cladosporium carrionis</i>	+	0
590	<i>Cladosporium gougerotii</i>	+	0
593	<i>Cladosporium sphaerospermum</i>	+	0
600	<i>Cladosporium elatum</i>	+	0
653	<i>Phialophora jeanselmii</i>	+	0
657	<i>Phialophora richardsiae</i>	++	0
565, 1, 625	<i>Phialophora jeanselmii</i>	0	++
556, 639	<i>Phialophora verrucosa</i>	+	+
656	<i>Phialophora obscura</i>	++	+
671	<i>Pullularia pullulans</i>	0	0
563, 579, 580	<i>Phialophora jeanselmii</i>	0	0
1012	<i>Cladosporium gougerotii</i>	0	0
603, 650, 697, 698, 651	Saprophytic cladosporia	0	0

Key: ++ = supplement (or one of its components) essential for growth, + = supplement (or one of its components) beneficial to growth, 0 = supplement has no effect on growth.

* Composition of media detailed in text.

however, was conversion to the parasitic (sclerotic cell) phase as complete as had been previously observed on 2 isolates (one of *P. verrucosa*, one of *P. pedrosi* included above) similarly cultured but on the original Francis cystine glucose blood agar¹¹. The differences between these 2 media and their possible effect on the induction of sclerotic cells need further study.

Another interesting response was that shown by the so called black yeasts. Although moldy on Sabouraud's glucose agar at room temperature, two of the isolates of *P. jeanselmii* and one of *C. gougerotii* became glistening and yeast-like in gross and microscopic morphology when subcultured on the CHH agar at 37° C.

Growth on inorganic versus organic nitrogen with and without B-complex vitamins. The same selection of isolates tested for ability to grow on cycloheximide and Bactopeptone agars at 37° C., and 4 additional strains of *P.*




FIGURE 4. Response of six representative isolates to inorganic versus organic nitrogen substrate with and without vitamin supplement. Columns 1 and 2 show tubes containing NH_4NO_3 as sole nitrogen source with added vitamins on the right. Columns 3 and 4 show tubes containing casein as nitrogen source, those with added vitamin on the right. (a) *Fonsecaea pedrosoi*, (b) *Cladosporium sphaerospermum* (Jangeron's), (c) *Phialophora jeanselmei*, (d) *L. terrucosa*, (e) *P. obscura*, (f) *Pullularia pullulans*.

jeanselmiei were used in this preliminary survey of nutritional requirements on the 4 media described above. As shown in TABLE 2, 4 types of response were obtained: (1) stimulation by vitamins but not by organic nitrogen, (2) stimulation by organic nitrogen but not by vitamins, (3) stimulation by both the vitamin supplement and organic nitrogen, and (4) no stimulation by either of the 2 enrichments. Type 1 response was shown by each of 2 isolates of *Ionospora pedrosi* (FIGURE 4a), *I. compacta* *C. carrioni*, and by single isolates of *C. gougerotii*, *F. dermatitidis*, *P. jeanselmiei*, *P. richardsiae*, *C. sphaerospermum* (*langeronii*) (FIGURE 4b), *C. elatum* and a saprophytic *Cladosporium* from leaves. The 2 saprophytic phialophoras, *P. obscura* and *P. richardsiae*, have an absolute deficiency for an undetermined component of the vitamin supplement. Type 2 response was demonstrated with 2 of 6 strains of *P. jeanselmiei* (both from the same patient, 1 strain illustrated in FIGURE 4c). Here too the requirement for organic nitrogen was absolute. Type 3 response was shown by the 2 isolates of *P. terrucosa* (FIGURE 4d) and by one of *P. obscura* (FIGURE 4e). Type 4 response, that is equal growth on all 4 media, was shown by 5 saprophytic cladosporia, by *Pullularia pullulans* (FIGURE 4f), by the remaining 3 isolates of *P. jeanselmiei*, and by the remaining isolate of *C. gougerotii*.

Discussion

Some of the results of the studies described herein are not entirely in accord with commonly accepted ideas. For example, the general impression that the faster growth rate at 25° C. of the air borne contaminants of *Cladosporium* than that of the fungi of chromoblastomycosis provided a reliable criterion for differentiation of these 2 groups was not borne out in our experiments. In our study, 4 saprophytic isolates of *Cladosporium* (Nos. 650, 651, 697, and 698) grew very rapidly, at rates ranging from 16 to 25 mm/week, attaining colony diameters ranging from 50 to 75 mm after 3 weeks on Sabouraud's glucose agar at 25° C., while 4 others (Nos. 593, 600, 603, and 604) grew more slowly, at a rate fully comparable to the rates shown by the fungi of chromoblastomycosis (9 to 11 mm/week). The conclusion, then, is that while a fast growing *Cladosporium* probably spells saprophyte, a slow growing one is not necessarily pathogenic for man. Indeed, the wide range of variation of growth rate with the saprophytes in this genus had already become evident from comparative studies such as those described by DeVries.¹¹

The second criterion examined, whether saprophytes would cease to grow or would slow down considerably in rate of growth at 30° C., gave a similar answer. Absence of growth or extreme slowing at 30° C. was found to be a fairly good sign of a saprophyte. Ability to grow well at this temperature, however, was not found to be the exclusive prerogative of a pathogen.

Many years ago I observed the superiority of Bactopeptone over Neopeptone as an ingredient in Sabouraud's glucose agar intended for cultivation of the fungi of chromoblastomycosis, this observation has been confirmed on a large number of isolates. Since this isolation and maintenance medium is widely marketed with Neopeptone, it would seem advisable to substitute a "home-made" medium prepared with the more favorable Bactopeptone when the medium is intended for use with the fungi of chromoblastomycosis. In ad-

dition to a more rapid and luxuriant growth, Bactopeptone prolongs the viability of cultures of this group maintained in a stock culture collection

Growth of the fungi of chromoblastomycosis on cycloheximide medium was a surprise, since their low virulence and ability to grow well on inorganic nitrogen has often been construed as a sign of weak pathogenicity. That this group could tolerate, and even "be stimulated by" cycloheximide was pointed out to me by Lucille Georg. Tolerance but not stimulation by this antibiotic has been confirmed with almost all the 85 isolates studied. Because this antibiotic is known to inhibit saprophytic fungi,^{11, 23} it had been hoped that this compound might serve in ruling out of saprophytes frequently confused with the fungi of chromoblastomycosis. With the exception of one isolate of *P. obscura*, all other saprophytic isolates tested grew well on this antibiotic. Cycloheximide, therefore, is not suitable for the proposed preliminary separation of saprophyte from pathogen in this instance.

The good growth shown on CHH agar at 37° C. by more than 60 isolates, including 17 that had failed to grow at this temperature even in the favorable Bactopeptone Sabouraud's agar was provocative. The possibility should be explored that temperature tolerance in these fungi may also be affected by growth factors such as those identified for various protists by Hutner *et al.*¹⁸

The observation of a marked stimulation of the fungi of chromoblastomycosis by the vitamin supplement confirms that of Aréa Leao and Cury¹ who identified thiamin as the responsible factor.

Finally, marked variation was observed among isolates sent to us as *P. jeanselmei* or *C. gougeroti* both in their response to CHH agar (mealy with chlamydospores versus yeasty with blastospores), and in their response to organic nitrogen and to B complex vitamins (stimulated or not stimulated). This observation opens up the possibility that more than one species may be represented among isolates now classified as either *P. jeanselmei* or *C. gougeroti*. The recommendation of Borelli² that these two species be considered synonymous should await further study.

Summary

This paper reviews and proposes criteria that may serve in the preliminary differentiation between the fungi of chromoblastomycosis and related saprophytes and pathogens. In the study 83 isolates were examined among which *Fonsecaea pedrosoi*, *F. compacta*, *F. dermatitidis*, *C. carrionii*, *P. verrucosa*, and *Torula poikilospora*,²⁴ served as representatives of etiologic agents of chromoblastomycosis, *P. jeanselmei* and *C. gougeroti* of causative agents of mycetoma. *C. sphaerospermum* (Jagerontii), *C. elatum*, *P. obscura*, *P. richardsiae*, *Pullularia pullulans* and six other isolates assigned to *Cladosporium*, represented the saprophytes.

Confirmation was obtained that whereas some air contaminants of the genus *Cladosporium* may grow at a rate considerably faster than the fungi of chromoblastomycosis, other saprophytic clado-poria grow at rates comparable to known pathogens.

Bactopeptone was shown to be superior to Acetopeptone as an ingredient for

Sabouraud's glucose agar intended for use with the fungi of chromoblastomycosis

With few exceptions, saprophytes as well as pathogens in this study grew well on cycloheximide at 25° C

Although 17 isolates representing a cross section of the various species studied failed to grow at 37° C on Sabouraud's Bactopeptone agar, these same isolates and nearly 50 others attained moderate to luxuriant growth at this same temperature on CHH agar

Serial streaking of mold phase cultures of 85 isolates on CHH agar incubated at 37° C induced partial conversion to the parasitic morphology This was manifested by a gradual change from a smooth velvety to a dull mealy type of aerial mycelium and the appearance of numerous, sometimes septate, chlamydospores along the mycelium Complete suppression of filaments was not attained, except with some isolates of *P jeanselmei* and one of *C gougerotii* where conversion was from a velvety filamentous to a smooth yeastlike type of aerial growth consisting entirely of blastospores

Two isolates each of four species causing chromoblastomycosis and one each of *C gougerotii*, *C elatum*, *C sphaerospermum* (*langeronii*), *P jeanselmei*, and *P richardsiae* grew equally well on inorganic and organic nitrogen but were markedly stimulated when a supplement of B complex vitamins was added to the medium Two isolates of *P terrucosa* and one of *P obscura* were stimulated by both organic nitrogen and the vitamin supplement Two isolates of *P jeanselmei* (from the same patient but different laboratories) did not grow on inorganic nitrogen even when vitamins were added, but grew as well on organic nitrogen (casein) with or without vitamins Three other isolates classified elsewhere as *P jeanselmei*, one of *C gougerotii* and one of *P pullulans* grew as well on inorganic as organic nitrogen with or without vitamins

Acknowledgments

I am indebted to Helen R Buckley for devoted assistance in these studies, to Mildred Zurfluh for secretarial help, to Paul Pelech for the photography, and to Benedetto Vasi for drawing the charts

References

1. ARÊA LEAO A M DE & A CURY 1949 Deficiencias vitamínicas de cogumelos patogénicos *Mycopathologia* 5: 65-90
2. BINFORD C H G Hess & C W JIMMONS 1944 Chromoblastomycosis: report of a case from continental United States and discussion of classification of the causative fungus *Arch Dermatol Syphilol* 49: 398-402
3. BORELLI D 1925 *Sporotrichum gougerotii* *Hormiscium dermatitidis* *Phialophora jeanselmei* *Phialophora gougerotii* (Mastruchot 1910) comb n *Mem VI Congreso Venezolano Ciencias Med Irensa Medica Venezolana* Caracas
4. CARRIÓN A L 1942 Chromoblastomycosis *Mycologia* 34: 424-441
5. CARRIÓN A L 1950 Chromoblastomycosis *Ann N Y Acad Sci* 50(10): 1255-1282
6. CARRIÓN A L 1950 Yeastlike dematiaceous fungi infecting the human skin Special reference to the so-called *Hormiscium dermatitidis* *Arch Dermatol Syphilol* 61: 996-1009
7. CARRIÓN A L & M SILVA 1947 Chromoblastomycosis and its etiologic fungi *In* Biology of Pathogenic Fungi (Annales Cryptogamiques et Phytopathologiques) W J Nickerson Ed 6: 20-62 *Chronica Botanica* Waltham Mass
8. CARRIÓN A L & M SILVA 1955 Sporotrichosis Special reference: a revision of so called *Sporotrichum gougerotii* *A M A Arch Dermatol* 71: 523-534

- 9 CONANT N F & D S MARTIN 1937 The morphologic and serologic relationships of the various fungi causing dermatitis verrucosa (chromoblastomycosis) *Am J Trop Med* 17 553-577
- 10 CONANT N F & D T SMITH R D BAKER J L CALLAWAY & D S MARTIN 1954 *Manual of Clinical Mycology* 2nd ed Saunders Philadelphia Pa
- 11 GEORG L K L AJELLO & C LAPAGEORGE 1954 Use of cycloheximide in the selective isolat on of fungi pathogenic to man *J Lab Clin Med* 44 422-428
- 12 GEORG L K & L B CAMP 1957 Routine nutrit onal tests for the ident ification of dermatophytes *J Bacteriol* 74 113-121
- 13 HUTNER H S AARONSON H A NATHAN H BAKER H SCHER & A CURY 1958 Trace elements in macroorganisms the temperature factor approach Chap 3 *In* Trace Elements Academic Press New York N Y
- 14 MARTIN D S R D BAKER & N F CONANT 1936 A case of verrucous dermatit s caused by *H. pedrosoi* (chromoblastomycosis) in North Carol na *Am J Trop Med* 16 593-619
- 15 MONTEMAIOR L DE 1949 Estudio de las propiedades biológicas de varias cepas de hongos patógenos causantes de la cromomucosis y de especies vecinas saprófitas y patógenas *Mycopathologia* 4 379-383
- 16 NEGRONI P 1936 Estudio micológico del primer caso argentino de cromomucosis *Fonse asa (n g) pedrosoi* (Brumpt 1921) *Rev Inst bacteriol* 7 419-426
- 17 RIDLEY M F 1957 The natural habitat of *Cladosporium carrionii* a cause of chromoblastomycosis in man *Austral an J Dermatol* 6 23-27
- 18 SEELIGER H 1958 *Mykologische Serod agnostik* Johann Ambros us Barth Leipzig Germany
- 19 SILVA M 1957 The parasitic phase of the fungi of chromoblastomycosis development of sclerotic cells *in vitro* and *in vivo* *Mycologia* 49 318-331
- 20 SILVA M 1958 The saprophytic phase of the fungi of chromoblastomycosis effect of nutrients and temperature upon growth and morphology *Trans N Y Acad Sci Ser II* 21(1) 46-57
- 21 SILVA M & R W BENHAM 1952 Nutrit onal studies of the dermatophytes with special reference to *Triclophyton megnini* Blanchard 1896 and *Triclophyton gallinae* (Megn n 1881) *comb nov* *J Invest Dermatol* 18 453-472
- 22 TASCHDJIAN C 1959 Hyphal fusion studies on *Histioplasma capsulatum* and *Histioplasma duboisii* (Vanbreuseghem 1952) *Mykosen* 2 16 Also personal communication
- 23 TREJOS A 1954 *Cladosporium carrionii* n sp and the problem of Cladosporia isolated from chromoblastomycosis *Rev biol trop Univ Costa Rica* 2 75-112
- 24 DE VRIES G A 1952 Contribution to the knowledge of the genus *Cladosporium* Link ex Fr Doctoral Dissertation Baarn Holland
- 25 WHIFFEN A J N BOHONOS & R L EMERSON 1946 The production of an anti-fungal antibiotic by *Streptomyces griseus* *J Bacteriol* 61 610-611
- 26 LEWIS G M & M E HOPFER 1948 *J Invest Dermatol* 11 155-168
- 27 YOUNG J M & E ULRICH 1953 *A M A Arch Dermatol* 67 44-52
- 28 EMMONS C W 1936 Puerto Rico *J Public Health Trop Med* 11 639-650

GEOGRAPHIC DISTRIBUTION AND PREVALENCE OF THE DERMATOPHYTES

Libero Ajello

Mycology Unit Communicable Disease Center, Public Health Service, Atlanta, Ga

A survey of published reports on twenty well defined dermatophyte species reveals that, while some species are cosmopolitan, others have a remarkably limited geographic distribution (TABLE 1)

The dermatophytes can be classified into three broad categories: the anthropophilic, the zoophilic, and the geophilic species.¹ This differentiation with respect to natural habitats and host preferences is believed to have played a significant role in determining the global distributions of the dermatophytes.

Of the eleven species that are cosmopolitan, seven are anthropophilic: *Epidermophyton floccosum*, *Microsporum audouinii*, *Trichophyton mentagrophytes* (downy form), *T. rubrum*, *T. schoenleini*, *T. tonsurans*, and *T. violaceum*. Because of their adaptability to a wide range of environmental conditions and their intimate association with man, these fungi occur wherever man dwells.

The animals that man domesticated also became hosts for certain dermatophytic fungi. As man and his domestic animals migrated throughout the world, some of the zoophilic species, *M. canis*, *T. gallinae*, *T. mentagrophytes* (granular form) and *T. verrucosum*, accompanied them.

M. gypseum is the only geophilic dermatophyte with a global distribution. The factors that established its geographic pattern are not known.

Six anthropophilic dermatophytes have a limited geographic distribution: *M. nanum*, *T. concentricum*, *T. ferrugineum*, *T. megninii*, *T. soudanense* and *T. yaoundei*. Four of these species are confined to single regions of the world. At present, *M. nanum* is known from only two Cuban isolates.² *T. megninii*^{3, 4} is confined exclusively to Europe. It has been recorded in Denmark,⁵ France,⁶ Germany,⁷ Great Britain,⁸ Hungary,⁹ Italy,¹⁰ the Netherlands,¹¹ Portugal,¹² Union of Soviet Socialist Republics,¹³ and Spain.¹⁴ It is especially common on the island of Sardinia.¹⁵

Africa has two endemic species: *T. soudanense* and *T. yaoundei*. *T. soudanense* occurs in Algeria,¹⁶ Angola (L. K. Georg, personal communication), Cameroon,¹⁶ French West Africa,¹⁷ and Nigeria,¹⁸ but there is also a record of the recovery of *T. soudanense* from a child in Brazil (L. K. Georg, personal communication). Its presence there may be a legacy of the infamous slave trade that flourished from the Fifteenth to the Nineteenth Centuries. This endoethrix fungus superficially resembles *T. tonsurans* and, until it is deliberately sought in Brazil, its true status will remain unknown.

T. yaoundei was first described in 1957 from the French Cameroons,¹⁹ now the Republic of Cameroon. There it proved to be one of the principal agents of tinea capitis. Subsequently, it has been found to be present in the Belgian Congo (L. K. Georg, personal communication).

T. concentricum is recorded from Oceania, Asia, and North, Central, and South America.²⁰ It is not present in the New World north of Mexico and it is absent from Europe and Africa. A supposed isolate of this species from

Africa,²⁰ when studied by Georg, proved to be *T. verrucosum*.²¹ Piper's report of this fungus in South Africa is erroneous,²² as the published descriptions of his isolate indicate that he was dealing with a saprophyte.

T. ferrugineum is present in Africa, in Angola,²³ Belgian Congo,²⁴ Cameroon,¹⁶ Cape Verde Islands,²⁵ in Asia, in China,²⁶ Formosa,²⁷ Hawaii,²⁷ India,²⁸ Japan,²⁹ Samoa,²⁷ Vietnam,²⁷ and in Europe, in Bulgaria,³⁰ Czechoslovakia,³¹ Hungary,³² Italy,³¹ Poland,³² Union of Soviet Socialist Republics,³⁴ and Yugoslavia.³⁵ This fungus is especially common in the Far East and parts of Africa. During World War II it apparently was introduced from Manchuria and Korea into several European countries. In Hungary, Poland, and the Union of Soviet Socialist Republics, it has become established in the native population although there is evidence that endemic foci existed in Bulgaria and Yugoslavia prior to World War II (L. Ozegovic, personal communication).

TABLE 1
GEOGRAPHIC CLASSIFICATION OF THE DERMATOPHYTES

Cosmopolitan species			Geographically limited species		
Anthropophilic	Zoophilic	Geophilic	Anthropophilic	Zoophilic	Geophilic
<i>E. floccosum</i> <i>M. audouinii</i> <i>T. mentagrophytes</i> ^a <i>T. rubrum</i> <i>T. schoenleii</i> <i>T. tonsurans</i> <i>T. violaceum</i>	<i>M. canis</i> <i>T. gallinae</i> <i>T. mentagrophytes</i> ^a <i>T. verrucosum</i>	<i>M. gypsum</i>	<i>M. nanum</i> <i>T. concentricum</i> <i>T. ferrugineum</i> <i>T. megninii</i> <i>T. soudanensis</i> <i>T. zoomides</i>	<i>M. distortum</i> <i>T. equinum</i>	<i>K. ajelloi</i>

^a *T. mentagrophytes* is equally prevalent as a parasite of man and lower animals. The downy form is associated with chronic human infections. The granular form is associated with animal ringworm and acute human infections.

An isolate of *T. ferrugineum* from Uruguay,³⁶ confirmed by Georg, leads one to suspect that small endemic foci of this fungus occur in South America. If this proves to be true, its presence in the New World may be another relic of the slave trade.

M. distortum and *T. equinum* are the two zoophilic dermatophytes with apparently restricted distribution. *M. distortum* is known to occur only in New Zealand and the United States.^{37,38} The fact that the American isolates were recovered from monkeys newly imported from Latin America, and from humans who were in contact with those monkeys, suggests that this fungus is present also in Central and South America.

T. equinum, essentially a parasite of horses and related animals, is known in Europe in Belgium, France, Germany, Great Britain, the Netherlands,⁴⁰ Italy,⁴¹ and Spain,⁴² in North America, in Canada⁴⁰ and the United States,⁴⁰ and in South America, in Argentina, Uruguay,⁴³ and Brazil.⁴⁴ It has not been recorded from equines in Africa, Asia, and Australasia. *T. equinum* probably exists in those continents but, until animal ringworm surveys are carried out, its status will remain unknown.

TABLE 2

DOMINANT ETIOLOGICAL AGENT OF *TRINEA CAPITIS* IN VARIOUS AREAS OF THE WORLD

NORTH AMERICA Canada <i>M. audouinii</i> ⁶¹ United States <i>M. audouinii</i> ⁶⁰ Mexico <i>T. tonsurans</i> ⁶²	AFRICA Algeria <i>T. violaceum</i> ⁶³ Angola <i>T. ferrugineum</i> (L. Re personal communication) Belgian Congo <i>T. ferrugineum</i> ⁶³ Cameroon <i>T. yaoundei</i> ⁶⁴ Cape Verde Islands <i>M. canis</i> ⁶⁴ Egypt <i>T. violaceum</i> ⁶³ Morocco <i>T. schoenleinii</i> ⁶⁵ Nigeria <i>M. audouinii</i> ⁶⁵ Spanish Morocco <i>T. schoenleinii</i> ⁶³ Tripoli <i>T. violaceum</i> ⁶³ Tunisia <i>T. violaceum</i> ⁶³
CARIBBEAN AREA Cuba <i>M. canis</i> ⁶⁴ Puerto Rico <i>M. canis</i> ⁶⁴	
SOUTH AMERICA Argentina <i>M. canis</i> ⁶⁴ Brazil <i>T. violaceum</i> ⁶⁷ Chile <i>M. canis</i> ⁶⁹ Peru <i>T. tonsurans</i> ⁶⁰ Uruguay <i>M. canis</i> ⁷⁰ Venezuela <i>T. tonsurans</i> ⁷¹	
EUROPE Denmark <i>M. canis</i> ⁷² Finland <i>M. canis</i> ⁷³ France <i>M. canis</i> ⁷⁴ Great Britain <i>M. canis</i> ⁷⁵ Greenland <i>T. schoenleinii</i> ⁷⁶ Italy <i>T. violaceum</i> ⁷⁷ Portugal <i>T. violaceum</i> ⁷⁸ U.S.S.R. <i>T. violaceum</i> ⁷⁹ Spain <i>T. violaceum</i> ⁸⁰⁻⁸¹ Yugoslavia <i>T. violaceum</i> ⁸⁰	ASIA China <i>T. violaceum</i> ⁸⁴ India <i>Trineia capitis</i> rare ⁸⁵ Iran <i>T. schoenleinii</i> ⁸⁶ Israel <i>T. violaceum</i> ⁸⁷ Japan <i>T. ferrugineum</i> ⁸⁸ Turkey <i>T. schoenleinii</i> ⁸⁹
	AUSTRALASIA Australia <i>M. canis</i> ⁹⁰ New Zealand <i>M. canis</i> ⁹¹

Keratinomyces ajelloi, a geophilic fungus recently found to be pathogenic, has been recovered from soil and animals in North America and Central America in Alaska,⁴² Canada,⁴³ United States,⁴² Costa Rica,⁴⁴ in Europe, in Belgium,⁴⁵ Czechoslovakia,⁴⁶ France,⁴⁷ Germany,⁴⁸ Great Britain,⁴⁹ Hungary,⁴⁸

Rumania,²⁷ in Asia, in Japan,²⁸ and in Australasia, in Australia,²⁹ and New Zealand.³⁰ As yet it has not been encountered in South America and Africa. As soil studies are carried out in those two regions, this fungus will undoubtedly be found to exist there.

This summary of the geographic distribution of the dermatophytes should not be considered definitive in any sense of the word, for it is based on incomplete data. The dermatophyte flora of many more regions of the world must be studied adequately before the distribution of these fungi will be known fully. More surveys, such as that of Pinetti on the dermatophyte flora of Italy,³¹ are needed to fill the gaps in our knowledge.

Information on the prevalence of dermatophytes is even more incomplete than that on geographic distribution. Since the dermatophytoses are not reportable diseases, published reports can provide only fragmentary information concerning total numbers of infections and their specific agents. There is evidence that the predominant species differ not only from region to region, but may change with the passage of time. One must also take care to distinguish between the prevalence of fungus infections and the prevalence of dermatophytes in the environment. *A. ajelloi*³² and *M. gypseum*³³ are abundant in soil, as indicated by the high percentage of soil isolates from many parts of the world, yet the number of infections that they cause is extremely low.

Despite the absence of adequate statistics, there is no doubt that the dermatomycoses are among the most common of human diseases. Tinea pedis afflicts millions of individuals. The principal etiologic agents involved in this disease in all parts of the world are *T. mentagrophytes* and *T. rubrum*.

The etiologic agents of the other types of dermatomycoses—tinea capitis, tinea corporis, and tinea unguium—vary from region to region. This is illustrated in the tabulation of the predominant agent of tinea capitis present in various countries of the world (TABLE 2).

The number of children and adults suffering from ringworm infections of the body, nails, and scalp must be numbered in the millions. In the United States alone it has been estimated that public expenditures for ringworm medications approximate \$25,000,000 per year (L. Ajello, unpublished data). The severity of postwar epidemics of tinea caused Yugoslavia to organize a nationally directed campaign against ringworm diseases that involved the establishment of a Mycological Observation Center to carry out a massive screening and therapeutic program.³⁴

It is evident that dermatophytes are widely disseminated in the environment in all parts of the world and that human and animal infections are extremely numerous.

Discussion

This essay on the geographic distribution and prevalence of dermatophytes has been an attempt to accomplish an impossible task: to draw a picture of a dynamic situation. The patterns of geographic distribution and prevalence of dermatophytes are not fixed. They are constantly changing under the influences of various forces such as climate, man's social and anti-social activities, his cultural habits, his migrations, and developments in therapy. Two world wars have produced changes that the present generation of medical mycologists are still observing. The prevalence of tinea pedis in-

creased tremendously in the male population of Europe and the United States as a direct consequence of wartime conditions. The communal life of the military and reduced opportunities for maintaining high personal standards of hygiene created conditions that lowered resistance to infection and increased the opportunity for transfer of infections. In addition the warm humid climatic conditions found in the Pacific Theatre during World War II exacerbated previously existing ringworm infections and favored the spread of infection.

Civilian populations were also affected as large scale epidemics of tinea capitis broke out in many countries of the world. This brought about a change in the relative prevalence of species. In the United States, *M. audouinii* replaced *M. canis* as the predominant agent of tinea capitis.²⁷ Reports from Europe and the United States document a similar change in the relationship between *T. mentagrophytes* and *T. rubrum*. *T. rubrum* infections have significantly increased in number since World War II, with the result that they outnumber those caused by *T. mentagrophytes*.^{28, 29}

The late war is also responsible for the development of endemic foci of *T. ferrugineum* in the western part of the Union of Soviet Socialist Republics, Poland, Hungary and Czechoslovakia. Soldiers returning from the Far Eastern Front and Korean orphans given asylum in Eastern Europe who were infected by this dermatophyte introduced *T. ferrugineum* and it became established in the native population.

In the United States migrations of farm laborers from Mexico and immigrants from Puerto Rico introduced *T. tonsurans* into the country on such a massive scale that this dermatophyte has become established in the native population.

The vast slave trade of the Fifteenth to the Nineteenth Centuries that brought millions of Africans into the Americas undoubtedly introduced new dermatophyte species into the New World. However at this late date it is impossible to cite specific examples with the possible exception of *T. ferrugineum* and *T. soudanense*.

The geographic distribution of *T. concentricum* may be of anthropological significance. This fungus is widespread among the inhabitants of Polynesia and the countries bordering the western shores of the Pacific Ocean. However it is only a sporadic parasite of Indians living in the tropical forests of Brazil, Guatemala, Mexico and San Salvador. The disparity in prevalence between the Asian endemic areas and those of Latin America leads me to speculate that the fungus was introduced from Asia into the New World. If this supposition has validity it tends to contradict Thor Heyerdahl's thesis that Polynesia was populated by pre-Columbian South American voyagers.³⁵

Social habits also influence the occurrence of dermatophyte infections. Shoe-wearing people are apt to develop tinea pedis to a greater extent than those who customarily walk barefooted. Other habits such as the use of vegetable oils as hair dressing may account for the rarity of tinea capitis in India in contrast to the situation that prevails in European countries, the United States and elsewhere.

As the dermatomycoses affected more and more of the world's population vigorous measures to stop the spread of infection and to institute therapy were

taken. Significant decreases in the prevalence of infections have been brought about by X ray treatment of tinea capitis in Europe. Recently the antibiotic griseofulvin has been shown to be effective in curing all types of ringworm infection. If its therapeutic promise is sustained, the geographic distribution of the dermatophytes and the prevalence of infections will be changed radically in a few years.

Note. Since this manuscript was submitted for publication J. C. Gentles, University of Glasgow, Department of Medical Mycology, Anderson College, Glasgow, Scotland, informed me that he had received several cultures of *U. manum* isolated from pigs in Kenya, Africa. Their identification was verified by L. K. Georg of this laboratory.

References

1. KAPLAN, W. L., K. GEORG & J. AJELLO. 1958. Recent developments in an mal ring worm and the public health implications. *Ann N Y Acad Sci* 70(3): 636-649.
2. FUENTES, C. A. 1956. A new species of *Microsporum*. *Mycologia* 48: 613-614.
3. SILVA, M. & R. W. BENHAM. 1952. Nutritional studies of the dermatophytes with special reference to *Trichophyton megnini* (Blanchard 1896) and *Trichophyton gallinae* (Mugn 1881). *Comb Nov J Invest Dermatol* 18: 453-472.
4. GEORG, L. K. 1952. Cultural and nutritional studies of *Trichophyton gallinae* and *Trichophyton megnini*. *Mycologia* 44: 470-492.
5. SYLVEST, B. 1949. The incidence of dermatophytes in Denmark. *Acta Dermatovenereol* 225-232.
6. MARSELAU, V. 1955. Sur une onychomycose à *Trichophyton rosaceum*. *Ann Inst Pasteur* 188: 265-267.
7. GOTZ, 1952. Klinische und experimentelle Untersuchungen über die Hautpilzkrankheiten im Gebiet von Hamburg 1948-1950. *Arch Dermatol und Syphilol* 195: 1-76.
8. DUNCAN, J. T. 1945. Cultivation and identification of ringworm fungi. *Mon Bull Ministry of Health* 4: 93-96.
9. NÉKÁM, L. & P. POLOKAR. 1951. L'emploi de la vitamine K dans le traitement des dermatomycoses profondes. *Acta Dermatol Venereol Stockh* 31: 344-348.
10. PINETTI, P. 1948. Studi sulla biologia dei dermatomyceti. *Mycopathologia* 4: 222-234.
11. MUIJS, D. 1916. *Trichophyton rosaceum*. *Ned Tijdschr Geneesk* 60: 1985-1992.
12. DA FONSECA, A. 1954. Estudo epidemiológico da tinea do couro cabeludo no norte de Portugal. In: *Inquérito e factores epidemiológicos*. *Medico* 1954: 165-168.
13. ARJEVITCH, A. M. & V. N. PEVROKOVSKAYA. 1952. *Trichophyton rosaceum* as agent of beard and mustache trichophytosis. *Vestnik Venerol i Dermatol* 5: 18-21.
14. PEREIRO MIGUEZ, M. 1954. Etiología de los tinias. *Acta Dermatol Sifilol Madrid* 8: 18.
15. CATANZI, A. 1933. Étude sur les teignes. *Arch Inst Pasteur* 11: 267-399.
16. COCHET, G. M., D. BOIS, S. DEBLOCK, J. M. DOBY & C. VAIVA. 1957. Contribution à la connaissance des teignes infantiles du Cameroun. *Ann parasitol humaine et comparée* 580-589.
17. JOYEUX, C. 1912. Sur le *Trichophyton soudanense* n. sp. *Compt rend soc biol* 77: 15-16.
18. CLARKE, G. H. & J. WALKER. 1953. Superficial fungus infections in Nigeria. *Trop Med Hyg* 56: 117-121.
19. NUNES ANDRADE, R. 1954. Tinea imbricata. *Gac med Méx* 50: 265-276.
20. LURIE, H. I. 1955. Fungal diseases in South Africa. *S African Med J* 29: 186-188.
21. GEORG, L. K. & L. B. CAMP. 1957. Routine nutritional tests for the identification of dermatophytes. *J Bacteriol* 74: 113-121.
22. PIJPER, A. 1918. Tinea imbricata in South Africa. *J Trop Med Hyg* 21: 45-47.
23. LEITE, V. S. B., D. L. Z. & V. DE MEIRA. 1947. Favus among Angola Negroes. *Acta Dermatol Sifilol* 38: 1173-1178.
24. VANBREUSEGHEM, R. 1950. Étude de 136 souches de *Trichophyton ferrugineum* (Ota 1921) Langeron et M. Iochevitch 1930 et de sa variété blanche isolées au Congo Belge. *Ann Parasitol* 25: 485-492.
25. DE MEIRA, V. T. V., J. P. NOGUEIRA & T. S. SIMÕES. 1959. Tinhas humanas em Cabo Verde. *Anais Inst med trop* 5: 867-877.
26. MU, J. W. & T. J. KUROKAWA. 1939. Statistical and mycological studies of dermatomycoses observed in Peiping. *Chinese Med J* 55: 201-219.

- 27 LEWIS, G M M I HOPFER J W WILSON & O A PELLAPATT 1958 An introduction to medical mycology 49 Year Book Publ Chicago III
- 28 DEY N C 1953 A review of ringworm of the hair in India Indian Med Gaz 88 194-196
- 29 TAKAYE M 1925 Studien über die Trichophyten in Japan Tohoku J Exptl Med 6 75-129
- 30 GRIN E I & L OZEGOVIC 1959 Problemi attuali delle dermatomycosi in Jugoslavia Minerva med 50 1245-1251
- 31 LANGER J 1953 *Mikrosporon ferrugineum* jeho proni izolace na uzemi nasi republiky Ces Dermatol 28 446-452
- 32 SEDLACEK V 1955 *Mikrosporon ferrugineum* detskych kolektinech Ces Pediat 10 756-760
- 33 LINETTI P 1957 La flora dermatomicetica d'Italia Rass med sarda 59 47-65
- 34 SLOVIMISAL L V 1957 Data relating to the study of species of the causative agents of dermatomycoses in the Uzbek SSR Voprosy Dermatol Venerol (Tashkent) 6 53-56
- 35 BRIL M 1951 A *Trichophyton* (*Microsporon*) *ferrugineum* epidemic in south east Serbia Med Prakt 9-10 32-38
- 36 TALICE, R V 1931 Sur une souche de *Trichophyton ferrugineum* (Ota 1921) (*Microsporum ferrugineum* Ota, 1912) isolée à Montevideo Ann parasitol humaine et comparée 9 77-85
- 37 DI MIGNA M & M J MARPLES 1954 *Microsporum distortum* sp nov for New Zealand Trans Brit Mycol Soc 37 372-374
- 38 KAPLAN W L & GEORG S L HENDRICKS & R A LEPPER 1957 Isolation of *Microsporum distortum* from animals in the United States J Invest Dermatol 11 449-453
- 39 BROOKS B F J H ALLI & C C CAMPBELL 1959 Isolation of *Microsporum distortum* from a human case J Invest Dermatol 33 23-26
- 40 GEORG L K W KAPLAN & L B CAMP 1957 Equine ringworm with special reference to *Trichophyton equinum* Am J Vet Research 18 798-810
- 41 NEGRONI P 1942 Dermatomicosis Diagnostico y Tratamiento Aniceto Lopez Buenos Aires Argentina
- 42 PEREIRO MIGLENS M 1958 La micología en España Revision de la bibliografía desde el año 1946 al 1956 Mycopathol 11 Mycol Appl 9 23-44
- 43 GEORG L K W KAPLAN L AJELLO W M WILLIAMSON & E B TILDEN 1959 The parasitic nature of the soil fungus *Aeratinomyces ajelloi* J Invest Dermatol 32 539-544
- 44 MATA L & G G MATA 1959 Demonstracion de *Microsporum gypsum* y *Aeratinomyces ajelloi* en suelos de Costa Rica Rev Biol Trop 7 119-123
- 45 RIETH H & A Y EL FIKI 1959 Dermatomykose beim Pferd durch *Aeratinomyces ajelloi* Vanbreuseghem 1952 Bull Pharmacol Research Inst 11 1-6
- 46 BANKEGY J 1959 Occurrence of *Microsporum gypsum* and *Aeratinomyces ajelloi* in Hungarian soil Ann Univ Sci Budapest 2 37-42
- 47 EVOLCEANU R & I ALTERAS 1959 Considerations à propos des caractères mycologiques et pathogéniques du *Aeratinomyces ajelloi* Vanbreuseghem 1952 saprophyte du sol Mycopathol et Mycol Appl 11 196-204
- 48 KOMIMAMI M 1957 A survey of keratinolytic or keratinophilic molds from soil in Japan Tohoku J Exptl Med 66 233-237
- 49 AJELLO L 1953 The dermatophyte *Microsporum gypsum* as a saprophyte and parasite J Invest Dermatol 21 157-171
- 50 DURIE E H & D M GREY 1955 Isolation of *Microsporum gypsum* and *Aeratinomyces ajelloi* from Australian soil Nature 176 936
- 51 DEY N C & L M KAROTI 1955 *Microsporum gypsum* in India J Indian Med Assoc 25 160-164
- 52 FUENTES C A Z E BOSCH & C C BOUDER 1955 The isolation of *Microsporum gypsum* from soil Arch Dermatol and Syphilol 71 684-687
- 53 GRIN E I & L OZEGOVIC 1957 *Microsporum gypsum* kao parazit i saprofit izoliran iz zemlje Naucno Drustvo N R Bosne i Hercegovine 8 5-11
- 54 HEJTMANEK M 1957 Saprofytická stadia dermatofytu v přírodě Biologia (Czechoslovakia) 12 928-938
- 55 HEJTMANEK M 1958 Dermatofyta v puđe Hrubého Jeseniku Přírodov sb Ostr kraje 19 1-6
- 56 HEJTMANEK M 1958 Príspevky k epidemiologii dermatomykos II Dermatofyt *Microsporum gypsum* v puđe na Morave Acta Univ Olomucensis 14 39-45
- 57 RODRIGUEZ M 1958 Aislamiento de hongos patogenos del suelo Rev ecuador hig y med trop (Guayaquil) 15 5-12

- 58 MATA L & G G DE MATA 1959 Demonstración de *Microsporum gypsum* y *Keratinomyces ajelloi* en suelos de Costa Rica. Rev Bol Trop 7 119-123
- 59 DOUPAGNE P 1959 Isolement de *Microsporum gypsum* du sol et de guano au Congo belge. Ann Soc belge méd trop 39 281-286
- 60 CAPRETTI C 1959 *Microsporum gypsum* dermatofito geofílico. Comprobación de su presencia en muestras de suelo recogidas en la ciudad de Mérida. Rev fac farm (Venezuela) 1 89-96
- 61 MACHOFFIE L P S F PENNY & E C BECK 1948 Ringworm of the scalp in Ottawa. Public School Children 1946-1947. Can J Public Health 39 89-94
- 62 SCHWARZ J & G I BAUM 1957 A critical review of medical mycology in the United States 1946-1956. Mycopathol et Mycol Appl 8 271-326
- 63 GONZALEZ OCHOA A & B ROMO VAZQUEZ 1945 Dermatofitos causantes de tina de la piel cabelluda en la ciudad de México. Rev inst salubridad y enfermedad trop Mex 6 145-148
- 64 PARDO CASTELLO V & M TRESPALACIOS 1959 Superficial and deep mycoses in Cuba. Southern Med J 52 7-15
- 65 CARRION A L & M SILVA 1944 Ringworm of the scalp in Puerto Rico. Puerto Rico J Public Health Trop Med 20 329-391
- 66 NEGRONT P 1936 The status of diseases caused by fungi in Argentina. Bull Intern Soc Human and Animal Mycol 1 15-16
- 67 DE ALMEIDA F C S LACAZ & O COSTA 1948-1949 Dados estatísticos sobre as principais mucoses humanas observadas em nosso meio. Anais fac med univ Sao Paulo 24 39-62
- 68 VACCARO H & A HONORATO 1949 Hongos productores de tinas en la provincia de Valparaíso. Rev med Valparaíso 2 75-89
- 69 AGUILAR CELI P 1948 Contribución al estudio botánico y clínico de las tinas en el Perú. Rev Med Exptl 7 70-93
- 70 MACKINNON J E 1949 Estadística sobre 1000 casos de micosis cutáneas en el Uruguay y determinación de las especies causantes. Ann inst hig Montevideo 8 83-94
- 71 BORELLI D 1956 Cenni di micopatologia venezueliana. Giorn ital dermatol e sifilol 6 507-526
- 72 SYLVEST B 1949 The incidence of dermatophytes in Denmark. Acta Dermato Venereol 29 225-232
- 73 PATIALA R & S HARO 1950 Review of fungi found on the skin on the basis of the 1948 material. Karstenia 1 48-59
- 74 COUDERT J & J C DOLLET 1950 Fréquence actuelle des teignes dans la région Lyonnaise. Ann Dermatol Syphilol 10 524-527
- 75 CARLIER G I M 1954 An eight year survey of the ringworm flora of Birmingham. J Hyg 62 264-271
- 76 BIGGAARD FRANTZEN H 1952 Om forekomst af ichthyosis vulgaris onychogryphosis dupuytren kontrakturer og favus i Grønland. Ugeskrift Laeger 114 812-815
- 77 PINETTI P 1959 Distribuzione e diffusione di *Trichophyton violaceum* (Bodin) nelle diverse parti del mondo. Rass med sarda 61 293-322
- 78 ESTEVES J 1953 Alguma característica etiológica da endemia portuguesa de tina. O Medico 4 831-832
- 79 KASHKIN P N 1959 Review of works on medical mycology published in the U.S.S.R. between 1946-1956. Mycopathol et Mycol Appl 10 227-268
- 80 PEREIRO MIGLENS M 1959 Estudio estadístico de las mucosis en Galicia. Acta Dermatol Sifilol 60 273-275
- 81 PEÑA LAÑEZ J 1953 Contribución al estudio de la epidemiología de las tinas en España. Rev sanidad e hig Pub 21 30
- 82 COUTELIN F G COCHET J BIGRET S MILLET M DOBRY DUBOIS & S DEBLOCK 1956 Contribution à la connaissance épidémiologique et mycologique des teignes infantiles de Tunisie. Ann parasitol humaine comparée 31 449-469
- 83 VANBREUSEGHEM R & F GATTI 1955 Enquête sur l'incidence des teignes du cuir chevelu chez les indigènes du Congo Belge. Ann soc belge med trop 35 805-816
- 84 DE VIRA M T V J P NOGUEIRA & T S SIMÕES 1958 Tinas humanas em Cabo Verde. Anais inst med trop 15 867 869 871 872 873-877
- 85 RAO V 1957 Fungus disease in India. Bull Calcutta School Trop Med 5 76-79
- 86 ANSARI N & M IAGHIH 1951 Determination of dermatophytes agents of teignes du cuir chevelu à Teheran. Ann Parasitol 26 245-253
- 87 SACHER F 1947 The laboratory aspect of fungus diseases of the skin and hair. Acta Med Orient 3 68-78
- 88 TAKAHASHI Y 1957 Medical mycology in Japan. Bull Intern Soc Human & Animal Mycol 3 11-13

- 89 FAKEN H. 1958 A survey of the dermatomycoses in Turkey Turk Ijyen Tecrub Biyoloji Deryisi 11 275-281
- 90 DURIE E. H. & S. BROWN. 1953 Fungous infections in hospital practice Med J Australia 40 813-814
- 91 MARPLES M. J. 1958 A critical survey of medical and veterinary mycology in New Zealand from 1946-1956 Mycopathol et Mycol Appl 9 45-55
- 92 CAJKOVAC S. 1958 Medical mycology in Yugoslavia Bull. Intern. Soc. Human and Animal Mycol 3 9-11
- 93 GRIMMER H. 1956 Der Wandel der Epidemiologie der Epidermophyten in den Jahren von 1952 bis 1956 in Berlin Arch klin u exptl Dermatol 203 125-129
- 94 MASAKI I. L. C. L. TASHIROJIAN & A. G. FRANKS. 1957 The etiology of dermatomycoses. Shift from *Trichophyton mentagrophytes* to *Trichophyton erenum* 1953-1954 Arch Dermatol and Syphilol 76 66-69
- 95 HEYERDAHL, T. 1950 Hon Tiki Across the Pacific by Raft Rand McNally Chicago Ill
- 96 GENTLES J. C. 1958 Experimental ringworm in guinea pigs oral treatment with griseofulvin Nature 182 476-477
- 97 BLANK H. & F. J. ROTH. 1959 The treatment of dermatomycoses with orally administered griseofulvin Arch Dermatol and Syphilol 79 259-266
- 98 KAPLAN W. & L. VJELLO. 1959 Oral treatment of spontaneous ringworm in cats with griseofulvin J Am Vet Assoc 135 253-261

THE EFFECTS OF CORTISONE ON EXPERIMENTAL FUNGUS INFECTIONS*

Donald H. Louria and Harry G. Browne

Infectious Disease Laboratory, Second (Cornell) Medical Division, Bellevue Hospital and the Department of Pathology, The New York Hospital-Cornell Medical Center
New York, N. Y.

The administration of adrenal glucocorticoids clearly enhances experimental infections due to a wide variety of microbial agents¹. Numerous studies have been performed in which fungi have been used as the challenge microorganism. In most of these investigations enhancement of infection was observed²⁻⁵.

Although these studies offered definite evidence that adrenal steroids can augment experimental mycotic infections, they did not provide information as to the relative propensity for various fungi to spread under the influence of cortisone and did not adduce convincing data on the mechanisms of steroid action.

The experiments summarized below were designed to delineate differences among fungi in the extent of cortisone enhancement. Groups of mice were infected intravenously with one of three fungi that had been recovered from infections in man.

Histoplasma capsulatum strain 6624, was isolated from a patient with disseminated histoplasmosis in 1952. *Cryptococcus neoformans*, strain 1148, a large capsule strain was recovered from the cerebrospinal fluid of a patient with chronic meningitis in 1954. *Candida albicans*, strain 851, had been cultured from the oropharynx of a patient with mucocutaneous moniliasis in 1956. These 3 strains had not altered in animal pathogenicity during serial passage on Sabouraud's agar. The inoculum size varied from 3×10^4 to 10^7 cells per mouse. Cortisone was administered in dosages of 0.1 to 20 mg intraperitoneally or subcutaneously. The experimental period varied from 28 to 35 days.

When cortisone was administered intraperitoneally starting 6 days prior to or the day after infection with *H. capsulatum* and was continued daily for 28 days after infection, the over all mortality and the rapidity of death were similar in cortisone treated and control animals at each inoculum.

The results with *cryptococcus* were similar. No increase in over all mortality and no alteration in the rapidity of death occurred in cortisone treated mice infected with various inocula from 2×10^4 to 2.5×10^6 cells.

The results were strikingly different in mice infected with *C. albicans*. A marked increase in mortality occurred in cortisone treated mice infected intravenously with 1×10^6 to 5×10^6 cells. Thus when 0.5 to 20 mg of cortisone was administered daily, starting 2 to 6 days prior to infection with 5×10^6 cells, the mortality was 10 per cent in normal mice and 90 per cent in cortisone treated animals. When treatment was started the day after infection, the mortality was 70 per cent. The administration of small amounts of cortisone produced no significant increase in mortality.

* The work described in this paper was supported in part by Grant E-2659 and Training Grant E-6 from the National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md., the Chas. Pfizer Co., Inc., Brooklyn, N. Y., The Health Research Council, New York, N. Y., and The New York Trudeau Society, New York, N. Y.

It seemed clear that, under similar experimental conditions, cortisone enhanced monilia infections to a far greater degree than infections due to *H. capsulatum* or *C. neoformans*.

Studies were then designed to analyze the tissue site of cortisone augmentation of mouse moniliasis, and to analyze the mechanisms underlying such enhancement.

Fungus census was determined in various tissues of control mice 5 min to 60 days after infection with 1×10^5 to 5×10^6 cells. Progression of infection occurred only in the kidneys with these inocula, and clearance of fungi was slowest in this organ. Thus, in 14 to 23 per cent of normal mice, renal census rose during the first 2 weeks of infection more than 2 standard deviations above the mean observed during the initial 24 hours of infection. In most mice, *Candida* populations remained stationary or fell progressively.

In the liver, spleen, heart, lung, and brain there was a progressive fall in fungus census, so that 2 weeks after infection all tissues were sterile.

When 0.5 mg of cortisone was given, starting 2 days prior to or the day following infection and was continued until 7 days after infection there was a marked and uniform elevation of renal census. The administration of 0.1 mg of cortisone was not associated with significant increase in kidney titers.

This is shown in FIGURE 1, which depicts studies in which an inoculum of 10^6 cells was employed. Renal populations were determined at the termination of steroid therapy.

In contrast, there was no evidence of progression of infection in the liver, lung, spleen and brains. The administration of cortisone delayed fungus clearance, but in no animal was there evidence of significant increase in fungus titers as compared to those found 24 hours after infection.

Studies on the lung and liver are summarized in FIGURE 2.

The results of population studies on the heart were slightly different. In 5 per cent of animals, there was clear increase in *Candida* titers under the influence of cortisone. In the other 95 per cent clearance was commonly delayed but monilia census did not increase as compared to those found during the first 24 hours of infections.

Thus, in cortisone-treated mice, progression of infection was confined almost exclusively to the kidneys, the organ of maximum infection in normal mice. Further tissue census studies were performed in cortisone-treated moribund mice dying within the first 7 days of infection with 5×10^6 cells. Increase in monilia titers was maximum in the kidneys but also occurred to a significant degree with regularity in the heart.

The bacteriological investigations summarized above suggested that there must be something unique in the host-parasite relationship within the kidneys to establish this organ as the only site of progressive infection in normal mice and as the site of maximum enhancement in cortisonized animals.

Therefore, serial histological studies were made of many tissues from normal and steroid-treated animals including heart, lung, brain, kidney, liver, spleen, muscle, adrenals, and pancreas. The findings appear to offer a plausible explanation for the renal localization of experimental moniliasis.

Following intravenous injection of 10^6 to 5×10^6 cells in normal mice, fungus cells were trapped in the capillaries of all tissues studied. During the

first 12 hours of infection the fungus multiplied within these vessels and then broke into the interstitial tissues, where growth continued. A considerable polymorphonuclear leukocyte response occurred rapidly, and fungi could be seen to be phagocytized by leukocytes within 30 min of inoculation. Morphologic events were similar in all tissues during the first few hours of infection.

Thereafter, histological events in the kidney were strikingly different from those in any other tissue studied. Twelve to 24 hours after infection, fungi in




FIGURE 1 Effect of cortisone on kidney populations in mice infected I V with 10^4 cells of *Candida albicans*. Cortisone was administered subcutaneously 2 days prior to or on the day following infection and was continued daily until sacrifice 7 days after infection.

the interstitial tissues of the kidney ruptured into both cortical and medullary tubules. Intratubular residence appeared to protect the fungus from host cellular defenses. The *Candida* cells grew rapidly within the intratubular environment and formed long filaments. This growth was not associated with significant leukocyte infiltration into tubular lumens.

Only when the fungus ruptured back into the interstitial tissue were host defenses effective. Then massive polymorphonuclear leukocyte reaction and abscess formation occurred. The extent of intratubular growth appeared to determine the outcome of the infection. When it was limited abscesses healed and the mouse recovered. When it was extensive large coalescent ab-

cesses formed, with severe reduction in the amount of viable renal tissue and subsequent death of the animal. In normal mice infected with up to 5×10^6 cells, extensive intratubular rupture and growth were uncommon.




FIGURE 2 Effect of cortisone on liver and lung populations in mice infected I.V. with 10^6 cells of *Candida albicans*. Cortisone was administered in dosage of 0.5 mg. per day beginning 2 days prior to infection and was continued until sacrifice 7 days after infection.

In all other tissues studied there appeared to be no site for protected fungus growth. Polymorphonuclear leukocytes appeared in large numbers and appeared to contain the infection. Host defenses invariably prevailed with steady regression of lesions between 24 and 72 hours after inoculation.

In cortisone treated mice, candida growth was increased in interstitial areas of all tissues and this was associated with an increased inflammatory response.

during the first 12 hours of infection. The enhanced interstitial growth was accompanied by a marked increase in the extent of rupture of fungus cells into renal tubular lumens. Subsequent abscess formation was likewise strikingly increased. The greater degree of intratubular residence and consequent abscess formation appeared adequate to explain the increased kidney *Candida* census, as well as the increased mortality in steroid treated animals.

The enhanced interstitial monilia growth and augmented cellular response in other tissues were associated with limitation and eventual eradication of the parasite, although this occurred somewhat slower than in normal animals.

Thus, it would appear that the renal localization of moniliasis in normal mice and the limitation of enhanced infection almost exclusively to the kidneys in cortisone treated mice infected with strain 851 can be explained readily by the ability of the parasite to gain access to the renal tubular lumen and to grow within this protected site. This hypothesis as to the pathogenesis and localization of *Candida* infections is summarized in FIGURE 3.




FIGURE 3 The pathogenesis of *Candida* infections in normal and cortisone treated mice

These studies were performed as indicated, with a single strain of *C. albicans*. This strain is considerably less virulent for mice than other strains such as the Fuentes strain used by Adriano and Schwarz¹⁰ or those studied by Blyth,^{11, 12} which produced significant mortality after the intravenous or intraperitoneal inoculation of 10^5 cells into normal animals. The kidneys, according to these histological investigations, were the site of major involvement. The renal lesions reported in Blyth's studies on normal mice were very similar to those described in the present experiments in mice treated with cortisone. The histological abnormalities observed following inoculation of strain 851 into normal mice were also similar to those noted by Blyth, but were far less extensive.

In mice dying within 2 to 4 days of infection with the more virulent strains, however, extensive lesions were also found in the heart and, in the case of the Fuentes strain, in the brain. It is of interest that similar myocardial pathology was seen in our studies only in cortisone treated mice dying within 7 days of infection with 5×10^6 cells of strain 851.

Thus, the administration of cortisone to animals infected with less virulent strain 851 enhanced the pathogenicity so that lesions were produced in the kidney, the organ of maximum infection, and occasionally, in the heart, that

were similar in nature and extent to those seen in normal mice infected with more virulent strains. The mechanisms of renal localization of progressive infection in normal or cortisone-treated animals infected with less virulent strain 851 or normal mice inoculated with the more virulent strains of Blyth appear to be similar and, in each case, are related to intratubular residence and growth.

The development of long filamentous forms was characteristic of intratubular growth. In contrast, early interstitial multiplication in kidneys and other tissues examined was predominantly in the yeast phase with small pseudomycelia. The problems of dimorphism in the growth of fungus pathogens *in vitro* and *in vivo* has been a subject of considerable debate. Young¹¹ and Blyth¹² have stated that the mycelial phase is necessary for the progression of *Candida* infection within tissues. On the other hand, many authors have argued that pathogenic fungi exist within tissues of warm blooded animals in the yeast phase, and that this phase is necessary for pathogenicity. The mycelial phase is supposedly controlled more readily by host defenses. This thesis and the phenomenon of dimorphism have been well summarized by Sherr and Wewer¹³. Sherr has also offered the hypothesis that fungus infections may possibly be controlled by alteration in the environment and metabolism of the parasite to compel its transformation into the less pathogenic mycelial phase.¹⁴

Our studies do not answer the question of the relative importance of the yeast and filamentous forms in the pathogenicity of dimorphic fungi. They do suggest that the persistence of *Candida* in tissues appears to be at least partly related to the formation of filaments within tubular lumens. It appears perfectly evident on the other hand, that certain other fungi such as *H. capsulatum* or *C. immitis* are pathogenic almost invariably in the yeast phase. It seems likely, therefore, that both the mycelial and yeast can be of major importance in the persistence and progression of deep seated mycotic infections caused by fungi with dimorphic growth cycles. The relative importance of the two types of growth in individual mycotic infections would appear to be dependent on the environment created by the host for the parasite and on the nature and adaptability of the invading fungus. In experimental candidiasis due to strain 851 the host parasite interrelationship clearly favors the host in normal mice. The fungus can alter the host parasite relationship to favor persistence and, in some cases, progressive multiplication only by gaining access to the protected environment of the renal tubule and by forming long filaments in this site that subsequently form nonphagocytatable foci around which abscesses develop.

In the experiments described above, we have investigated the relatively late events, occurring at least 12 to 24 hours after infection, that appear to be unique to the host parasite relationship in moniliasis and determine the localization of candida infections to the kidneys in normal and cortisonized mice. These investigations have not dealt thoroughly with the early generalized increase in interstitial *Candida* growth and cellular response during the initial 12 hours of infection under the influence of cortisone. This augmented interstitial fungus multiplication appears to determine the extent of subsequent intratubular rupture and growth. The mechanisms underlying such an

hancement are probably not unique to candidiasis, but are applicable to the enhancing effects of steroids on many infections

Numerous theories have been proposed to explain the adverse effects of cortisone on infection. Each has some supporting experimental evidence. These hypotheses include decreased mobilization of phagocytes,¹⁴ diminished phagocytosis,¹⁷ impaired killing within phagocytes,¹⁸ depression of the inflammatory response,¹⁹ impaired reticuloendothelial function,²⁰ diminished antibody production,²¹ decreased circulating antibody or opsonins,²² abnormalities of antigen antibody interaction,²³ and decreased vascular permeability.²⁴ It is also possible that potassium depletion or altered carbohydrate metabolism may be of importance.

Preliminary quantitative studies of mouse myositis and peritonitis suggest that delayed mobilization of inflammatory cells may be of major significance. When 5×10^7 cells of *C. albicans* are injected intraperitoneally, the numbers of inflammatory cells appearing in the peritoneal fluid in cortisonized animals during the first 3 hours of infection vary from 15 to 40 per cent of those found in normal mice. Furthermore, killing within phagocytes appears impaired in cortisone-treated animals. Thus, slide cultures of infected muscle suggest that more fungi survive within and grow out of polymorphonuclear leukocytes after phagocytosis. Other experiments indicate that potassium deficiency, altered carbohydrate metabolism, impairment of circulating inhibitors of mononuclear growth, and dysfunction of the reticuloendothelial system are not major factors in cortisone enhancement.

In summary, cortisone enhances experimental *Candida* infections to a far greater degree than infections due to *H. capsulatum* or *C. neoformans*. Enhancement of infection is first generalized. This may be related to decreased mobilization of inflammatory cells and to dysfunction of polymorphonuclear phagocytes.

The subsequent limitation of progressive infection to the kidney, its limited occurrence in normal mice, and its uniform occurrence in cortisone-treated animals probably can be explained by the ability of the fungus to break into and proliferate within renal tubules, a site in which the fungus is protected from host-cellular defense mechanisms.

References

1. KAS, F. H. & M. FINLAND. 1953. Adrenocortical hormones in infections and immunity. *Ann. Rev. Microbiol.* 7: 361.
2. LEVINE, H. H., M. ZIMMERMAN & A. SCORZA. 1957. Experimental cryptococcosis (torulosis). *Am. J. Pathol.* 33: 385.
3. KÖNIGSBAUER, H. 1954. Über die Wirkung von Corton auf die Experimentelle Torulose und Chromoblastomycose. *Zentr. Bakteriell. Parasitenk.* 100: 637.
4. FARFELL, R. I., C. R. COLE, J. A. PRIOR & S. SASLAW. 1954. Experimental histoplasmosis. I. Methods for production of histoplasmosis in dogs. *Proc. Soc. Exptl. Biol. Med.* 88: 51.
5. MANKOWSKI, L. T. 1955. The influence of hormonal conditions on experimental fungus infection. In *Therapy of Fungus Diseases*, 90-99. Little Brown, Boston, Mass.
6. VOGEL, R. A., M. MICHAEL, JR. & A. TIMPE. 1955. Cortisone in experimental histoplasmosis. *Am. J. Pathol.* 31: 535.
7. SILVERTON, J. T., A. WERDER, J. FRIEDMAN, F. J. ROTH, JR., A. B. GRAHAM & O. J. MIRA. 1952. Cortisone and roentgen radiation in combination as synergistic agents for production of lethal infections. *Proc. Soc. Exptl. Biol. Med.* 80: 123.

- 8 SFLIGMANN F 1953 Enhancement of *Candida albicans* by antibiotics and cortisone Proc Soc Exptl Biol Med 83 778
- 9 RAEDAPLI P C CAVALLERE, M BOROSI G SALA & A AMIRA 1951 Infezione Sperimentale da Coccidioides Immitis e Steroidi Corticosteroidi Mycopathol et Mycol Appl 6 7
- 10 ADRIANO E M & J SCHWARZ 1955 Experimental moniliasis in mice Am J Pathol 31 859
- 11 BLYTH W 1958 Host parasite relationships in experimental moniliasis I *Candida albicans* Mycopathol et Mycol Appl 10 269
- 12 BLYTH W 1958 The influence of antibiotics on experimental moniliasis I Penicillin streptomycin chloramphenicol and viomycin Mycopathol et Mycol Appl 10 91
- 13 YOUNG, G 1958 The process of invasion and the persistence of *Candida albicans* injected intraperitoneally into mice J Infectious Diseases 102 114
- 14 SHERR G H & R H WEAVER 1953 The dimorphism phenomenon in yeasts Bacteriol Rev 17 51
- 15 SHERR G H 1952 Studies of the dimorphism mechanism in *Saccharomyces cerevisiae* Mycopathol et Mycol Appl 6 182
- 16 ROBINSON H J & A I SMITH 1953 The effect of adrenal cortical hormones in experimental infection Ann N Y Acad Sci 56(4) 757
- 17 CREFFA S B G I MAGNIN & C V SPASTONF 1951 Effect of ACTH and cortisone on phagocytosis Proc Soc Exptl Biol Med 77 704
- 18 CLAWSON B J & S T WERNBERG 1953 The effect of large doses of cortisone upon the ability of the reticulo-endothelial cells to phagocytose streptococci J Lab Clin Med 42 746
- 19 REBLICK J W & R C MELLINGER 1953 Interruption by topical cortisone of leukocytic cycles in acute inflammation in man Ann N Y Acad Sci 56(4) 715
- 20 THOMAS L 1953 Cortisone and infection Ann N Y Acad Sci 56(4) 799
- 21 STEVENSON A M & J M McKENNA 1957 Studies on antitoxin synthesis initiated *in vitro* J Exptl Med 107 537
- 22 BJØRNEBOE M E I FISCHL & H C STORER 1951 The effect of cortisone and adrenocorticotrophic hormone on the concentration of circulating antibody J Exptl Med 93 37
- 23 GERMUTH F G JR 1953 The mechanism of action of cortisone in experimental hypersensitivity II Hypersensitivity of the serum sickness type J Exptl Med 98 1
- 24 WYMAN L C G P FLITON & M H SHULMAN 1953 Direct observations on the circulation in the hamster cheek pouch in adrenal insufficiency and experimental hypercorticalism Ann N Y Acad Sci 56(4) 643

THE PATHOGENESIS OF 'EPIDEMIC' HISTOPLASMOSIS

J Schwarz

Clinical Laboratories Jewish Hospital Cincinnati Ohio

G L Baum

The Pulmonary Disease Section Veterans Administration Hospital and the Department of Medicine University of Cincinnati College of Medicine Cincinnati Ohio

H Floyd

Eugene Hughes Memorial Hospital Hamilton Ohio

Histoplasmosis has come to be recognized as an infectious disease of significant incidence in the endemic area. Its manifestations are protean and in most cases they mimic tuberculosis clinically, radiologically, and anatomically. Differentiation is possible by demonstration of a rising titer of complement fixing antibodies for *Histoplasma capsulatum* or, preferably, of *H capsulatum* by microscopy and culture.

The primary infection is caused by inhalation of spore containing dust and usually heals without major clinical symptomatology but frequently with massive calcification. This calcification may produce symptoms many years later.

The development of active disease, as in most infections depends greatly on the infective dose and virulence of the organism on the one hand and what is called the resistance of the patient on the other. Numerous cases of overwhelming infection with *Histoplasma* have been observed in the so called epidemics of histoplasmosis.¹⁻⁶ We have observed several such massive infections in the past two and one half years and find the principles revealed by these cases not only pertinent to the understanding of epidemics but also to understanding the pathogenesis of the disease.

In the first outbreak, which occurred in a rural community just outside of Cincinnati 3 persons (2 adults and 1 child) had entered an abandoned chicken house and spent several hours cleaning it. There was much dust, and all were exposed to it. In 7 to 10 days both of the adults were clinically ill, but only 1 had severe pulmonary and systemic symptoms. In 14 days the child developed symptoms. X rays of all 3 taken about 5 to 6 weeks after the exposure revealed diffuse miliary and nodular infiltrates throughout both lungs. In addition, the child had prominent hilar adenopathy. All 3 patients recovered after several weeks. 2 with hospitalization and amphotericin B therapy and 1 with no treatment. A high titer of complement fixing antibodies with a negative tuberculin skin reaction and conversion of a negative to a positive histoplasmin skin test reaction comprised the presumptive evidence of histoplasmosis in the child, and the clinical course and history made this diagnosis appear certain in the adults.

Three more cases, 2 in one family were seen in Hamilton Ohio and, although the relationship to the source of the organism was not established, the clinical picture combined with rising titer of complement fixing antibodies pointed unmistakably to the diagnosis. One of the 2 cases from the one family was a

12 year old girl. The only male dated the onset of his disease to 2 weeks following his cleaning out a chicken house. The patient C. K., is particularly noteworthy since he cleared his disease markedly, but developed a recurrence 2 years later. At this time a lung biopsy was done and revealed active granu-



FIGURE 1. Milk glass appearance due to extremely heavy pulmonary infiltrates in child L. T. after exposure. Marked hilar involvement.

lomatus lesions with yeast cells morphologically identical with *H. capsulatum*. The patient was then begun on treatment with amphotericin B and has responded clinically although X ray worsening has appeared to occur temporarily. Subsequent follow up has shown improvement.

Comments and Discussion

The history and X ray findings of the B people clearly follow the pattern of massive inhalation of spore containing dust observed in previous epidemics^{1,2}. The pathogenesis of the multiple foci would indicate 2 possibilities. One is

that these represent multiple primary foci due to the huge infective dose contained in dust entering the airway. The second is that there develops a single primary focus from which hematogenous dissemination occurs. The clinical picture and X ray experience undoubtedly point to the former. The




FIGURE 2. Widespread nodular lesions in both lung fields and heavy hilar infiltrates patient C. K. October 1956 (three weeks after exposure)

lesions appear 1 week to 10 days after exposure and are rather uniform in size and rather large when first seen. It is much more likely that this represents the appearance of multiple primary foci⁸ than multiple hematogenous foci. Multiple primary foci of similar appearance exist in dogs (M. Straub in preparation). This observation plus the sequence observed in case C. K. combined with the pulmonary biopsy strongly support this view.

We consider the isolated observation of the following case significant because

it represents the terminal stage (calcification) of a massive exposure to spore-containing dust. A 36-year old white male was shown in many medical meetings as a classic example of multiple pulmonary calcification supposedly related to mitral stenosis. At autopsy hundreds of uniformly calcified round foci 2 to 5 mm in diameter were found. We were very easily able to demon-




FIGURE 3 Marked improvement in December 1957

strate morphologically organisms of *H. capsulatum* in each of the numerous examined lesions. Microscopically all of the lesions showed a similar structure: a bony rim with calcification of the center. Frequently the bony rim had a cavity filled with bone marrow and the whole structure was surrounded by a considerable area of scar tissue. The scar formation clearly indicated that originally a perifocal inflammation had existed. Each of these lesions if seen alone would be indistinguishable from ordinary solitary primary foci seen in spontaneous human infections.

It therefore can be concluded that in a so-called epidemic the concentration of infectious material in the air is such that numerous simultaneous primary foci are formed in the pulmonary tissue. These foci undergo necrosis, calcification and even ossification.

It was a fortunate circumstance that in the case of C. K. a biopsy was taken



FIGURE 4 Relapse in April 1959

The active lesions in the lungs of this patient can be considered multiple primary foci. They represent a developmental stage which terminates in the formation of completely calcified foci with an osseous rim.

It is this terminal stage that was found to exist in the lungs of our patient C. K. who obviously many years after exposure died from cardiac complications unrelated to the infection with *H. capsulatum*.



FIGURE 5 Gross appearance of biopsy specimen, same patient




FIGURE 11 The individual foci were well circumscribed but active and yeast cells were demonstrated in all (same patient) Hematoxylin eosin $\times 25$



FIGURE 7 Multiple calcified foci in lung of patient with aortic stenosis. October 1970.
(C. K.)



FIGURE 8 X ray of inflated autopsy specimen (1953), same patient



FIG. 9a and 9b. Low magnification photomicrographs of tissue from a patient with epidemic histoplasmosis. The organisms are large, rounded, and pale-staining, surrounded by a dense cellular reaction. (a) and (b) are from the same field. $\times 35$.




FIGURE 10 Yeast cells 3 to 5μ in size were easily demonstrated in the focus of a Goett silver stain same patient $\times 600$

TABLE
CLINICAL CASES

Case	Age Sex Race	Clinical	X-ray	Tests	Complement fixation on antigen				Remarks
					Dates	Yeast	Mycel	Agar	
T F	42 W	12-23-1957 cleaned chicken house. Weight loss, weakness, tiredness, achng	1946 clear X-ray 12-1958 mildy densit es w/ spread		1-30-1959	Neg	Neg		
L T	28 W	12-23-1957 cleaned chicken house. Fever, anorexia, cough, weight loss 11-1-1959	1-29-1958 mildy nodular densit es severe		1-20-1958	1 128	1 32		Rx w th Ampho-teric n B
L T Jr	21½ W	12-23-1957 cleaned chicken house. Fever, nausea, weakened by 1-6-1958. Cleared by 1-22-1958	1-6-1958 mildy involvement w th hilar adenopathy	PPD No 1 neg histoplasma n neg 1 58 h sto-plasma n pos 2 26-1959	1-6-1958 1-28-1958	1 128 1 246	1 32		Rx w th Ampho-teric n B
L H	12 F	No symptoms at night in 1-1958	11-26-1956 hilar adenopathy 12-24-1956 10 gression w th LUL nfltrate 3-9-1957 LUL in filtrate resolving	PPD No 1 neg histoplasma n pos 1 58	1-4-1957	1 8	1 32		
B L	24 F	Weight loss, cough, fever, dyspnea, headache	11-21-1956 mass ve nodular infiltrate 11-29-1956 progression w h consolidation 12-8-1956 marked clearing 1-4-1957 no clearing	PPD No 2 neg histoplasma n positive	12-26-1956 1-23-1957	1 128 1 64	1 8 1 16		Very sick Rx O ₂ prior to chemo-therapy
C A	16 W	Cleaned chicken house. Flu-like syndrome cleared in 1 month	10-20-1956 mild nodular infiltrate 12-3-1956 slight improvement 12-31-1956 more clearing 12-4-1957 more clearing w th calc fcat on 9-4-1958 increase in size of lesions 1-5-1959 left in te increase 4-2-1959 marked increase in parenchymal and hilar lesions 5-6-1959 definite	PPD No 2 neg histoplasma n positive	11-30-1956 12-4-1956 1-10-1957 2-10-1959	1 64 1 32 1 32 1 64	1 32 1 8 ?		Rx w th Ampho-teric n B

Summary

Histoplasmosis is acquired by inhalation of spore containing dust. In special circumstances (massive infective dose) when the air becomes densely loaded with spores there occurs a special clinical, radiological, and anatomical picture, consisting of multiple primary foci in the lung. The majority of cases recover.

Seven examples of multiple widespread densities in the lung are given one definitely proved by biopsy to be active and one shown at autopsy to have multiple healed primary lesions. *Histoplasma* organisms were demonstrated microscopically in both.

References

1. ADRIANO S. J. SCHWARTZ & F. N. SILVERMAN. 1955. Epidemiologic studies in an outbreak of histoplasmosis. *J. Lab. Clin. Med.* 46: 592.
2. FERCOLOW M. L. 1958. Recent studies on the epidemiology of histoplasmosis. *Ann. N. Y. Acad. Sci.* 72(3): 129.
3. FERCOLOW M. L. & J. T. GRAVESTON. 1952. Nontuberculous chest diseases: occurrence of histoplasmosis in epidemics. *Trans. Natl. Tuberc. Assoc.* 48: 83.
4. LEHAN P. H. & M. L. FERCOLOW. 1957. Epidemic histoplasmosis. *J. Chronic Diseases* 8: 489.
5. MURRAY J. F. H. I. LERIES J. KAYE C. KOMINS R. BOROK & M. WAI. 1957. Benign pulmonary histoplasmosis (cave disease) in South Africa. *S. African Med. J.* 31: 245.
6. STRALB M. & J. SCHWARTZ. 1955. The healed primary complex in histoplasmosis. *Am. J. Clin. Pathol.* 22: 727.

Part II : Epidemiology, Biochemistry, and Physiology

THE OCCURRENCE OF *CANDIDA* AND OTHER YEASTS IN THE INTESTINAL TRACTS OF ANIMALS

N Van Uden

Department of Microbiology Botanical Institute University of Lisbon Lisbon Portugal

Yeasts are extremely widespread in nature. They can be isolated from almost any surface soil. They are also encountered in rivers and lakes and in the water and mud of the oceans and seas. Recently they were encountered regularly even by an Arctic expedition (Kriss 1955) that cultured water samples taken at a distance of about sixty miles from the North Pole.

In light of what is known about the nutritional requirements of yeasts this ubiquity is rather surprising. In fact the yeasts prefer, and in most cases exclusively use as carbon sources, simple carbohydrates that do not accumulate in appreciable amounts in soil and certainly not in sea water. A number of yeast species cannot attack naturally occurring carbohydrates other than glucose, mannose, and fructose. Many also use one or more other hexoses, pentoses, oligosaccharides, alcohols, organic acids, and related compounds, not too many are capable of breaking down starch or inulin, and a few have proteolytic or lipolytic capacity. However, the breaking down of compounds such as cellulose or lignin is already beyond the biochemical means of the yeasts. Therefore, it seems reasonable, as suggested by Lund (1954), that normally the multiplication of yeasts in soil is transitory or nonexistent. The soil would be a reservoir where yeasts survive while awaiting opportunities for invading their natural substrata. These natural substrata, including materials such as sweet fruits, decaying mushrooms, exudates of trees and flower and tree-visiting insects are rich in simple carbohydrates.

Simple carbohydrates are also readily available in the intestinal tract of animals where they are produced in the process of digestion or, as such are already present in ingested food. They are also readily available in amino acids which are happily accepted by yeasts as a source of nitrogen and of vitamins of the B group, one or more of which are required by a great many species of yeasts. There is normally a generous supply of these in the animal digestive tract and it appears quite understandable that several species of yeasts have become adapted to this comfortable environment.

Virtually nothing is known of the ecology of marine yeasts. Possibly the natural substrata of these yeasts are aquatic vegetables and animals that may supply adequate amounts of simple carbohydrates. Recently some preliminary evidence was obtained in my laboratory indicating that the intestinal tracts of fishes may constitute such a substratum.

I now propose to consider in some detail the yeasts that occur in the digestive tracts of certain terrestrial mammals and birds. Given the ubiquity of yeasts in nature their introduction with food and dirt into the digestive tract of humans and animals must be a daily occurrence. Those yeasts that resist the destructive action of the digestive enzymes will eventually appear alive in feces, from which they can be isolated. However, how can we

yeast isolated in this way is an habitual inhabitant of the digestive tract rather than a passer by sufficiently fortunate to escape from a dangerous environment?

A first approach to this problem is a qualitative survey intended to isolate and identify yeasts from not too small a number of specimens of the host species under study. The relative frequencies of the yeast species encountered as compared with their occurrence outside the animal body constitute a primary basis for the ecological classification of the intestinal yeasts.

In this way the intestinal yeast flora of man and to a much lesser extent of other warm blooded animals have been subjected to study for many years but unfortunately much of the older, and some of the more recent work has been executed with rather unsatisfactory techniques.

A first point of great practical importance is the choice of the isolation medium. Sabouraud's medium for example is not appropriate because it may lack essential growth factors needed by some true intestinal yeasts. Classic Sabouraud's medium prepared with maltose is still worse as many yeasts cannot use this sugar. A glucose peptone broth enriched with liver or yeast extract and made selective with antibiotics will suffice. The only known yeast that will not grow well in such a medium is *Saccharomycopsis guttulata* an inhabitant of the digestive tracts of rabbits.

A second point is concerned with growth temperature. Mycologists are very much accustomed to doing their isolation and identification work at room temperature and often this is satisfactory. However care should be taken under such circumstance not to conclude—as occasionally happens—that a yeast strain or any other fungus encountered is a saprophyte or even a pathogen of warm blooded animals when the strain is not even able to grow at the body temperature of its supposed host or victim. In so far as surveys on the intestinal yeast flora of warm blooded animals are concerned isolations should be done at about 37° C. In this way may passers by unable to grow at body temperature are eliminated a priori but there is another important reason for using this temperature. A few yeast species such as *Candida slooffii* and *Torulopsis pintolopesii* highly adapted to warm blooded hosts cannot be isolated at room temperature because their minimum temperature for growth is higher.

The third practical point that I shall stress is concerned with identification methods. That these methods should be sound is self evident. However until recently they were far from standardized and were based partly on erroneous concepts. At the time yeast taxonomy was still much confused. The identification of a yeast strain not belonging to one of a few well known species was sometimes a question of courage rather than knowledge. Consequently some of the older work on yeasts associated with man and animals must be regarded with suspicion. However even today occasional workers in the field do not seem to be aware of the progress that has been made in yeast taxonomy and identification methods. Certainly anyone who wishes to identify yeasts should find it worthwhile to make himself acquainted with the work of modern yeast monographers such as Lodder and Kreger van Rij (1952) in the Netherlands and Wickerham (1951) in the United States.

When the results of surveys done on large numbers of specimens of various warm blooded host species are compared it appears at once that certain yeast species are encountered much more frequently than others. We may suppose

that the former are true intestinal yeasts, whereas the others are concomitants that happen to be able to grow at body temperature and simultaneously to resist the destructive action of the digestive enzymes.

Within the group of true intestinal yeasts, that is, the yeasts for which the digestive tract is a natural habitat, two subdivisions are defined rather sharply: obligate saprophytes and facultative saprophytes. The former have their natural habitats exclusively in the digestive tracts of animals, the latter may grow under natural conditions also on certain substrata outside the bodies of animals. Within the group of obligately saprophytic intestinal yeasts, various degrees of host specificity and nutritional fastidiousness are found, and it would seem that these two characteristics are correlated.

S. guttulata represents an extreme type. This saprophyte of the rabbit's digestive tract although known since 1845 (Remak) has resisted for more than a century all efforts to grow it in pure culture. Only recently Parls (1956) and Shurine and Phaff (1958) succeeded, independently, in doing so. The latter two authors made a thorough study of this species and found among other interesting properties that the temperature range for growth of *S. guttulata* is rather narrow, being limited by the very high minimum temperature of 35° C.

Inability to grow at room temperature in a yeast species encountered regularly in the digestive tract constitutes the strongest evidence that the yeast in question is a true obligate saprophyte. This inability to grow at room temperature thus far has been found only in two other yeast species both identified in my laboratory.

C. slooffii (Van Uden and Carmo-Sousa 1957a) will not grow below 28° C. Although less fastidious than *S. guttulata* it is more so than ordinary yeasts. We found it to require biotin, pantothenate, inositol, niacin, pyridoxine, and threonine, and Cury informed us that a number of amino acids are also essential growth factors for this species. Its host specificity is somewhat less pronounced than that of *S. guttulata*. Whereas the latter seems to be exclusively an inhabitant of the rabbit and probably of the chinchilla, with an incidence of nearly 100 per cent, *C. slooffii* is a saprophyte of the domestic pig's digestive tract with an incidence of about 50 per cent. We have found this species also in African bush pigs (*Potamochoerus choeropotamus*) but not in two other relatives of the domestic pig: the wart hog (*Phacochoerus aethiopicus*) and the hippopotamus (*Hippopotamus amphibius*). Neither did we isolate this species from humans, baboons (*Papio cynocephalus*), African pied crows (*Corvus albus*), cattle, goats or sheep. The type strain however was isolated from 6 of 252 horses.

The other thermophilic species is *Torulopsis pintolopessi* (Van Uden, 1957). This yeast does not grow below 24° C. and is slightly less fastidious than *C. slooffii*. It is a frequent inhabitant of the digestive tracts of rats and from which it has been isolated by several investigators. It occurs also in other small rodents and in pigeons. A number of strains isolated from C. W. Immons from these birds proved to be *T. pintolopessi*. *Candida boydii*, a species that I described with Carmo-Sousa (1957), a strain isolated from the fecal contents of a cow, takes an intermediate position between the thermophilic fastidious

phytes and the other obligate saprophytes such as *C. albicans*, which grows easily at room temperature on ordinary culture media and can be isolated from a wide range of hosts. *C. botryna* grows slowly at 20° C. It has been isolated from cattle, swine, rodents, and turkeys. This does not mean necessarily that these four groups of animals are its true hosts. A yeast that is a true saprophyte of certain animal species may occur as a fortuitous concomitant in others. In this case also numbers are helpful. A single strain of *C. botryna* isolated from cattle (Van Uden and Carmo-Sousa, 1957) suggests that *C. botryna* is such a concomitant when occurring there, but an incidence of 14 per cent found in swine (Van Uden, Carmo-Sousa, and Farinha, 1958) strongly points to these animal species as natural hosts for *C. botryna*.

Recently Van der Walt (1957) described as *Saccharomyces telluris* a yeast that he had isolated from soil. Kreger-Van Rij (1958) discovered that this sporulating yeast is the perfect form of *C. botryna*. On the other hand, Shifrine and Phaff (1958) showed that *S. guttulata*, although incapable of vegetative growth below 35° C, will sporulate at room temperature and even at 18° C. These interesting findings permit the conclusion that these yeasts, although highly specialized for life in the digestive tract of warm blooded hosts, may form spores outside the animal body and survive as such. When these spores happen to find their way into the digestive tracts of the proper animal species vegetative growth will start again.

We now come to the problem of *C. albicans*. This species, unlike *S. guttulata*, *C. slooffii*, *T. pinolopsii*, *C. botryna*, and *S. telluris* is not distinguished by a high minimum growth temperature or unusual nutritional fastidiousness. Nevertheless it is a true obligate saprophyte of warm blooded animals and it has been isolated from substrata outside the animal body on a few occasions only. It should be worthwhile to determine whether *C. albicans* survives outside the animal body through its capacity, unique among the yeasts of forming chlamydospores.

The host specificity of *C. albicans* is of a low degree, and this species has been isolated from a wide range of hosts. However, before reporting the findings in the material studied in my laboratory, I herewith introduce the term total yeast index.

The total yeast index is the quotient of the total number of isolated strains and the total number of the individuals of the same host species sampled. This index number may become higher than 1 when more than one yeast species is isolated from a number of individuals. In addition to the total yeast index, a percentage number may be used to indicate the proportion of individuals found to harbor yeasts regardless of the number of different species isolated from each of them. As the incidence of a single yeast species, for example *C. albicans* can never be higher than 100 per cent in a group of host individuals, it can be expressed conveniently in a percentage number.

In this way TABLE I shows the total yeast indexes, the percentage numbers of positive individuals and the incidences of *C. albicans* found in our material.

It can be seen at once that under natural conditions big differences exist between the various host species with regard to the occurrence of yeasts in their digestive tracts. Not much is known of the factors that may determine the degree of suitability of warm blooded animals for harboring yeasts, but it

gestive tract In Portugal the three primary types of alimentation used in raising pigs showed the following correlation with the occurrence of *C. slooffii*: (1) most pigs that did not reveal the presence of *C. slooffii* had been kept on a green food diet, (2) most pigs with low cell numbers of *C. slooffii* throughout the digestive tract had been kept on a mixed diet, including refuse from the human kitchen and (3) most pigs with high counts for *C. slooffii* in one or more sites of the digestive tract had been kept on a grain diet chiefly corn. Consequently, it seems a promising proposition to direct more research in this direction that is the relationship between diet and the intestinal yeast flora.

In so far as *C. albicans* and its importance in pathology are concerned more knowledge of the factors influencing its occurrence in the normal digestive tract is desirable as there is evidence that the digestive tract is the base from which *C. albicans* launches most of its disease producing attacks. The best example studied is yeast vulvovaginitis. The question has been raised where may yeasts harmless or not enter the vagina? Yo Bwan Hie (1954) in a well-conducted study was able to show that feces are the principal source of infection and reinfection in yeast vulvovaginitis. Magara *et al* (1955) considered the urinary tract also as a reservoir from which the vagina might become infected and reinfected. Together with Meleiro de Sousa I studied this problem in Portuguese women. Correlation studies were done with the two species that in Portugal are more frequently isolated from the vagina *C. albicans* and *T. glabrata*.

Of 53 women with positive vaginal cultures for *C. albicans* 76 per cent had this yeast also in the feces. In a control group of 170 women with negative vaginal cultures only 25 per cent were positive for *C. albicans* in the feces. With *T. glabrata* a similar situation was encountered. Eighty two per cent of 21 women with positive vaginal cultures for *T. glabrata* were found to harbor this same species in the digestive tract whereas only 11 per cent in a control group of 204 women had positive fecal cultures for *T. glabrata*.

Still more pronounced was the correlation between the presence or absence of yeasts in the vagina and their simultaneous presence or absence in the urinary tract. Accordingly 54 per cent of 33 women with positive vaginal cultures also had positive urine cultures. Of a control group of 91 women only 2 per cent had yeasts in the urinary tract. Therefore it appeared that most women whose vaginas were infected with *C. albicans* or *T. glabrata* harbored simultaneously the same species in their digestive and their urinary tracts.

When the women were cleared of vaginal yeasts by local vaginal treatment cultures were done repeatedly from urine and feces and it was found in all cases that yeasts had disappeared spontaneously from the urinary tract within a few days whereas the occurrence of *C. albicans* or *T. glabrata* in the digestive tract was not influenced by the disappearance of these yeasts from the vagina. This strongly suggests that the digestive tract is an important source of infection in yeast vulvovaginitis whereas the urinary tract is invaded only secondarily from an infected vagina.

Finally I shall briefly discuss the kind of information we may obtain when intestinal yeasts are studied by the use of quantitative techniques.

In most cases intestinal yeast populations are not sufficiently dense to allow

fowls, and turkeys are natural hosts of *C. albicans*. Most reports give percentage numbers between 20 and 30 per cent. In a group of 225 Portuguese women we isolated *C. albicans* from the feces of 38 per cent of the individuals which is of about the same order. The fact that, bird species other than fowls and turkeys may also constitute suitable hosts for *C. albicans* is shown by our findings in African pied crows 111 per cent of which were positive for this yeast. Also certain members of the pig family, including domestic swine, African wart hogs and African bush pigs were on the higher side with regard to the incidence of *C. albicans*. However, even in animal groups with a very low total yeast index *C. albicans* was found. From 503 sheep only 34 yeast strains were obtained but of these 26 were *C. albicans*. Strangely, I found rather low incidences in 2 groups of East African natives. In a group of 100 men on a low animal protein diet only 12 per cent were found positive for *C. albicans*. In another group of 102 men on a high animal protein diet the incidence of *C. albicans* was still lower—only 4 per cent. It is well known that Americans of African ancestry are certainly not less prone to *C. albicans* invasion than Americans of European ancestry. Race may not be a satisfactory explanation for the low *C. albicans* incidences found in my two groups of East African men.

This brings us to an interesting problem. When a certain animal species apparently is a suitable host for a certain microorganism for example *C. albicans* why should only a proportion of the specimens belonging to this host species actually harbor the microorganism in question? Nothing is known of the importance that individual genetic differences may have for the host-*C. albicans* relationship but some factors that influence the capacity of humans to support growth of *C. albicans* are well known to medicine: pregnancy, diabetes, and treatment with broad spectrum antibiotics are some of these. Another point to consider is the chance of infection. However given the high incidence of *C. albicans* in humans every individual probably introduces *C. albicans* quite frequently into his digestive tract. Once again a factor of real influence may be the type of diet. The group of Africans with the incidence of only 4 per cent of *C. albicans* and the relatively low total yeast index of 0.79 had a high daily intake of animal proteins in the form of dried fish and game. The group with the *C. albicans* incidence of 12 per cent and the total yeast index of 1.30 lived almost entirely on a vegetarian diet. I do not feel it justifiable to conclude from this meagre evidence that the type of diet influences the incidence of *C. albicans* in the digestive tract but there is other evidence that points in the same direction.

Rolle and Mehnert (1957) found *S. guttulata* regularly in the stomachs of rabbits and chinchillas as long as the animals were on an uncooked vegetarian diet. On the contrary in the stomachs of rabbits and chinchillas on a milk diet no cells of *S. guttulata* were encountered.

In my laboratory some evidence was obtained that the occurrence of *C. slooffii* in the digestive tracts of swine is influenced by the type of food on which the pig lives. As already related *C. slooffii* occurred in the digestive tracts of about 50 per cent of the swine studied by us. In one group of 57 swine we gave attention to the type of diet on which the animals had been kept which in most cases is recognized easily from the aspect of the contents of the di-

gestive tract. In Portugal the three primary types of alimentation used in raising pigs showed the following correlation with the occurrence of *C. slooffii*: (1) most pigs that did not reveal the presence of *C. slooffii* had been kept on a green food diet, (2) most pigs with low cell numbers of *C. slooffii* throughout the digestive tract had been kept on a mixed diet, including refuse from the human kitchen, and (3) most pigs with high counts for *C. slooffii* in one or more sites of the digestive tract had been kept on a grain diet, chiefly corn. Consequently it seems a promising proposition to direct more research in this direction, that is, the relationship between diet and the intestinal yeast flora.

In so far as *C. albicans* and its importance in pathology are concerned more knowledge of the factors influencing its occurrence in the normal digestive tract is desirable, as there is evidence that the digestive tract is the base from which *C. albicans* launches most of its disease-producing attacks. The best example studied is yeast vulvovaginitis. The question has been raised: where may yeasts harmless or not enter the vagina? Yo Buan Hie (1954) in a well-conducted study was able to show that feces are the principal source of infection and reinfection in yeast vulvovaginitis. Magara *et al.* (1955) considered the urinary tract also as a reservoir from which the vagina might become infected and reinfected. Together with Meleiro de Sousa I studied this problem in Portuguese women. Correlation studies were done with the two species that in Portugal are more frequently isolated from the vagina, *C. albicans* and *T. glabrata*.

Of 55 women with positive vaginal cultures for *C. albicans* 76 per cent had this yeast also in the feces. In a control group of 170 women with negative vaginal cultures only 23 per cent were positive for *C. albicans* in the feces. With *T. glabrata* a similar situation was encountered. Eighty-two per cent of 21 women with positive vaginal cultures for *T. glabrata* were found to harbor this same species in the digestive tract, whereas only 11 per cent in a control group of 204 women had positive fecal cultures for *T. glabrata*.

Still more pronounced was the correlation between the presence or absence of yeasts in the vagina and their simultaneous presence or absence in the urinary tract. Accordingly 54 per cent of 33 women with positive vaginal cultures also had positive urine cultures. Of a control group of 91 women only 2 per cent had yeasts in the urinary tract. Therefore it appeared that most women whose vaginas were infected with *C. albicans* or *T. glabrata* harbored simultaneously the same species in their digestive and their urinary tracts.

When the women were cleared of vaginal yeasts by local vaginal treatment cultures were done repeatedly from urine and feces, and it was found in all cases that yeasts had disappeared spontaneously from the urinary tract within a few days, whereas the occurrence of *C. albicans* or *T. glabrata* in the digestive tract was not influenced by the disappearance of these yeasts from the vagina. This strongly suggests that the digestive tract is an important source of infection in yeast vulvovaginitis, whereas the urinary tract is invaded only secondarily from an infected vagina.

Finally I shall briefly discuss the kind of information we may obtain when intestinal yeasts are studied by the use of quantitative techniques.

In most cases intestinal yeast populations are not sufficiently dense to allow

a quantitative evaluation by the direct microscopic examination of intestinal contents. *S. guttulata* is an important exception. By the use of this simple semiquantitative method several investigators found that *S. guttulata* is adapted to life in the rabbit's stomach. There the vegetative cells propagate by budding. On passage through the digestive tract growth stops or is considerably reduced. For quantitative studies of other intestinal yeast species plate counts may be used. We conducted such studies with 57 pigs. One gram samples of intestinal contents were taken from the stomach, from three sites in the small intestine, from the cecum, and from the rectum.

In 27 animals *C. slooffii* was found in one or more sites in the digestive tract in numbers ranging from less than 300 to 9,000,000 cells/gm of wet content. Generally, the cell numbers of *C. slooffii* varied considerably from site to site in the digestive tract of the same animal. The trend was an increase of cell numbers in the oral-anal direction. The highest cell number found in each animal was obtained more often from rectal contents than from other sites of the digestive tract, and the second highest counts were most frequent in samples from the cecum.

Although *C. slooffii*, both qualitatively and quantitatively, was the prevailing yeast, in many cases other yeast species were found in appreciable numbers. However, only from 3 of the 57 animals were counts of more than 100 cells of *C. albicans* per gram wet intestinal content obtained. On the other hand, 3 species, *C. krusei*, *Pichia membranaefaciens*, and *Saccharomyces cerevisiae* appeared, their cell numbers ranging from more than 100 to more than 2 million/gm wet content in about 12 per cent of the animals.

Since these three yeasts are frequently encountered in food, their frequent occurrence in the digestive tracts of many warm blooded animal species therefore does not constitute in itself proof that they would be anything more than mere concomitants.

Even their occurrence in the digestive tract with high cell numbers does not constitute such proof, as the ingested food might have been heavily infested. However, as in *C. slooffii* and also in the three yeasts just mentioned, we found a cell number increase in the anal direction, with highest counts in the rectum. Therefore, it must be concluded that the latter multiply actively while passing through the digestive tract and therefore must be classified ecologically as facultative saprophytes of the digestive tracts of warm blooded animals.

Summary

The yeasts, although widespread in the soils and the seas seem adapted primarily to substrata where simple carbohydrates are readily available. The digestive tract of warm blooded animals is one of these.

Intestinal yeasts may be recognized through qualitative and quantitative surveys. Essentials for successful surveys include an isolation medium sufficiently rich in growth factors to support fastidious species such as, *C. slooffii*, an isolation temperature appropriate for thermophilic yeasts, and soundness of methods of identification.

The suitability of the digestive tract for yeasts depends on the host species and on individual factors, including type of diet. The following total yeast

indices (number of strains, number of individuals) have been found in my laboratory (the incidence of *C. albicans* is indicated in parentheses) African bush pigs (*Potamochoerus choeropotamus*), 200 (11 per cent), Portuguese women, 148 (38 per cent), African pied crows (*Cortus albus*), 134 (18 per cent), baboons (*Papio cynocephalus*), 131 (8 per cent), East Africans on a low animal protein diet, 130 (12 per cent), swine, 116 (9 per cent), East Africans on a high animal protein diet, 079 (4 per cent), horses, 058 (4 per cent), African wart hogs (*Phacochoerus aethiopicus*) 056 (22 per cent), cattle, 052 (0 per cent), hippopotami (*Hippopotamus amphibius*), 037 (0 per cent), sheep, 007 (4 per cent), and goats, 006 (1 per cent).

Yeasts occurring in digestive tracts may be divided into three ecological groups: (1) obligate saprophytes, (2) facultative saprophytes, and (3) passers-by.

Certain obligate saprophytes show a high degree of host specificity. *S. guttulata* is adapted to rabbits, *C. slooffii* to swine, *T. pintolopesii* to mice and other small rodents. Other true intestinal yeasts seem slightly better adapted to certain host species than to others. *C. albicans* is encountered more frequently in humans and certain birds than in other host species but was found with low incidences in two groups of East Africans.

Obligate saprophytes may survive outside the animal body as spores, whereas the other intestinal yeasts are more or less capable of growth outside the animal body.

The type of diet seems to influence considerably the density and the composition of intestinal yeast populations.

The human intestinal tract constitutes the principal source of vaginal infection from *C. albicans* and other yeasts, whereas the urinary tract is infected secondarily from an infected vagina.

Within the digestive tract different species may be adapted to different sites. Whereas *S. guttulata* has a preference for the stomach, *C. slooffii*, *C. krusei*, *P. membranaefaciens*, and *S. cerevisiae* show a cell number increase in the anal direction, the highest counts being obtained from the rectum.

References

- KEIJFER VAN RIJ N. J. M. 1958. The relationship between *Saccharomyces telluris* and *Candida bormii*. *Leeuwenhoek ned Tijdschr* 24: 137.
- KRINE A. I. 1945. Microbiological research in the region of the North Pole. *Vestnik Akad. Nauk SSSR* 3: 30. (Translation by Jean S. Zofell. Scripps Institution of Oceanography, La Jolla, Calif.)
- LOBBER J. & N. J. M. KEIJFER VAN RIJ. 1952. *The Yeasts*. North Holland Publ. Co., Amsterdam, Holland.
- LUND A. 1954. Studies on the Ecology of Yeasts. Munksgaard, Copenhagen, Denmark.
- MAGARA M. H. NITTONO & T. SPADA. 1955. *Antibiotic Med* 1: 394.
- MELFARO DE SILVA H. & N. VAN UDEN. On the mode of infection and reinfection in yeast vulvovaginitis. *Am. J. Obstet. Gynecol.* In press.
- PHAFF J. N. 1946. Cited by Shifrine & Phaff (1958).
- REMAA R. 1945. Cited by Shifrine & Phaff (1958).
- ROLLE M. & H. MEHNERT. 1957. Hefen als Symbionten bei Säugetieren. *Z. Bakteriol. Orig.* 168: 268.
- SHIFRINE M. & H. J. PHAFF. 1958. On the relation ecology and taxonomy of *Saccharomyces guttulata*. *Leeuwenhoek ned Tijdschr* 24: 193.
- VAN UDEN N. 1962. Zur Kenntnis von *Torulopsis pintolopesii* sp. nov. *Arch. Microbiol.* 17: 199.

- VAN UDEN N & L DO CARMO SOLSA 1957a *Candida slooffii* nov sp a thermophilic and vitamin deficient yeast from the equine intestinal tract Portugaliae Acta Biol Ser A5 7
- VAN UDEN N & L DO CARMO SOLSA 1957b Yeasts from the bovine caecum J Gen Microbiol 16 385
- VAN UDEN N L DO CARMO SOLSA & M FARINHA 1958 On the intestinal yeast flora of horses sheep goats and swine J Gen Microbiol 19 435
- YO BWAN H 1954 Mycotic vulvovaginitis in Pregnancy Thesis Univ Utrecht Utrecht Holland
- WALT J P VAN DER 1957 Three new sporogenous yeasts from soil Leeuwenhoek ned Tijdschr 88 23
- WICKERHAM I J 1951 Taxonomy of yeasts Tech Bull U S Dept Agr No 1029

EPIDEMIOLOGY OF THE DERMATOPHYTOSIS SOURCES OF INFECTION MODES OF TRANSMISSION AND EPIDEMICITY

Presented by Lucille K. Georg

The dermatophytes and the diseases that they produce may be divided into several groups on the basis of sources of infection, host preference, and epidemicity.

As might be expected human infections in rural areas are commonly acquired from domesticated or wild animals. Such infections usually evoke considerable tissue reaction in the host and are characterized by suppuration, kerion formation and allergic phenomena that appear to be responses to fungi not well adapted to existence in human tissues.

Until recently we have had little knowledge of the prevalence of ringworm infections of animals or information regarding the frequency of their transmission to humans. In the past few years, however, several epidemiological studies and surveys such as those conducted in England by Ainsworth and Austwick,¹ La Touche,² Genik and O'Sullivan,³ and McPherson⁴ in Yugoslavia by Olegovic and Gern,⁵ and in the United States by the Communicable Disease Center in Atlanta (Griffith) have been carried out. The results of these studies have shown the high prevalence of ringworm in animals and have given considerable evidence on the manner in which these infections are transmitted to humans.

The individual dermatophytic species have varying degrees of host specificity. Some are primarily animal pathogens. These are the so-called zoophilic fungi. Although animals appear to be the natural hosts for this group of fungi, such infections frequently are transmitted to humans. Six dermatophytic species that commonly cause ringworm in animals have been found to be important in relationship to human infection. These include *Microsporum canis*, *M. distortum*, *Trichophyton verrucosum*, *T. mentagrophytes* (var. *granulosum*), *T. equinum*, and *T. gallinarum*.

Human infections due to *M. canis* are common in both rural and urban communities and there is little doubt that most cases are of animal origin. *Trichophyton* is the most common cause of ringworm in cats and dogs. In the Communicable Disease Center survey 32% of feline specimens yielded dermatophytes. Of these 318 or 97.8 per cent were *M. canis*. Of 495 canine specimens 32% or 66.9 per cent were *M. canis*. Cats and dogs appear to be the most important sources of *M. canis* infections in man.

Human infections due to *T. verrucosum* are confined almost entirely to the rural population. This fungus causes the vast majority (98 to 100 per cent) of some areas of ringworm infections in cattle. Most human infections are easily traced to direct contact with ringworm infected cattle. In a series of cases of indirect transmission have been reported also. In one instance it appears that infected cattle hairs have been carried on the coat of the farmer into his home where children, including infants, have become infected indirectly. Walker⁶ has shown that *T. verrucosum* may remain viable

infected hairs in the laboratory for 15 months, and she has demonstrated the presence of *T. verrucosum* infected hairs on a scratching post used by cattle infected with ringworm.

Infections due to *T. mentagrophytes* (var. *granulare*) occur also largely among the rural population of the United States.¹⁸ However, in contrast to ringworm due to *T. verrucosum* that usually is traced to contacts with infected cattle the source of *T. mentagrophytes* infections often is not easy to discover. Although *T. mentagrophytes* has been reported as a cause of ringworm in cattle and horses,^{19, 20} results of recent surveys indicate that such infections are relatively rare.^{1, 21} In the Communicable Disease Center survey, *T. mentagrophytes* was isolated only once from a cow and once from a horse. Ainsworth and Austwick¹ recorded only one equine case and no cattle infections in their survey in Great Britain. Infections in cats and dogs appear to be somewhat more common. In the Communicable Disease Center survey, 3 isolates were made from cats and 45 from dogs (this latter constituted 9.1 per cent of 493 canine hair specimens).

In contrast to this rather low prevalence of *T. mentagrophytes* infection among domesticated animals, there is considerable evidence that infections are common among rodents. The disease often is seen in the laboratory guinea pig and mouse.²² It also has been shown that the disease is not uncommon among wild rodents.²³ It is noteworthy that *T. mentagrophytes* is recovered frequently from animals even though they do not have skin lesions or hair invasion that can be detected either grossly or microscopically.

The fact that rodents are commonly infected by this fungus suggests that certain areas of farm premises frequented by rodents, especially feed bins and barns, may be contaminated by spores and infected hairs shed by these animals. It is felt that rodents play an important role in the transmission of *T. mentagrophytes* infections in rural areas. A number of human outbreaks have in fact been reported as occurring following the handling of grain and straw contaminated by infected mice.^{24, 25}

Human infections due to *M. distortum*, *T. gallinae*, and *T. equinum* are rare. *M. distortum* was first described by Di Menna and Marples in 1954²⁶ as the cause of tinea capitis among 12 children in New Zealand. These authors were unable to determine the source of the infection. In 1957 Kaplan *et al.*²⁷ described the isolation of *M. distortum* from 4 monkeys (3 in Iowa and 1 in Florida) and 1 dog in the United States, and gave evidence for 6 possible human contact infections. Recently a human infection derived from a monkey was reported by Brooks *et al.*²⁸ in Washington, D. C. It is interesting that this monkey came from the same pet shop in Des Moines, Iowa where the first monkey infections had been found in the United States. All of the monkeys had apparently originated in Central America.

With respect to *T. equinum* and *T. gallinae*, two zoophilic fungi that may infect man, these fungi are almost specific for the horse and gallinaceous birds, respectively, and only rarely produce infections in other animals or man.^{29, 30} In the case of *T. equinum* the specificity appears to be based on a physiological requirement for nicotinic acid or its precursors that are available in equine hair, but not in the hair of other animals.³⁰

Ringworm of those parts of the body covered by clothing, which includes the

feet in those who wear shoes appears to be due almost entirely to fungi of human origin. These so-called 'anthropophilic fungi' include *T. mentagrophytes* (var. *interdigitale*), *T. rubrum*, and *Epidermophyton floccosum*.

T. mentagrophytes (var. *interdigitale*) represents the downy or fluffy colonial form of this fungus. It is isolated only rarely from infections in animals, but is associated commonly with chronic *tinea pedis* in the temperate zones of the world. Rare instances of *T. rubrum* infections in animals have been reported.^{14, 15} In one of these cases, in which *T. rubrum* infection occurred in a dog, there was evidence that the disease had been transmitted from the owner to his dog, as he had a habit of rubbing the dog's back with his infected feet. *E. floccosum* has never been reported from lower animals.

T. mentagrophytes and *T. rubrum* are by far the commonest causes of *tinea pedis* in this country, and in many other parts of the world. The disease produced is usually of a chronic nature, with little tissue reaction. The heavily keratinized soles and the intact skin of the feet offer little opportunity for the fungi to penetrate deeply enough to obtain the nutrition that appears to be essential for effective parasitism. In fact in many individuals, particularly during the winter months when the feet are cool and dry, the dermatophytes exist on the tissues of the feet in an almost saprophytic state, apparently deriving nutrition from the epithelial debris on the skin surfaces and giving no visible evidence of infection. Symptomatic infection of the feet usually is observed first in the toe webs. In these areas conditions of warmth and humidity and macerated skin allow the fungus the conditions necessary for it to proliferate. From these areas, the infection may spread to an injured nail bed or over large areas of the feet. In tropical climates the infection may spread onto the body. The opportunity to invade the lanugo hairs offers further opportunity for the fungi to produce disease.

The relationship between the downy form of *T. mentagrophytes* isolated from chronic *tinea pedis* and the granular form isolated from suppurative ringworm acquired from animals is a most interesting one. My experimental studies¹⁶ using monospore isolates of *T. mentagrophytes* have shown that the downy and granular forms indeed represent two cultural forms of the same species. The downy type, which apparently has low virulence for man, also shows low virulence for the guinea pig and the dog. Virulence, however, may be enhanced by serial passage in guinea pigs, and this increased virulence is accompanied by a morphologic change to a granular type culture similar to that seen in spontaneous animal ringworm. The same transformation may also be observed in man when conditions of heat and humidity and communal life as experienced among military personnel in tropical areas are provided. This is demonstrated quite clearly in the epidemiological studies by Sanderson and Sloper.^{17, 18} A survey by Walker¹⁹ had indicated that *T. interdigitale* or the downy type culture of *T. mentagrophytes* was isolated consistently in all cases of ringworm of the feet which he had observed in Great Britain. However, when groups of army men were sent from England to Malaya and Hong Kong, Sanderson and Sloper reported that not only was the incidence of ringworm of the feet greatly increased, but the cultures isolated in the majority of the cases were of the granular type that they identified as *T. mentagrophytes*. Correlated with the change of cultural type were an increased severity of the lesions and a large

number of cases of *T. mentagrophytes* infections of the body, face, and scalp. The lesions on these latter areas frequently showed deep involvement of the hair follicles and suppurative reactions. Sanderson and Sloper presented evidence that these body lesions probably had been acquired largely from active foot infections that had spread from the patient's own feet. In a number of cases, '*T. interdigitalis*' was isolated from a primary infection, but later *T. mentagrophytes* was isolated from recurrent lesions. These investigators show quite clearly that the climatic conditions in southeast Asia that caused intense sweating especially in new arrivals were an important factor in increasing the incidence of ringworm disease among these men. In addition, the conditions of army life—communal living, poor bathing facilities, interchanges of boots, and borrowing of socks probably increased the spread of the infections from man to man. The authors suggest that "if a transformation of '*T. interdigitalis*,' present on the feet of these men when they left the United Kingdom, into *T. mentagrophytes* were postulated, the rapid spread of trichophytic ringworm in this unit could be more easily explained."

The experimental proof that such a transformation can occur does aid in explaining this phenomenon. Conditions more favorable for the growth and transmission of the fungi from person to person permitted this dermatophyte to invade the tissues to a greater extent than previously and to produce more tissue reaction. Concurrently with the production of more active infections, the fungi became granular.

T. mentagrophytes therefore, cannot be classed as either zoophilic or anthropophilic but rather should be recognized as having two forms. These are the downy form (var. *interdigitalis*) associated with chronic tinea pedis and the granular form (var. *granulare*) associated with animal infections, or human infections of either animal or human origin that have become acute and progressive.

It would appear that, besides conditions of reduced resistance of the host and favorable conditions of warmth and humidity, symptomatic and progressive ringworm may be caused by virulent strains that have been developed selectively wherever better nutrition is afforded by opportunity for invasion deep into the skin or hair follicles. It has been well established that the dermatophytes seek the areas of newly forming keratin deep in the skin or hair follicles for their maximum development.

In many areas of the world, *T. rubrum* is the common cause of tinea pedis and tinea corporis. In India, where it is the most important ringworm agent, the disease among the large low income group which does not wear shoes, is confined almost entirely to the covered parts of the body. Most of these infections, although covering large areas, are chronic in nature, which suggests that this fungus has become well adapted to existence in human tissues. However, a tropical climate and crowded living conditions have increased the prevalence of this fungus disease in the tropical areas of India. According to a recent study of ringworm infections in Bombay by S. C. Desai (personal communication) there is considerable evidence for familial transmission of *T. rubrum* infections. Studying the family contacts of 25 individuals with *T. rubrum* infections, Desai found an infection rate of 41 per cent in the 25 families concerned.

This high rate of infection among family contacts suggests that *T. rubrum* infections are more contagious than many other diseases.

I have had an opportunity to study a number of the *T. rubrum* isolates from India. Some of the strains were similar to the white fluffy isolates that are commonly obtained from *linea pedis* in the United States. However, many of the strains formed the heaped and folded type of colony with a velvety surface and deep rose to purplish red pigmentation on the front as well as on the reverse of the colonies. This type is usually described as the granular form of *T. rubrum* and is characterized by the production of many micro- and macroconidia. Desai has demonstrated that experimental human infections are easily accomplished with his Indian strains. In my opinion this not only reflects (1) susceptible individual, possibly due to poor nutrition and (2) favorable conditions of warmth and humidity, but it also suggests that there may be an increased virulence in the Indian strains resulting from frequent human passage and favorable conditions for parasitism. Experimental infections are usually difficult to produce with strains isolated in the United States.⁴³

Experimental evidence that animal passage may increase the virulence of *T. rubrum* has been shown recently by Iatridge⁴⁴ who demonstrated by serial passage on the chorioallantoic membrane of the developing chick that the virulence of *T. rubrum* may be enhanced gradually. Accompanying this increase in virulence there was a morphologic change from the fluffy to the granular type.

Studies of *T. rubrum* infections in families by English⁴⁵ in Great Britain and by Rothman⁴⁶ and Many *et al.*⁴⁷ in the United States give further evidence for familial transfer of *T. rubrum* infections. In the study by Many *et al.*⁴⁷ the relation of exposure and infection of *T. rubrum* within 30 household groups representing 127 people was presented. The study revealed that multiple infections occurred in 37 per cent of the 30 household contacts examined. Long periods of exposure in some instances 6 months to a year appeared to be necessary in the spread of many of these infections among family contacts.

The mode of transmission of *linea pedis* from one individual to another has long been a source of conjecture as there is little evidence of direct contagion. Studies by Baer and Rosenthal and their associates^{48, 49} suggested that *linea pedis* is not a transmissible disease in the usual sense and that the environment does not play an important role in acute outbreaks. These authors based their conclusions on the facts that (1) dermatophytes were isolated from normal skin, (2) feet placed in suspensions of dermatophyte cultures did not become infected and (3) they had poor success in the isolation of dermatophytes from the environment.

It is my belief that these authors did not create the proper conditions for producing infections and that they did not use adequate procedures for the isolation of dermatophytes from the environment. Ability to produce experimental infections depends upon many factors including conditions of warmth and humidity, opportunity for the fungi to penetrate the skin, virulence of the fungus strain and individual susceptibility of the host.

By the use of selective media such as the Cycloheximide Medium⁴¹ and special collecting techniques such as developed by Gentile⁴² many isolations

of dermatophytes from floors, shower stalls, foot baths and from socks and shoes have been made.^{10, 11} The importance of socks and shoes as a source of infection or reinfection has been stressed by Ajello and Getz¹ and Brough¹². There is considerable evidence that, once the disease has been acquired it may be maintained throughout a lifetime with periods of remission and exacerbation.

Recent studies by Trusman and Vanbreevenghem,¹³ Gentles and Holmes,¹⁴ and English and Gibson¹⁵ have demonstrated the importance of the following in the epidemiology of tinea pedis:

- (1) Age of the host is probably not a factor. The increase in the incidence of infection with age is probably a reflection of increased opportunity for infection rather than increased susceptibility.
- (2) The high rate of infection in communal bathers, as compared to those who bathe only at home, gives good evidence that cross infection occurs and is an important factor.
- (3) The fact that the rate of infection varies widely in different schools and in groups of individuals using different baths or swimming pools gives further evidence for the epidemicity of this disease.
- (4) The percentage of infected individuals can be correlated indirectly with the amount of washing and cleaning of the swimming pool or bathing environment that they regularly use.

That the incidence of tinea pedis in institutionalized children may be very high has been reported by Spoor and Yang.¹⁶ The development of outbreaks of tinea pedis in schools and institutions may be based on both favorable climatic conditions for infection and heavy contamination of the environment. Severe outbreaks may also reflect the development of virulent strains that have been selected by frequent transmission from one individual to another.

In addition to the evidence for transmission of infections, the simple fact that the fungi that cause tinea pedis do not have a saprophytic existence in nature indicates the necessity for either human or animal sources of infection.

With regard to ringworm of the scalp due to the anthropophilic species *Microsporum tonsurans*, *T. violaceum*, and *T. schoenleii*, there is little doubt as to the source of infection or their epidemicity. These species appear to be highly adapted to existence in human tissues and have never been isolated here in lower animals. To my knowledge *T. tonsurans* has never been isolated here in lower animals. The epidemiology of tinea capitis due to these organisms has been treated extensively by a number of workers and will not be discussed here.

Besides the zoophilic and anthropophilic fungi, a third group, the geophilic dermatophytes, remains to be discussed. Two dermatophyte species, *M. gypseum* and the recently described *Acremonium gypaeum*, exist as saprophytes in soil. Infections of man by *M. gypseum* are quite rare.¹⁷ Animal infections appear to be more common. There is considerable evidence to show that infections in both animals and man are acquired directly from the soil. The higher prevalence in animals is due, no doubt, to their closer contact with soil. It is interesting to note that soil isolates of *M. gypseum* have very low virulence compared to strains isolated from animals or man. It would appear that either only particularly virulent strains have the ability to produce infections in animals or humans or that once a strain of low virulence has become parasitic,

due to low resistance of a particular host or opportunity for invasion afforded by an injury to the skin its virulence becomes enhanced and infections may then be transmitted readily to other hosts. This would appear to account for the *M. gypsum* epidemics that have been reported among horses.²² It might also explain the outbreak among nursery workers in England reported by Whittle.²³

The epidemiology of the dermatomycoses involves many factors—source of infection, virulence of the infective agent, favorable conditions of the environment such as warmth and humidity and abrasions of the skin, and individual host susceptibility.

In this presentation only a few of these factors have been discussed, however, all are undoubtedly important in the epidemiology of this disease.

References

1. AINSWORTH G. C. & P. A. C. AUSTWICK. 1935. A survey of animal mycoses in Britain: general aspects. *Vet Record* 67: 85-97.
2. LA TOUCHE C. J. 1952. The Leeds campaign against microsporiasis in children and domestic animals. *Vet Record* 64: 398-399.
3. GENTLES J. C. & J. G. O'SULLIVAN. 1957. Correlation of human and animal ringworm in west of Scotland. *Brit Med J (III)* 678-682.
4. McPHERSON F. A. 1957. A survey of the incidence of ringworm in cattle in Northern Britain. *Vet Record* 69: 673-679.
5. OZGOVIC L. & I. F. GRAY. 1957. Dermatomycosis in domestic animals in our country with special attention to their extension in Bosnia and Herzegovina. (Yugoslavian English Summary) *Vietnana (Sarajevo)* 6: 1-12.
6. GRAY I. F. & L. OZGOVIC. 1959. I problemi attuali delle dermatomycosi in Jugoslavia. *Minerva Med* 80: 1243-1251.
7. MENOFF R. W. & L. K. GROSS. 1957. Survey of animal ringworm in the United States. *Public Health Reports U. S.* 72: 503-509.
8. KAPLAN W. L. K. GROSS & L. VJELLO. 1958. Recent developments in animal ringworm and their public health implications. *Ann N. Y. Acad Sci* 70(3): 636-647.
9. FIDLE I. P. & L. K. GEORGE. 1947. Suppurative ringworm contracted from cattle. *Arch Dermatol & Syphilol* 55: 780-793.
10. BLANK F. & G. I. CRAG. 1954. Family epidermids of ringworm contracted from cattle. *Can Med Assoc J* 71: 234-235.
11. GEORGE I. K. F. A. HAND & R. A. MENOFF. 1956. Observations on rural and urban ringworm. *J Invest Dermatol* 27: 335-353.
12. GRAY I. F. OZGOVIC L. & A. VASILJEVIC. 1956. Ringworm in cattle and endemic dermatophyte infections of the scalp of man. Radovi VI Naučno društvo (Yugoslavian English Summary) *VRHII* 143-68.
13. ROOK A. J. & W. FRANK BELL. 1954. Cattle ringworm. *Brit Med J (II)* 1199-1200.
14. BLANK F. 1953. Ringworm of cattle due to *Trichophyton discoides* and its transmission to man. *Can J Comp Med* 17: 277-281.
15. WALKER J. 1955. Possible infection of man by direct transmission of *Trichophyton discoides*. *Brit Med J (II)* 1430-1433.
16. SABOTAUD H. 1923. *Trichophyton megaloconium* pyogène du cheval. *Ann Inst Pasteur* 7: 497-524.
17. MENDON I. & I. WEBB. 1957. Ringworm fungus growing as a saprophyte under natural conditions. *Arch Dermatol and Syphilol* 36: 991-999.
18. CATANZI A. 1939. Fitte les teignes des animaux en Algérie. *Arch Inst Pasteur Algérie* 17: 420-429.
19. PEREZ CORNEJO S. 1954. Contribución al estudio micológico de la tiza del caballo. *Zootecnia (Méx)* 3: 7-17.
20. GEORGE I. K. W. KAPLAN & I. B. CAMP. 1957. Equine ringworm with special reference to *Trichophyton equinum*. *Am J Vet Research* 18: 999-1010.
21. VIGNON L. 1932. *Trichophyton lactaceum* cultivado en dos casos de tiza espontánea de la colaza. *Rev Soc Arg La L.* 8: 7-9.
22. EVERTS C. A. & R. ANDERLARI. 1955. *Trichophyton mentagrophytes* from apparently healthy guinea pigs. *Am J Arch Dermatol* 71: 478-480.
23. MENOFF R. W. & L. K. GROSS. 1946. An epizootic of ringworm among guinea pigs caused by *Trichophyton mentagrophytes*. *J Am Vet Med Assoc* 128: 315-319.

- 24 PARRISH H J & S CRADDOCK 1931 A ringworm epizootic in mice *Brit J Exptl Pathol* 12 209-212
- 25 CATANFI A 1942 Les teignes de la souris blanche à Alger *Arch Inst Pasteur Algérie* 20 305-308
- 26 BOOTH H 1952 Mouse ringworm *Arch Dermatol and Syphilol* 66 65-69
- 27 DOLAN M M & M KLIGMAN P G KOBYLINSKI & M A MONTAGNE 1958 Ringworm epizootics in laboratory mice and rats. Experimental and accidental transmission of infection *J Invest Dermatol* 30 23-25
- 28 MENGES R W G J LOVE W W SMITH & I K GEORG 1957 Ringworm in wild animals in Southwestern Georgia *Am J Vet Research* 18 672-677
- 29 BUCHANAN R F 1919 Favus herpeticus or mouse favus Possibility of production of favus in man from Australian wheat *J Am Med Assoc* 74 97-100
- 30 SCHNEIDER W 1954 Favusepidemie durch Felhmause *Hautarzt* 5 348-351
- 31 FRAGNER P & J KRALSCHOFF 1956 *Trichophyton gypsum* Bodin 1902 var *Quinckea* num 1885 Blanchard 1896 the cause of epidemic infection in processing straw *Česká Mycol X/2* 47-49 (Czechoslovakian & English)
- 32 DI MENNA M & M J MABLES 1954 *Microsporum distortum* Sp nov from New Zealand *Trans Brit Mycol Soc* 37 372-374
- 33 KAPLAN W L & GEORG S L HENDRICKS & R A LEPER 1957 Isolation of *Microsporum distortum* from animals in the United States *J Invest Dermatol* 29 449-453
- 34 BROOKS B F J H ALLI & C C CAMPBELL 1959 Isolation of *Microsporum distortum* from a human case *J Invest Dermatol* 33 23-26
- 35 TORRES G & L K GEORG 1956 A human case of *Trichophyton gallinae* infection Disease contracted from chickens *Arch Dermatol* 74 191-197
- 36 CHAKRABORTY A & S GOCH & F BLANK 1954 Isolation of *Trichophyton rubrum* (Castellani) Sabouraud 1911 from animals *Can J Comp Med* 18 436-438
- 37 KAPLAN W & R H GUMP 1958 Ringworm in the dog caused by *Trichophyton rubrum* *Vet Med* 53 139-142
- 38 GEORG L K 1954 The relationship between the downy and granular forms of *Trichophyton mentagrophytes* *J Invest Dermatol* 22 123-141
- 39 SANDERSON P H & J C SLOPER 1953 Skin disease in the British army in S E Asia I Influence of the environment on skin disease *Brit J Dermatol* 65 252-264
- 40 SANDERSON P H & J C SLOPER 1953 Skin disease in the British army in S E Asia II Tinea corporis Clinical and pathological aspects with particular reference to the relationship between *T. interdigitale* and *T. mentagrophytes* *Brit J Dermatol* 65 300-309
- 41 SANDERSON P H & J C SLOPER 1953 Skin disease in the British army in S E Asia III The relationship between mycotic infections of the body and of the feet *Brit J Dermatol* 65 362-372
- 42 WALKER J 1950 The dermatophytoses of Great Britain Report of a three years survey *Brit J Dermatol* 62 239-251
- 43 SILVA M H M KESTEN & R W BENHAM 1955 *Trichophyton rubrum* infections A clinical mycologic and experimental study *J Invest Dermatol* 25 311-328
- 44 PARTRIDGE H M 1959 The use of the chorioallantoic membrane of the developing chick for culture of dermatophytes—a modified technique A preliminary report upon its use for serial passage *J Invest Dermatol* 32 605-619
- 45 ENGLISH M P 1957 *Trichophyton rubrum* infection in families *Brit Med J* 3 5021 (March 30)
- 46 ROTHMAN S G KNOX & D WINDHORST 1957 Tinea pedis as a source of infection in the family *AMA Arch Dermatol* 75 270-271
- 47 MANY H V J DERBES & L FRIEDMAN & M A Arch Dermatol In press
- 48 BAER H L S A ROSENTHAL & D FURVARI 1955 Survival of dermatophytes applied on the feet *J Invest Dermatol* 24 619-622
- 49 BAER H I S A ROSENTHAL J Z LITT & H ROGACHEFSKY 1956 Experimental investigations on mechanism producing acute dermatophytosis of feet *J Am Med Assoc* 160 184-190
- 50 ROSENTHAL S A H L BAER J Z LITT H ROGACHEFSKY & D FURVARI 1956 Studies on the dissemination of fungi from the feet of subjects with and without fungous disease of the feet *J Invest Dermatol* 26 41-51
- 51 GEORG L K L AJELLO & C PAPAGEORGE 1954 Use of cycloheximide in the selective isolation of fungi pathogenic to man *J Lab Clin Med* 44 422-428
- 52 AJELLO L & M E GETZ 1954 Recovery of dermatophytes from shoes and shower stalls *J Invest Dermatol* 22 17-21
- 53 BOCOBO F C & A C CURTIS 1958 Accidental isolation of *Trichophyton mentagrophytes* from the floor of a schoolhouse *Mycologia* 50 164-168

- 54 ENGLISH M P & M D GIBSON 1959 Studies in the epidemiology of tinea pedis I. Tinea pedis in school children II. Dermatophytes on the floors of swimming baths Brit Med J (i) 1442-1448
- 55 BROUGHTON R H 1955 Reinfection from socks and shoes in tinea pedis Brit J Dermatol 67 249-254
- 56 TRITSMAN E & R VANBREUSEGHEM 1955 Over het voorkomen van athlete's foot bij Belgische sporthoefenaars Belg Tijdschr Geneesk 11 13 625-633
- 57 GENTLES J C & J G HOLMES 1957 Foot ringworm in coal miners Brit J Ind Med 14 22-29
- 58 SPOOR H J & D YANG 1951 A study of athlete's foot infection in children Bull N Y Med Coll 24 112-118
- 59 VANBREUSEGHEM R 1952 Interest théorique et pratique d'un nouveau dermatofyte isolé du sol Keratinomyces ajellii gen nov sp nov Bull Classe Sci 5th Ser 38 1068-1077
- 60 GEORG I K W LAPLAN I AJELLO W M WILLIAMSON & E H TILDEN 1949 The parasitic nature of the soil fungus Keratinomyces ajellii J Invest Dermatol 22 539-544
- 61 AJELLO L 1953 The dermatofyte Microsporum gypseum as a saprophyte and parasite J Invest Dermatol 21 157-171
- 62 LAPLAN W J I HORRING & I K GEORG 1957 Ringworm in horses caused by the dermatofyte Microsporum gypseum J Am Vet Med Assoc 131 329-332
- 63 WHITTIE C H 1954 A small epidemic of M. gypseum ringworm in a plant nursery Brit J Dermatol 66 353-356

NATURAL AND EXPERIMENTAL EPIDEMIOLOGY OF HISTOPLASMOSIS*

Howard W. Larsh

Department of Plant Sciences, University of Oklahoma, Norman, Okla. and Kansas City Field Station, Communicable Disease Center, Public Health Service, Kansas City, Kans.

The epidemiology of histoplasmosis has been the subject of many investigations since 1946. There are several postulations as to the natural environment and modes of transmission of *Histoplasma capsulatum*. Furcolow, in his *Recent Studies On The Epidemiology of Histoplasmosis*,¹ adequately presents these views, although not to the complete satisfaction of all epidemiologists.

Noteworthy contributions to the epidemiology of histoplasmosis have resulted from recent investigations. Endemic areas with high incidences of skin test sensitivity to histoplasmin have been discovered in Georgia and Michigan. These areas are of epidemiological interest in that they are urban locations and situated in areas where the surrounding histoplasmin sensitivity is low. In addition to these two localities where histoplasmin sensitivity and lung calcification have been studied, two epidemics of human histoplasmosis have occurred in Wisconsin and Missouri. In each of these epidemics the source of *H. capsulatum* proved to be within the city limits and not associated with enclosures.

In northwestern Georgia a high frequency of pulmonary calcifications was found in routine X-ray films. These findings were remarkable in that many of the patients showed sputum negative for tubercle bacilli, and some failed to react to tuberculin. Such observations have been relatively common in highly endemic areas of systemic mycoses, especially histoplasmosis. However, Whitfield and Murray counties of Georgia are not considered to be in the highly endemic area of this fungus, but may be considered to be on the 'fringe area'. For these reasons, a great deal of interest developed, and a search was undertaken to determine the cause of the pulmonary calcifications. In March 1957, Edwards *et al.*² instituted a skin test survey in 6 public high schools in this area. Approximately 90 per cent of the students (2111) in these schools received tuberculin, histoplasmin and coccidioidin skin tests. The most surprising result was that reactors to histoplasmin ran high in the individuals tested. In addition, there was a definite reversal in the usual ratio of rural urban histoplasmin reactors. The rural population has generally been considered the most highly sensitized group. Students living in the urban area of Dalton, Ga., Negro as well as white, had a sensitivity rate of approximately 55 per cent as compared with a rate of 22 per cent for the rural students. The high frequency of histoplasmin reactors among students attending the two urban schools, as compared to the lower number of reactors in the four rural schools, suggested a source of inoculum within the urban area of Dalton. The authors postulated that contact with a source within the city of Dalton could account for many, if not most, of the histoplasmin reactors found among the rural residents, also, that this source has been present for several years.

* The work described in this paper was supported in part by Grant E 1292 from the National Institutes of Allergy and Infectious Disease, Public Health Service, Bethesda, Md., to the University of Oklahoma Research Institute, Norman, Okla.

Larsh Epidemiology of Histoplasmosis

79

A similar high incidence of histoplasmosis was discovered in Milan, Mich. by Whitehouse *et al*.¹ These investigators were particularly interested in the differential diagnosis of the increasing number of intrathoracic lesions. In this southern peninsula area of Michigan the number of tuberculin reactors was 20 per cent or less, while the number exhibiting histoplasmin sensitivity was calculated to be 10 to 20 per cent. However nearly 90 per cent of the school children studied in Milan were reactors to histoplasmin by the age of 14. In addition to this striking finding 61.5 per cent of the townspeople proved to be reactors to histoplasmin. In comparison the population tested in 5 other cities in the area yielded a histoplasmin sensitivity of 2.5 to 10.7 per cent. These findings like those of Dalton would strongly suggest a source or sources of inoculum within the city of Milan. Here too there is a reversal of the usual rural urban sensitivity to histoplasmin.

In the article Walforth Wisconsin Epidemic of Histoplasmosis Wilcox *et al*² have presented a classic in the epidemiology of the disease. The epidemic resulted from activity associated with the construction of a new home on a vacant lot in the residential area of the city. Nineteen individuals became ill after being exposed for varying periods of time to the source of inoculum. These illnesses ranged from mild to severe with an incubation period of 7 to 16 days. The nature of the outbreak was such that the investigators were able to determine the exact date and extent of exposure of each individual.

There are many interesting points to this epidemic but the failure to ascertain a history of exposure of the lot to chicken enclosures or bird droppings is a significant one. Also the fungus was isolated from soil samples collected in the front of the lot and from two scalene nodes. It is noteworthy that *H. capsulatum* was isolated from soil samples from the front of the lot only. The pH of the soil was determined and the positive isolations were from samples having a pH of 6.0 and 6.55. Negative samples were obtained from the rear of the lot where a higher pH prevailed. The organism was isolated from collections made in September, October, December and April.

The Walforth epidemic occurred in a nonendemic histoplasmosis area since only 11.4 per cent or less of the population were reported to be histoplasmin reactors. In the study of this epidemic the residents of Walforth Village were found to have a much higher histoplasmin reactor rate (15.7 per cent compared to 4.3 per cent) than the rural residents.

Another epidemic of histoplasmosis occurred among Boy Scouts in Mexico Mo.³ The site of the epidemic was an eleven acre plot within the city. The property was made available to the city for a historical museum. At the time of the transaction there were several trees on the property and considerable undergrowth had developed in recent years. It was the removal of the latter growth in which the Boy Scouts were engaged that led to their illness. Considerable amounts of bird droppings were present at some locations on the site when the clearing activity took place. Since the location is in the endemic area for histoplasmosis skin test sensitivity was known to be high. However of the Scouts who worked on the property 97 per cent proved to be histoplasmin reactors whereas among the Scouts who did not work on the property only 40 per cent were reactors. Comparing the sensitivity of individuals in the same age range in the high school of Mexico

Mo, the non Boy Scouts showed a reaction rate of 65 per cent and the girls 48 per cent

Fifty two sera were collected from the Boy Scouts who had worked on the property. Thirty-one of these were positive (60 per cent), whereas only 6 of 27 (22 per cent) sera from Scouts who did not work on the property showed positive titers. A similar observation was made in regard to positive X ray findings. Twenty six of 57 (46 per cent) of those working on the property and 10 of 34 (29 per cent) of those who did not work on the property had positive X ray findings.

To date 38 isolations of *H. capsulatum* have been made from samples collected on this eleven acre site.

The complete epidemiological, serological, and X ray findings of this epidemic will be reported by my colleagues at the Kansas City Field Station at an early date.

In summarizing these investigations, there are some points that are similar and others that are dissimilar. The most remarkable finding was that the source of the inoculum in each instance was within the environs of the particular city. In addition, the histoplasmin sensitivity was greater in the urban than in the rural residents. This is a distinct reversal in the usual ratio of rural to urban reactors. In the Mexico, Mo. outbreak, however, the comparison must be limited to those who worked and those who did not work on the site. This is particularly important since this city is in an area of high histoplasmin sensitivity. Another important observation was that, in so far as possible, no association could be made with chicken or other bird droppings in the foci in Georgia, Michigan, and Wisconsin. On the other hand, a distinct correlation can be made in the Missouri epidemic. Similar findings were reported in X ray films, and a greater percentage of reactors was found in boys than in girls in all of the studies.

The finding of foci of inocula in urban areas does not invalidate the usual observations that *H. capsulatum* is frequently associated with chicken enclosures or with other sources of bird droppings. To rule out such an association the history of the area over a long period of time must be available. It is possible that such an enclosure may have been present but usually this can be ascertained. However, contamination by migratory birds may be more difficult to determine. Contamination could have occurred many years previously, and the fungus established itself in such foci at that time. One must recall that *H. capsulatum* does not require only this environment for growth, development, and survival. Laboratory investigations have shown that it will thrive on several different types of substrata, providing the humidity and temperature are conducive for growth. From all indications *H. capsulatum* is a common soil organism and will flourish only in environments that fulfill its minimal or optimal requirements. It is obvious that this must have been the case in all of the foci in the studies reviewed.

To compare naturally occurring histoplasmosis laboratory studies have been completed that simulate those existing in nature. It is these contributions that warrant additional discussion. In the study of natural epidemics of histoplasmosis, it is clear that all of the factors that influence the development of an epidemic may be

most difficult to determine. In comparison, laboratory epidemiology can be studied under precisely controlled experimental conditions. For these reasons a long range program has been instituted in which studies covering many facets of airborne transmission of systemic mycoses will be investigated.

Sufficient evidence has been reported in recent years to show quite conclusively the importance of airborne transmission in histoplasmosis. *H. capsulatum* was first isolated from the soil by Simmons in 1949. Since that time the fungus has been recovered with great regularity from nature in the endemic areas of histoplasmosis. The organism has been isolated from the air¹ and investigations have shown that the mycelium of many isolates forms an abundance of microconidia having a diameter of 3 μ or less. The size of these spores is significant since it has been shown that particles larger than 3 μ rarely reach the alveoli of the lungs.² The respiratory tract seems to be the major portal of entry of the organism under natural conditions. Therefore, the route of inoculation for the study of sensitivity as well as immunological or pathological manifestations elicited by *H. capsulatum* in experimental animals should simulate naturally occurring histoplasmosis.

Sensitivity to histoplasmin has generally been attributed to a past or present exposure to *H. capsulatum* although cross reactions with related system fungi do occur and must be considered in diagnosis or epidemiological studies. There have been some indications that a positive histoplasmin skin test indicates increased resistance to disease.³ True sensitivity to histoplasmin has been demonstrated in infected laboratory animals.⁴ Many investigators have also shown increased resistance to *H. capsulatum* by prior infection or by intraperitoneal infection and others. The introduction of aerosolized cells of *H. capsulatum* into experimental animals by the airborne route has not previously been investigated. For these reasons guinea pigs were exposed to aerosols containing *H. capsulatum* particles with a view to determining whether they would become histoplasmin sensitive.

The procedures and results can be summarized best as laboratory studies demonstrating histoplasmin sensitivity in guinea pigs. In the preparation of fungal cell suspensions the scratchable isolate of *H. capsulatum* originally cultured from a human case of histoplasmosis was used in all of these investigations. Mycelial phase cultures of the organism were grown on the surface of Sabouraud's dextrose agar contained in 250 ml. Petri dishes at room temperature. The age of the cultures used varied from 1 day to 3 weeks. A 100 ml. of sterile physiological saline solution was introduced into each dish and then sterile glass beads were added. The dishes were stirred to dislodge the mycelium from the surface of the medium and the cell suspensions were transferred to sterile 50 ml. centrifuge tubes. Mycelial particles were washed 3 times by centrifugation and then resuspended in sterile saline. This suspension was transferred to sterile 50 ml. centrifuge bottles and sterile glass beads added to make up one third of the total volume. The suspension was shaken for 4 hours on a Kahn shaker. Fungal fragments were removed with a sterile pipette and a hemocytometer count was made on the suspension. The combination of spores and mycelial fragments was made on this suspension. The particles were then either killed by adding formalin or used for infection studies.

tion of sufficient formalin to make a 1 per cent concentration or diluted to make appropriate viability determinations. The former suspensions were cultured for viability after storage in the dark for at least 1 week by transferring several loopfuls to Sabouraud's dextrose agar slants. Initial viabilities of live cultures were determined by plating 0.5 ml of 2 concentrations of the suspension onto the surface of Sabouraud's dextrose agar plates. These plates were incubated at room temperature and colony counts made at 14 and 21 days.

Yeast phase cultures of *H. capsulatum* were grown at 37° C on the surface of brain heart infusion agar slants containing 5 per cent blood. Growths from 3 to 4 day-old cultures were suspended in sterile physiological saline containing 0.1 per cent cysteine, washed 3 times by centrifugation and resuspended in cysteine saline. Hemocytometer counts were made on this suspension. Cells were then either rendered nonviable by adding formalin to a final concentration of 0.5 per cent or diluted to make appropriate viability determinations. Growth determinations were made on the formalin treated suspensions after storage at room temperature in the dark for at least 1 week. Sterility was indicated by failure of the organisms to grow on brain heart infusion blood agar at 37° C or room temperature. Initial viabilities of live yeast suspensions were determined by plating out 0.5 ml quantities of 2 concentrations onto the surface of Rowley's medium¹⁵ contained in 250-ml Erlenmeyer flasks. The flasks were incubated at room temperature and colony counts were made after 12 days.

The aerosols used in these experiments were produced in an apparatus originally developed by D. W. Henderson. The techniques used and the formulae for the determination of the spray factors and suspension concentrations were those outlined by Elberg and Henderson¹⁶. The Porton all glass short stem impinger was used as the sampler and the Collison nebulizer as the atomizing instrument. The total flow on the machine was 28 l/min, the spray flow through the nebulizer 8 l/min. The collection or impinger fluid was physiological saline containing 1.0 per cent gelatin to which was added Dow Corning Antifoam Emulsion A. Ten drops of Antifoam A were delivered through a 26-gauge needle to 100 ml of the saline-gelatin solution. In each study 10 impingers each containing 10 ml of fluid were used to determine the spray factor. The aerosol was sampled before and after exposure of the guinea pigs. One ml and 0.1 ml samples of liquid from each impinger were plated onto the surface of either Sabouraud's dextrose agar plates or Rowley's medium contained in flasks. The former medium was used for counts of viable mycelial particles and the latter for viable yeast cells. All plates or flasks were incubated and colonies counted as previously described.

Guinea pigs of the Hartley strain weighing optimally 350 to 400 gm were the experimental animals used. All animals were skin tested prior to each experiment and at weekly intervals thereafter with 0.1 ml of a 1:10 dilution of histoplasmin H.K.C. 7. Tests were read at 24 and 48 hours. Induration of 5 mm or greater was considered a positive reaction at either time interval. Control guinea pigs, those not exposed to cells of *H. capsulatum* were included with each experimental group. These animals were skin tested along with the exposed group to rule out the possibility of tissue sensitivity development as a result of frequent exposure of the animals to histoplasmin.

Larsh Epidemiology of Histoplasmosis 83

Sensitization of Guinea Pigs Using Formalin Inactivated Mycelial Particles and Yeast Cells

Groups of guinea pigs were given a series of injections of nonviable yeast or mycelial phase cells of the fungus. This study served as a check on the antigenicity of the cells that were to be used subsequently for attempted airborne induced tissue sensitivity. In preliminary investigations, using suspensions of whole cells and cell wall material, it was found that these materials could elicit allergy to histoplasmin when injected subcutaneously into guinea pigs. In the present study, guinea pigs were inoculated subcutaneously with 0.2 ml of a nonviable suspension of mycelial particles or yeast cells. In both instances the suspensions contained 2 million cells per ml. These injections were administered biweekly until the pigs became positive or the experiment was terminated.

TABLE 1
SENSITIZATION OF GUINEA PIGS BY A SINGLE EXPOSURE TO HENDERSON AEROSOL AND BY SUBCUTANEOUS INJECTIONS USING MYCELIAL PARTICLES AND YEAST CELLS OF *HISTOPLASMA CAPSULATUM**

Inoculum	Route of inoculation	Results			
		% guinea pigs per group	% guinea pigs positive to <i>H. capsulatum</i>	Percent positive	% pigs required treatment
Mycelial particles†	Aerosol 600/g pig	12	8	67.5	5 to 10
	Subcutaneous	12	12	100.0	8 to 10
Whole yeast cells‡	Aerosol 3000/g pig	12	8	66.7	4 to 12
	Subcutaneous	12	0	0.0	4 to 18
Nine (control)				0	

* Formalin killed.

† Particles from 3 day-old cultures.

‡ Experiment terminated after 20 weeks.

In the first experiment (TABLE 1) 12 of 12 guinea pigs became sensitive to histoplasmin when nonviable mycelial particles were injected subcutaneously and 6 of 12 guinea pigs became sensitive when nonviable whole yeast cells were used. The time required was 8 to 10 weeks for the mycelial group and 4 to 18 weeks for the yeast cell group.

In the second experiment (TABLE 2), 10 of 10 guinea pigs became sensitive to histoplasmin when nonviable mycelial particles were used and all of 10 guinea pigs became sensitive when nonviable whole yeast cells were used. The number of weeks required was 5 to 12 in the first case and 7 to 10 in the latter.

Two groups of guinea pigs were exposed to aerosols of formalin inactivated mycelial particles of *H. capsulatum*. The first group received a single 1 min exposure to the aerosolized suspension containing 2 million particles per ml. The second group of animals was exposed twice to the aerosol in this case, exposure being 6 weeks after the first. The aerosolized suspension in this case contained 1 million particles per ml and the lengths of exposure were 1 and 2 min respectively.

Two groups of guinea pigs were exposed to aerosols of formalin inactivated yeast cells of the organism in the same manner as described for inactivated mycelial particles. One group received a single 1 min exposure to an aerosol nebulized from a suspension containing 2 million yeast cells per ml, and the second was exposed twice to aerosols nebulized from a suspension containing 1 million cells per ml. The lengths of exposure were again 1 and 2 min, with the second exposure given 6 weeks after the first.

With a single exposure to aerosolized nonviable mycelial particles 8 of 13 (61.5 per cent) of the guinea pigs became hypersensitive to histoplasmin in 5 to 10 weeks (TABLE 1). When 14 animals were exposed twice to aerosols of particles, 100 per cent of the animals became sensitized in 7 to 10 weeks (TABLE 2).

A single exposure of guinea pigs to an aerosol of nonviable whole yeast cells of *H. capsulatum* was sufficient to sensitize 8 of 12 (66.7 per cent) in 4 to 12 weeks

TABLE 2

SENSITIZATION OF GUINEA PIGS BY TWO EXPOSURES TO HENDERSON AEROSOL AND BY SUBCUTANEOUS INJECTIONS USING FORMALIN KILLED YEAST AND MYCELIAL PHASE CELLS OF *HISTOPLASMA CAPSULATUM*

Inoculum	Route of inoculation	No. guinea pigs per group	No. guinea pigs positive to histoplasmin	Per cent positive	No. weeks required to sensitize
Mycelial particles	Aerosol†	14	14	100	7 to 10
	Subcutaneous	10	10	100	5 to 12
Whole yeast cells	Aerosol‡	10	8	80	7 to 11
	Subcutaneous	10	10	100	7 to 10
None (control)	—	14	0	0	—

* Experiment terminated after 20 weeks.

† Five hundred particles/g pig initial dose 1000/g pig after 3 weeks.

‡ Nineteen hundred cells/g pig initial dose 3800/g pig after 6 weeks.

(TABLE 1). When animals were given 2 exposures to this aerosol, 8 of 10 (80 per cent) converted to a positive skin test (TABLE 2).

Sensitization of Guinea Pigs by Exposure to Aerosols of Viable Mycelial Particles and Yeast Cells

Guinea pigs were exposed to aerosolized viable mycelial particles. According to calculations made from initial virility of cells in the nebulized suspension and from the results of plate counts made from impinger fluid, each guinea pig received approximately 3 viable particles. Eleven of 13 (84.6 per cent) of the animals became sensitive to histoplasmin in 1 to 6 weeks (TABLE 3).

Animals also were exposed to an aerosol of viable yeast cells of the fungus. The calculated number of living yeast cells inhaled per pig in those groups was 76. Ten of 11 (90.9 per cent) became sensitive to histoplasmin within 3 to 4 weeks (TABLE 3).

In calculating the dose of living inoculum, an estimation was made that each guinea pig would inhale either 500 particles or yeast cells of *H. capsulatum*

This was based on our experiences with the viability of the inoculum. However, the inoculum proved extremely fragile during the procedure of atomization. Although the viability of the mycelial phase is quite low, allowance was made for this factor in the preparation of the suspension concentration. This has not been the case with the yeast, in which the viability is usually greater than 30 to 35 per cent. Because of the diverse viability of the inoculum it would seem inconceivable that one could state unequivocally that sensitivity was due to the viable particles or cells. However, one significant observation can be made in that the sensitivity occurred much more rapidly in the experiment where small numbers of living particles or yeast cells were present.

TABLE 3
HISTOPLASMIN SENSITIVITY IN GUINEA PIGS AS A RESULT OF EXPOSURE TO AEROSOLS OF VIABLE MYCELIAL AND YEAST CELLS OF *HISTOPLASMA CAPSULATUM*

Inoculum	No. viable cells per guinea pig	No. guinea pigs per group	No. guinea pigs positive to 1:10 histoplasmin	Per cent positive	No. weeks required to sensitization
Mycelial particles	3	13	11	84.6	1 to 6*
Whole yeast cells	76	11	10	90.9	3 to 4†
None (control)	0	13	0	0	—

* Experiment terminated after 16 weeks

† Experiment terminated after 16 weeks

Skin Testing of Uninoculated Control Guinea Pigs

In the three experiments a total of 39 uninoculated control animals was given regular weekly histoplasmin skin tests. No conversion to a positive reaction occurred (tables 1, 2 and 3). This fact should be emphasized where the test antigen was used in a dilution of 1 to 10. Some investigators would discourage the use of histoplasmin of such potency although no unequivocal evidence exists that supports that sensitivity results from its use. The control animals in these investigations received a great number of skin test dosages over a period of 16 to 20 weeks. It would suggest that the sensitivity engendered in the experimental animals must have been of a low order.

Studies on Viability of Mycelial Particles of *Histoplasma capsulatum*

The number of infectious or sensitizing particles must play an important role in the epidemiology of histoplasmosis. If sensitivity to histoplasmin in humans results only from living inoculum then the percentage of viable cells of an isolate may be the limiting factor. This was not found to be true for experimental guinea pigs in which nonviable particles stimulated a reaction.

Does skin test sensitivity to histoplasmin signify immunity to histoplasmosis? One of the goals of the airborne studies was to determine the relationship of histoplasmin sensitivity to immunity. The procedure was carried out under natural conditions by using the mycelial phase for the skin test antigen. Unfortunately early in these studies viability of the aerosolized inoculum proved to be a serious problem. Impinger samples plated on yeast

an extremely low viability and, in some instances, there was no growth from the sample

To determine the degree of immunity elicited in the experimental animals a series of sensitized animals was to be challenged with varying doses of viable inoculum. This could not be done with certainty, as demonstrated by preliminary results with aerosols containing live mycelial particles. Past experiences with the mycelial phase had shown that the viability of most isolates on artificial media was low. However, no thorough study of the viability of mycelial phase suspensions had been conducted. In view of these factors it was necessary to make a complete study of the viability of the isolates that were to be used in the airborne investigations.

TABLE 4
VIABILITY OF MYCELIAL PARTICLES FROM FOUR ISOLATES OF *HISTOPLASMA CAPSULATUM**

Isolate	Age of culture in weeks											
	0.5		1		2		3		4		5	
	Average colonies per plate	Percent viability	Average colonies per plate	Percent viability	Average colonies per plate	Percent viability	Average colonies per plate	Percent viability	Average colonies per plate	Percent viability	Average colonies per plate	Percent viability
Scratchfield	9.4	3.1	16.9	5.6	52.8	17.6	3.3	1.1	15.1	5.0	43.0	14.3
Santhuff	2.6	0.9	57.8	19.3	2.8	0.9	16.6	5.5	5.8	1.9	33.1	11.0
Stimpson	12.1	4.0	48.6	16.2	3.8	1.3	12.4	4.1	17.2	5.7	32.2	10.7
Gangel	2.0	0.7	27.4	9.1	0.5	0.2	0.5	0.2	0.5	0.2	0.3	0.1

* Three week-old seed cultures

† Ten plates for each determination; plates each seeded with 300 particles

The viability of mycelial particles prepared from 4 recent isolates of the fungus was determined. These cultures were originally isolated from human cases of histoplasmosis. Each isolate was grown on Sabouraud's dextrose agar for 3 weeks at room temperature and designated a seed culture. The mycelial particles were harvested and prepared as previously discussed, and a series of 250-ml Erlenmeyer flasks containing 25 ml of media were seeded with each isolate. At designated periods flasks were selected randomly and the inoculum harvested for each isolate. In each instance approximately 300 particles were plated on each of 10 plates of test medium for viability determinations. In this procedure all mycelial components, not only spores, were counted. In TABLE 4 are presented the average numbers of colonies per plate and the percent viability obtained from each suspension. In FIGURE 1 the data are shown graphically. It is evident that none of the 4 isolates had a viability greater than 20 per cent. The highest viability occurred within the first 2 weeks of incubation in all 4 isolates. In 3 of the isolates there was a precipitous drop in viability during the second week after seeding. The Scratchfield isolate had the highest viability at 2 weeks and dropped from 17.6 to 1.1 per cent

viable between the second and third weeks of incubation (TABLE 5). The Gangel isolate had a viability of 91 per cent at 1 week then dropped to less than 10 per cent and remained low during the next 5 weeks. In the other isolate there was a rise in viability at either 4, 5, or 6 weeks. There were many



FIGURE 1. Viability of mycelial particles from four isolates of *Histoplasma capsulatum* three weeks of seed cultures.

TABLE 5

EFFECT OF AGE OF SEED CULTURES ON THE VIABILITY OF MYCELIAL PARTICLES OF *HISTOPLASMA CAPSULATUM* (Scratchfield Isolate)

Age of seed culture (weeks)	Age of culture in weeks											
	1		2		3		4		5		6	
	Average no. colonies per plate*	Per cent colonies viable	Average no. colonies per plate	Per cent colonies viable	Average no. colonies per plate	Per cent colonies viable	Average no. colonies per plate	Per cent colonies viable	Average no. colonies per plate	Per cent colonies viable	Average no. colonies per plate	Per cent colonies viable
2	128.9	43.0	31.3	10.4	14.7	4.9	38.3	12.7	24.0	8.0	33.0	11.0
3	56.9	5.6	52.8	17.6	3.3	1.1	55.1	5.0	43.0	14.3	49.3	16.4
6	80.4	26.8	33.2	11.1	30.6	10.2	15.7	5.2	14.1	4.7	21.7	7.2

* Ten plates for each determination; 10 plates each seeded with 300 particles.

factors perhaps associated with these rises in viability percentages but spore germination and germination played a significant role.

The findings in these studies raised the question as to what effect the age of the seed culture may have on the viability of an isolate. The Scratchfield isolate was chosen for study because of its uniform growth and because we had preliminary data on its behavior in the Henlerson apparatus. In

TABLE 2 the average number of colonies and per cent viability by age of culture from 2, 3, and 6-week seed cultures are presented. In FIGURE 2 the comparison of age of seed culture and viability by weeks is shown. It is obvious, with the Scritchfield isolate, that the inoculum from a 2-week-old seed culture has the highest viability after 1-week transfer to new medium. In all of the additional studies no greater than 43 per cent viability was observed.

The viability factor is an important one in inhalation studies when the Henderson apparatus is employed. The suspension of inoculum atomized by the Collison Nebulizer must contain particles of a certain size range. Therefore, it is mandatory that hemacytometer counts be made of the inoculum to




FIGURE 2 Effect of age of seed cultures on the viability of mycelial particles of *Histoplasma capsulatum* (Scritchfield isolate)

determine the kind of components and the size distribution of the particles in the suspension. Unfortunately, there are disadvantages that have become apparent in our experiences in that mycelial particles, as well as yeast cells, seem to be quite fragile. Attempts to increase the efficiency in the atomization of the particles by further breaking up the mycelium led to a much lower viability of the inoculum. A great many problems still need to be solved before a satisfactory challenge with live mycelial particles can be obtained with aerosols in the Henderson apparatus. However, challenge with living yeast cells is quite feasible, but not infallible.

Summary

High histoplasmin sensitivity rates among school children in areas of low endemicity for histoplasmosis have been reported in Georgia and Michigan.

A definite reversal in the usual higher incidence of positive skin test reactors in rural as compared to urban residents was established. The epidemiological studies suggested the possibility of a source or sources of inoculum within the urban locations. Direct or indirect contact with these sources resulted in significant histoplasmin sensitivity rates among the urban residents. Acute histoplasmosis epidemics have occurred in Wisconsin and Missouri the nature of these permitted thorough epidemiological studies. Illness could be correlated with the activity of the individuals at the sites of each epidemic. *H. capsulatum* was isolated from point sources within the environs of each city. Bird droppings were obvious at the site of the outbreak in Missouri but none were as evident in the soil samples from the Wisconsin area.

The development of experimental histoplasmin sensitivity in guinea pigs has been investigated. Initial studies showed that tissue sensitivity could be elicited by subcutaneous or intranasal inoculation of either whole yeast cells or yeast cell walls of *H. capsulatum*. In each of these instances a series of inoculations was used. Positive skin reactions were best demonstrated 24 hours after intradermal injection of histoplasmin.

Efforts to develop histoplasmin sensitivity in guinea pigs by exposure to aerosols produced in many instances by the use of small inoculum. This has been accomplished in many instances by the use of small inoculum. Challenge of large numbers of these animals have proved highly successful. The low viability of mycelial particles has yielded scanty sporadic results. The low viability of mycelial particles has been a deterrent in this regard and this fact prompted a thorough study of the whole question of viability. It has been found that many factors influence the viability of mycelial particles of the fungus, the most important being age of the culture. (One to two-week-old cultures have consistently yielded the highest viabilities.)

Yeast cells of *H. capsulatum* have been found suitable for aerosol studies utilizing the Henderson apparatus. It has been necessary, however, to alter many previously existing experimental procedures in view of the slow growth and fragile nature of these cells.

Acknowledgments

I express my sincere appreciation to Michael L. Furcolow and his staff for their continued support and aid in these studies. The aerosol investigations were done at the Kansas City Field Station, Public Health Service, Kansas City, Kansas.

Special gratitude is due my colleague, George C. Cozad, for his assistance in the preparation of the manuscript and for his expert technical assistance throughout these studies.

References

1. FURCOLOW, M. L. 1958. Recent studies on the epidemiology of histoplasmosis. *Ann. N.Y. Acad. Sci.* 72: 129-163.
2. FURCOLOW, M. L., G. C. COZAD, & D. BARRETT. 1958. Sensitivity to tuberculin histoplasmin and coccidioidin among high school students in northwestern Georgia. *The cases of* *Chest* 51: 467-493.

TABLE 2 the average number of colonies and per cent viability by age of culture from 2, 3, and 6-week seed cultures are presented. In FIGURE 2, comparison of age of seed culture and viability by weeks is shown. It is obvious, with the Scritchfield isolate, that the inoculum from a 2-week-old culture has the highest viability after 1 week transfer to new medium. In all of the additional studies no greater than 43 per cent viability was observed.

The viability factor is an important one in inhalation studies when Henderson apparatus is employed. The suspension of inoculum atomized by the Collison Nebulizer must contain particles of a certain size range. Therefore, it is mandatory that hemacytometer counts be made of the inoculum




FIGURE 2 Effect of age of seed cultures on the viability of mycelial particles of *Histoplasma capsulatum* (Scritchfield Isolate)

determine the kind of components and the size distribution of the particles in the suspension. Unfortunately, there are disadvantages that have become apparent in our experiences in that mycelial particles as well as yeast cells seem to be quite fragile. Attempts to increase the efficiency in the atomization of the particles by further breaking up the mycelium led to a much lower viability of the inoculum. A great many problems still need to be solved before a satisfactory challenge with live mycelial particles can be obtained with aerosols in the Henderson apparatus. However, challenge with living yeast cells is quite feasible but not infallible.

Summary

High histoplasma sensitivity rates among school children in areas of low endemicity for histoplasmosis have been reported in Georgia and Michigan

A definite reversal in the usual higher incidence of positive skin test reactors in rural as compared to urban residents was established. The epidemiological studies suggested the possibility of a source or sources of inoculum within the urban locations. Direct or indirect contact with these sources resulted in significant histoplasmin sensitivity rates among the urban residents.

Acute histoplasmosis epidemics have occurred in Wisconsin and Missouri the nature of these permitted thorough epidemiological studies. Illness could be correlated with the activity of the individuals at the sites of each epidemic. *H. capsulatum* was isolated from point sources within the environs of each city. Bird droppings were obvious at the site of the outbreak in Missouri but none were as evident in the soil samples from the Wisconsin area.

The development of experimental histoplasmin sensitivity in guinea pigs has been investigated. Initial studies showed that tissue sensitivity could be elicited by subcutaneous or intranasal inoculation of either whole yeast cells or yeast cell walls of *H. capsulatum*. In each of these instances a series of inoculations was used. Positive skin reactions were best demonstrated 24 hours after intradermal injection of histoplasmin.

Efforts to develop histoplasmin sensitivity in guinea pigs by exposure to aerosols produced in the Henderson apparatus have proved highly successful. Large numbers of these animals have been sensitized by exposure to aerosols of viable and nonviable mycelial particles of *H. capsulatum*. This has been accomplished in many instances by the use of small inoculum. Challenge of guinea pigs by exposure to aerosols of viable mycelial particles of the pathogen has yielded scanty sporadic results. The low virility of mycelial particles has been a deterrent in this regard and this fact prompted a thorough study of the whole question of viability. It has been found that many factors influence the viability of mycelial particles of the fungus the most important being age of the culture. One- to two-week-old cultures have consistently yielded the highest viabilities.

Yeast cells of *H. capsulatum* have been found suitable for aerosol studies utilizing the Henderson apparatus. It has been necessary, however, to alter many previously existing experimental procedures in view of the slow growth and fragile nature of these cells.

Acknowledgments

I express my sincere appreciation to Michael L. Furcolow and his staff for their continued support and aid in these studies. The aerosol investigations were done at the Kansas City Field Station Public Health Service, Kansas City, Kans.

Special gratitude is due my colleague George C. Cozad for his assistance in the preparation of the manuscript and for his expert technical assistance throughout these studies.

References

1. FURCLOW, M. L. 1958. Recent studies on the epidemiology of histoplasmosis. *Ann. N. Y. Acad. Sci.* 72(3): 129-163.
2. EDWARDS, P. Q., C. F. JACOBS, & D. RABIZZO. 1958. Sensitivity to tuberculin, histoplasmin and coccidiosis among high school students in north eastern Georgia. *Diseases of Chest* 34: 467-483.

- 3 WHITEHOUSE, W M, W N DAVEY, H K FACHELLE & J F HOLT 1959 Roentgen findings in histoplasmin positive school children Mich State Med Soc J 88: 1266-1269
- 4 WILCOX, K R, B A WAISBREN & J MARTIN 1958 The Walworth, Wisconsin, epidemic of histoplasmosis Ann Internal Med 49: 388-418
- 5 THE MEXICO MISSOURI EPIDEMIC OF HISTOPLASMOSES To be published
- 6 EMMONS, C W, H B MORLEY & E L HILL 1949 Isolation of *Histoplasma capsulatum* from soil Public Health Repts U. S 64: 892-896
- 7 IBACIT, M J, H W FARSH & M L FURCOLOW 1954 Isolation of *H. capsulatum* from the air Science 119: 71
- 8 ROOKS, R 1954 Air borne *H. capsulatum* spores Science 119: 385-386
- 9 COZAD, G C & M L FURCOLOW 1953 Laboratory studies of *Histoplasma capsulatum* II Size of the spores J Infectious Diseases 92 77-84
- 10 BROWN, J H, K M COOK, F G. NEY & T HATCH 1950 Influence of particle size upon the retention of particulate matter in the human lung Am J Public Health 40 450-459
- 11 BUCKLAND, F E, G J HARPER & J H MORTON 1950 Use of spores labelled with radiophosphorous in the study of the respiratory retention of aerosols Nature 166 334
- 12 GRAYSTON, J T & M L FURCOLOW 1953 Occurrence of histoplasmosis in epidemics Epidemiological studies Am J Public Health 43: 665-676
- 13 HOWELL, A 1947 Studies of fungus antigens I Quantitative studies of cross-reactions between histoplasmin and blastomycin in guinea pigs Public Health Repts U S 62: 631-651
- 14 SALVIN, S B 1953 Immunization of mice against *Histoplasma capsulatum* J Immunol 70 267-270
- 15 SALVIN, S B & E RIBI 1955 Antigens from yeast phase of *Histoplasma capsulatum* II Immunologic properties of protoplasm vs cell walls Proc Soc Exptl Biol Med 90 287-294
- 16 ROWLEY, D A & M HUBER 1956 Growth of *Histoplasma capsulatum* in normal superinfected and immunized mice J Immunol 77: 15-23
- 17 HILL, H A & S MARCUS 1959 Resistance induced against *Histoplasma capsulatum* Quantitative aspects J Infectious Diseases 105 26-30
- 18 ROWLEY, D A & M HUBER 1955 Pathogenesis of experimental histoplasmosis in mice I Measurement of infecting dosages of the yeast phase of *Histoplasma capsulatum* J Infectious Diseases 96: 174-183
- 19 ELBERG S S & D W HENDERSON 1943 Respiratory pathogenicity of *Brucella* J Infectious Diseases 53 302-306

EMMONSIA CRESCENS SP. N. AND ADIASPIROVIRICOSIS
(HAPLOVIRICOSIS) IN MAMMALS

C. W. Emmons

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.

W. L. Jellison

Rocky Mountain Laboratory, Hamilton Mount, and Department of Microbiology, School of Public Health, Harvard University, Boston, Mass.

Studies of host range, ecology, and natural history of *Coccidioides immitis* Ruxford and Gilchrist, in the deserts of southern Arizona (Emmons 1942, Emmons and Ashburn 1942) revealed that many rodents in that area had mycotic pulmonary lesions. Two fungi were isolated in culture from these animals. One fungus, *C. immitis*, was isolated from 25 of 303 rodents. The other, previously unknown, was isolated from 101 of 303 animals. The fungi were isolated in culture from these animals had double infections and both

The new fungus was found only in pulmonary tissue where it appeared in the form of spherical cells which reached a diameter of 14μ but did not bud or exhibit any type of reproduction. When isolated in culture, the fungus colony grew rather slowly on glucose peptone agar at room temperature, reaching a diameter of 2 inches in 2 weeks (FIGURE 1). Some strains produced a fluffy colonies, others developed glabrous zones, more or less concentric in arrangement and some strains produced short coremia. Conidia were nearly spherical (3 to 4μ in diameter), but with the vertical axis perceptibly shortened so that spores appeared slightly flattened. They were borne on simple or compound conidiophores (FIGURE 2). In culture the fungus bore some resemblance to *Histioplasma capsulatum* Darling, but it did not produce macroconidia. In tissue its parasitic form was much larger than that of *Histioplasma*, and it did not reproduce by budding.

Young cells of the parasitic forms of the two fungi resembled each other, and this made it difficult at first to differentiate them. Further examination of pulmonary sections of many naturally infected animals, comparisons of the characteristics of fungus cells seen in sections with those of the fungi isolated from the same animal, and experimental infections of laboratory mice (in which the new fungus reached diameters of 35μ) finally resolved this confusion (Ashburn and Emmons, 1945). The new fungus never reproduced in tissue, and it stained more deeply with eosinate methylene blue and induced much less host reaction than did *C. immitis* (FIGURES 3-4). In culture there was no resemblance to *C. immitis*. Nevertheless, the close association of the two fungi in pulmonary mycoses in desert rodents and their similarities during early stages of parasitic growth led to the conclusion that they were genetically related. Moreover there were serologic cross reactions that indicated possession of common antigens.

Emmons (1942), having accepted the interpretation that *C. immitis* is a Phycomycete, compared the new fungus with members of some of the anomalous

genera of that class in an attempt to identify the new fungus. Although the hyphae were thinner than those of most Phycomycetes, there appeared to be some resemblance to *Haplosporangium* Thaxter. Through the courtesy of David Linder, the fungus was compared with the herbarium material of Thaxter and it was concluded that the fungus might be placed in *Haplosporangium*. Accordingly, it was named *Haplosporangium parvum* Emmons and Ashburn, the specific epithet referring to its smaller dimensions in culture than those of *Haplosporangium bisporale*.

Dowding (1947a) reported a fungus similar in culture to *H. parvum*, but with spherules reaching a diameter of 270μ , in the lungs of the red squirrel and white-footed mouse in western Canada. She isolated the fungus in culture and identified it by its conidial and mycelial characters with the Arizona fungus but noted the greater size of its parasitic form. Jellison in 1944 had observed in the lungs of a rock rabbit, *Ochotona princeps*, a parasite that he was unable to identify or to have identified, and he reported this in 1947 as an undetermined parasite (Jellison, 1947). Later he (Jellison, 1950) observed or isolated in culture from 61 Montana mammals a fungus that he recognized as similar to the fungus reported by Dowding. From his collections and studies it became apparent that a fungus of this type is frequently present in the lungs of rodents (including the pine squirrel, white footed mouse, and such aquatic rodents as the muskrat and beaver) and in the cottontail rabbit, mink, weasel, pine marten and skunk. Jellison also demonstrated its widespread geographic distribution in the northern United States, Korea, Japan, Africa and Sweden (Jellison, 1950, 1954, 1956, 1958) and in Norway, Finland, France, Yugoslavia and Ecuador (Jellison *et al.* 1959).

Erickson (1949) reported a similar fungus (without cultures) in the beaver in Minnesota. Bakerspigel (1956) found it in the white footed mouse in Saskatchewan. McDiarmid and Austwick (1954) found the fungus present in a very high percentage of moles in England, and Tevis (1956) reported he had seen in the lungs of several species of rodents in England objects which in retrospect, he believed were spherules of *Haplosporangium*. Because of the isolation of the fungus from animals in so many widely separated geographic areas it is apparent that the original concept of *Haplosporangium* as a desert species with a limited geographic distribution is erroneous.

It is reasonable to suppose that the natural habitat of *Haplosporangium* is soil and that this is the source from which mammals are infected. Menges and Habermann (1954) have reported the isolation of this fungus from soil in Missouri, but their description of the histopathology of experimentally infected animals arouses doubt as to the correctness of the identification.

FIGURE 1. Colony of *Emmonsia parva* on modified Sabouraud agar after incubation for 2 weeks at 30°C .

FIGURE 2. Immature conid ophores and conidia (aleurospores) of *E. parva*. $\times 1120$.

FIGURE 3. *E. parva* and *Coccidioides immitis* in naturally infected pocket mouse (*Perognathus sp.*). One small adiaspore of *E. parva* is outside the coccidioidal granuloma and two have been incorporated into the granuloma. $\times 250$.

FIGURE 4. Mature adiaspore of *E. parva* in lung of experimentally infected white mouse. $\times 400$.




Emmons, after examining their fungus, reported to them that the culture bears some resemblance to *Haplosporangium* but is unlike any strain I have seen." Ciferri and Montemartini (1959) reported that Ciferri isolated *H. parvum* from soil in Italy.

The systematic position of *H. parvum* within the Phycomyces has been challenged justifiably by several mycologists. Continued studies of naturally infected rodents and of experimentally infected mice and guinea pigs fail to reveal any type of sporulation in the large spherical Coccidioideslike cells of the fungus in its parasitic form in the lung. We have long accepted the opinions of other mycologists that the fungus was improperly placed in the Phycomyces and in the genus *Haplosporangium*.

Dowding (1947b) discussed the taxonomic position of *H. parvum* and called attention to the resemblance of this species to *Histoplasma* and *Blastomyces*. Carmichael (1951) reinvestigated the question of segregating the northern North American strains of the fungus (which reach a diameter of 400 μ in lung tissue) in a separate species, but he concluded that there were strains intermediate in size and that a clear separation on the basis of differences in dimensions could not be made. He stated that the fungus must be excluded from *Haplosporangium* Thaxter and that its closest relationship is to *B. dermatitidis*. Breslau (1955) stated that the cell wall of *Haplosporangium* is composed of cellulose lying in a protein matrix relatively free of phospholipid while the wall of *Coccidioides* "contains chitin, which lies in a protein matrix having an exterior wall of phospholipid." He stated that the two fungi therefore, were not related. Blank (1957), however, found no cellulose in the cell wall of *Haplosporangium*, but demonstrated the presence of chitin.

Ciferri and Montemartini (1959) have created a new monotypic genus *Emmonsia*, for *H. parvum*. We accept this designation, but with some reluctance, because we expect that a suitable earlier generic name eventually may be found. It seems improbable that a fungus that so frequently invades the lungs of rodents and presumably inhabits soil or humus should have escaped the notice of mammalogists and mycologists until 1942. Jellison *et al.* (unpublished data, 1959) found this fungus in the preserved lungs of a rodent (*Microtus agrestis*) trapped as long ago as 1845 in Sweden. The pulmonary lesions in rodents are conspicuous, and the individual fungus cells themselves with a diameter reaching 480 μ , are often visible to the unaided eye just below the lung pleura. The fungus grows slowly but freely on ordinary culture media at temperatures of 20 to 30° C, and it may have been isolated in the past by soil microbiologists. However, a search of mycologic literature has failed to reveal a genus suitable to contain this fungus. In culture, in spite of the resemblance of its conidia (aleuriospores) to the microconidia of *Histo*

- FIGURE 5 *E. crescens* Conidiophores and conidia (aleuriospores) $\times 1575$
 FIGURE 6 *E. crescens* Ahaq spores after 3 weeks incubation at 37° C on blood agar $\times 205$
 FIGURE 7 *E. crescens* Adiaspore after 8 months incubation at 37° C on blood agar $\times 205$
 FIGURE 8 *E. crescens* Ahaq spore after 8 months incubation at 37° C on blood agar $\times 205$
 FIGURE 9 *F. crescens* Adiaspore after 8 months incubation at 37° C on blood agar
 Note irregular fracture of wall and partial loss of contents $\times 205$



plasma, it never produces macroconidia of the *Histoplasma* type, and its tissue form differs from that of *Histoplasma* by its enormous size and its failure to bud or reproduce in any manner. In culture it differs from *B. dermatitidis* by the uniformity of size of its conidia and in tissue by its large size and failure to bud.

Geomyces vulgaris Traaen, which Ciferri and Montemartini (1939) state "is strictly allied, if not identic [*sic*], with *H. parvum*," is distinctly different in growth habit and morphology from *H. parvum*. We have examined what we believe to be authentic cultures of this fungus obtained from the American Type Culture Collection (No. 6685), Washington, D. C., and from the Central bureau voor Schimmelcultures, Baarn, Holland, and we agree with Bisby (1945) that this fungus belongs in the genus *Aleurisma* of Vuillemin. The conidophores of *Aleurisma* are tapered and diverge from the vegetative mycelium at an acute angle and most aleuriospores are asymmetrical, with one side more convex than the other. This genus does not produce large spherules in the lungs of experimentally infected animals nor when incubated at 37° C. In fact, temperatures as high as 30° C. inhibit its growth. Other fungi mentioned by Ciferri and Montemartini such as *Glenosporiella*, *Botryotrichum*, and *Staphylo-trichum*, seem to us to be so different from *H. parvum* in colony and morphologic characteristics that transfer to one of these genera need not be considered. We therefore follow these mycologists and accept the name *Emmonsia parva*.

In our experience mature cells of *Emmonsia* in pulmonary tissue of naturally or experimentally infected animals fall into two groups, usually well separated on the basis of size. This obvious difference is correlated with other differences that are more fundamental in specific differentiation. Accumulated experience with several hundred isolates of these fungi including experimental infections with many strains, induces us to describe the large form as a new species. The specific name refers to the parasitic form of the species and signifies its increase in size.

Emmonsia crescens n. sp. Colony white, reaching a diameter of 3 to 5 cm. in 10 days at 30° C. on Sabouraud's agar. Growth poor on cornmeal and Czapek's agar media. Colony varying with the strain from floccose and uniform throughout to coremiform or with irregularly scattered or zonate glabrous areas, mycelium delicate, hyphae 0.5 to 2 μ in diameter, septate freely branching, conidiophores arise at right angles from vegetative hyphae varying from simple, short lateral branches 1 to 2 \times 2 to 10 μ to compound and 2 to 5 \times 8 to 20 μ , with secondary short conidiophores arising at right angles from the primary conidiophores, conidia (aleuriospores) borne single or rarely in chains of two, subspherical, slightly shortened along the vertical axis, 2 to 4 \times 2.5 to 4.5 μ , minutely spiny, adherent to the conidiophore (FIGURE 5).

-
- FIGURE 10 *E. crescens* Adiaspore in lung of *Arvicola terrestris* Natural infection type specimen $\times 63$
 FIGURE 11 Same as #10 Note minimal host reaction $\times 63$
 FIGURE 12 *E. parva* Adiaspores after incubation for 3 weeks at 40° C. on blood agar $\times 400$
 FIGURE 13 *E. parva* Adiaspore from experimental infection in white mouse Note single nucleus $\times 1575$

When incubated at 37° C on any media, but preferably on an enriched medium such as glucose blood agar, the conidia and some hyphal cells enlarge to spherical multinucleate cells up to 400 μ in diameter with walls reaching a thickness of 70 μ , no budding endosporeulation or reproduction of any type observed, although metabolic products and eventually degeneration artefacts may superficially resemble endospores (FIGURES 6-9)

These large cells appear to be identical in nature to the parasitic form of the fungus seen in lungs of animals (FIGURES 10, 11). In animal tissue, inhaled or experimentally introduced conidia enlarge to multinucleate spherical cell that may reach a diameter of 480 μ , walls strongly Schiff positive, up to 70 μ thick of two definite layers, the outer surface rough or sculptured, mature cells contain many nuclei 1 to 1.5 μ in diameter and small globules of metabolic materials that usually coalesce to form one or two irregularly shaped bodies no budding, endosporeulation or reproduction of any kind, calcium may be deposited in the fungus cell after its death. Presence in pulmonary tissue especially if fungi are few, induces minimal host tissue response during early stages of growth. Fungi, when present in very large numbers, reduce effective lung tissue by mechanical displacement. Recovery in culture is easily accomplished with immediate reversion to mycelial form if cultured at 20° to 30° C.

The habitat is presumably soil, humus, or decomposed vegetation, but known principally from the lungs of several species of rodents and other animals.

We designate as the type culture an isolate from the lungs of a rodent *Articola terrestris*, captured at Hamar, Norway, in 1959. Sections of tissue and cultures have been deposited in the American Type Culture Collection under the number 13704. Sections of the lung of this rodent host are deposited also in the National Mycological Herbarium and in the files of the Armed Forces Institute of Pathology, both in Washington, D. C.

Emmonsia crescens sp. n. Colonius albis et floccosis cultitatis in gelosa cum dextroso peptonique, hyphis 0.5-2 μ diam., conidiophoris ad angulos rectos vel simplicibus et 1-2 \times 2-10 μ vel compositis et 2-5 \times 8-20 μ , conidis cum spinis minutis, brevialis in axe verticali, 2-4 \times 2.5-4.5.

In pulmonibus animalis et ad 37° C in vitro, conidia possunt fieri cellulas globosas, interdum 480 μ diam. et cum parietibus 10-70 μ cr.*

We propose the epithet *crescens* to indicate the enormous increase in size of conidia in animal tissue and in vitro at 37° C.

We propose the term *adiaspore* for the large spherule which, in the species *E. crescens*, grows to a volume 1,000,000 times that of the inhaled or incubated conidium from which it arises.

We propose the name *adiaspiromycosis* to designate the pulmonary disease caused by species of *Emmonsia*. *Adiaspiromycosis* is derived from *αδιασπείρειν-μυκησις* *osis*, a term descriptive of this mycosis in which there is no multiplication or dissemination of the fungus beyond its original site of implantation.

* Colonies on dextrose peptone agar white floccose hyphae 0.5-2 μ in diameter conidophores borne at right angles simple and 1-2 \times 2-10 μ or branched and 2-5 \times 8-20 μ conidia with minute spines shortened in vertical axis 2-4 \times 2.5-4.5 μ .

In lungs of animals and in vitro at 37° C conidia increase in size reaching a diameter of 480 μ and with walls 10-70 μ thick.





FIGURE 14 *E. crescens*. Edge of adiaspore from experimental infection on white mouse. Note very numerous peripheral nuclei. $\times 1575$.

FIGURE 15 *E. crescens*. Adiaspores which were incubated for 3 weeks at 37°C on blood agar then removed to room temperature. Note multiple germ tubes from two adiaspores and the rupture of one which was not viable. $\times 200$.

Colonies of *E. crescens* are indistinguishable from those of *E. parva* in culture at 30° C. They fall within the limits of colony variability of that species. *E. crescens* resembles *E. parva* also in morphology, but produces slightly more compound conidiophores. The conidia of the two species are indistinguishable (FIGURES 2-5). However when incubated on blood agar at 37° C. the conidia of *E. crescens* grow by spherical enlargement from their original size of 2.5 to 4 μ to a diameter of 250 to 400 μ (FIGURES 6-9). The wall, which is Schiff positive, may reach a thickness of 70 μ . *E. parva* on the contrary grows in mycelial form at 37° C. but if the temperature of incubation is raised to 40° C. some strains of this species produce asexual spores (FIGURE 12) comparable to those of its parasitic form. These cells *in vitro* usually reach a diameter of only 10 to 25 μ with walls not exceeding 2 μ thick. In the mouse lung they reach a diameter of 40 μ with a wall 4 μ in thickness (FIGURE 13). *E. parva* may be described as more thermophilic than *E. crescens* (which does not grow at 40° C.) in attribute perhaps related to its occurrence in hot climates.

The asexual spores of *E. crescens* *in vitro* and *in vivo* are multinucleate (FIGURE 14) while those of *E. parva* are uninucleate (FIGURE 13) even after reaching their mature size (Ashburn and Emmons 1945). Asexual spores of both species contain globules of metabolic products that at certain stages may resemble endospores but usually in older asexual spores these bodies coalesce into one mass. Natural infection has been observed only in the lungs.

When asexual spores of *E. crescens* incubated at 37° C. for 2 or 3 weeks are incubated subsequently at 30° C. or room temperature they germinate by producing many hyphae (FIGURE 15). This germination by multiple germ tubes presumably is related to the multinucleate condition of the asexual spore of *E. crescens*. When the incubation temperature of an asexual spore of *E. parva* is lowered from 40° to 30° C., the spore germinates by a single germ tube.

The persistent uninucleate condition of asexual spores of *E. parva* and the multinucleate condition of those of *E. crescens* constitute a remarkable and important difference between these two species. The nuclei of these fungi can be demonstrated only after special handling. The tissues illustrated in FIGURES E and D in the paper by Ashburn and Emmons (1945) and those illustrated in FIGURES 4-13 and 14 of this paper were processed in the laboratory of one of us (C. W. E.) following procedures outlined in a recent description of fungus nuclei (Emmons 1959).

There appears to be a geographic separation of the two species although this must be studied further by additional collections of specimens. In so far as we know *E. parva* has been isolated in culture only in the arid Southwest the most northerly collection being from St. George, Utah. One collection from Africa (without culture) may be *E. parva*. *E. crescens* on the other hand has been reported or found by one of us (W. L. J.) in Montana, Korea, Sweden, Africa, Norway, Finland, France, Yugoslavia, Ecuador and as previously stated by other mycologists in Canada, England and Italy.

Summary

Transfer of *Haplosporangium parvum* to Ciferri's and Montemartini's new genus *Emmonsiopsis* as *Emmonsiopsis parva* is noted. *Emmonsiopsis crescens* sp. n. is segregated from the former species on the basis of its greater size in the

adospore or parasitic form (200 to 480 μ versus 14 to 60 μ), a thicker wall (10 to 70 μ versus 2 μ) the lower temperature required to produce adiaspores *in vitro* (37° C versus 40° C), and the multinucleate condition of the adiaspore. *E. parva* is known at the present time only from animals in the arid Southwest of the United States and possibly Africa, whereas *E. crescens* has been found in animals in the northern United States, Canada, England, Korea, Sweden, Norway, Japan, Africa, Finland, France, Yugoslavia, and Ecuador. *E. crescens* has been isolated in culture from animals in Canada, the United States, England, Norway, Sweden, and Finland. An isolate from *Arvicola terrestris* collected at Hamar, Norway, has been designated as the type culture of this new species. The pulmonary disease caused by species of *Emmonsia* is designated adiaspiromycosis to signify the absence of multiplication and dissemination of the fungus in the animal host.

Acknowledgment

We are indebted to W. H. Everhardy for preparing the Latin diagnosis of the fungus and devising the name of the disease.

References

- ASHBURN, L. L. & C. W. EMMONS. 1945. Experimental *Haplosporangium* infection. *A. M. A. Arch. Pathol.* 39: 3-8.
- BAHRSPIGEL, A. 1936. *Haplosporangium* in Saskatchewan rodents. *Mycologia* 48: 568-572.
- BIBBY, G. R. 1945. Notes on British Hyphomycetes. *Brit. Mycol. Soc. Trans.* 27: 101-112.
- BLANK, F. 1937. Note on the chemical composition of cell wall of *Haplosporangium parvum*. *J. Histochem. Cytochem.* 6: 500-502.
- BRESLAU, A. M. 1955. Comparative histochemical studies on *Coccidioides immitis* and *Haplosporangium parvum*. *J. Histochem. Cytochem.* 3: 141-147.
- CARMICHAEL, J. W. 1951. The pulmonary fungus *Haplosporangium parvum*. II. Strain and generic relationships. *Mycologia* 43: 603-624.
- CIFERRI, R. & A. MONTMARTINI. 1950. Taxonomy of *Haplosporangium parvum*. *Mycologia Applicata* 10: 303-316.
- DOWDING, F. B. 1947a. *Haplosporangium* in Canadian rodents. *Mycologia* 39: 372-373.
- DOWDING, F. B. 1947b. The pulmonary fungus *Haplosporangium parvum* and its relation to *Coccidioidomycosis*. *Can. J. Research* E28: 193-206.
- DOWDING, F. B. 1942. *Coccidioidomycosis*. *Mycologia* 34: 452-463.
- EMMONS, C. W. 1939. Fungus nuclei in the diagnosis of mycoses. *Mycologia* 51: 227-236.
- EMMONS, C. W. 1942. The isolation of *Haplosporangium parvum* n. sp. and *Coccidioides immitis* from wild rodents. Their relationship to coccidioidomycosis. *Public Health Repts. U. S.* 57: 1715-1727.
- ERICKSON, A. B. 1949. The fungus (*Haplosporangium parvum*) in the lungs of the beaver (*Castor canadensis*). *J. Wildlife Management* 13: 419-420.
- JELLISON, W. L. 1947. An undetermined parasite in the lungs of a rock rabbit *Ochotona princeps* Richardson (Lagomorpha: Ochotomidae). *Proc. Helminthol. Soc. Washington* 14: 75-77.
- JELLISON, W. L. 1950. Haplosporangiosis in Montana rabbits, rodents and carnivores. *Public Health Repts. U. S.* 65: 1037-1063.
- JELLISON, W. L. 1954. The presence of a pulmonary fungus in Korean rodents. *Public Health Repts. U. S.* 69: 996-997.
- JELLISON, W. L. 1956. Haplosporangiosis in Sweden. *Nord. Veterinärmed.* 8: 504-506.
- JELLISON, W. L. 1958. Haplosporangiosis in Japan and Africa. *Mycologia* 50: 580-583.
- JELLISON, W. L. & P. K. C. ALSTEDT. 1954. Occurrence of *Haplosporangium parvum* in the lungs of the mole (*Talpa europaea*). *Nature* 174: 843.
- MENGES, R. W. & R. T. HABERMANN. 1954. Isolation of *Haplosporangium parvum* from soil and results of experimental inoculations. *Am. J. Hyg.* 60: 106-116.
- TEVIS, L. JR. 1956. Additional records of *Haplosporangium parvum* in mammals in Brit. *Nature* 177: 437.

STUDIES OF THE GROWTH AND METABOLISM OF *COCCIDIOIDLS IMMITIS*

George W. Lones and Carl L. Parcock

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.

The *in vitro* growth of the spherule form of the dimorphic fungus *Coccidioides immitis* has been reported frequently since it was first observed by MacNeal and Taylor¹ in 1914. The literature concerned with the occurrence of the spherules in culture has recently been reviewed by Liese.² For the most part the early reports described the formation of spherules accompanied by considerable mycelial growth. More recently Lubarsky and Plunkett³ cultured spherules in the absence of mycelium in a medium containing chicken serum and embryo extract under increased carbon dioxide tension. An important contribution is that of Converse⁴ who devised a simple defined medium and procedure for the conversion of arthrospores and mycelial fragments of strain M 11 of the fungus to spherules. The spherule form was maintained successfully for three serial transfers.

It is the purpose of this report to describe our experience with prolonged cultivation by serial transfer of the spherule form of strain M 11 of *C. immitis* and to describe initial experiments intended to contribute to our meager knowledge of the metabolism of this fungus.

Arthrospores and mycelial fragments were prepared in shake cultures in a modification of the defined medium of Roessler and his co-workers⁵ containing K_2HPO_4 0.015 M, KH_2PO_4 0.015 M, MgSO_4 0.0008 M, ammonium acetate 0.08 M, glucose 2 per cent, and zinc 2 ppm. The magnesium concentration was reduced from the level recommended by Roessler to avoid precipitation of magnesium phosphate.

The medium and method of Converse⁴ were used for the conversion of arthrospores and mycelial fragments to spherules. This medium is similar to that of Roessler but contains the ingredients in a lower concentration and in addition 0.05 per cent of the dispersing agent Tamol N*. Ten to 25 ml. quantities of the autoclaved medium in Erlenmeyer flasks of a capacity 5 times the volume of medium were heavily inoculated with a suspension of arthrospores and mycelial fragments. The initial incubation was for 72 hours at 36° C. on a rotary shaker of 1 inch amplitude and 120 cycles/min. At the end of this period many spherules were present, some of them mature along with developing mycelium. Most of the mycelium could be removed as Converse has pointed out by filtration through several layers of sterile surgical gauze. The spherules were harvested by centrifugation and the supernatant fluid discarded. The cells were returned to fresh medium and reincubated. Thereafter transfers of the filtered, centrifuged cultures were at daily intervals with the entire yield of cells returned to the culture until the density of the inoculum amounted to about 1 mg. dry weight of cells per

* Rohm & Haas Company, New York, N. Y., described as a neutral sodium salt of a condensed aryl sulfonic acid.

ml. The volume of the culture was then gradually increased at each transfer but never to more than double the previous volume. When a culture volume of 100 ml was achieved the density at inoculation was controlled at 20 mg of cells per milliliter and the incubation period at 16 hours. For continued growth 200-ml cultures in liter flasks were found convenient. When larger quantities of cells were wanted multiple cultures were prepared.




FIGURE 1. Photomicrograph of a wet mount of *Coccidioides immitis* spherules after 41 transfers in liquid culture. X212

The determination of cell densities for the control of size of inocula and the determination of yields of cells were made by filtration of a measured volume of a suspension of cells through a dried and weighed HAMIL pore membrane followed by washing, drying to constant weight at 105° C. and reweighing. Under the conditions of culture here employed the cell density increased from 20 mg/ml at the time of inoculation to 40 to 45 mg/ml at the time of harvest.

The development of small amounts of mycelium along with the spherules continued for a time but with repeated transfer the amount of mycelium diminished and the frequency of filtration through gauze was reduced. After about 45 transfers the filtrations were discontinued entirely. The amount of mycelium present in these well established cultures was very small. Although

there is no known method for accurately measuring the proportion of a culture that is in the mycelial form. It is felt that the amount of mycelium was certainly less than 1 per cent and probably less than 0.1 per cent of the total cellular material. Spherule cultures have been carried in the manner described for as many as 160 consecutive transfers. Figure 1 is a photomicrograph of a wet mount of such a culture at the forty first transfer.

We have recently presented evidence showing that the beneficial effect of a large inoculum on the maintenance of the spherule growth form is due to the greater concentration of metabolic carbon dioxide in such cultures.⁴

The availability of an adequate and continuing supply of spherules facilitates the examination of this modification of the fungus in a manner not heretofore possible. The remainder of this report will describe the beginning of a study of the metabolic character of this microorganism.

Spherules grown as previously described were harvested and washed 3 times with sterile water in the centrifuge. Starved or depleted cells were obtained by shaking washed cells at a density of 20 mg/ml in sterile water for 16 hours at 36° C. Respiration and fermentation studies were carried out at 31° C in the conventional manner in a Warburg apparatus with 20-ml double side arm vessels. Unless otherwise noted flasks contained 1.5 ml of 0.05 M phosphate citrate buffer at pH 6.0 and 5.0 mg dry weight of cells in the main compartment. Either 0.5 ml of water or 20 μ mole of glucose in water was placed in 1 side arm and tipped in after equilibration. Where needed 0.5 ml of 0.1 N H₂SO₄ was added to the second side arm to release bound carbon dioxide at the end of the experiment. Where oxygen uptake was measured 20 per cent KOH solution was present in the center well. The total liquid volume was 3 ml. Anaerobiosis was created in vessels by sweeping with nitrogen freed of oxygen by passage over hot copper. When the contents of vessels were to be analyzed the vessels were chilled in ice water immediately after the final manometer reading opened and the contents quickly filtered through a millipore membrane. Glucose determinations were made on the filtrate as reducing sugar by the method of Folin and Malmros as described by Umbreit *et al.*⁵ Ethanol was determined by the microdiffusion method of Conway.⁶ Carbon 14 counts were determined with a Packard Tri Carb liquid scintillation spectrometer in methanol toluene water solution with 2,5-diphenylorazole and *p*-bis 2 (5 phenylorazoly) benzene as phosphors.

In TABLE 1 are summarized the results of a typical experiment in which the rates of respiration and fermentation of spherules were measured over a 3 hour period. For comparison the results of a similar experiment performed with the mycelial phase of strain M 11 are included. The mycelium was grown in shake culture for 16 hours at 36° C in the modified medium of Roessler previously described. The inoculum of 1 mg/ml was less than that of the spherule cultures because of the greater viscosity of the mycelial suspensions. At harvest the thick suspension obtained by centrifugation was dispersed by treatment for 30 sec in a chilled blender to facilitate handling of the suspension with pipettes. It was washed 4 times with sterile water before use in the metabolic studies. The starvation procedure was the same as that described for the spherules but at a density of 10 mg/ml.

Washed spherules exhibited an appreciable endogenous respiration that was reduced slightly by depletion. Respiration was stimulated by the addition of an excess of glucose. Anaerobically fermentation occurred that responded to added substrate. It is of interest that starvation of the spherules resulted in a substantial stimulation of the ability of the cells to ferment glucose. The reason for the activation of an anaerobic process by exposure of the cells to aerobic conditions in the starvation procedure is not known. The same stimulation was not obtained when the cells were shaken for 16 hours in nitrogen. Although the spherules possess the capacity for anaerobic metabolism we have been unable to detect any growth of either spherules or mycelium under completely anaerobic conditions.

The washed mycelium exhibited a higher endogenous oxygen uptake than the spherules and the rate was affected only slightly by glucose. However, the endogenous rate was reduced substantially in the starved mycelium and a response to glucose was now more apparent. A notable difference from the

TABLE 1
EFFECT OF STARVATION AND ADDED GLUCOSE ON RESPIRATION AND FERMENTATION
OF *COCCIDIOIDES IMMITIS*

Cells	Added substrate	$\mu\text{L}/\text{mg}$ of cells per hour			
		Spherules		Mycelium	
		O_2	Anaerob c CO_2	O_2	Anaerob c CO_2
Unstarved Unstarved Starved Starved	None	5.6	3.3	13.8	6
	20 μM glucose	18.7	7.7	15.7	5
	None	4.5	2.2	4.5	8
	20 μM glucose	18.9	12.6	12.0	1.3

spherules is seen in the much lower fermentative activity of the mycelium. It would be hazardous to attribute the differences noted solely to the morphological modifications of the organism since the mycelium was grown in a higher concentration of nutrients and at a lower cell density than the spherules. However, mycelium grown in the spherule medium from which Tamol N was omitted exhibited metabolic characteristics similar to those just described. In the mycelium grown on this dilute medium there appeared to be an increased tendency for fragmentation and arthrospore formation which became especially pronounced during the starvation procedure.

Under anaerobic conditions equimolar amounts of carbon dioxide and ethanol were formed by spherules as seen in TABLE 2. The glucose utilized is in good agreement with the theoretical amount required to account for the fermentation products only if it is assumed that the endogenous fermentation is suppressed by added glucose. Alternatively a small amount of glucose may be assimilated.

The optimal pH for both respiration and fermentation of spherules in buffer 0.03 M with respect to citrate phosphate and tris(hydroxymethyl)amino

TABLE 2
FERMENTATION OF GLUCOSE BY *COCCIDIOIDES IMMITIS* SPHERULES

Added substrate	μM per vessel		
	CO_2	Ethanol	Glucose d appearance
None	1.9	1.9	
20 μM glucose	5.3	5.4	2.7

methane (Tris) was found to be at or near 6, as seen in FIGURE 2. Initial pH values were used in preparing the figure. Measurements at the end of the experiment indicated no change greater than 0.2 of a pH unit except at pH 9 which dropped to 8.65. Phthalate and borate as buffers were found to inhibit metabolism. Acetate and succinate are oxidized by spherules. In




FIGURE 2. Effect of pH on fermentation and respiration of *Coccidioides immitis* spherules

addition at pH 4, acetate was an effective inhibitor of both respiration and fermentation to such an extent that a 0.03 M concentration completely abolished the utilization of glucose.

In order to determine the amount of glucose assimilated during respiration and the possible occurrence of metabolic products other than carbon dioxide, washed spherules were allowed to respire in the presence of glucose uniformly labeled with carbon 14. Analyses were made at the beginning and after 3 hours of respiration. The results are summarized in TABLE 3. It will be seen that approximately one half of the 19.9 μ mole of glucose added per vessel was utilized. Of this, 14 per cent was converted to carbon dioxide and 15 per cent to as yet unidentified substances remaining in the filtrate. It is

TABLE 3
OXIDATION OF C¹⁴ GLUCOSE BY *COCCIDIOIDES IMMITIS* SPHERULES

per cent to as yet

TABLE 3

OXIDATION OF C¹⁴ GLUCOSE BY COCCIDIOIDES IMMITIS SPOROZOITES

Time (hours)	μ M O ₂ consumed	μ M glucose found	Counts per vessel per minute*		
			Filtrate	CO ₂	
3	10.0	19.9	20 460	1199	
		10.4	12 036		
<div> <div>O consumption in absence of glucose</div> <div>Stimulation of O₂ consumption by glucose</div> <div>Glucose utilized</div> <div>Glucose converted to C compounds in filtrate</div> <div>Glucose derived CO₂</div> <div>Glucose assimilated (by difference)</div> </div>			μ M		
				2.8	
				7.2	
				9.5	
				1.5	
				8.1	
				6.7	

been de luted

* Background counts have been deducted

hoped that identification of these metabolic products may offer a clue to metabolic pathways in this fungus. By difference it may be calculated that 70 per cent of the glucose utilized was assimilated by the cells.

In conclusion the ease of prolonged cultivation of strain M 11 of *C. immitis* in the spherule phase suggests its use for the evaluation of antifungal agents of potential usefulness in the treatment of coccidioidomycosis. In addition the availability of almost unlimited quantities of cells produced in liquid culture recommends the method for production of material for fractionation and immunological studies.

An examination of certain of the metabolic properties of washed spherules has shown that respiration is increased by the addition of a metabolizable substrate such as glucose and that most of the glucose utilized is assimilated. Under the conditions of these experiments marked stimulation of respiration of the mycelial form by added glucose was obtained only after starvation of the cells. *C. immitis* is capable of anaerobic metabolism with the formation of carbon dioxide and ethanol from glucose. This activity, which is stimulated by starvation, is present in a much lower degree in mycelium than in spherules.

The optimal pH in citrate phosphate Tris buffer for both respiration and fermentation is at or near 6

References

- 1 MACNEAL W J & R M TAYLOR. 1914 *Coccidioides immitis* and coccidioidomycosis. J Med Research 30 261
- 2 FIFE M J. 1958 Coccidiomycosis. Thomas Springfield Ill
- 3 LUBARSKY R & O A PULASKI. 1955 *In vitro* production of the spherule phase of *Coccidioides immitis*. J Bacteriol 70 182
- 4 CONVERSE J L. 1957 Effect of surface active agents on endospore formation of *Coccidioides immitis* in a chemically defined medium. J Bacteriol 74 106
- 5 ROSSITER W G F J HERBST W G McCULLOUGH E C MILLS & C. R. BARNES. 1946 Studies with *Coccidioides immitis*. I Submerged growth in liquid media. J Infectious Diseases 70 12
- 6 LONES G W & C L PEACOCK. 1960 Role of carbon dioxide in the development of *Coccidioides immitis* strain M11. J Bacteriol 79 308
- 7 UMBREIT W W R H BURRIS & J F STAUFFER. 1957 Manometric Techniques. 238 Burgess Minneapolis Minn
- 8 CONWAY F J. 1957 Microdiffusion Analysis and Volumetric Error. 248 Crosby Lockwood & Son Ltd London England

APPROACHES TO THE PHYSIOLOGY OF COCCIDIOIDES IMMITIS*

Demosthenes Pappagianis† and George S. Kobayashi‡
University of California, School of Public Health, Naval Biological Laboratory,
Berkeley Calif

The report of Lones and Peacock in this publication provides striking and much needed advances in our knowledge of the physiology of *Coccidioides immitis*. It is indeed noteworthy that ethanol is produced by the spherule form. This may provide taxonomists with another point of similarity between *Coccidioides* and the Phycomycetes for, as Louis Pasteur showed, *Mucor racemosus* carried out alcoholic fermentation associated with reduced oxygen tension and a morphologic change. The significance of this mode of metabolism in pathogenesis by *C. immitis* and its possible susceptibility to potential therapeutic agents, for example, tetraethylthiuram disulfide, pose still further questions concerning this pathogen.

It is to be expected that further studies of interest and importance will result from the development of spherule culture method by Converse¹ and by their extension by Lones and Peacock and by Cobb and Levine² at the Naval Biological Laboratory. For example, in addition to metabolic studies, immunological explorations can be carried out on spherules. The development of immunity to coccidioidomycosis is supported strongly by clinical as well as by experimental evidence in this respect. Various cellular as well as cell free extracts of both spherules and mycelial forms now can be prepared, and improvements can be anticipated in experimental immunization procedures. In addition, the vexing problem of achieving success *in vitro* with experimental drugs and then meeting with failure when these are tested against the disease in experimental animals is familiar to all who have worked on the chemotherapy of coccidioidomycosis. Moreover spherules *in vitro* may provide a screening method.

Preoccupation with the production of spherules should not cause the problem of discouraging spherule formation *in vivo* to be overlooked. Two observations relative to this are the following.

First, the early stages after inoculation of *C. immitis* are attended by an active inflammatory response. This is exemplified in FIGURE 1, which shows the vigorous exudation of polymorphonuclear cells even phagocytosis of arthrospores, in alveoli of a mouse inoculated intranasally. Spherule formation with progressive disease then would follow if a virulent strain were used.

Second, it is recognized that a person with systemic coccidioidal disease but without dermal lesions may occasionally develop suppurative lesions draining at the skin if some trauma of the skin is incurred. This may suggest a predilection on the part of the *Coccidioides* cells for the resulting inflamed site. These

* The work described in this paper was supported in part by the Bureau of Medicine and Surgery, United States Navy and the Office of Naval Research, Washington D C under a contract with the Board of Regents of the University of California. Opinions contained in this report are not to be construed as reflecting the views of the Naval Service.

† Present address: Stanford University School of Medicine, Stanford, Calif.

‡ Present address: Department of Microbiology, Tulane University School of Medicine, New Orleans, La.

The optimal pH in citrate-phosphate Tris buffer for both respiration and fermentation is at or near 6

References

- 1 MACNEAL W J & R M TAYLOR. 1914 *Coccidioides immitis* and coccidioidal granuloma. J Med Research 30 261
- 2 FIESE M J. 1958 Coccidioidomycosis. Thomas Springfield Ill
- 3 LUBARSKY R & O A PRINKEET. 1955 *In vitro* production of the spherule phase of *Coccidioides immitis*. J Bacteriol 70 182
- 4 CONVERSE J L. 1957 Effect of surface active agents on endospore formation of *Coccidioides immitis* in a chemically defined medium. J Bacteriol 74 106
- 5 ROESSLER W G E J HERBST W G McCULLOUGH H C MILLS & C R BREWER. 1946 Studies with *Coccidioides immitis*. I Submerged growth in liquid mediums. J Infectious Diseases 79 12
- 6 LONES G W & C L LEACOCK. 1960 Role of carbon dioxide in the dimorphism of *Coccidioides immitis* strain M11. J Bacteriol 79 308
- 7 UMBREIT W W R H BURRIS & J F STAUFFER. 1957 Manometric Techniques. 238 Burgess Minneapolis Minn
- 8 CONWAY H J. 1957 Microdiffusion Analysis and Volumetric Error. 248 Crosby Lockwood & Son Ltd London England

Demosthenes Pappagianis† and George S. Kobayashi‡

University of California School of Public Health Naval Biological Laboratory
Berkeley Calif

The report of Lones and Peacock in this publication provides striking and much needed advances in our knowledge of the physiology of *Coccidioides immitis*. It is indeed noteworthy that ethanol is produced by the spherule form. This may provide taxonomists with another point of similarity between *Coccidioides* and the Phycomycetes for, as Louis Pasteur showed, *Mucor racemosus* carried out alcoholic fermentation associated with reduced oxygen tension and a morphologic change. The significance of this mode of metabolism in pathogenesis by *C. immitis* and its possible susceptibility to potential therapeutic agents for example, tetraethylthiuram disulfide, pose still further questions concerning this pathogen.

It is to be expected that further studies of interest and importance will result from the development of spherule culture method by Converse¹ and by their extension by Lones and Peacock and by Cobb and Levine² at the Naval Biological Laboratory. For example, in addition to metabolic studies, immunological explorations can be carried out on spherules. The development of immunity to coccidioidomycosis is supported strongly by clinical as well as by experimental evidence in this respect. Various cellular as well as cell free extracts of both spherules and mycelial forms now can be prepared, and improvements can be anticipated in experimental immunization procedures. In addition the vexing problem of achieving success *in vitro* with experimental drugs and then meeting with failure when these are tested against the disease in experimental animals is familiar to all who have worked on the chemotherapy of coccidioidomycosis. Moreover, spherules *in vitro* may provide a screening method.

Preoccupation with the production of spherules should not cause the problem of discouraging spherule formation *in vivo* to be overlooked. Two observations relative to this are the following.

First the early stages after inoculation of *C. immitis* are attended by an active inflammatory response. This is exemplified in FIGURE 1 which shows the vigorous exudation of polymorphonuclear cells, even phagocytosis of arthrospores in alveoli of a mouse inoculated intranasally. Spherule formation with progressive disease then would follow if a virulent strain were used.

Second it is recognized that a person with systemic coccidioidal disease but without dermal lesions may occasionally develop suppurative lesions draining at the skin if some trauma of the skin is incurred. This may suggest a predilection on the part of the *Coccidioides* cells for the resulting inflamed site. These

* The work described in this paper was supported in part by the Bureau of Medicine and Surgery United States Navy and the Office of Naval Research Washington D. C. under a contract with the Board of Regents of the University of California. Opinions contained in this report are not to be construed as reflecting the views of the Naval Service.

† Present address Stanford University School of Medicine Stanford Calif

‡ Present address Department of Microbiology Tulane University School of Medicine New Orleans La

ENDOGENOUS OXYGEN UPTAKE BY MYCELIA OF TWO
STRAINS OF COCCIDIODES IMMITIS




FIGURE 2 · Endogenous respiration by mycelia of two strains of *C. immitis*

Pappagianis & Kobayashi Physiology of *Coccidioides immitis*
 ENDOGENOUS OXYGEN UPTAKE BY ARTHROSPORES
 OF TWO STRAINS OF *COCCIDIODES IMMITIS*




FIGURE 3 Endogenous respiration by arthrospores of two strains of *C. immitis*

devoted attention to this in *C. immitis* and it is possibly in the area of endogenous physiology that biochemically vulnerable patterns may be sought. The extraction of mycelium with hot ethanol yielded approximately 10 per cent of the dry weight as ether soluble lipid. This was a soft yellowish wax that melted at 36 to 38° C. Thus far attempts to determine whether this

lipid might constitute the endogenous substrate, compatible with an RQ in the range of 0.7 to 0.8 have given indefinite results. In addition one would wonder about its immunological importance.

Another cellular constituent of *C. immitis* has received the attention of several workers. Baker *et al.*¹⁰ suggested the presence of chitin in the cell wall and Blank and Burke¹¹ and Tarbet and Breslau^{12, 13} have applied X-ray diffraction and chemical and histochemical methods to determine its presence. We have demonstrated the presence of glucosamine after hydrolysis of cell wall preparations from mycelia by paper chromatography, and by measurement of the optical rotation of the chromatographically isolated material. The $[\alpha]_D^{25}$ for hexosamine isolated from two strains of *C. immitis* were $+68^\circ$ and $+71.5^\circ$ and for known glucosamine, $+68^\circ$. The values given in *Organic Syntheses*¹⁴ were from $+69.8^\circ$ to $+70.1^\circ$. Estimation of the hexoamine in the cell wall material by the colorimetric method of Diche and Borenfreund¹ suggested the presence of about 3 to 4 per cent chitin of the dry mycelium weight. Further indication that chitin was present was the liberation of reducing sugar by chitine isolated from a *Streptomyces* species by D. M. Reynolds.¹⁵

Tarbet and Breslau^{12, 13} have shown chitin in spherules which may imply a relative resistance of the structure of *C. immitis* to known mammalian enzymes although of course chitin is likewise recognized in nonpathogenic fungi and per se would not determine pathogenicity.

From time to time many authors have noted the shaggy or prickly appearance of spherules in infected tissue (P. Negroni, personal communication).¹⁷ In FIGURE 4a is shown such a spherule in a section stained with hematoxylin and eosin. The protrusions are visible at the surface and on the endopores within. The same slide was destained and then the periodic acid Schiff stain was applied. As shown in FIGURE 4b, the shaggy border was not polysaccharide, indeed the spherule wall appears deficient in polysaccharide which is limited to a thin inner ring and possibly a scattering at the periphery of the wall. Of course one should certainly examine the illustrations of Breslau and Tarbet^{12, 13} for a clear notion of the histochemical appearance of *C. immitis*.

However, the periodic acid Schiff stained spherule contains striking endospores with what appears to be a carbohydrate shell as well as polysaccharide intracellularly. Thus far we have not distinguished the types of polysaccharide that may be represented in these two loci. Immunologically both regions may be significant. For example, if the polysaccharide of the endospore wall can react with precipitating antibody then agglutination may occur. We have indications that this can take place although earlier workers using mycelial phase organisms did not observe such a reaction. Perhaps some type of neutralization reaction may be sought in the resistant host or in one with precipitins.

The events leading to the release of immunologically or serologically active materials may be pertinent to the examination of these cellular components. As yet we have not carried out such studies on the *in vitro* spherules but earlier we described the method of producing antigens by autolysis of young mycelia of *C. immitis*.¹⁸ As is generally known, there are two important




FIGURE 4 (a) Spore of *C. immitis* in subcutaneous tissue of a mouse. Hematoxylin and eosin stain.



FIGURE 4. (b) Same as herule after destaining and application of periodic acid-Schiff stain for polysaccharide. Polysaccharide sparse in the cell wall; conspicuous in wall and inside of endospores.

serologic tests applied in coccidioidomycosis.¹⁹ The precipitin test is a diagnostic aid, precipitins appearing early in the course of the disease and usually diminishing early. The complement fixation test provides a prognostic criterion of the infection, it becomes positive later and the complement fixing titer rises with worsening of the disease. By autolysis of mycelium, antigen solutions were obtained that gave reactions in both precipitin and complement fixation reactions. It was not known whether the same or different antigens were involved in the two serologic reactions. An approach to this was made




FIGURE 5. Changes during autolysis of mycelium of *C. immitis*

by examining early changes occurring in autolysis and by testing for serologic activity. Accordingly, a large mass of young (3-day-old) mycelium was autolyzed in the presence of toluene, and aliquots were removed at intervals for various assays. The measurements obtained are depicted in FIGURE 5. Mycelium weight decreased steadily to about 50 per cent in the first 24 hours, then slowed over the next two days to a final 35 per cent of the original weight. Of course, the soluble solids liberated in this period showed a reciprocal rise with the drop in mycelial weight. The nondialyzable solids included the polysaccharide and nitrogenous material designated as "protein" (this reservation is prompted by the fact that this fraction contains amino acids, but its protein nature has not been established).²⁰ After an initial increase in nondialyzable substances, between

8 and 24 hours there occurred a drop in this fraction. The reason for this is not clear but the concomitant drop in nondialyzable protein suggested that the latter material might have undergone lysis which produced smaller constituents removed by dialysis. Polysaccharide was continuously liberated although its rate of release was not affected during the 8 to 24 hour period.

The serologic activity of the filtrates at different stages was measured against human coccidioidomycotic serum. The complement fixation titers of the filtrates (which were totally devoid of anticomplementary activity) were as follows. At zero (0) time there was 4+ fixation of complement (2 units) at a dilution of 1/64. An increase in titer was such that 4+ fixation occurred at a dilution of 1/128 of the 4 hour sample. The 8 hour and 24 hour specimens gave complete fixation (4+) at 1/256. The titer then rose again and was 1/512 at 48 hours and 1/1024 (the highest dilution tested) at 72 hours.

The immediate temptation was to point to the polysaccharide curve of the graph and to suggest that the rise in complement fixing titer was causally associated. However we feel that the filtrates must be examined more closely for example for qualitative changes, before such a relationship can be upheld.

The precipitin antigen activity of the filtrates was apparently increased during the progressive liberation of nondialyzable substances. However our experience with quantitative precipitin tests with *Coccidioides* filtrates indicates that antisera may give precipitates with polysaccharide components and with noncarbohydrate substances accompanying the former. Thus mixed precipitating antigens may be present in the autolysates indicated in FIGURE 5.

As we have established earlier, the soluble polysaccharide in *Coccidioides* lysates and coccidioidins contains predominantly mannose with some galactose and another reducing sugar^{1,2,3} which Goldschmidt has characterized as monomethylmannose¹. It is of interest that Salvin recently reported mannose and galactose present in serologically active extracts of yeast phase *Histoplasma capsulatum*²⁷. Perhaps herein lies the basis of immunological cross reactivity of *C. immitis* and *H. capsulatum*.

Although it may appear even more remote from the physiology of *C. immitis* one other aspect of work with this fungus deserves mention. As we are aware the surroundings may have a pronounced effect on the metabolic activity of an organism. For this reason one might expect different behavior of *Coccidioides* by varying its *in vivo* ecology. For example as shown in FIGURE 6 a relatively avirulent strain of *C. immitis* (strain 46) when given in doses up to 10,000 spores intraperitoneally, had no apparent effect on the health of mice. However when given intranasally, as low a dose as 100 cells induced lethal progressive infections. Intramuscularly and subcutaneously, as many as 1000 cells did not cause progressive disease. The other strain (Silveira) included in FIGURE 6 was highly virulent when given intranasally as well as intraperitoneally. By intramuscular route it manifested somewhat less virulence and when given subcutaneously, was localized in a small abscess²⁸. As recorded in human cases by Wilson *et al.*²⁹ and Trimble and Doucette³⁰ infection with *C. immitis* in the skin was arrested before inducing extensive lesions. As indicated above for the mouse and by several workers for other animals including the dog, sheep, calf and guinea pig (K. Maddy, personal

communication) ¹² subcutaneous inoculation generally resulted in an arrested lesion. When 100 spores of strain Silveira were injected subcutaneously into cynomolgous monkeys (*Macacus irus*) the result was a large fluctuant abscess 2 to 3 cm in diameter but in the mouse this dose gave a lesion usually 3 mm in diameter. Thus the size of the animal in this case was not significant. Intratracheal inoculation of dogs by Hagenholtz *et al*¹³ produced severe disease at doses of 1000 spores or more. Lowe *et al*¹⁴ and we have similarly induced extensive pulmonary lesions in the monkey by inhalatory exposure to




FIGURE 6. Comparative virulence of two strains of *C. immitis* (Silveira and 46) by intranasal route.

arthrospores (we used a dose of 750 spores per monkey). On the other hand Maddy instilled 1 million spores intratracheally in a cow without inducing illness (K. Maddy personal communication). The interesting results of Iubarsky and Plunkett showed that *C. immitis* could survive passage through the alimentary canal of mice without causing overt disease.¹⁵ On the other hand intravenous inoculation whether carried out in the mouse as by Emmons and Iggott¹⁶ and by L. E. Gordon (personal communication) in the calf by Giltner¹⁷ or in the horse by C. E. Smith (personal communication) results in overwhelming infection. These examples raise the question as to the nature of the variation in pathogenesis by different routes of inoculation. The lung appears to be a favorable site for development of *C. immitis*. Is this due to the copious blood supply or the oxygen tension? Is there sufficient difference in the quantity of con-

nective tissue elements between the lungs and subcutaneous region to result in the difference in susceptibility observed in these two tissues? Is there some demonstrable physiological difference, for example, catecholamine-type precursors of melanin, to account for the greater susceptibility to coccidioid disease in dark skinned persons?¹⁹ Such questions are not unique to medical mycology, but the fungus diseases may permit some direct approaches.

Some practicable concepts may derive from such animal studies also. First, despite continued recommendation or use of guinea pigs by some textbooks or laboratories, it is probable that most investigators who have worked with *Coccidioides* would recommend the mouse for diagnostic work. Second, intranasal challenge of the mouse provides a more rigorous test in experimental chemotherapy and experimental immunization. Furthermore, examination of susceptibility of animal hosts to inoculation by different routes may be of importance in the development of immunization with viable organisms, as has been attained by subcutaneous inoculation.²⁰ Perhaps the innocuousness of *C. immitis* by the gastrointestinal route could lead to examination of this as well as parenteral routes in experimental immunization.

Acknowledgments

We thank John Schutz for photographic work and Margaret Saito for complement fixation tests.

References

1. CONVERSE J. L. 1946. Effect of physico-chemical environment on spherulation of *Coccidioides immitis*. *J. Bacteriol.* 72: 784-792.
2. COBB J. M. & H. B. LEVINE. The growth and purification of the spherule phase of *Coccidioides immitis*. *Ann. N. Y. Acad. Sci.* In preparation.
3. BAKER O. & A. I. BRAUDE. 1956. A study of stimuli leading to the production of spherules in coccidioidomycosis. *J. Lab. Clin. Med.* 47: 169-181.
4. GILTNER I. T. 1918. Occurrence of coccidioid granuloma (oidiomycosis) in cattle. *J. Agr. Research* 24: 533-542.
5. BLUM W. S. 1925. Observations on growth of *Coccidioides immitis*. *J. Infectious Diseases* 36: 561-565.
6. STEWART H. A. & F. MEYER. 1938. Studies in the metabolism of *Coccidioides immitis* (Stiles). *J. Infectious Diseases* 63: 196-205.
7. BAKER I. F. & C. L. SMITH. 1942. Utilization of carbon and nitrogen compounds by *Coccidioides immitis* (Rixford and Gilchrist 1896). *J. Infectious Diseases* 70: 51-53.
8. ROFFSLER W. G. & J. HERBST W. G. McCULLOUGH R. C. MILLS & C. R. BREWER. 1946. Studies with *Coccidioides immitis*. I. Submerged growth in liquid media. *J. Infectious Diseases* 70: 12-22.
9. PAPIAGIANIS H. & G. S. KOBAYASHI. 1958. Isolation of extracellular polysaccharide in cultures of *Coccidioides immitis*. *Mycologia* 50: 229-234.
10. BAKER I. F., E. M. MIRAK & C. E. SMITH. 1943. The morphology, taxonomy and distribution of *Coccidioides immitis*. Rixford and Gilchrist 1896. *Parlowia* 1: 199-244.
11. BLANK H. & R. C. BURKE. 1954. Chemical composition of the cell wall of *Coccidioides immitis*. *Nature* 173: 829.
12. TARBET J. F. & A. M. BRESLAU. 1953. Histochemical investigation of the spherule of *Coccidioides immitis* in relation to host reaction. *J. Infectious Diseases* 81: 183-190.
13. BRESLAU A. M. 1955. Comparative histochemical studies on *Coccidioides immitis* and *Haplosporangium parvum*. *J. Histochem. Cytochem.* 3: 141-147.
14. ORGANIC SYNTHESIS. 1946. 26: 36. Wiley, New York, N. Y.
15. DISCHE Z. & L. BORENTREUND. 1950. A spectrophotometric method for the micro-determination of hexosamine. *J. Biol. Chem.* 184: 517.
16. REYNOLDS D. M. 1954. Extracellular chitinase from a *Streptomyces* sp. *J. Gen. Microbiol.* 11: 150-159.
17. DICKSON E. C. 1937. *Coccidioides* infection. Part I. *Am. J. Arch. Intern. Med.* 69: 1029-1044.

Pappagianis & Kobayashi Physiology of *Coccidioides immitis* 121

- 18 PAPPAGIANIS D C E SMITH M T SARITO & G S KOBAYASHI 1957 Preparation and properties of a complement fixing antigen from mycelia of *Coccidioides immitis*. Public Health Service Publ 575 57-63
- 19 SMITH C E 1955 Factors associated with virulence of *Coccidioides immitis*. Thesis Univ Calif Berkeley Calif
- 20 GOLDSCHEIDT E 1958 Composition of an extracellular polysaccharide fraction produced by *Coccidioides immitis*. Bacteriol Proc 127
- 21 SALVAY S B & R F SMITH 1959 Antigens from the yeast phase of *Histoplasma capsulatum*. III Isolation properties and activity of a protein-carbohydrate complex. J Infectious Diseases 106 45-53
- 22 WILSON J W C E SMITH & O A PLEVAKE 1953 Primary cutaneous coccidioidomycosis. Calif Med 79 233-239
- 23 TRIMBLE J R & J DOUCETTE 1956 Primary cutaneous coccidioidomycosis report of a case of a laboratory infection. JAMA Arch Dermatol Syphilol 74 403-410
- 24 PAPPAGIANIS D C E SMITH R J BERMAN & G S KOBAYASHI 1959 Experimental subcutaneous coccidioidomycosis in the mouse. J Invest Dermatol 32 589-598
- 25 HEGGENHOLTZ P G R E REED K T MADDOX R J TRAUTMAN & J D BARGER 1958 Experimental coccidioidomycosis in dogs. Am J Vet Research 19 433-439
- 26 LOWE E P J L CONVERSE & L CASTLEBERRY 1954 Survival of *Coccidioides immitis* in passage through the digestive tract of mice. Public Health Repts U S 69 494-497
- 27 LUBARSKY R & O A PLEVAKE 1959 Amphoteribin B and Griseofulvin in the treatment of experimental systemic mycoses. Antihotoc & Chemotherapy 9 550-556

MECHANISMS OF ACTION OF ANTIBIOTICS*

S G Bradley and I A Jones

Department of Bacteriology University of Minnesota Minneapolis Minn

The discovery and development of antibiotics have brought about a new era in medical and biological sciences. Tuberculosis which was responsible for 45.2 deaths/100,000 citizens of the United States in 1939 caused only 3 deaths/100,000 in 1957. Mortality resulting from acute rheumatic fever, appendicitis and syphilis has also decreased sharply during this period (35 to 0.5, 9.9 to 1.2 and 11.2 to 2.2 per 100,000 citizens of the United States respectively)¹. The widespread use of penicillin, streptomycin, the tetracyclines and other antibacterial antibiotics has been responsible to a great extent for these dramatic reductions. Effective antifungal antibiotics have been developed only recently, partially because severe mycotic infections are less frequent and less contagious than grave bacterial infections. Moreover the prevalence of fungus diseases has been underestimated, it is seldom realized that North American blastomycosis, candidiasis, cryptococcosis and aspergillosis cause as many deaths as tetanus, salmonellosis, chicken pox and bacillary dysentery. In 1955 aspergillosis, blastomycosis, bacillary dysentery, salmonellosis and tetanus each was responsible for the death of 2 Minnesotans, candidiasis was responsible for 3 deaths. In 1956 cryptococcosis and chicken pox each was the cause of 2 deaths in Minnesota². In addition the incidence of candidiasis has been increasing especially following prolonged treatment with broad spectrum antibacterial antibiotics³. Cancer patients, particularly those receiving X-ray therapy, and diabetics seem to be more susceptible to mycoses than the population as a whole^{4, 5}.

Nystatin, the first clinically accepted antifungal antibiotic, alters favorably the course of candidiasis⁶ but not of dermatophytoses or deep seated mycoses⁷. Clinical results reported in this publication indicate that griseofulvin and amphotericin B are becoming firmly established as effective drugs of choice for dermatophytoses and deep mycoses respectively (J H Seabury, H F Dascomb and F J Roth). Unfortunately our current understanding of the mode of action of these antibiotics is limited. This discussion therefore reviews briefly known and postulated mechanisms of action and outlines our approach to this problem using *Candida stellatoidea* and nystatin as the test system. In order to elucidate the mode of action of an antibiotic the cellular function(s) affected by the drug must be determined. Possible physiological loci include: (1) protein synthesis, (2) nucleic acid synthesis, (3) synthesis or activity of coenzymes, (4) energy generation or transfer, (5) permeation, (6) cellular and subcellular organization and (7) the metabolic self-regulating feedback system. The foregoing categories can not always be delineated sharply for example anabolism and catabolism are dependent on protein (enzyme) synthesis. A similar series of interactions involves active transport of precursor fabrication of complex molecules and integration of these into cellular structure and function; all of these steps require abundant energy.

* The new work reported in this paper was supported by a research grant from the Brown Hazen Fund of the Research Corporation, New York, N. Y.

Nature of the Antifungal Activity of Nystatin

R Brown and E Hazen (elsewhere in this monograph)⁸ have noted that 1.5 to 13 μg nystatin/ml prevented growth of a wide variety of yeasts and molds but that higher levels were fungicidal. Similarly we have found that as little as 1 μg /ml inhibited growth of *C. stellatoidea* completely and that 0.5 μg /ml decreased the final crop of cells (TABLE 1). As the nystatin in the growth medium lost potency the yeasts exposed to an initial concentration of 1 μg /ml began to grow. Viable cell counts revealed that even after 48 hours exposure to the drug at an initial concentration of 2 μg /ml a significant number of fully sensitive persistors could be recovered. When 4 μg nystatin/ml of nutrient medium was added to a population of *C. stellatoidea* in the exponential phase of growth there was an immediate increase in turbidity followed by cessation of growth (FIGURE 1). If the pH of the milieu

TABLE I
EFFECT OF NYSTATIN ON GROWTH AND SURVIVAL OF *CANDIDA STELLATOIDEA*

Nystatin concentration on $\mu\text{g}/\text{ml}$	Viable count yeasts/ml		
	0 time	24 hours	48 hours
0			
0.5	6.9×10^4	1.5×10^5	3×10^4
1	6.9×10^4	5×10^4	3×10^4
2	6.9×10^4	5.4×10^4	1.1×10^4
3	6.9×10^4	2.5×10^4	2.6×10^4
4	6.9×10^4	6×10^3	4×10^3
		$< 10^3$	$< 10^3$

Cultures were incubated at 30°C on a reciprocal shaker

was maintained above 4.5 the effect of nystatin was fungistatic conversely if the pH of the medium was permitted to fall below 4.5 the antibiotic was fungicidal. The primary action of this drug therefore seemed to be suppressive rather than lethal. The latitude between inhibitory and destructive concentrations was very narrow however and dependent on the chemical and physical environment. While studying the mode of action of nystatin it is well to keep in mind that fungicidal and fungistatic manifestations of the interactions among cell environment and drug may proceed simultaneously. The physiological locus (loci) for the two effects may be identical sequential or diverse.

Tests for Indirect Action

A drug need not interact directly with the susceptible cell in order to exert its deleterious effect. An antibiotic can conceivably react with essential nutrients in the medium thereby rendering them unavailable to the cell. A chelating agent for example may deplete the milieu of needed calcium ions inasmuch as nystatin exerted progressively greater antifungal activity at increasing insoluble levels its primary effect may have involved extracellular chelation. Because nystatin is only slowly dialyzable⁹ this hypothesis was tested directly. To double strength growth medium¹⁰ 8 μg nystatin/ml was

added After 2 hours' incubation at 30° C , 10 ml of this medium was transferred to a dialyzing tube, the sterile bag was placed aseptically into 10 ml deionized water After 2 more hours the dialyzing chambers were removed and the dialysate was inoculated with *C stellatoidea* Growth in dialyzed




FIGURE 1 Effect of nystatin on growth of *Candida stellatoidea* To cultures in the exponential phase of growth (○) 4 μg nystatin/ml was added (as indicated by arrows) at hour 1 (●) hour 3 (○) or hour 5 (○) Growth was measured with a Klett Summerson photoelectric colorimeter (filter 42)

nystatin treated medium was identical to growth obtained in dialyzed but untreated medium. The primary effect of the drug, therefore, was not on the composition of the nutrient substrate. This experiment did not rule out the possibility that nystatin leached an essential component from the cells. To test this hypothesis, 10 ml of growth medium containing 40 to 400 μg antibiotic was dispensed into dialyzing bags. The bags were transferred to flasks that held 20 ml growth medium. The drug free milieu was inoculated with *Candida*, growth was equivalent in control cultures and the experimental series. Nystatin, therefore, did not leach the yeasts of dialyzable, essential nutrients.

TABLE 2
INFLUENCE OF HYDROGEN ION CONCENTRATION ON FUNGICIDAL ACTIVITY OF NYSTATIN

pH	Survivors/ml		
	0 nystatin	4 μg nystatin/ml	40 μg nystatin/ml
1	5×10^6	3×10^6	10^6
2	5×10^6	5×10^6	$<10^6$
3	5×10^6	4×10^6	10^6
4	5×10^6	1×10^6	10^6
5	5×10^6	2×10^6	5×10^4
6	5×10^6	2×10^6	1.5×10^4
7	5×10^6	3×10^6	2×10^4
8	5×10^6	3×10^6	2×10^4
9	5×10^6	3×10^6	3×10^4
10	5×10^6	3×10^6	2×10^4
11	3×10^6	2×10^6	4×10^4

Yeasts were treated in growth medium for 2 hours at 30°C.

Binding

In a series of enlightening studies, Lampen *et al.*¹¹ have shown that nystatin is absorbed (or adsorbed) by yeasts. "Absorption" of antibiotic was found to be dependent on hydrogen ion concentration, temperature, and availability of energy. Their findings, and ours, using viability as the index of drug activity, are parallel. *C. stellatoidea* survived exposure to 4 μg nystatin/ml best at neutral or alkaline pHs, maximal killing occurred at pH 2 (TABLE 2). Over the range of pH 3 to 9, Lampen *et al.* found that absorption was maximal at pH 3, unfortunately drug uptake at pH 1 and 2 was not determined. They also demonstrated that baker's yeast bound little nystatin at 4° C, and that cell death was negligible. Our findings with *C. stellatoidea* confirmed their observations: at pH 2.5, 4 μg nystatin/ml rendered 90 per cent of the plating units nonviable after 60 min at 30° C, but at 0° C, more than 90 per cent of the treated cells remained viable (TABLE 3). Moreover energy was required for killing as well as for binding. Starved *Candida* cells in buffer adjusted to pH 2.5 were not harmed by nystatin but when glucose was added survival dropped precipitously (TABLE 4).

Prophylaxis

It has been reported that cysteine,¹² serum,¹³ and bile salts¹⁴ reduced substantially the power of nystatin to inhibit growth of *C. albicans*. Additionally Lampen *et al*¹⁵ demonstrated that zymosan and serum prevented binding and Bradley¹⁶ found that inorganic phosphate protected glycolysis from inhibition by nystatin, but did not affect fungicidal activity of the drug. We have screened several substances for capacity to protect *Candida* from nystatin.

TABLE 3
EFFECT OF TEMPERATURE ON FUNGICIDAL ACTIVITY OF NYSTATIN

Temperature (°C)	Survivors in 4 μ g nystatin/ml.			
	0 time	30 min	60 min	120 min
0	5×10^4	5×10^4	4.5×10^4	4.5×10^4
10	5×10^4	2.5×10^4	2×10^4	5×10^3
20	5×10^4	7.5×10^3	5×10^3	2.5×10^3
25	5×10^4	6.5×10^3	3.6×10^3	2.1×10^3
30	5×10^4	6.1×10^3	4.1×10^3	1.7×10^3
37	5×10^4	6.3×10^3	4.8×10^3	2.3×10^3

Yeasts were treated in growth medium adjusted to pH 2.5

TABLE 4
EFFECT OF NYSTATIN ON ENERGY DEPRIVED CELLS

Treatment of cells	Suspending milieu	Atmosphere	Survivors
Washed 3 times	Buffer	Air	5×10^4
Washed 3 times	Buffer	N ₂	5×10^4
Washed 3 times	Buffer + nystatin	Air	4×10^4
Washed 3 times	Buffer + nystatin	N ₂	4.8×10^4
Washed & starved	Buffer	Air	5×10^4
Washed & starved	Buffer + nystatin	Air	3×10^4
Washed & starved	Buffer + glucose	Air	5.6×10^4
Washed & starved	Buffer + glucose + nystatin	Air	3×10^4

Candida stellatoidea was starved by shaking washed cells in M/15 phosphate buffer pH 4.5, for 4 hours at 30° C. Milieu was adjusted to pH 2.5 and maintained at 30° C. Yeasts were exposed to 4 μ g nystatin/ml and to 4 mg glucose/ml, when indicated, for a period of 2 hours.

toxicity. Only serum, oxgall, nucleic acid, vitamin E, ascorbic acid, cysteine, sodium thioglycolate, and glutathione were able to protect at the concentrations tested (TABLES 5 and 6). These substances were required in amounts far in excess of growth-factor levels. It should be noted that most of these substances lower the oxidation-reduction potential (Eh) of the milieu, the facts that an increase in pH usually results in a lowering of Eh,¹⁷ and that fungicidal potency becomes more marked as pH decreases are consistent with the hypothesis that Eh is inversely correlated with killing power.

Permeability

One of the cell's most vulnerable sites is the plasma membrane. Failure of selective permeability leads to loss to the environment of vital components of

the cell and allows qualitatively and quantitatively deleterious materials to enter the protoplasm. We have attempted to determine whether nystatin acts by disrupting cell permeability by correlating dye uptake and viability.

TABLE 5
ADDITIVES UNABLE TO PROTECT *CANDIDA STELLATOIDEA* AGAINST NYSTATIN TOXICITY

Alkali inactivated nystatin†	Marganic acid
Ascorbic acid	Methanol
Brucine alkaloid	Mercaptobenzthiazole
5 bromo-2,4 dihydroxypyrimidine	Nickelous sulfate
* Caprylic acid*	Nystatin sensitive methanol killed
* Caproic acid	<i>Candida stellatoidea</i> †
Cadmium chloride	Nystatin resistant methanol killed
	<i>Candida stellatoidea</i> †
Calcium chloride	Oxgall
Citric acid	Phenylhydrazine HCl
L cysteine (HCl)	Sitosterol
Dibutyl phthalate	Sodium arsenate
Disodium ethylenediamine tetraacetate	Sodium cyanide
2 ethoxy 6,9 diaminocrotonosulfonamide	Sodium fluoride
Ferrous sulfate	Sodium hydrosulfite
Formamide	Sodium thiocyanate
Ghatti gum	Silicic chloride
4-hydroxy 2 thiopyrimidine	Thallium chloride
Indole-3 acetic acid	Thioflavin TG*
Keratin	Tween 80
Lithium chloride	Uracil
Magnesium sulfate	2% vitamin E
Manganous sulfate	Zinc oxide
	Zymosan

Nutrient substrate contained 4 µg nystatin/ml and 5 or 50 µg additive/ml
 * Fifty micrograms additive/ml was toxic to *Candida stellatoidea* in the absence of nystatin
 † 10⁶ and 10⁷ dead cells/ml
 ‡ Heated at 60° C for 10 min at pH 9

TABLE 6
ADDITIVES EFFECTIVE IN PROTECTING *CANDIDA STELLATOIDEA* FROM NYSTATIN TOXICITY

Additive	Minimum protective concentration
Sodium thio glycolate	1 mg/ml
(Vitamin E) tocopherol	200 µg/ml
Oxgall	1 mg/ml
Cysteine	100 µg/ml
Ascorbic acid	200 µg/ml
Nucleic acid	200 µg/ml
Glutathione	200 µg/ml
Human serum	5 mg/ml
	5 mg/ml

Nutrient substrate contained 4 µg nystatin/ml

If this antibiotic destroys selective permeability, stain should enter the cell concurrently with or prior to cell death as measured by viable counts. Using 6 different dyes we found that viability in 4 µg nystatin/ml at pH 2.5 dropped concurrently with or before dye penetration was detected (TABLE 7). The discrepancy between dye uptake and loss of viability was even more striking.

with 4 μ g drug/ml at pH 3.5, where killing proceeded more slowly. Methylene blue and crystal violet, for example, each stained only 5 per cent of the cells after 30 min exposure to the antibiotic, but less than one half of the population was viable after 1 hour, 12 per cent of the population was viable but 90 per cent of the yeasts were unstained, after 2 hours, only 3 per cent of the cell were able to produce colonies, however, 75 per cent remained unstained. These data suggest that nystatin does not destroy selective permeability completely but may alter specifically active transport of a limited class of substances. The latter alternative is supported by the observations of Gottlieb *et al*¹⁷ who have studied filipin another polyene antibiotic¹⁸. It seems reasonable to compare mechanisms of action of filipin, nystatin, and amphotericin directly inasmuch as they are similar chemically. Moreover mutants of *C. stellatoidea* selected

TABLE 7
CORRELATION OF VIABILITY AND DYE UPTAKE

Time in minutes	Per cent stained cells						Viable count	Per cent kill
	Methylene blue	Crystal violet	Janus green B	Safranin O	Neutral red	Trypan blue		
0	1	1	2	3	1	1	5×10^4	0
15	78	78	82	3	1	4	1×10^4	80
30	88	83	82	68	6	7	8×10^4	88
60	92	87	87	72	12	29	5×10^4	90
90	95	95	92	95	25	75	3×10^4	94
120	99	99	99	99	60	99	2×10^4	96

Yeasts were treated with 4 μ g nystatin/ml at pH 2.5 incubation temperature was 30 C. Dyes were used at a concentration of 250 μ g/ml except for crystal violet that was at 25 μ g/ml.

for resistance to nystatin manifested increased resistance to amphotericin B and filipin. By measuring oxygen consumption manometrically, Gottlieb *et al* found that filipin inhibited oxidative utilizations of glucose and sodium acetate by *Saccharomyces cerevisiae*. Surprisingly, they noted that respiratory capability of cell free preparations was not suppressed by this antibiotic. Their results can be interpreted as evidence that polyene antibiotics act by preventing permeation of organic carbon compounds rather than by inhibiting the degradative enzymes directly.

Energy Generation and Transfer

Nystatin inhibits oxidative and fermentative utilization of glucose and several other energy sources^{19, 20}. Glycolysis by *C. stellatoidea* was suppressed most at pH 2,²¹ which correlated precisely with our observation that greatest fungicidal activity was manifested at pH 2. However, energy generation does not seem to be the primary site of nystatin activity because aerobic utilization of sodium glutamate and sodium citrate was unaffected by the drug yet growth would not proceed in medium in which citrate or glutamate replaced glucose as the principal energy source (TABLE 8). Moreover glycolysis by a nystatin resistant variant, which grew in milieu containing 20 μ g antibiotic/ml was as susceptible to nystatin as the sensitive parental strain.

Protein and Nucleic Acid Synthesis

As our understanding of biosyntheses expands, it becomes increasingly evident that ribonucleic acid plays an important role in the fabrication of proteins. Simply stated, amino acids individually are "activated" by adenosine triphosphate, each amino acid is then transferred to a soluble ribonucleic acid molecule, the amino acid soluble ribonucleic acid complex then attaches specifically to the ribonucleoprotein template of the microsome, there the amino acids join, by peptide bonds, to form proteins, the soluble ribonucleic acid then floats free of the template and is available for another cycle.²² The specificity of the ribonucleoprotein template is determined by the "genetic material," that is, the desoxyribonucleoprotein. It is difficult, therefore, to differentiate between a primary effect on protein synthesis, ribonucleic acid synthesis, and desoxyribonucleic acid synthesis.

TABLE 8
EFFECT OF NYSTATIN ON GROWTH AND RESPIRATION OF *CANDIDA STELLATOIDEA* IN SODIUM CITRATE AND SODIUM GLUTAMATE

Carbon source	Growth (turbidity)		Respiration (O ₂ uptake)	
	Control	1 μ g nystatin/ml	Control	1 μ g nystatin/ml
Basal medium only	35	0	9	11
Sodium glutamate	110	0	165	145
Sodium citrate	90	0	186	167
Glucose	325	0	239	12

Basal medium was growth medium lacking glucose. 10 mg/ml citrate or glutamate was added when indicated. Cultures were incubated for 18 hours at 30°C. growth was measured turbidimetrically with a Klett-Summerson photoelectric colorimeter (filter 42). Oxygen uptake was measured manometrically at pH 4.5. vessels contained 100 mg carbon source and 5 mg dry weight of cells in $M/15$ phosphate buffer.

Primary suppression of protein fabrication can occur by (1) interference with amino acids synthesis, (2) prevention of permeation of exogenously required amino acids, (3) inhibition of amino acid activation, (4) interference with the amino acid soluble ribonucleic acid complex, or (5) prevention of attachment of the complex to the template. Chloramphenicol, at bacteriostatic concentrations, does not inhibit oxidation or fermentation of glucose, permeation of amino acids, ribonucleic acid or desoxyribonucleic acid synthesis, amino acid activation, or synthesis of simple peptides, but does inhibit inducible enzyme formation and general protein synthesis.^{23, 24} Present evidence indicates that chloramphenicol forms an inactive complex with the transfer (soluble) ribonucleic acid. Cycloheximide, like chloramphenicol, inhibits protein synthesis, but does not inhibit respiration, fermentation, or ribonucleic acid synthesis. Cycloheximide, unlike chloramphenicol, does inhibit desoxyribonucleic acid synthesis.²⁵ Amphotericin likewise fails to suppress oxidative metabolism but it does inhibit protein synthesis and nucleic acid synthesis (E. Drouhet *et al.*, elsewhere in this monograph).²⁶ Results with nystatin are not as clear cut, it is obvious that phosphate metabolism is affected by this drug, but the exact physiological locus (or loci) is not known.²⁷ There is

suggestive evidence that suppression of protein synthesis by nystatin is a secondary effect²⁰ However, nystatin at concentrations that do not affect growth of *Penicillium chrysogenum* does inhibit production of the enzyme amylase²¹

Effects on Coenzymes

There are two general classes of coenzymes the vitamins and the heavy metals Heavy metals, as cations, are required in trace amounts by all cells The tetracycline antibiotics are chelating agents whose antibacterial toxicity can be reversed, in large part, by manganic ions Enzymes isolated from chlortetracycline sensitive and resistant bacteria were found to differ in the firmness with which the metal was bound to the apoenzyme, sensitivity was correlated with ease of dissociation²²

Studies on the mode of action of chemotherapeutic agents may contribute substantially to our understanding of basic biology Perhaps the best example of this is the work with the sulfonamides that led to the discovery of para amino benzoic acid It is generally accepted today that sulfonamides exert their growth inhibitory action by competing for an enzyme that catalyzes the metabolism of this vitamin Folic acid, which is the product of this reaction is the coenzyme involved in the transfer of one carbon residues²³

Effects on Structure

The cell wall has proved to be a sensitive target for antibiotic activity because microbes with aberrant outer membranes die quickly in most environments Moreover, bacterial cell walls contain substances not found in mammals (muramic acid, D-alanine, D-glutamic acid, and diaminopimelic acid);²⁴ therefore, drugs having detrimental effects on the cell wall will possess minimal toxicity for the host Penicillin is the best known agent that interferes with synthesis of the outer membrane At low concentrations of antibiotic, sensitive bacteria grow as long filaments, at higher concentrations, the cells become spherical and lyse In hypertonic media, the cells form osmotically fragile protoplasts that resemble L forms²⁵ It is apparent that penicillin interferes in some way with polymerization of cell wall material Similarly, griseofulvin affects plasticity of the cell wall of fungi This antibiotic, also produced by members of the genus, *Penicillium*, causes stunting, branching and spiral twisting of the hyphae in fungi having chitinous cell walls, but does not affect molds with cellulosic cell walls²⁶ Another fungistatic antibiotic, designated only as the bulging factor, induces hyphal distortion²⁷ It is not known whether the action of the bulging factor is on the biosynthesis of cell wall material or upon water balance

Effects on Metabolic Control

Conceivably, microbes can be killed, not by inhibiting an essential synthesis but by stimulating a synthesis An artificial system employing a thymineless prolineless mutant of *Escherichia coli* may be used as an example In medium lacking the two growth factors, Barner and Cohen found that about 50 per cent of the population died within 3 hours, if proline was added, less than 1 per cent

of the population was viable after 3 hours' incubation. Even though survival dropped sharply in medium containing proline but deficient in thymine, there was a substantial increase in cellular material, as measured turbidimetrically.²⁵ It may be possible to contrive conditions in which a drug that normally suppresses growth will be germicidal. For example, sulfonamide inhibition can be reversed by para amino benzoic acid, or by a mixture of substances whose synthesis is mediated by folic acid (amino acids, pantothenic acid, and thymidine).²⁶ In the presence of such compounds as sulfonamide, amino acids, vitamins, and purine nucleotides but in the absence of thymidine, cells may be killed more rapidly. Alternatively, nonutilizable inducers of adaptive enzymes can conceivably make stringent demands on the supply of activated amino acids, thereby stopping essential syntheses.

Effects on Lipids and Sterols

Although few microorganisms are known to have exogenous lipid or sterol requirements, these substances undoubtedly play an important role in cellular metabolism and integration. Gottlieb *et al.* have suggested that filipin might prevent the synthesis of sterols necessary for growth or competitively replace sterol cofactors in essential metabolic steps.²⁷ The finding that led to this intriguing hypothesis was that cholesterol, ergosterol, sitosterol, and stigmasterol protected *Hansenula subpelliculosa* from the toxic effects of filipin. It should be noted, however, that the possibility of an extracellular interaction between the sterols and filipin has not yet been conclusively eliminated. Another inhibitor of fungi, hexachlorocyclohexane, seems to be antagonistic to meso inositol,²⁸ which is a constituent of phospholipids.²⁹ Analogues, either of chemical or biological origin, may prove to be useful chemotherapeutic agents. Test systems employing lipoic acid with *Streptococcus faecalis* or divalonic acid with *Lactobacillus acidophilus* are awaiting exploitation.

Approaches to the Study of Mechanisms of Action of Antibiotics

It is necessary to determine which, if any, of the major synthetic systems are affected by a drug (protein, ribonucleic acid, or deoxyribonucleic acid synthesis). Effects on the energy generation system and on over-all cellular integrity as determined cytologically should be examined. Products accumulated within the cell or milieu should be analyzed qualitatively and quantitatively. Based on this information and on data from comparative studies on intact cells and cell free preparations, deductions about permeation can be made. Knowledge about the fate of an antibiotic, that is, its binding site, provides much insight into its action. Materials that protect against or reverse the toxicity of an antibiotic should be sought. Comparative studies using the sensitive parental strain and resistant variants help locate specifically the site of action. Moreover, cross resistance patterns, with respect to other drugs and metabolic poisons, may point out similarities with better-known models. Interactions between drug-substrate, and isolated enzyme systems may reveal definitively the physiological locus affected by a drug. Methodology for the recognition of primary effects on cellular integration and metabolic control is still relatively crude. To date the mode of action of few

antibacterial antibiotics and no antifungal antibiotic is well understood. We are confident that better understanding of drug action will lead to improved therapeutic procedures and that new, superior chemotherapeutic agents may be developed as a result of such work.

Summary

The success of antibiotics that kill or suppress pathogenic microbes should not cause us to ignore other avenues leading to the control of infectious diseases. Drugs that prevent synthesis of toxins or inhibit production of enzymes needed for invasion may be equally effective therapeutic agents. Manipulation of the genetic make up of the parasite, by transduction, transformation or other genetic processes, may enable us to convert highly virulent germs into harmless saprophytes. Drugs aimed at the host rather than the intruding microbe are in order. The defense mechanisms of man frequently wall-off the pathogen, protecting it from effective antibiotics. Reducing the host's response by adrenocorticotrophic hormone (ACTH), for example, has proved to be a useful adjunct in the treatment of tuberculosis. Moreover, the reaction between the antibody forming system and an antigen may be too efficient leading to hypersensitivity or to immunological paralysis of the host, that is, inability to produce antibodies against the antigen. If immunological paralysis can be prevented protective antibody may provide adequate resistance to disease. Drugs stimulating production of phagocytes and antibody synthesizing cells may be practicable. Nevertheless, the search for new antibiotics, particularly against fungi, viruses, and cancer, and the modification of existing ones must continue.

References

1. FACTS ON THE MAJOR KILLING AND CRIPPLING DISEASES IN THE UNITED STATES TODAY 1959. National Health Education Committee Inc. New York N. Y.
2. BARR, R. N. 1958. Minnesota vital statistics 1957. Minnesota Department of Health. Section of Vital Statistics. St. Paul, Minn.
3. SPILGMANN, I. 1952. Virulence enhancing activities of aureomycin on *Candida albicans*. Proc. Soc. Exptl. Biol. Med. 79: 481-484.
4. ROBINSON, R. C. V. 1956. *Candida albicans* infection of the skin and mucous membranes treated with nystatin. In Antibiotics Annual 1955-1956. 851-855. Medical Encyclopedia Inc. New York N. Y.
5. WRIGHT, I. T., J. H. GRAHAM, V. D. NEWCOMER & T. H. STERNBERG. 1956. The use of nystatin in the treatment of moniliasis. In Antibiotics Annual 1955-56. 846-850. Medical Encyclopedia Inc. New York N. Y.
6. STOUGH, A. R., J. T. GROEL & W. H. KROEGER. 1959. Amphoteracin B: a new antifungal agent for the prophylaxis of antibiotic induced moniliasis. Antifungal Med. Clin. Therapy 6: 653-661.
7. SUTLIFF, W. H. 1958. Fungal infections and chemotherapy. Ann. Rev. Med. 9: 15-30.
8. BROWN, R. & F. HAZEN. 1957. Present knowledge of nystatin: an antifungal antibiotic. Trans. N. Y. Acad. Sci. (Ser. II) 447-456.
9. IAMPEN, J. O., I. R. MORGAN, A. SMITH & J. BACTERIOLOGICAL. 1959. Absorption of nystatin by microorganisms. J. Bacteriol. 117: 1174-1179.
10. BRADLEY, S. G. & P. J. FARMER. 1959. Nystatin uptake by *Candida stellatoidea*. Antifungal Med. Clin. Therapy 6: 653-661.
11. IAMPEN, J. O. & P. ARNOW. 1959. Action of nystatin on *Candida albicans*. Proc. Soc. Exptl. Biol. Med. 110: 1174-1179.
12. DONOVICK, R. F. & E. PANSY, H. A. C. 1955. Some *in vitro* characteristics of nystatin. In T. J. Wright & T. H. Sternberg (eds.), Antibiotics Annual 1954-55. 846-850. Medical Encyclopedia Inc. New York N. Y.

Bradley & Jones Mechanisms of Antibiotics

133

- Diseases An International Symposium 168-175 T H Sternberg & V D New
comer Eds Little Brown Boston Mass
- 13 PARANO J F & F STANDER 1953 A Therapy of Fungous Diseases An International Symposium 186-194 T H
Sternberg & V D New
- 14 SCHNITZERSON S S D AUSTRUM Eds Little Brown Boston Mass 1958 Inactivation of am
photericin B chloramphenicol gentian violet and nystatin by bile salts Proc Soc
Exptl Biol Med 99 241 244
- 15 BRADLEY S G 1958 Interactions between phosphate and nystatin in *Candida*
stellatoidea Proc Soc Exptl Biol Med 98 786-789
- 16 CLARK W M & B COHEN 1923 Studies on oxidation reduction II An analysis
of the theoretical relations between reduction potentials and pH Public Health
Repts U S 38 666-683
- 17 GOTTLIEB D H E CARTER J H SLOVEKER & E GARDY Mechanism of fungus
inhibition by filipin In preparation
- 18 BALL S C J BESSELL & A MORTIMER 1957 The production of polyenic antibiotics
by *Streptomyces* J Gen Microbiol 17 96-103
- 19 LAMPEN J O E R MORGAN & C SLOCUM 1957 Effect of nystatin on the utilization
of substrates by yeasts and other fungi J Bacteriol 74 297-302
- 20 BRADLEY S G 1957 Effect of nystatin on *Candida stellatoidea* Antibiotics &
Chemotherapy 8 282-286
- 21 BRADLEY S G & P J FARDER 1959 Effect of nystatin on glucose fermentation by
Candida stellatoidea Bacteriol Proc 1959 82
- 22 ROBERTS R B K McQUILLEN & I Z ROBERTS 1959 Biosynthetic aspects of
metabolism Ann Rev Microbiol 13 1-48
- 23 HARRINGTON M G 1958 The action of chloramphenicol on protein and nucleic
acid synthesis by *Escherichia coli* strain B J Gen Microbiol 18 767 773
- 24 GALE E F 1958 Specific inhibitors of protein synthesis In The Strategy of Chemo-
therapy 212 246 Cambridge Univ Press Cambridge England
- 25 KERRIDGE D 1958 The effect of actidione and other antifungal agents on nucleic
acid and protein synthesis in *Saccharomyces carlsbergensis* J Gen Microbiol 19
497 506
- 26 HIRTH L G LEBURIER & E DROCHET 1959 Action de l'amphotericine B sur le
métabolisme de certains composés phosphorés au cours de la croissance de *Candida*
albicans Comptes rendus des séances de l'Académie des Sciences 249 3733-3735
- 27 SCHOLZ R H SCHMITZ T BUCHER & J O LAMPEN 1959 Über die Wirkung von
Nystatin auf *Bacteriophage* Biochem Z 331 71-86
- 28 HORVATH I & A SZENTIMAI 1959 Inhibitory effect of fungistatic antibiotics on
the production of amylase by *Penicillium chrysogenum* Nature 184 57 58
- 29 SAE A K & L M MARTINEZ 1956 Enzymatic basis of resistance to aureomycin
I Differences between flavoprotein nitro reductases of sensitive and resistant *Escherichia*
coli J Biol Chem 223 285-292
- 30 WOODS D D & R G TICLER 1958 The relation of strategy to tactics some general
biochemical principles In The Strategy of Chemotherapy I 28 Cambridge
Univ Press Cambridge England
- 31 PARK J T & J L STROMINGER 1957 Mode of action of penicillin Science 123
99-101
- 32 LEDERBERG J & J ST CLAIR 1958 Protoplasts and λ type growth of *Escherichia*
coli J Bacteriol 114 143-160
- 33 BRIAN P W 1949 Studies on the biological activity of griseofulvin Ann Botany
London 13 59-77
- 34 LINKS J J E ROMPOUTH & P KELLEN 1957 The bulging factor a fungistatic
antibiotic produced by a *Streptomyces* strain with evidence of an active water excreting
mechanism in fungi J Gen Microbiol 17 596-601
- 35 BARNER H D & S S COHEN 1957 The isolation and properties of amino acid
requiring mutants of a thymineless bacterium J Bacteriol 74 350-355
- 36 GOTTLIEB D H E CARTER J H SLOVEKER & A AMMANN 1958 Protection of
fungi against polyene antibiotics by sterols Science 128 361
- 37 BARNES W N & P SAGAR 1954 The effect of the γ and δ isomers of hexachloro-
cyclohexane on the growth fermentation and respiration of three species of yeasts
J Gen Microbiol 10 475-481
- 38 MAGASANA B 1957 Nutrition of bacteria and fungi Ann Rev Microbiol 11
221 252

Part III. Immunology of Mycoses

SOME ASPECTS OF THE MODE OF ACTION OF POLYENE ANTIFUNGAL ANTIBIOTICS

E. Drouhet, L. Hirth, G. Lebeurier

Institut Pasteur Service de Mycologie et de Physiologie 1 église Paris France

Introduction

Since the discovery of nystatin in 1951 by Hazen and Brown,¹ a new class of antifungal agents has been described in recent years, most of these are products of various *Streptomyces* fermentations. These agents, characterized by a chromophore group formed by conjugating double bonds, are grouped under the name of polyene antibiotics;²³ they exhibit characteristic ultraviolet absorption spectra and are of low solubility in water, but dissolve more readily in aqueous solutions of the lower alcohols or pyridine. They inhibit the growth of a wide range of fungi including yeasts and filamentous fungi, pathogenic or non-pathogenic, but are ineffective against bacteria, actinomycetes, and viruses. On animal cells, they are not toxic when given by mouth, but show some toxic side effects, such as hyperthermia, when injected into animals and humans.²⁴ The important success of the polyene antibiotics, such as nystatin⁷ and amphotericin B²⁵ in the treatment of mycotic infections, focused the attention of some workers on the mode of action of these antibiotics and the factors contributing to their activity.^{2-4,24-26,27,28,29,30,31}

The key to successful chemotherapy is contained in the selective toxicity, the antibiotic is more toxic to the pathogen than to the host.¹⁻¹⁹ If a chemotherapeutic agent acts by inhibiting an enzymatic system of fundamental importance to the pathogen, then this system must be absent from the host or if present, less susceptible to the drug.²⁰ The discovery of the site of primary injury of antibiotics is not easy, as Hotchkiss pointed out ten years ago.²⁰ He compared the investigator to an expert "trying to examine a crashed airplane for evidences of the initial mechanical failure which led to the accident, since the mechanical system is now grossly disrupted and he does not understand it very well anyway, he naturally places greater weight upon any testimony obtainable as to events before the crash, the earlier the better."²⁰

The first study on the effect of polyenes on the fungal metabolism was the work of Lampen *et al.*,^{22,23} who established the fact that nystatin inhibits the endogenous respiration and the aerobic and anaerobic utilization of glucose by yeasts and other fungi, however, these authors observed that with certain levels of nystatin there is an initial stimulation of oxygen consumption, then metabolism ceases abruptly. Bradley^{2,4} showed that nystatin as well as arsenate inhibited the glucose fermentation of *Candida stellatoidea*. However, several different workers, including Harman and Masterson²⁴ with nystatin, and Fujii³⁰ with trichomycin in their experiments attained the stimulation of the respiration of *Candida albicans* and *Trichophyton*.

Our preliminary work¹⁴ on the action of amphotericin B on the respiratory metabolism of *C. albicans*, supplemented with further investigations on other polyene antibiotics, emphasized the fact that one of the primary effects of the

polyenes ■ the stimulation of O_2 uptake the inhibition of respiration being the final result of the death of the cells. The analogy of the action with dinitrophenol, an agent that stimulates the cellular oxidations and controls the respiratory rate by processes related to oxidative phosphorylation, led us to extend our work to the effect of amphotericin B on the phosphorus metabolism and on the nucleic acids and protein synthesis during the growth of *C. albicans*^{21, 22}. All these aspects will be developed in this paper.

TABLE 1
DATA ON THE ANTIBIOTICS STUDIED

Antibiotic* producing organism	Type of polyene ($CH=CH$) _n	Action on <i>C. albicans</i> (st. AB)	
		Fungicidal effect M.I.C. (μ g/ml/24 hours)	Fungicidal effect 4×10^7 yeasts/ ml. = 1 mg. dry weight % lethal t _y
Amphotericin B <i>Streptomyces</i> sp.	Heptasene	0.2 μ g	pH 7.1 15 min 30% 20 min 50% 6 hours 75% pH 4.1 6 hours 90% 1.5 μ g
Ascocin <i>Streptomyces coenobius</i>	Heptasene	0.1 μ g	pH 7.1 3.12 μ g 6 hours 47% 6.25 μ g 6 hours 90%
Amphotericin A <i>Streptomyces</i> sp.	Tetraene	3.12 μ g	
Nystatin <i>Streptomyces noursei</i>	Dodecetetraene	3.12 μ g	

* Potency of the antibiotics used: amphotericin B (lot DIAB 824CR) 850 U/mg; amphotericin A (lot II V 733) 995 U/mg; nystatin (commercial sterile powder) 2500 U/mg; ascocin (lot R16 and R17). The first 3 antibiotics furnished by the Squibb Institute for Medical Research, New York, N.Y.; ascocin by Commercial Solvents Corporation, New York, N.Y. Five to 10 mg of each antibiotic dissolved in 0.2 ml of dimethylacetamide followed by appropriate dilution in water and buffer solution.

† Minimal inhibitory concentration/ml of the following synthetic medium: glucose 2 gm, $SO_4(NH_4)_2$ 1 gm, $PO_4HNa_2 + 12H_2O$ 3.34 gm, $FeCl_3 \cdot 6H_2O$ 0.54 gm, $SO_4Mg + 7H_2O$ 0.25 gm, 100 ml 10^{-4} trace elements dissolved in 1000 ml. Continuous agitation 34°C. 3×10^8 yeasts/ml initial concentration.

Action of Polyene Antibiotics on the Respiratory Metabolism

Some representative data on the antifungal antibiotics studied are given in the TABLE 1. The fungicidal effect on *C. albicans* is measured under the same conditions as those used in Otto H. Warburg's techniques on 1 ml of a suspension of yeasts representing 4×10^7 cells (equivalent to 1 mg dry weight). Fifty μ g of amphotericin B, the usual concentration utilized in the respiratory studies at pH 7, kills 30 per cent of the cells after 15 min, 50 per cent after 20 min and at the end of the experiments using Warburg flasks after 6 hours this concentration kills 75 per cent of the cells. At an acid pH only 1.5 μ g is required to kill 90 per cent of the cells after 6 hours. This is in accordance with the results of Lampen *et al*²⁴ on the influence of pH on the fungicidal effect

ACTION OF AMPHOTERICIN B ON O₂ UPTAKE OF *C ALBICANS* AT pH 4.1




FIGURE 3 Effect of amphotericin B on the endogenous respiration of yeasts suspended in an acid buffer solution (McIlvaine citric acid phosphate buffer pH 4.1) Growing yeasts after 16 hours incubation, in the same concentration as in FIGURE 1 Amphotericin B (final concentrations noted on the curves) added where shown by the arrow

TABLE 3
ACTION OF AMPHOTERICIN B ON THE RESPIRATION OF *C ALBICANS* AT pH 4.1

Time (min)	Control			Amphotericin B 15 μg/ml.			
	O ₂ (μl)	CO ₂ (μl)	RQ	O ₂ (μl)	%	CO ₂ (μl)	RQ
Endogenous respiration							
30	13.13	14.29	1.08	Antibiotic at 30 min			
60	21.90	22.87	1.04	20.08	-8	19.09	0.95
120	34.13	35.57	1.04	35.11	+3	32.70	0.92
180	43.56	44.32	1.01	52.83	+21	49.19	0.93
Exogenous respiration—1% glucose							
30	21.87	32.99	1.50	Antibiotic at 30 min			
60	41.61	49.31	1.18	48.36	+16	62.30	1.28
120	93.09	123.87	1.33	101.59	+9	127.18	1.25
180	132.22	171.86	1.29	131.90	-0.2	164.11	1.18

Citrate phosphate buffer pH 4.1, 1 ml of growing cells (1 mg dry weight) per flask
Citric acid—Na₂ phosphate Key +, per cent stimulation, —, per cent inhibition

μg amphotericin B as shown in FIGURE 3 and in TABLE 3. These results are explained by the fungicidal effect, which is greater at an acid pH. The O_2 uptake of the washed yeasts after contact with amphotericin B for various lengths of time is not stimulated as are normal yeasts in the presence

RESPIRATION OF WASHED CELLS AFTER CONTACT WITH AMPHOTERICIN B




FIGURE 4 Buffer phosphate pH 7. Growing yeasts at the same concentrations as in FIGURE 1 were put in contact with amphotericin B ($50 \mu\text{g}/\text{ml}$ final concentration) for 15 and 30 min. After 4 successive washings with distilled water the O_2 uptake of the yeast was measured under the same conditions as in the experiments made in the presence of amphotericin B. The same final concentration was attained in both experiments. Curves 2 3 measurement of respiration 1 hour after washing; 4 5 measurement after 2 hours.

ACTION OF AMPHOTERICIN B ON OXYGEN UPTAKE OF LEAVES OF *NICOTIANA TABACUM*




FIGURE 5 Discs of tobacco leaves 4.5 cm diameter immersed in amphotericin B (100 $\mu\text{g}/\text{ml}$ of buffer phosphate pH 7.1) or in buffer phosphate (control) for 4 hours before respiration, O_2 uptake studied in special flask of 30 ml. Endogenous respiration

of the same concentrations, it is strongly inhibited, and the inhibition is a function of the duration of the contact. The data from one of these experiments on the respiration of washed yeasts after contact with amphotericin B at pH 7 are summarized in FIGURE 4.

The experiments prove that the amphotericin B penetrates rapidly into the cells even after 6 successive washings the antibiotic is still found in the cells. It is possible that the washings eliminate the products given off by the yeasts that were submitted to the action of the antibiotic. These products may be

ACTION OF AMPHOTERICIN B ON CO₂ PRODUCTION IN N₂ ATMOSPHERE




FIGURE 6 Fermentation in N₂ atmosphere. Suspensions of growing yeasts (16 hours growth period) in buffer phosphate pH 7.1. Curves 1 2 +0.25 per cent glucose, 3 4 +0.10 per cent glucose, 5 6 without glucose. Amphotericin B (50 μg /ml final concentration) added where shown by the arrow.

responsible for stimulation of the O₂ consumption. A loss of essential metabolites and phosphorylated compounds diffusing out of the cells after contact with nystatin was observed independently by Oseur and his co-workers¹⁰ and by Scholz *et al*.¹¹ These authors showed that the disorder in the permeability of the cell membrane takes place within a few minutes after the addition of the antibiotic. Some disorders in the membrane permeability accompanied by a

ACTION OF ASCOSIN ON THE RESPIRATION OF *C. ALBICANS* AT PH 7.1




FIGURE 7 Growing yeasts in 0.01 M phosphate buffer pH 7.1 same conditions as in FIGURES 1 and 2. Ascospores at various concentrations added where shown by the arrow.

release of soluble cell constituents have also been observed on fungi submitted to different antifungal agents (10, 21, 22, 23, 24).

Amphotericin B stimulates the respiration of both fungi and plant tissues. The O_2 consumption of discs of tobacco leaves immersed in amphotericin B for

4 hours is stimulated to the order of 16 to 20 per cent at pH 7, as is shown in FIGURE 5

In an atmosphere of nitrogen, in the presence or the absence of glucose at pH 7, CO₂ production is also stimulated. In the absence of carbon substrate this stimulation may rise to 66 per cent and, in the presence of glucose, to 20 to 40 per cent (FIGURE 6)

The stimulation of oxidations is also observed with the other polyenes studied (FIGURE 7 illustrates the results obtained with ascocin, a heptaene antibiotic somewhat more toxic than amphotericin B). The stimulation of O₂ uptake at pH 7 is obtained with a small concentration such as 3.12 µg. With this concentration, after an initial stimulation the O₂ consumption is diminished, but the CO₂ production is particularly high, and the RQ rises from 1.30 to 3.16 (TABLE 4)

TABLE 4
ACTION OF ASCOCIN ON THE RESPIRATION OF *CANDIDA ALBICANS* AT pH 7.1 IN PRESENCE OF 1 PER CENT GLUCOSE

Time (min.)	Control			Ascocin							
	O ₂ *	CO ₂ *	RQ	3.12 µg				6.25 µg			
				O ₂	%	CO ₂	RQ	O ₂	%	CO ₂	RQ
30	29.37	38.49	1.31								
60	48.14	56.33	1.17								
90	77.02	80.39	1.04	55.80	+15	59.51	1.06	60.99	+26	78.37	1.28
120	98.21	105.07	1.06	87.35	+13	124.91	1.42	67.41	-12	156.55	2.32
150	119.36	131.14	1.09	108.93	+10	180.10	1.65	78.96	-19	215.73	2.73
180	144.42	178.10	1.23	122.91	+2	249.24	2.02	91.81	-23	290.61	3.16
				136.24	-5	331.67	2.43	109.14	-35	367.02	3.36

Phosphate buffer pH 7.1, 1 ml of growing cells (1 mg dry weight) per flask.
* Microliter of gas.

A similar stimulation of endogenous and exogenous O₂ uptake of *C. albicans* is obtained with tetraene polyenes such as amphotericin A and nystatin (TABLES 5 and 6), the greatest effect is observed on endogenous respiration.

In our opinion, the stimulation of O₂ consumption and the rapid oxidation of carbohydrate reserves are the earliest effects of the polyenes on the respiratory metabolism, the inhibition of respiration seems to be a later effect, resulting from the death of the yeasts.

The contradiction between the results showing the inhibition of respiration and fermentation^{2-4, 22, 24} and the results showing the burst of metabolic activity^{14, 20, 23} can be explained by the wide range of pH (from pH 2.0 to pH 7.5) employed by these workers in their studies. In anaerobiosis, at pH 4.5 Lampen *et al.*²³ found that yeast glycolysis and oxidation are stimulated by 0.4 µg of nystatin/ml, but strongly inhibited by 3.3 µg/ml. Harman and Masterson²⁴ observed at pH 7 a 300 per cent stimulation of O₂ uptake of *C. albicans* submitted to the action of nystatin. On the other hand, Bradley⁴ noted a rapid inhibition of glucose fermentation in anaerobiosis at pH 2, but at pH 5.6 the fermentation is not inactivated. Ribereau Gayon *et al.*¹⁴ found that 5 µg

nystatin/ml inhibits strongly the fermentation of glucose by *Saccharomyces ellipsoideus* at pH 3.8 to 4.8, but produces an initial stimulation of respiration and fermentation at pH 7.

Actidione (cycloheximide), another antifungal antibiotic different from the polyenes, inhibits the endogenous and exogenous oxidations of the sensitive yeasts without any initial stimulating effect, our results on *C. tropicalis* show

TABLE 5
EFFECT OF POLYENES, ANTIBIOTICS, AND DINITROPHENOL ON O_2 UPTAKE OF *CANDIDA ALBICANS*

Time (min)	Polyenes and antibiotics						Dinitrophenol	
	Ascoquin		Amphotericin B		Nystatin		50 μ g (%)	100 μ g (%)
	3.12 μ g (%)	6.25 μ g (%)	50 μ g (%)	100 μ g (%)	50 μ g (%)	100 μ g (%)		
30	+15	+26	+20	+14	+21	+48	+4	+10
60	+13	-12	+18	+10	+30	+37	+5	+12
90	+10	-19	+16	+5	+20	+23	+10	+16
120	+3	-23	+15	II	+16	+8	+10	+15
150	-5	-24	+14	-5	+12	-1	+10	+14

Conditions: buffer phosphate pH 7.1, glucose 1 per cent, growing cells of *C. albicans* (1 mg of dry weight) per flask. Key: +, stimulation, -, inhibition of O_2 uptake.

TABLE 6
EFFECT OF POLYENES, ANTIBIOTICS, AND DINITROPHENOL ON THE ENDOGENOUS RESPIRATION OF *CANDIDA ALBICANS*

Time (min)	Ascoquin		Amphotericin B	Amphotericin A	Dinitrophenol
	3.12 μ g (%)	6.25 μ g (%)	50 μ g (%)	50 μ g (%)	50 μ g (%)
30	+24	+45	+42	+10	+259
60	+52	+71	+63	+30	+253
90	+62	+85	+73	+36	+280
120	+64	+79	+56	+40	

Conditions: buffer phosphate pH 7.1 without substrate, 1 ml growing cells of *C. albicans* (1 mg dry weight) per flask.

that actidione, at concentrations varying between 16.2 and 50 μ g, has only an inhibitor effect on respiration. The results of Walker and Smith⁴⁵ on *Myrothecium verrucaria* and of Kerdige⁴¹ on *Saccharomyces carlsbergensis* are similar. Other antifungal agents affect slightly the respiration of sensitive fungi.^{41, 45}

Some stimulatory effects on respiration and on fermentation were observed in the past with low concentrations of various mineral or organic antifungal agents^{4, 44, 47} and more recently, with fatty acids on the respiration of dermatophytes.¹⁰ The stimulation of O_2 consumption by antiseptics such as phenol and 2-phenoxyethanol is explained by Hugo⁴⁹ by an increase in the permeability

of the microorganisms, thereby facilitating substrate oxidation. An apparent stimulation of oxygen uptake by cyanide is observed in *C. albicans* by Ward and Nickerson¹¹ and is explained on the basis of its inhibitory effect on catalase activity. The action of most of these agents seems to be different from the effect of the polyenes.

ACTION OF DNP AND AMPHOTERICIN ON THE O₂ UPTAKE OF *C. ALBICANS* AT PH 7.1




FIGURE 8 Comparative effect of 2,4-dinitrophenol and amphotericin B on the O₂ consumption of yeasts in phosphate buffer pH 7.1 same conditions as in FIGURE 1

The stimulation of the O₂ uptake of yeasts by polyene antibiotics can be compared with the action of dinitrophenol (DNP) an agent that uncouples the oxidative phosphorylation from the respiration^{12,13}. At fungistatic concentrations of DNP we obtain the stimulation of the respiration of *C. albicans* (FIGURE 8, TABLES 5 and 6) similar to the stimulation obtained on yeasts^{14,15,16} molds¹⁷ bacteria¹⁸ and mitochondrial preparations of animal cells^{19,20} by various authors. The first observation on the increase of metabolism in animals after the

administration of dinitrophenol or related compounds was reported in 1883 by Cazeneuve and Léprieu.¹⁶ Magne *et al.*¹⁷ observed during World War I that hyperthermia in persons working with DNP and proved its stimulating effect on cellular oxidations in various warm- and cold-blooded animals. From the point of view the analogy with the hyperthermia produced by the polyene antibiotics must be emphasized. The intravenous infusion of therapeutic doses of nystatin (200,000 U/day) or amphotericin B (1 mg/kg/day) may produce a transitory rise of body temperature from 37° C. to 40° C.

The stimulating effect of DNP on cellular oxidations was extended to plant tissues, yeasts, and molds by Plantefol for the first time in 1931,¹⁸ since that time various authors have confirmed this work.^{17-19, 45} However, some authors






FIGURE 9. Curve of growth of *C. albicans*. ●—● normal cells ○—○ cells cultured in presence of 0.2 µg amphotericin B/ml. Culture medium as TABLE 1 but with 1% glucose. Cultures shaken at 34° C in Fernbach flasks of 400 ml. Number of yeasts per ml at 0 hour = 3×10^6 . At the stationary growth period about 8×10^7 yeast/ml.

observed an inhibitory effect of DNP on respiration, but this effect is explained by the acid pH utilized in their experiments, as for the polyenes, the stimulating effect of DNP is a function of pH and is related to the dissociation of the active form.

It has been known for more than twenty years that respiration is linked with the esterification of inorganic phosphate, but it was only in 1948, in the work of Loomis and Lipmann,¹⁶ that DNP was shown to uncouple phosphorylation from respiration and to control the respiratory rate. DNP seems to stimulate the adenosine triphosphatase (ATPase) activity. The DNP stimulates ATPase reactions of liver mitochondria, characterized by pH optima at 6.3, 7.4, and 8.5, these are explained by the following reactions as proposed by Slater and Hulsmann:⁴⁹






FIGURE 10 Evolution of protein nitrogen per milligram of dry weight of treated and normal cells during the growth of *C. albicans*. Growth conditions described in FIGURE 9. Measurement of N by Kjeldahl method after treatment of the yeasts with 70 per cent alcohol.

In this reaction P_i is inorganic phosphate and $X \sim P$ and $X \sim I$ are energy rich intermediates

The adenosine diphosphate (ADP) formed by the action of DNP produces

RIBONUCLEIC AND DEOXYRIBONUCLEIC ACIDS CONTENT OF TREATED AND NORMAL YEASTS




FIGURE 11 Ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) measured by spectrophotometry after successive extractions with perchloric acid using the technique of Ogur and Rosen ⁴⁶

short increase in the rate of O_2 uptake and finally, the adenosine triphosphate (ATP) regeneration is blocked and vital synthesis compromised

For this reason in the following experiments we tried to relate the effect of amphotericin B on the respiratory metabolism to the effect on other cellular metabolisms such as phosphorus protein, and nucleic acids during the growth of *C. albicans* (FIGURE 9)

FIGURE 10 shows that the treated yeasts are richer in protein nitrogen than the normal cells, but observation of the amounts of protein nitrogen after 6 days when the treated cells are in the exponential period, shows that the synthe-




FIGURE 12 Total phosphorus and soluble P in 10 per cent trichloroacetic acid (TCA) determined by DeLiss technique¹⁰ on samples of washed cells at different times during the growth of *C. albicans* (FIGURE 9)

Synthesis of ribonucleic acid (RNA) and desoxyribonucleic acid (DNA) by the treated cells is slightly inhibited particularly of RNA, as shown in FIGURE 11. From this point of view, amphotericin B differs from other antifungal antibiotics such as actidione, frequentin, viridin gliotoxin all antibiotics having little effect on respiration, but a marked inhibitor effect on protein and DNA synthesis and less on RNA synthe-

The curves representing the total amount of phosphorus show that yeasts in the presence of amphotericin B have considerably less P than the normal

EVOLUTION OF THE ORTHOPHOSPHATE OF TRICHLORACETIC EXTRACTS OF *C. ALBICANS*




FIGURE 13 The amount of orthophosphate extracted with trichloroacetic acid is diminished in treated yeasts

EVOLUTION OF NONNUCLEIC PHOSPHORUS
OF PERCHLORIC EXTRACTS




FIGURE 14 Nonnucleic phosphorus obtained by perchloric acid extractions is considerably greater in normal than in treated yeasts

cells (FIGURE 12). On the other hand, the amount of total phosphorus soluble in trichloroacetic acid (TCA) is greater than the amount in normal cells. The orthophosphate of trichloroacetic extracts of *C. albicans* is diminished in treated yeasts (FIGURE 13), especially the nonnucleic phosphorus of perchloric extracts, which is very abundant in normal cells (FIGURE 14). This *P* represents the insoluble polyphosphate of yeasts.

Therefore, amphotericin B seems to inhibit the penetration of mineral phosphorus from the culture medium or to accentuate the loss of this compound from the cells. Other studies confirmed the disorder of phosphorus metabolism of fungi treated with polyene antibiotics,^{4, 40, 41} to be compared with metabolic aberrations appearing in yeasts submitted to inhibitors of the cell division.^{42, 43} Osteux *et al.*⁴⁰ observed that the phosphorylated compounds marked by P^{32} are excreted by the cells submitted to the action of nystatin and that the speed of discharge is related to the concentration of the antibiotic. By utilizing chromatography and autoradiography they found that most of the total P^{32} released is in the form of orthophosphate ions. Fujii⁴² found an inhibition of P^{32} incorporation on *Trichophyton gypsum* submitted to the action of trichomicin, a heptaene antibiotic. Scholz *et al.*⁴³ show that under the influence of nystatin on yeast there is an increase in the content of hexose phosphate. From this, the authors concluded that nystatin produced a restriction of phosphate utilization which controls physiologically the phosphorylation of reserve carbohydrates.

Possible Mode of Action of Polyene Antibiotics

The stimulation of fungal respiratory metabolism that is related to the disturbance of phosphorus metabolism under the action of polyene antibiotics supports the possibility that the mode of action of these antibiotics may be somewhat similar to that of the uncoupling agents such as dinitrophenol^{18, 24, 44} and gramicidin.^{18, 27} These agents may accelerate the decomposition of adenosine triphosphate (ATP) to adenosinediphosphate (ADP). This activity on ATP can explain the inhibition of the synthesis of carbohydrate reserves and proteins, and of polyphosphates, all of which are metabolites requiring energy-rich compounds such as ATP. Under the action of polyenes, ATP may be blocked, and ADP is made available for the respiratory metabolism that is stimulated, at the same time inorganic *P* is released.

The exact site of action of the polyenes is yet to be determined. The antibiotics may act by stimulating the ATPase activity or, more probably, by stimulating some particular uncoupling agent naturally found in fungi, as shown recently for a mitochondrial respiration releasing factor described in animal cells. Such naturally occurring controlling factors specific for fungi may explain the activity of the polyenes only on fungi and not on bacteria, actinomycetes, viruses, or animal cells.

Summary

The action of various polyene antibiotics, particularly of amphotericin B was studied on the metabolism of respiration, of proteins, of nucleic acids and of phosphorus compounds of *Candida albicans*.

At concentrations suppressing the growth of *C. albicans*, amphotericin B produces an increase in O_2 uptake by resting or growing cells, in the presence or the absence of carbon substrate, in phosphate buffer pH 7. The stimulation is greater on endogenous respiration, rising to 73 per cent. The stimulating effect on O_2 consumption is no longer observed on yeasts which have been washed after contact with the antibiotic, on the contrary, an inhibitory effect is seen. It is possible that the washing discards the products responsible for the increase in O_2 uptake, products released by alteration of cell permeability. At pH 4.2 the stimulation of O_2 uptake is obtained only with small concentrations of antibiotic. In an atmosphere of N_2 in the absence or presence of dextrose, at pH 7 the CO_2 production is stimulated by the antibiotic.

In the growing phase of yeasts, amphotericin B produces an inhibition of the synthesis of proteins, ribonucleic acid, carbohydrate and polyphosphate reserves, the penetration of inorganic P into the cells seems to be inhibited, but a release of P compounds is also possible. The disturbance of phosphorus metabolism produced by amphotericin B is related to the stimulation of endogenous or exogenous oxidations. The action of other polyenes such as amphotericin A (a tetraene), nystatin (a diene-tetraene), ascocin (a heptaene), trichomycin (a heptaene) is similar to the action of amphotericin B (a heptaene), this effect on respiration is distinct from the effect of other antifungal antibiotics such as actidione (cycloheximide). Under certain aspects, the action of polyene antibiotics is compared to the action of such uncoupling agents of phosphorylation as 2,4-dinitrophenol antifungal polyenes such as dinitrophenol, which stimulates the oxidations of animal and vegetable cells, introduced by parenteral means in man and animals, produce hyperthermia.

References

- 1 ALBERT A. 1951 Selective Toxicity. Methuen, London, England.
- 2 BRADLEY M. G. 1958 Effect of nystatin on *Candida stellatoidea*. Antibiotics & Chemotherapy 8: 282-286.
- 3 BRADLEY M. G. 1958 Interactions between phosphate and nystatin in *Candida stellatoidea*. Proc. Soc. Exptl. Biol. Med. 98: 786-789.
- 4 BRADLEY, S. G. 1959 Effects of nystatin on glucose fermentation by *Candida stellatoidea*. Proc. Soc. Exptl. Biol. Med. 102: 82.
- 5 BRADHAM S. F. 1929 Effects of certain chemical upon the course of gas production by baker's yeast. J. Bacteriol. 18: 247-264.
- 6 BRIAN P. W. & J. R. MCGOWAN. 1945 Viridin, a high fungistatic substance produced by *Trichoderma viride*. Nature 166: 144.
- 7 BROWN R. & I. L. HAZEN. 1957 Present knowledge of nystatin, an antifungal antibiotic. Trans. N. Y. Acad. Sci. 19: 447-456.
- 8 HARDF R. I. W. & G. C. WINSFORTH. 1958 The chemotherapy of fungal diseases. Eighth Symposium of the Society for General Microbiology. In The Strategy of Chemotherapy. 309-335. Cambridge Univ. Press, Cambridge, England.
- 9 (AZEULY P. & R. LEFÈVRE. 1885 Sur les effets produits par l'ingestion et l'injection intraveineuse de trois colorants jaunes dérivés de la houille. Comp. rend. acad. sci. (Paris) 101: 1167-1170.
- 10 CHATTAWAY F. W., C. C. THOMPSON & J. E. BARLOW. 1946 The action of inhibitors on dermatophytes. Biochem. J. 63: 648-656.
- 11 CURTIS P. J., H. G. HEMMING & W. K. SMITH. 1951 Frequentin, an antibiotic produced by some strains of *Penicillium frequentans* Westling. Nature 167: 557.
- 12 DIFESAL J. L. & H. MANHOUT. 1958 Etude comparative des dosages colorimétriques du phosphore. IV. Dosage de l'orthophosphate en présence d'esters phosphoriques. Bull. Soc. Chim. Biol. 40: 1623-1636.

- 13 DROUET E 1957 Antifongiques et thérapeutique des mycoses Sem. des Hôp (Paris) 33 843-866
- 14 DROUET E L HIRTH & G LEBFRIER 1958 Influence de l'amphotéricine B sur le métabolisme respiratoire de *Candida albicans* Compt rend acad sci (Par. 247 2416-2419
- 15 DUROS R J R D HOTCHKISS & A F COBLER 1942 The effect of gramycin and tyrocidine on bacterial metabolism J Biol Chem 146 421-426
- 16 DUTCHER J B J R JOHNSON & W F BRICE 1945 Gliotoxin VI The nature of the sulfur linkages conversion to deshydrogliotoxin J Am Chem Soc 67 1736
- 17 FIELD J A W MARTIN & S M FIELD 1933 Action of 2,3-dinitrophenol on yeast respiration and fermentation Proc Soc Exptl Biol Med 31 56-57
- 18 FIELD J & W MARTIN 1935 Action du dinitrophenol 1,2,4 sur les levures laines Compt rend soc biol 119 458
- 19 FRY B A 1953 The Nitrogen Metabolism of Microorganisms Methuen London England
- 20 FUJII T 1957 Biochemical studies on pathogenic fungi VIII The effect of an antibiotic trichomycin on the respiration and phosphorus metabolism of *Trichophyton* Pharmacol Bull Japan 6 511-514
- 21 GALE G R 1953 The effect of β -propiolactone on the metabolism of *Blastomyces dermatitidis* J Bacteriol 65 505-508
- 22 GENEVOIS L & R SARIC 1934 Action des dinitrophénols sur la respiration des levures et des bactéries de la fermentation lactique Compt rend soc. biol 117 III
- 23 GOLD W H A STOLT J F PAGANO & R DONOVICK 1955-1956 Amphoterins I and II antifungal antibiotics produced by a Streptomyces Antibiotics Ann 579-586
- 24 HARMAN J W & J G MASTERSON 1957 The mechanism of nystatin action Inst J Med Sci 376 249-253
- 25 HIRTH L G LEBEUFRIER & E DROUET 1959 Action de l'amphotéricine B sur le comportement des protéines et des acides nucléiques au cours de la croissance de *Candida albicans* Compt rend acad sci (Paris) 248 3333-3335
- 26 HIRTH L G LEBEUFRIER & E DROUET 1959 Action de l'amphotéricine B sur le métabolisme de certains composés phosphorés au cours de la croissance de *Candida albicans* Compt rend acad sci (Paris) 248 3733-3735
- 27 HOTCHKISS R D 1946 Gramicidin tyrocidine and tyrothricin Advances in Enzymol 4 153
- 28 HOTCHKISS R D 1950-1951 The effect of penicillin upon protein synthesis by bacteria Ann N Y Acad Sci 53 (1) 13-17
- 29 HUGO W B 1956 The action of phenol and 2-phenoxyethanol on the oxidation of various substances by *Escherichia coli* and by disrupted cell preparation of the organism J Gen Microbiol 16 315-323
- 30 KATCHMAY B J W O LETTY & K A BLISCH 1959 Effect of cell division inhibition on the phosphorus metabolism of growing cultures of *Saccharomyces cerevisiae* J Bacteriol 77 331-333
- 31 KERRIDGE D 1958 The effect of actidione and other antifungal agents on nucleic acid and protein synthesis in *Saccharomyces carlsbergensis* J Gen Microbiol 19 497-506
- 32 LAMPEN J O G R MORGAN & A C SLOCUM 1956 Inhibition of sugar utilization by nystatin Federation Proc 15 295
- 33 LAMPEN J O E R MORGAN & A C SLOCUM 1957 Effect of nystatin on the utilization of substrates by yeast and other fungi J Bacteriol 74 297-302
- 34 LAMPEN J O G R MORGAN A SLOCUM & P ARNOW 1959 Absorption of nystatin by microorganisms J Bacteriol 78 282-289
- 34a LAMPEN J O & P ARNOW 1959 Significance of nystatin uptake for its antifungal action Proc Soc Exptl Biol Med 101 792-797
- 35 LEHNINGER A L C L WADKINS & L F REMMERT 1959 Control points in phosphorylating respiration and the action of a mitochondrial respiration releasing factor In Ciba Foundation Symposium on the Regulation of Cell Metabolism 130-145 Churchill London England
- 36 LOOMIS W F & F LIPMANN 1948 Reversible inhibition of the coupling between phosphorylation and oxidation J Biol Chem 173 807
- 37 MAGNE H A MAYER & L PLANTÉPOL 1932 Etudes sur l'action du 2,4-dinitrophénol (thermol) Ann Phys 8 191
- 38 OGUR M & G ROSEN 1950 The nucleic acids of plant tissues I The extraction and estimation of desoxyribose nucleic acid and pentose nucleic acid Arch Biochem 25 262

- 39 OROSHNIK W L C VINTAG A D MEBANE & W A TABER. 1955 Polyene anti
b o t c s Science 122 147
- 40 OSTEUX R. TRAN VAN KY & J BIGUET. 1958 Contribution à l'étude du mode
d'action de la nystatine sur *Candida albicans* Compt rend acad sci (Paris) 247
2475-2478
- 41 PLANTFOL L. 1932 Action du dinitrophenol 1 2 4 sur la respiration de cellules et
t s s u s v é g é t a u x Ann Physiol 8 124-156
- 42 PLANTFOL L. 1935 Les levures et le dinitrophenol 1 2 4 Ann Fermentations 1
149-162
- 43 RIBERAU GAYON J E. PEYNAUD S. LAFOURCADE & M LAPON. 1958 Mode d'action
des antibiotiques antifongiques sur les levures Bull soc chim biol 40 189-201
- 44 RICHEL C. 1906 De l'action des doses minuscules de substances sur la fermentation
lactique Périodes d'accélération et de ralentissement A M A Arch Intern Physiol
4 203
- 45 ROTHSTEIN A & A BERKE. 1952 Effects of 2 4-dinitrophenol concentrations on
rates of respiration and fermentation of yeast Proc Soc Exptl Biol Med 81
559-563
- 46 SCHOLZ R. H. SCHMITZ T. BUCHER & J O LAMFEN. 1959 Über die Wirkung von
Nystatin auf Bäckerhefe Biochem Z 331 71-86
- 47 SCHULZ H. 1889 Über Hefegifte Arch ges Physiol 42 517
- 48 SHEPHERD C J. 1958 Inhibitors of protein and nucleic acid synthesis in *Aspergillus
nidulans* J Gen Microbiol 18 IV
- 49 SLATER E C & W C HULSMAN. 1959 Control of rate of intracellular respiration
In Ciba Foundation Symposium on the Regulation of Cell Metabolism 58-83
Churchill London England
- 50 SPOERLE E & R CARLTON. 1954 Studies on cell division nitrogen compound changes
in yeast accompanying an inhibition of cell division J Biol Chem 210 521-529
- 51 SPOERLE E & D LOONEY. 1958 Phosphorus metabolism in yeast accompanying
an inhibition of cell division by X rays J Bacteriol 76 63
- 52 STEWART G T. 1958 The mode of action of antifungal drugs In Fungous Diseases
and Their Treatment 183-191 R W Riddell and G T Stewart Eds Butter
worth London England
- 53 UMBREIT W W R H BURRIS & J F STAUFFER. 1960 Manometric Techniques
Burgess Minneapolis Minn
- 54 VANDEPUTTE J J L WACHTEL & E T STILLER. 1955-1956 Amphoterins A and
B antifungal antibiotics produced by a Streptomycete II The isolation and proper
ties of the crystalline Amphoterins Antibiotics Ann 587 591 Medical Encyclo
peda New York N Y
- 55 WALKER A T & F G SMITH. 1952 Effect of actidione on growth and respiration of
Myrothecium verrucaria Proc Soc Exptl Biol Med 81 556-559
- 56 WAKSMAN S A. 1959 The Actinomycetes I Nature Occurrence and Activities
Williams & Wilkins Baltimore Md
- 57 WARD J M & W J NICKERSON. 1958 Respiratory metabolism of normal and
divisionless strains of *Candida albicans* J Gen Physiol 41 703-724
- 58 WORK T S & E. WORK. 1943 The Basis of Chemotherapy Oliver & Boyd Lon
don England

VIRULENCE AND GROWTH RATES OF *CRYPTOCOCCUS NEOFORMANS* IN MICE

H. F. Hensclevier and William O. Mitchell

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases,
Public Health Service, Bethesda, Md.

Previous studies of the virulence of *Cryptococcus neoformans* have investigated the relationship of encapsulation to virulence. Drouhet *et al.* (1930) found that a nonencapsulated variant had less virulence than the encapsulated parent yeast. Kro and Schwarz (1937), studying strains of *C. neoformans* isolated from pigeon nests, reported no correlation between capsule size and virulence. Gadebusch (1939) found that yeast cells of a nonencapsulated variant were more readily phagocytized by polymorphonuclear leukocytes from anesthetized mice than yeast cells of the encapsulated parent strain. The studies of Limman and Fsuburn (1939) indicated that an enlargement of capsule width by cultivation of *C. neoformans* on capsule agar did not increase the virulence when compared to the same strain grown on Sabouraud's agar.

The results to be presented here show the range of mouse lethality for three isolates of *C. neoformans* and their rates of *in vitro* multiplication.

Materials and Methods

The three strains of *C. neoformans* used in this study were isolated from different cases of human cryptococcosis and are designated as strains B, J, and S. They were typical with reference to fermentation and carbon assimilation reactions; did not utilize KNO_3 as a sole source of nitrogen; and grew readily at 37°C. Strains B and J had wide capsules and strain S had a narrow capsule *in vitro*. All strains showed wide capsules *in vivo*.

Suspensions of yeast cells for inoculation of mice were made from 24- to 48-hour cultures grown on 1 per cent neopeptone-2 per cent glucose agar. Incubation was at 30°C. Yeast cell numbers were determined by direct count in a Levy hemocytometer and diluted to contain the desired number of cells per milliliter.

Female Swiss white mice weighing 17 to 20 gm. and obtained from the Animal Production Section of the National Institutes of Health were used in this study.

The approximate virulence for mice of each strain was determined in preliminary experiments. For the mortality studies 5 serial fivefold dilutions of the initial suspensions were used. Ten mice were injected intravenously with 0.2 ml. of each dilution. Since the strains differed in virulence the numbers of cryptococcal cells injected into the test animals varied with each strain. The mice were observed for 3 months and deaths were recorded as they occurred.

In vitro growth rate studies of each strain of *C. neoformans* were undertaken to determine the number of yeast cells present in an organ or blood from immediately after injection and at specified intervals, to and including the terminal stages of disease. A standard dose of 10^5 yeast cells was injected intravenously into each mouse and 50 to 75 mice were inoculated with a strain

Groups of 3 mice were sacrificed at 10 min, 4 hours, 1 day, 3 days, 6 days, 10 days, 14 days, and further intervals after injection. Whole blood samples (in heparin), spleen, liver, kidney and adrenal, lung and brain from each mouse were collected separately. Each organ was weighed, ground separately in a sterile mortar and pestle, and mixed with 9 parts of sterile saline, tenfold serial dilutions were made. One tenth of 1 ml of the dilutions from each tissue suspension was placed in each of 3 Petri dishes. Molten 2 per cent glucose trypticase soy agar at a temperature of approximately 45° C was added and agitated with a circular motion to ensure mixing of the suspension and agar. These pour plates were incubated for 48 hours at 30° C and the colonies were counted. The lowest dilutions of those pour plates in which the colonies of *C. neoformans* varied from approximately 20 to 200, were counted. The average number of colonies on the triplicate plates was determined and, since 3 mice were autopsied, the average colony count from the organs of the 3 mice was calculated. The numbers of viable *C. neoformans* cells per 0.1 gm of the various organs were calculated and are shown in the figures. The number of plating experiments varied with each strain. With strain B the final plating was made 16 days after injection because all the remaining experimental mice died before another plating could be done. Some of the mice injected with strain J, however, survived longer, and the final plating was made 52 days after injection of the infecting dose. With all strains the final plating experiment was made when the remaining mice were in the terminal stages of cryptococcosis.

Similar experiments, for which mice were injected intracerebrally, were conducted. For these studies each mouse was inoculated with 0.05 ml of a suspension containing 4×10^4 *C. neoformans* yeast cells. The injections were made about one-eighth inch laterally to the midline cranial suture and about three-eighths inch above the left eye. The same plating schedule was followed as with the mice that received the intravenous inoculations but the disease progressed more rapidly under these conditions, and fewer platings could be done.

Results and Discussion

The results of mortality studies are shown in TABLE I. It was evident that strain B had a high degree of virulence for mice considerably more so than for the other 2 strains. It must be emphasized that surviving mice were observed for a 3 month period. Most of the animals that received strain B died between 1 and 2 months following injection, whereas some of the mice that were inoculated with the higher dilutions of strain J died at a slower rate. Strain S was intermediate in its virulence.

The *in vivo* growth rate of strain B is presented in FIGURE 1. The values plotted on the graph indicate the number of viable cryptococcal cells per 0.1 gm of tissue that were isolated at the designated time. Each point on the line represents the results obtained from a different organ by averaging colony counts on 3 plates (3 mice). Ten minutes after inoculation the lungs contained the largest number of cryptococcal cells, but viable yeast cells were found in every organ. The numbers of viable yeast cells in the lungs decreased

progressively through the third day postinoculation, but by the sixth day there was some multiplication. Four plates of the other organs showed little change in numbers of *C. neoformans* cells during the first 3 plating experiments (10 min to 1 day), but an increase was apparent by the third day postinfection. The numbers of cryptococcal cells in the brain increased over one thousand fold from the third to the tenth day postinoculation. Other organs showed a more gradual increase, however, the spleen and the liver showed a drop on the tenth day that was not observed in cultures of the other organs. After the tenth day of infection most of the organs showed a gradual increase of yeast cell numbers through the sixteenth day, but the lungs exhibited a hundredfold increase during this period. It is apparent that in the terminal stages of disease the majority of viable *C. neoformans* cells were found in the brain.

TABLE 1
VIRULENCE OF STRAINS FOR MICE

Yeast cells injected	10 ²	200	40	8	16
Strain B	10/10	9/10	5/10	4/10	1/10
Yeast cells injected	2 × 10 ⁴	4 × 10 ⁴	8 × 10 ⁴	16 × 10 ⁴	320
Strain J	10/10	6/10	4/10	2/10	0/10
Yeast cells injected	5 × 10 ⁴	10 ⁵	2 × 10 ⁴	4 × 10 ⁴	800
Strain S	10/10	10/10	8/10	4/10	2/10

Numerator indicates the number of mice dead, denominator indicates the number of mice injected. All mice were injected intravenously.

FIGURE 2 shows the growth rate of strain J in mice. The results obtained from the plating experiments through the tenth day postinfection were similar in most respects to those from strain B. After this point, however, there was a significant change. The numbers of viable cryptococcal cells cultured from the mice 14 to 44 days postinoculation remained about the same. There were considerable variations in some instances, but the growth curve during this period was relatively level. The results of the final plating experiment indicated an increase of yeast cell numbers over the previous plating, but the level in the brain was not as high as with strain B.

The multiplication of strain S *in vivo* is shown in FIGURE 3. The results obtained with this strain for the first 6 plating experiments (10 min to 10 days) were quite similar to those obtained with the other 2 strains. The greatest difference when compared to the other 2 strains is the larger number of viable yeast cells that were isolated from the kidneys for the last 4 plating experiments.

The *in vivo* multiplication of strain B following intracerebral inoculation is presented in FIGURE 4. All 3 strains were studied in this manner. Since strains B and J gave similar results, only the results obtained with strain S are shown. The mice inoculated by this route received approximately 10^4 cells.

C. neoformans, STRAIN B, INTRAVENOUS INOCULATION, 10^5 CELLS




FIGURE 1 Multiplication of strain B in mice following intravenous inoculation with 10^5 yeast cells.

C. neoformans, STRAIN J, INTRAVENOUS INOCULATION 10^5 CELLS




FIGURE 2 Multiplication of strain J in mice following intravenous inoculation with 10^5 yeast cells.

C. neoformans, STRAIN S, INTRAVENOUS INOCULATION 10^5 CELLS




FIGURE 3 Multiplication of strain S in mice following intravenous inoculation with 10^5 yeast cells

C. neoformans, STRAIN S, INTRACEREBRAL INOCULATION, 2×10^4 CELLS




FIGURE 4 Multiplication of strain S in mice following intracerebral inoculation with 2×10^4 yeast cells

cells. As expected, the brain had more viable yeast cells 10 min. after injection than the brains of mice that received intravenous inoculations, but the lungs still showed the greatest number per unit weight. Otherwise the initial plating experiments gave similar results when compared to those of mice receiving intravenous injections. Growth of *C. neoformans* was more rapid and the greatest rate of multiplication occurred in the brain from 3 to 6 days after injection. The large numbers of cells isolated from kidney tissue after intravenous inoculation with this strain were not observed in this experiment. The reduced experimental time may have been an important factor in this observation.

Examination of the results of these experiments indicated a number of factors that merit discussion. It was quite apparent that most of the yeast cells were removed from the circulating blood quite rapidly following infection and tended to accumulate in the lungs. This was demonstrated by mice inoculated either intravenously or intracerebrally and most probably was a mechanical phenomenon. The cells of *C. neoformans*, being quite large, possibly were trapped in the pulmonary capillaries. The gradual decrease of viable yeast cells in the lungs suggested that they were either cleared out subsequently or that they were destroyed by the host. The small numbers of viable cryptococcal cells were isolated 4 to 24 hours after injection in this observation supports the contention that the host defenses were able to destroy some of the yeast cells.

Multiplication *in vivo* of all the strains injected intravenously during the first three days was generally the same. Three days after infection, however, strain B multiplied quite rapidly, and the mice were dead or dying ten days after injection. These observations were compatible with those presented in TABLE 1, which indicated a high level of virulence for this strain. Strain J, which possessed considerable virulence according to TABLE 1, was less virulent than strain B, as indicated by FIGURE 2. The most interesting result obtained with that strain was the relatively constant numbers of viable yeast cells that existed in the organs of the infected mice from the fourteenth to the forty-fourth day postinfection. While this appeared to be a more compatible host-parasite relationship than existed with the other strains, eventually the host resistance broke down, and further multiplication was observed. The number of yeast cells in the brain, however, was not as high as with strain B but was comparable to the levels observed in mice that received strain S. Mice were considerably more susceptible to intracerebral inoculation of *C. neoformans* than to intravenous injection. An inoculum one-fifth that used for intravenous studies produced terminal cryptococcosis in about one-half the time.

The results that have been presented were obtained from surviving mice that had been sacrificed at the specified time intervals and do not account for animals that died of cryptococcosis during the experimental period. While the mice that were autopsied were not selected with regard to overt cryptococcosis, the methods employed measure the growth rate in the more resistant animals, particularly in the experiments that were extended over longer periods of time. This must be considered especially in the interpretation of the data.

obtained from the intravenous inoculation with strain J and, to a lesser extent with strain S

These results indicated that all of the strains utilized in this study demonstrated considerable virulence for mice, but there were variations in respect to the rates of multiplication and the total numbers of *C. neoformans* cells isolated

Summary

Mortality studies in mice with three strains of *C. neoformans* revealed a considerable variation in virulence that was not correlated with capsule width

In vivo growth rates of the same strains, obtained by making colony counts from pour plates made from blood, ground spleen, liver, kidney, lungs and brains from intravenously infected mice autopsied at specified time intervals indicated similar rates of multiplication during the first 3 days. Thereafter 1 strain grew rapidly, and the test animals were in the terminal stages of disease 16 days postinoculation. The other 2 strains produced similar stages of disease in surviving mice 32 and 52 days after injection. Immediately after inoculation the lungs contained the largest numbers of yeast cells. The colony count decreased 1 to 1.5 logs on days 1 to 3 and subsequently reached a level of approximately $10^4/0.1$ gm lung tissue. In terminal cryptococcosis the largest numbers were isolated from the brain.

C. neoformans inoculated intracerebrally showed a faster rate of multiplication than when injected intravenously, and the mice were moribund sooner even though a smaller dose was given.

References

- DROUHET E. G. SEGRETAINE & J. P. AUBERT. 1950. Polyside capsulaire d'un champignon pathogène *Torulopsis neoformans* relation avec la virulence. Ann. Inst. Pasteur 79: 891.
- GADEBUSCH H. H. 1959. Phagocytosis of *Cryptococcus neoformans* in anemic mice. J. Bacteriol. 78: 259.
- KAO C. J. & J. SCHWARZ. 1957. The isolation of *Cryptococcus neoformans* from pigeons nests with remarks on the identification of virulent cryptococci. Am. J. Clin. Pathol. 27: 652.
- LITTMAN M. L. & E. TSUBURA. 1959. Effect of degree of encapsulation upon virulence of *Cryptococcus neoformans*. Proc. Soc. Exptl. Biol. Med. 101: 773.

THE ACCURACY OF SEROLOGIC METHODS IN DIAGNOSIS

Charlotte C Campbell

Department of Bacteriology, Walter Reed Army Institute of Research, Washington D

Serologic tests have been employed increasingly during the past decade in the diagnosis and study of coccidioidomycosis, histoplasmosis, and blastomycosis. These tests have played a prominent role in the detection of less new cases, especially of coccidioidomycosis and histoplasmosis and, of this, their contribution to the increased over all knowledge of these infections has been considerable. The alleged shortcomings, of which there are many, of these tests are due in part to the crudeness of the antigens rather than to the tests per se, but also to the failure of many persons to recognize the dynamic nature of these infections as dynamic diseases. That antibody response will vary with type, severity, duration and, particularly, with the activity of a mycotic infection, as it does in an infection produced by any other microorganism, has been especially difficult to convey.

Certainly, too, the earlier claims of even a qualified specificity for these antigens were unwarranted.¹⁻³ There are strong cross reactions between culturally verified cases of histoplasmosis and coccidioidomycosis with histoplasma antigens, and in those of blastomycosis and coccidioidomycosis with blastomycosis antigens. Even with coccidioidin, the most specific of these commonly employed, there are reactions in sera from frank cases of histoplasmosis sometimes to significant titer.⁴ Moreover there is little reason to doubt that some of these antigens also react with sera from others of the systemic mycotic infections that have not yet been studied serologically principally coccidioidomycosis.⁵

To assess the accuracy of serologic diagnosis one must consider also not only the specificity of an antigen, but the type and stage of an infection from which a serum is taken, as well as certain natural sequelae that obtain thereafter. If it can be assumed that antibodies are stimulated in direct proportion to the number of accessible organisms, one would expect the concentration of antibody to be minimal, and perhaps not even of a demonstrable level in an asymptomatic individual with a single, pulmonary lesion, just as one would expect concentration of antibody to be high in patients with extensive pulmonary infiltration. In addition, there is the matter of viability of the organism and the host's ability to eradicate it. When microorganisms are phagocytized by mobile defense cells, they probably not only are rendered nonviable but are rapidly eliminated from the host, and a rapid loss of antibody production following removal of the stimulus ensues. There are other organisms, however, that escape the mobile agents of defense and become "trapped" by the stationary cells, they have parasitized. Here, in protest, the host's calcific, granulomatous, or fibrotic tissues are produced, in which the organisms usually meet a slow disintegrating death. However, as long as the organisms or fragments of the organisms are present in these tissues, even though they are nonviable and culturally impossible to recover,⁶⁻¹⁰ it is possible that they continue to produce antibodies to some of the several antigenic components they contain. These residual anti-

bodies may persist for very long periods, depending upon the extent and site of the lesion, the state of the patient's immune mechanism, and a host of other factors. Such residuals are an inherent part of the immunological process and their production and tenure always must be regarded in the assessment of the activity and specificity of an antigen. Because of the widespread and as yet not completely defined geographic distribution of some of the mycotic agents,¹¹⁻¹² there is reason to believe that the serologic titers observed in many apparently healthy persons are residuals from earlier unrecognized infections caused by mycotic agents rather than nonspecific reactions of the antigens as is so often implied.

With these elemental considerations in mind, the serologic findings in coccidioidomycosis, histoplasmosis, and blastomycosis, the problem of cross reaction and some of the factors involved in the development of improved antigens are reviewed and discussed.

Materials and Methods

The materials, methods, and procedures most widely employed in the routine serologic diagnosis of coccidioidomycosis, histoplasmosis, and blastomycosis are described in numerous earlier reports.^{1-6, 13-22}

Complement fixation (CF) is the serologic procedure most universally used generally with four antigens in simultaneous tests. These antigens are

(1) *Coccidioidin*. An asparagine-broth filtrate in which strains of *Coccidioides immitis* are grown in the filamentous phase for periods of several months.⁴ This antigen is referred to as C in this report.

(2) *Histoplasmin*. A similar preparation from strains of *Histoplasma capsulatum* in the filamentous phase.^{23, 24} This is the antigen referred to as D in this report.

(3) *Histoplasma whole yeast phase antigen*. A standardized suspension of killed 48 to 72 hour-old whole yeast cells of *H. capsulatum* in buffered saline solution, prepared from single or multiple strains.^{19, 25} This type of preparation is referred to as the H antigen in this report.

(4) *Blastomyces antigen*. A saline extract of mechanically disrupted yeast cells of *Blastomyces dermatitidis* prepared from single or multiple strains.⁶ This antigen is the one referred to as B in this report.

Precipitin tests are also used routinely in suspected coccidioidomycosis⁴ and by some laboratories in suspected histoplasmosis.²⁶ The filtrate antigens coccidioidin (C) and histoplasmin (D) are employed.

Colloidal agglutination is a third procedure used in several laboratories in the study of histoplasmosis.²⁷ Histoplasmin (D) is the antigen utilized.

Serologic Reactions in Coccidioidomycosis

In many cases of mild to moderately severe primary, pulmonary coccidioidomycosis, CF antibodies are never demonstrable. This is in contrast to precipitins that, as shown in FIGURE 1, can be demonstrated in 90 per cent of the patients with this type of infection during the second to fourth week of illness. Precipitins however are transitory. They no longer are demonstrable in approximately 50 per cent of the primary nondisseminating cases by the fifth to seventh

week of disease. The establishment of diagnosis by serologic methods in this type of case, therefore, is especially dependent upon the time after onset that sera are tested.

In those primary nondisseminating cases in which CF antibodies are produced, demonstrable levels usually remain low (1:2 to 1:16), are much later in developing, and persist for much longer periods than the precipitins. In the series of cases shown in FIGURE 1, it will be noted that less than 10 per cent of the patients were CF positive during the first week of illness in contrast to the 50 per cent with positive precipitin tests. During the twenty-fourth week, however, 90 per cent of the 49 persons remaining under observation in this




FIGURE 1. Precipitins and CF antibodies in sera of patients with primary nondisseminating coccidioidomycosis.²

particular study still had demonstrable CF antibodies, whereas approximately 95 per cent no longer had precipitins.²

Although the CF test is of limited value in the diagnosis of many mild to moderately severe primary cases, it is invaluable in the prognostic evaluation of infections that are more severe. A CF level of 1:32 or above is generally regarded as an indication of dissemination, with the magnitude of the titer indicating the amount of extrapulmonary tissue involved. Persisting high CF levels of 1:64 to 1:256, or progressively increasing titers of 1:32 to 1:128-512, are indicative of progressively disseminating disease, while progressively diminishing levels of CF antibody, despite former higher ones, are generally associated with clinical improvement.²

As shown in FIGURE 2, however, changes in a patient's clinical status and

serologic pattern may occur within weeks or not for months or years. Curve A is illustrative of the CF levels observed in progressively disseminating cases and generally occurs within weeks or months, but may occasionally take years. The CF levels in curve B are seen in "stabilized" disseminated infections of long duration. This pattern generally foreshadows further dissemination although patients may occasionally recover. The decreasing CF titers in curve C are observed in patients showing progressive clinical improvement in spite of earlier dissemination. Curve D is of particular importance as it is the notable exception to the association of low CF titer and good prognosis. While it is true that low levels of this order are seen in many patients with pulmonary cavities or single extrapulmonary lesions for whom prognosis is




FIGURE 2 CF antibody patterns in disseminated (extrapulmonary) coccidioidomycosis

fair or good, this pattern is also observed in patients in whom the solitary lesion is located in a vital meningeal area. In the usually fatal meningeal infections with no other tissue involvement, the low CF levels thus fail to support the grave prognosis.² In the serologic study of coccidioidomycosis there is another little mentioned element of danger. Residual CF titers of 1:2 to 1:8 may persist in some persons for many years following recovery from a disseminated infection. This possibility of residual coccidioidomycosis is perhaps too seldom considered in the differential diagnosis of a more recently acquired upper respiratory illness that is of bacterial or viral origin, especially in persons removed from the endemic areas for coccidioidomycosis.

Serologic Reactions in Histoplasmosis

The serologic findings in histoplasmosis are not as well classified or as meaningful as they are in coccidioidomycosis in spite of, or perhaps because of the more widespread geographic distribution of *H. capsulatum*.^{11,12} In coccidioidomycosis the serologic data were comparatively rapidly accumulated in the comprehensive study of thousands of service personnel newly introduced into the endemic areas during the years of World War II. These studies moreover

were carried out by a single team of imaginative and energetic investigators who employed a single lot of coccidioidin in two unvarying serologic procedures.¹ In contrast the serologic findings in histoplasmosis have been pieced together from fragments of information obtained by a number of different investigators from sporadic cases or sporadic small series of cases in widely separated geographic regions. To a large extent the antigens were prepared by the individual investigators and thus varied not only from lot to lot but even as to the biphasic morphology of the organism.^{1,2} Because no one lot of antigen proved to be reactive in all types of cases antigens from both growth




FIGURE 3 CF antibody patterns in histoplasmosis. B mild primary pulmonary D fatal infantile type or rapidly disseminating C severe primary pulmonary F chronic pulmonary F large cavity (single or multiple) G small cavity (single or multiple) A & H solitary pulmonary nodule disseminated with lymphadenopathy and ST skin test

phases of *H. capsulatum* have been used simultaneously in all routine CF tests for the past several years.

CF is the one serologic procedure employed universally in the study of histoplasmosis. In some laboratories this is augmented by the precipitin test¹¹ and in others by the colloidal agglutination test.¹² Both of the latter assist primarily in the early detection of mild primary pulmonary cases for as in coccidioidomycosis CF antibodies are never demonstrable in some of the milder primary infections caused by *H. capsulatum*.^{6,13,16}

The recognized serologic patterns in histoplasmosis moreover are not transitional from one type of the infection to another as they appear to be in disseminated and nondisseminated cases of coccidioidomycosis. Instead they are merely a series of patterns that have been observed repeatedly in certain types of culturally verified but unrelated cases.^{6,13} As illustrated by

curves C, D, E, F and, possibly, G in FIGURE 3, some of these patterns have attained diagnostic stature even when attempts to isolate the organism meet with failure. At this point, it is pertinent to note that *H. capsulatum* is perhaps the most difficult of all the pathogenic mycotic agents to recover by cultural procedures, and is especially difficult in the primary pulmonary case. In this regard, it is fortunate that the severe to moderately severe primary infection as shown in curve C, FIGURE 3, elicits a high CF antibody response during the first month of illness. In uncomplicated cases, the elevated titers persist for several additional weeks or months and then rapidly decrease to residual levels of 1:8 or 1:16. These residual levels may remain unchanged for from 3 to 5 years, or the patient's titer may become negative in as little as 6 months. In either instance, the patient has apparently completely recovered clinically within 3 to 5 months after onset. In still a third type of apparently uncomplicated primary case, the elevated CF levels shown in curve E persist for as long as a year, although clinical recovery also appears to be complete after only a few weeks or months. The first portion of curves C and E is often indistinguishable from that of the CF patterns seen in fulminating and usually fatal infections in infants or young children and, occasionally, in adults whose infections are complicated by one of the prognostically grave blood dyscrasias. In these more severe cases, however, CF titers rarely decrease, but remain high even in sera collected at autopsy (curve D). Curve F is characteristic of the serologic pattern of persons in whom single or multiple large pulmonary cavities remain unchanged throughout several years of observation. In these cases, very high CF levels persist, with little variation over a period of years. By contrast, when cavities are small there is much less serologic response, as shown by curve G. The CF titers usually are not remarkably high and tend to diminish when the patient is treated by bed rest alone. For this reason, the patient with small cavities is easily overlooked if serologic results are the sole criteria for excluding the infection. CF titers observed in curves C, D, E, and F, however, are generally regarded as diagnostic.

On the other hand, curves AH, B, and ST have little, if any, diagnostic significance, except perhaps to increase the physician's index of suspicion in diagnostically puzzling cases. Curve AH is representative of the low CF titers and, in some cases, even these are absent, as seen in patients with the single pulmonary nodule that requires differentiation from carcinoma. In this very common type of the infection (histoplasmosis), serologic tests have no diagnostic value. The concentration of CF antibody because of the limited amount of tissue involved does not exceed that carried by a substantial percentage of the normal population. Paradoxically, curve AH is also representative of the highest serologic response demonstrable in the most severely disseminated and usually fatal type of histoplasmosis that often is concurrent with Hodgkin's Disease, Addison's Disease, or sarcoidosis.^{6,10} In most of these cases serologic reactions are negative for months prior to death although at autopsy the major organs are teeming with *H. capsulatum*. Curve B is seen in the milder cases of primary, pulmonary histoplasmosis but unless it is observed in an epidemic in which there are more severe infections it has doubtful diagnostic significance. The magnitude and duration of CF titers in such

cases are remarkably similar not only to those observed in culturally verified cavitary cases (curve G) but also to those in previously sensitized or infected persons (curve ST) whose antibody production has been stimulated by the recent application of the histoplasmin skin test.²⁵

In brief CF titers of 1:8 or 1:16 with histoplasma antigen are not to be used as diagnostic criteria. A recent summary of serologic findings in 63 persons hospitalized with chest diseases revealed that titers of 1:5 or higher were observed in approximately 80 per cent. In contrast, serologic titers reached or exceeded 1:32 in 75 per cent of the 52 culturally verified cases in this study. The verified cases that did not react at the 1:16 level had all healed minimal and generally inactive infections.²⁶ To establish a presumptive diagnosis of active histoplasmosis on CF titer alone is therefore appears to be an extremely tenuous procedure.

Serologic Reactions in Blastomycosis

In our experience, the serologic diagnosis of blastomycosis is more encouraging than that of histoplasmosis. With the antigen employed in the laboratory and sera from 107 culturally verified cases, three fourths (66 per cent) proved to be serologically negative. On the other hand, the titers obtained with this same antigen have equaled or exceeded those of the homologous ones in a high percentage of the culturally verified cases of histoplasmosis and coccidioidomycosis coming to our attention during the past 10 years.⁴ This antigen not only is one of the least specific of the four now employed in routine tests but it is also strikingly unreactive in sera from many culturally proven cases of blastomycosis. A CF reaction to blastomycin antigen may be helpful in evaluating the prognosis of a verified case but not the type of antigenic preparation we employ. CF reactions merit no place in the diagnosis of this disease as further demonstrated below.

The Problem of Cross Reactions

In some of the earlier reports, qualified claims of specificity were made for each of the antigens used in serologic as well as dermal sensitivity tests.²² When with further use, numerous strong cross reactions were observed it was maintained that the commonly shared or cross-reactive components could be eliminated or diminished by appropriate dilution.^{24, 26}

The antigens used at the Walter Reed Army Institute of Research for the serologic study of mycotic diseases are critically standardized in sera from a variety of types of histoplasmosis, blastomycosis and coccidioidomycosis in humans. Moreover, because the patients involved usually are military personnel many of whom have lived in each of the areas known to be most highly endemic for these three mycotic diseases, each serum submitted is tested simultaneously with antigens of *H. capsulatum*, *B. dermatitidis* and *C. immitis* in the CF test. Colloidal agglutination with histoplasmin and precipitin tests with coccidioidin also are done. The results of CF tests on more than 50,000 sera reveal that cross reactions are extensive. In precipitin and colloidal agglutination tests cross reactions are even more confusing.

Although some of these findings were discussed in considerable detail in an

earlier report,⁶ the magnitude of the problem with the CF test antigens alone is illustrated further in FIGURE 4. Of the 10,000 serum specimens most recently received in this laboratory, 6759 were CF negative with all 4 of the antigens used, and 602 were anticomplementary. A total of 2639 had CF titers of 1:8 or above with one or more of the antigens. Single reactions were observed in 684, 389, 293, and 193 specimens with the D, B, H, and C antigens, respectively, and a total of 231 additional specimens reacted only with the 2 types of histo-




FIGURE 4. Distribution of cross reactions with mycotic antigens in 2639 consecutive specimens submitted for routine serology.

plasma antigen. In the remaining 849 sera, however, strong cross reactions were present. There were 354 that reacted to essentially equal CF titers with antigens H, B, and D (Column C), 283 with antigens H and B (Column E), 111 with B and D (Column H), 60 with H and C (Column I), 22 with H, B, and C (Column J), and 6 with all 4 of the antigens, H, B, C, and D (Column K). Other sporadically observed combinations are also illustrated.

The Transitory and Variable Nature of Cross Reactions

Cross reactions are most extensive in sera from primary, pulmonary cases of both histoplasmosis and coccidioidomycosis, in which it is not unusual for CF

titers with blastomyces antigens to exceed the levels of those with either of the homologous ones. This pattern is never seriously suggestive of blastomycosis, however, as the acute, febrile, respiratory illnesses are more common units with infections caused by *C. immitis* or *H. capsulatum*. On the other hand, this particular cross reaction poses a serious differential problem between coccidioidomycosis and histoplasmosis, especially if the serum is drawn from a patient with a mild case of coccidioidomycosis in which CF antibodies to coccidioidin are never demonstrable. Unfortunately, it is not uncommon for both histoplasma and blastomyces antigens to react to CF titers as high as 1:64 in coccidioidin CF negative sera from patients with primary coccidioidomycosis. Coccidioidin CF titers, conversely, are observed in the sera of patients with histoplasmosis only when the homologous CF titers are very high (1:512), and then only at levels of 1:8 to 1:32.⁴ A cross reaction that is even more difficult to evaluate occurs in pulmonary cavitory cases of histoplasmosis, blastomycosis, and coccidioidomycosis. Histoplasma and blastomyces antigens react to high and equal CF levels in many of these cases regardless of the etiological agent, while CF titers with coccidioidin are low or absent even in the cavitory disease produced by *C. immitis*.^{3, 6, 7, 24} In primary pulmonary cases increasing titers with homologous antigens, accompanied by diminishing levels with heterologous ones in subsequent serial serum specimens frequently help resolve the diagnosis, and this is one of the reasons serial specimens over an extended period are requested. In the cavitory and more chronic type of mycotic infection in which strong crosses occur, however, the confusing serologic pattern may remain unchanged for months or even years.²⁴

These findings leave little doubt that there are antigenic components commonly shared by these three and possibly other systemic mycotic agents. It is inconceivable that there are this many dual infections. The transitory and variable nature of the cross reactions, moreover, suggests that different types and concentrations of antibodies are produced by the various antigenic components of these agents at different stages of an infection.

A hypothetical schema, attempting to illustrate the dynamic and progressive processes involved in the production of antibodies at different stages of an infection to a number of antigenic components, some of which are shared by other organisms, is presented in FIGURE 5. In the configurations, also hypothetical, of the crude antigens of *H. capsulatum*, *B. dermatitidis*, and *C. immitis*, it will be noted that the *B. dermatitidis* antigen contains three times as much component A as coccidioidin and almost twice as much as the histoplasma antigen. Let it be assumed that the serum to be tested for CF antibody is from an active case of histoplasmosis early after onset. The antibody composition of this serum is a constant just as the higher concentration of component A in the blastomyces antigen is a constant. Therefore, if at the time the serum is drawn the patient has produced only a minimal amount of antibody to component A and none to the other components of *H. capsulatum*, this serum will react to higher titer with the blastomyces antigen than with the homologous one. However, if in later specimens the concentration of antibody to fraction A increases, the CF titer with the histoplasma antigen will more nearly approach the level of the blastomyces antigen. When anti-

body to A is produced in very high concentration, even the small quantity of fraction A in coccidioidin will react, but always at lower levels than the other two antigens. Attempts to eliminate this cross reaction with blastomyces antigen either by dilution of the antigen or by adsorption of the serum will lead only to either negative reactions with histoplasma antigen and coccidioidin, as these contain the lesser concentrations of component A.




FIGURE 5 Schema (theoretical) illustrating basis for cross reactions in sera from culturally verified cases of histoplasmosis, blastomycosis, and coccidioidomycosis.

In an infection that is active and of sufficiently long duration antibodies to the other components of *H capsulatum* in time also will be produced by the patient, while antibodies to A may or may not diminish. In any event antibodies to these other fractions will then react with the components of *H capsulatum* which neither *B dermatitidis* nor *C immitis* possess, and titers with the histoplasma antigen may begin to exceed those with the blastomyces antigen. However, the blastomyces antigen will continue to react as long as antibodies to component A persist, and to higher titer than the histoplasma antigen as long as production of antibody to component A exceeds the production of antibody to any of *H capsulatum*'s other components.

If components in addition to A are shared commonly by these agents the problem becomes increasingly complex. For example component R in *C immitis* might also be related closely to component M in *B dermatitidis* and both of these in turn might be essentially the same as component B in *H capsulatum*. Antibodies to this component might also be produced at different stages of these three as well as other mycotic infections.

The development of different types of antibody at different stages of an infection is perhaps illustrated more comprehensively in *C immitis* infections because of the varying morphology of this organism *in situ*. For example let it be assumed that the chemical composition of the walls of endospores (component A, FIGURE 5) differs from that of the walls of mature spherules (component Y, FIGURE 5) due to lengthened or more complex polysaccharide moieties in the latter.^{11,12} In the patient in whom few endospores have yet developed into mature spherules the antibody produced by component A could be expected to predominate and, at certain early stages of the infection, be the only one demonstrable, in a second patient in whom there is a continuous cycle of maturation of spherules and further release of new endospores antibodies might be developed to both components A and Y and, in a third patient whose infection has stabilized with innumerable mature spherules and no further release of endospores, antibody could be expected to be produced primarily to component Y. Provided component A is the one shared by both *B dermatitidis* and *H capsulatum*, the latter antigens would react to equal or higher CF titers than coccidioidin in early mild to severe primary nondisseminating and in rapidly disseminating infections of coccidioidomycosis. In disseminated infections, or in those in the process of slow dissemination, antibody to component Y would supersede antibody to component A. Eventually, therefore, coccidioidin—the only one of these three antigenic complexes that contains the Y component—would also be the only antigen that would react with sera from the cases of coccidioidomycosis of longer duration.

As noted earlier something of this nature does appear to occur in naturally acquired coccidioidomycosis. Histoplasma and blastomyces antigens react to higher CF titers in early sera from primary pulmonary cases in which coccidioidin CF titers are low or are frequently absent, to essentially equal CF titers with coccidioidin in rapidly disseminating infections and not at all in moderately severe to severe disseminated and nondisseminated cases of longer duration.*

In histoplasmosis, there is also considerable evidence that the antibody

produced in early infections differs from that demonstrable in chronic or older cases. As described in an earlier report, high CF titers with the whole yeast phase antigen of *H. capsulatum* were observed in sera from primary, pulmonary cases in which histoplasmin failed to react, whereas in chronic infections of longer duration the high CF titers were obtained with histoplasmin in contrast to negative reactions with the whole yeast phase antigen. There were also sera from certain cases, as might be anticipated, which reacted with both types of antigen to essentially equal CF titers. This difference in reaction with the two types of histoplasma antigen is illustrated further in FIGURE 4 where more than twice as many specimens reacted with histoplasmin (D) as with the whole yeast phase antigen (H), and an additional 231 specimens reacted with both antigens (H and D) to essentially equal CF levels. There is little reason to doubt, moreover, that the same variation in antibody concentration to various antigenic components of *B. dermatitidis* does not also occur in blastomycosis, or that certain of the components of *B. dermatitidis* do not elicit antibody at certain stage(s) of this infection that are readily demonstrable by histoplasmin as by blastomyces antigens. As in histoplasmosis and coccidioidomycosis, there are also cases of blastomycosis in which cross reactions do not occur, although the same antigens are employed.

Discussion

The accuracy of serologic diagnosis in these three mycotic diseases is thus difficult to assess as it depends not only on the composition of an antigen but on the type, severity and duration of infections from which sera are taken. In the assessment of any biological procedure it is important to know what factor one is measuring and in the serology of mycotic diseases, there are still countless unknown entities.

The crude antigens currently employed have been used to good advantage in many ways, but further progress can not be expected from their continued use in their present state. Not only is the antigenic composition of such preparations unknown, but the concentration of the various components varies from lot to lot and, possibly from strain to strain. Moreover, there is little evidence to suggest that the antibodies with which they react are protective, as CF titers frequently increase with dissemination and decrease with clinical improvement. The protective antigenic component either is not present or is overshadowed by higher concentrations of other less important, and perhaps cross reactive, components. In addition, there doubtlessly are other components associated with residual antibody from past infections, or involved in the stimulation of antibody following skin tests that possibly could be differentiated from those of importance in the more active stages of these infections.

All pertinent serologic findings up to the present time indicate that the various antigenic components and the antibodies they produce can not be resolved independently of each other if serologic analysis is to contribute further to the knowledge of the mycotic infections. Efforts to develop crude antigens containing a maximum number of components for fractionation studies perhaps would represent the first step in this direction, as components can not be isolated from preparations in which they do not exist. Even in

the same type of preparation, the number and concentration of components vary. For example, in four lots of histoplasmin simultaneously tested by agar gel diffusion in this laboratory, the number of reactive components varied from one to six with the same serum. Evidence that they vary even more with change in nutritional factors and time and temperature of incubation of the etiologic agent is provided by the dissimilar reactions observed with crude antigens prepared from yeast and filamentous growth phases of *Capsulatum* (FIGURE 4).

On the other hand, the possibility that different antibodies are produced by different antigenic components at different stages of an infection should not be overlooked. Heiner, using a single lot of histoplasmin in an agar gel diffusion technique, demonstrated that the number of reaction bands varied in sera from individual patients as well as in those from persons with positive histoplasmin skin tests.²⁰

It is possible, of course, that the variable and transitory nature of reactions and cross reactions in mycotic diseases might be explained on the basis of inhibitory substances, antigen excess or immunological paralysis in the early stages, but there are many instances in which none of the long accepted explanations for serologic failures seem to apply. It is perhaps pertinent to note that many of the current concepts of antigen antibody reactions were derived from studies with bacterial agents that reproduce so rapidly that antigenic flagellar, somatic, or capsular constituents appear to arise simultaneously. Because of the rapid overlapping of generations antibodies to one constituent would appear to develop as rapidly as those to any other. The rate of growth in pathogenic mycotic agents, by contrast, is so extremely slow that antibodies elicited by an agent's antigenic complex at one stage of its development might be readily distinguished from those developed later in an infection to the more complex array of chemical moieties in the mature organism. This difference in the rate of growth might be of importance in the immunological process of mycotic diseases and appears to merit further consideration.

Accurate serologic analysis, therefore, can not be achieved except by the isolation and characterization of each antigenic component an organism produces, related as well as unrelated, and the further correlation of these components' activities with antibodies produced throughout all stages of an infection. In the serologic study of mycotic infections it is hoped that the cross reactive components can be deleted in order that those involved in the production of protective or residual antibody, or both, can be more carefully evaluated.

The resolution of this formidable, challenging problem will require the collaborative efforts of immunochemists, pathologists, serologists, mycologists, and clinicians. However, we are not alone in this dilemma. In a recent study of the venerable tubercle bacillus reported by Williams and Dubos,²¹ the following statements were made. It must be remembered, on the other hand, that the whole tubercle bacillus is a rich packet of biological activities, all theoretically residing in substances capable of chemical definition. Combined in fractions or associated in complex in their natural state, or recombined in test tubes, it is reasonable to suppose that the activities of such substances,

revealed by suitable experiments in suitable animals, could be complementary, supplementary, masked, antagonistic, inhibitory, or combinations of these. It remains to be seen whether the changing morphology of the pathogenic fungi renders the mycologist's problem more or less complex than that of the bacteriologist.

References

1. FURCOLOW M I I L BUNNELL & D J TENENBERG 1948 A complement fixation test for histoplasmosis II Preliminary results with human sera Public Health Repts U S 63 169-173
2. CAMPBELL C C & S SASLAW 1949 Use of yeast phase antigens in a complement fixation test for histoplasmosis III Preliminary results with human sera Public Health Repts U S 64 551-560
3. SMITH C E M T SAITO R E BFARD H M KFFR R W CLARK & B V FORD 1950 Serologic tests in the diagnosis and prognosis of coccidioidomycosis Am J Hyg 52 1-21
4. SALVIN S H 1952 Discussion of serology of histoplasmosis Proc of the Conference on Histoplasmosis 46-47
5. SMITH D T 1949 Immunologic types of blastomycosis A report of 40 cases. Ann Internal Med 31 463
6. CAMPBELL C C & G F BIVALEN 1953 Serologic diagnosis with respect to histoplasmosis coccidioidomycosis and blastomycosis and the problem of cross reactions. J Lab Clin Med 42 896-906
7. HELLER S R A McLEAN C C CAMPBELL & I H JONES 1957 A case of coexistent non meningitic cryptococcosis and Boeck's sarcoid Am J Med 22 936
8. PUCKETT T F 1953 A study of twenty two cases with identification of *H. capsulatum* in resected lesions Am Rev Tuberc 67 453
9. ZIMMERMAN L E 1957 Some contributions of the histopathological method to the study of fungus diseases Trans N Y Acad Sci 19(5) 358-371
10. DAVIS F W J W PEABODY JR & S KATZ 1957 The solitary pulmonary nodule Med Ann Dist of Columbia 26 1-7
11. EDWARDS P Q & J H KLAER 1956 World wide distribution of histoplasmosis and histoplasmin sensitivity J Trop Med Hyg 6 235-257
12. PALMER C E P Q EDWARDS & W F ALLFATHER 1957 Characteristics of skin reactions to coccidioidin and histoplasmin with evidence of an unidentified source of sensitization Am J Hyg 66 196-213
13. MARTIN H S 1935 Complement fixation in blastomycosis J Infectious Diseases 57 291
14. SALVIN S H 1947 Complement fixation studies in experimental histoplasmosis Proc Soc Exptl Biol Med 66 342-345
15. SASLAW S & C C CAMPBELL 1948 The use of yeast phase antigens in a complement fixation test for histoplasmosis I Preliminary results with rabbit sera J Lab Clin Med 33 811-818
16. CAMPBELL C C & S SASLAW 1948 The use of yeast phase antigens in a complement fixation test for histoplasmosis II Results with ground antigens J Lab Clin Med 33 1207-1211
17. SASLAW S & C C CAMPBELL 1948 A method for demonstrating antibodies in rabbit sera against histoplasmin by the colloidal agglutination technique Proc Soc Exptl Biol Med 68 559-562
18. SASLAW S & C C CAMPBELL 1949 A colloidal agglutination test for histoplasmosis Public Health Repts U S 64 424-429
19. GRAYSTON J T 1952 A study of the complement fixation reaction in histoplasmosis J Lab Clin Med 40 90-101
20. SALVIN S H M M L FURCOLOW 1954 Precipitins in human histoplasmosis J Lab Clin Med 43 259-274
21. SCHUBERT J H L AJELLO J S COOPER & L C RUNYON 1954 Evaluation of histoplasmin and yeast phase antigens derived from a single strain of *Histoplasma capsulatum* in the complement fixation test J Bacteriol 69 558-562
22. HILL G B & C C CAMPBELL 1956 A further evaluation of histoplasmin and yeast phase antigen of *Histoplasma capsulatum* in the complement fixation test J Lab Clin Med 48 255-263
23. SMITH C E E G WHITING E E BAKER H G ROSENBERGER R R BEARD & M T SAITO 1948 The use of coccidioidin Am Rev Tuberc 57 330

- 24 HOWELL, A. JR. 1947 Studies of fungus antigens. I. Quantitative studies of reactions between histoplasman and blastomycin in guinea pigs. *Public Health Reports U. S.* 62: 631.
- 25 SASLAW, H. & C. C. CAMPBELL. 1953 Effect of histoplasman skin testing on results. *Proc. Soc. Exptl. Biol. Med.* 82: 689.
- 26 CAMPBELL, C. C., S. C. McDONALD, G. B. HILL & E. ULRICH. The value of skin tests in the study of histoplasmosis. *Trans. 19th VA Armed Forces Conference on Chemotherapy of Tuberculosis*. In press.
- 27 TARBET, J. L. & A. M. BRESLAU. 1953 Histochemical investigation of *Coccidioides immitis* in relation to host reaction. *J. Infectious Diseases* 92: 190.
- 28 BRESLAU, A. M. 1957 Histochemical studies of *Coccidioides immitis* in relation to Coccidioidomycosis. 189-190. *Phoenix Ariz.*
- 29 O'HEEN, E. M. & H. S. HENRY. 1957 An electron microscope study of *Coccidioides immitis*. *Proc. Symposium of Coccidioidomycosis*. 191-197. *Phoenix Ariz.*
- 30 HEIVER, D. C. 1958 Diagnosis of histoplasmosis using precipitin gel. *Pediatrics* 61: 616.
- 31 WILLIAMS, C. A. JR. & R. J. DUBOS. 1959 Studies on fractions of tubercle bacilli. I. Fractions which increase resistance. *Exptl. Med.* 110: 981-1004.

THE QUESTION OF IMMUNITY IN RINGWORM INFECTIONS*

Lorraine Friedman and V. J. Derbes

Departments of Microbiology and Medicine Tulane University School of Medicine
New Orleans, La.

There is some indication that an immune response against dermatophytes is developed in experimental animals in view of the early work of Delamater¹ and Delamater and Benham² with *Trichophyton mentagrophytes* and of the more recent work of Reiss and Leonard³ with *Microsporum canis* and of Keeney and Huppert⁴ with *T. mentagrophytes*. Also Huppert and Keeney⁵ felt that they had demonstrated an acquired resistance against dermatophyte infections in human volunteers previously immunized with antigens of *T. mentagrophytes*. For the most part, however, the immunity developed has been partial in that the course of the disease following immunization was only shorter and milder than that normally observed. The role of such an altered response under natural conditions is nebulous in part because of so called "natural resistance" to dermatophyte infections that has been described by many, particularly well by Barlow.⁶ It is generally assumed that most persons are exposed to dermatophyte infections yet relatively few develop clinical disease. This is well exemplified by the study of Klugman⁷ who found that only 5 per cent of a group of institutionalized children had acquired a natural infection during an epidemic of tinea capitis caused by *Microsporon audouinii* despite the intimate and prolonged contact this situation provided. The factors that limit the spread of such epidemics would seem to be more complex than merely the natural resistance of certain individuals and might well be strongly influenced by other factors such as infectivity and virulence of the strain, size of the inoculum received by the individual and the effect of local trauma as well as the possibility of altered response following infection. For example, it is our impression, based more on speculation than data, that *M. audouinii*, although perhaps more virulent than other of the causative agents of tinea capitis, may not be as infectious. It was our desire to determine the presence or absence of immunity under natural conditions following recovery from naturally acquired tinea capitis. The observation that children usually do not have second bouts with this disease would seem at first glance sufficient evidence for a concept of acquired immunity. However, since the opportunity for first infections often is not great, the failure to acquire a second infection might well be attributable to lack of opportunity rather than immunity. Of 718 children treated for tinea capitis in the Tulane University clinic during a three year period, not one returned with a second infection despite entirely free medical care including medication.

At the time griseofulvin first became available, a deliberate effort was made to set up studies to explore the possibility of immunity following infection. It seemed to us that treating one sibling and then leaving that child exposed to one or more untreated children would provide a long awaited opportunity

* The work described in this paper was supported in part by Grant # 1224 from the National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.

This we did and are in the process of continuing. Thus far 15 of tinea capitis patients treated with griseofulvin have not become reinfected after known exposure. An interpretation of these results was not possible however unless we first determined the rate of infectivity of normal individuals under similar exposures. It seemed to us that we should ascertain those conditions that would provide maximum exposure and infectivity for normal individuals then if our previously infected individuals did not become infected under such conditions there might be some grounds for the concept of acquired immunity. To do this a study was made of 460 *M. audouinii* infections among 257 Negro families. Three hundred and fifty-one of the total infections occurred in males 331 of whom had tinea capitis and 20 claimed to have had only tinea corporis. This ratio was only slightly higher than the incidence usually

TABLE I
FAMILIES WITH SINGLE CASES OF NONINFLAMMATORY TINEA CAPITIS CAUSED BY *MICROSPORUM AUDOUINII* WHO EXERCISED NO PRECAUTION TO PREVENT INFECTION OF SUSCEPTIBLE MALES

Infected males		Non infected susceptible males	
Age	Duration of disease (mos.)	No.	Ages
6	2	1	9†
8	12	6	11† 11† 10† 9 3 6
10	6	2	9† 7
9*	7	1	8†
7	9	3	13† 11 2
8*	3	3	5† 4
7	7	2	5† 12
8	9	1	3†
5	4	1	1
7	5	2	8† 4

* Same comb used

† Slept with infected male

observed. It is of interest however that of 109 females infected 37 or 34 per cent claimed to have had only one or a few ringworms on the body that disappeared within a few weeks following home medications. This high incidence of tinea corporis is of course entirely out of line with that generally accepted. Tinea corporis was of further interest to us in that in only one family was a skin infection incriminated as a source of additional infections. Thus we anticipated because of the short duration of the disease and the undoubtedly fewer organisms being shed. We realized therefore we could not use tinea corporis as a locus for reinfection in our immunological studies.

Only single infections occurred in 130 of the families providing further evidence of the low infectivity of *M. audouinii*. Forty of the 130 families had seemingly ideal situations for cross infection in that they had susceptible males as well as infected males with noninflammatory tinea capitis of long duration to serve as sources of infection. However questioning revealed that 30 of these 40 families exercised at least some precaution to prevent spread of the

disease to other members of the family. Five enforced rather stringent procedures that included daily shampooing and clipping of the scalp as well as isolation of the sleeping quarters. The infected boys of 18 of the families slept alone and 7 families had the infected person sleep at the foot of the bed or wear protective clothing or both. However, 10 of the 40 single-infection families with susceptible males did nothing to prevent cross infections. In TABLE 1 may be seen the age and numbers of the susceptible males of the 10 families and duration of the focus of infection as estimated by period of fluorescence sleeping and other habits of the siblings. Cross infection did not

TABLE 2

A DESCRIPTION OF FOUR FAMILIES WITH ONE OR MORE MALES WITH NONINFLAMMATORY *TINEA CAPITIS* CAUSED BY *MICROSPORUM AUDOUINI* AND ONE MALE WHO ESCAPED INFECTION

4 Susceptible Males Escaped Infection

Jordan family	4 boys
3 infected (ages 4 7 10)	>1 year
1 noninfected (age 6)	all 4 slept together
Rhodes family	4 boys
3 infected (ages 3 4 6)	>1 year
1 noninfected (age 9)	slept with 2 infected boys
Dixon family	4 boys
1 infected (age 6)	>1 year
3 noninfected (ages 3 4 7)	1 (age 7) slept with infected boy
Napoleon family	4 boys
3 infected (ages 6 3 7)	>6 months
1 noninfected (age 7)	slept with 3 year-old infected boy

TABLE 3

DESCRIPTION OF THREE LARGE FAMILIES WITH SUSCEPTIBLE MEMBERS NEARLY ALL OF WHOM ACQUIRED *TINEA CAPITIS* CAUSED BY *MICROSPORUM AUDOUINI*

Green family	8 children (4 boys 4 girls)
7 infected (1 girl age 6 not infected)	
Hurst family	7 children (2 boys 5 girls)
5 infected (2 girls ages 3 and 10 not infected)	
Harvey family	5 children (3 boys 2 girls)
All infected	

occur even though in 2 instances a single comb was used by all members of the family and prolonged contact, such as sleeping together, occurred among all of the families. In one family, 4 children 1 of whom was infected slept abreast in one bed. It would seem that most of the members of these 10 families were 'naturally resistant' or that contact such as sleeping together did not provide a suitable means of transferring an infective inoculum. However a study of 49 families with a total of 150 boys indicated that sleeping together might serve as an effective means of providing conditions conducive for cross infection. Of the 150 boys in this group, 113 had noninflammatory tinea capitis. Forty nine obviously acquired their infections from outside the family but 64 cases were probably acquired as a result of cross infection. Of these 64 boys 45 or 70 per cent slept regularly with an infected member of

the family and thus may have acquired their infections in this manner. Nine teen or 30 per cent did not sleep with an infected person and must have become infected through other contact. Of perhaps greater interest of the 37 sus ceptible males that escaped infection 33 or 89 per cent slept alone or with a noninfected individual and only 4 slept with an infected person. Thus it appears that the chance of escaping infection is greatest if sleeping with an infected person is avoided. TABLE 2 shows the conditions of exposure of the 4 boys who escaped infection even though they regularly slept with an infected person. These observations attest to the usual low infectivity of *M. audouinii*.

It is worthy of note that in only 3 of 257 families with at least 1 member infected with *M. audouinii*, did all or nearly all susceptible children including females have tinea capitis. A description of these families is shown in TABLE 3. The high rate of infectivity observed with this small percentage of the families studied was indeed exceptional in that never did as many members of

TABLE 4
RESISTANCE TO REINFECTION OF RECOVERED NONINFLAMMATORY TINEA CAPITIS PATIENTS

Non infected		Re-exposure to noninflammatory tinea capitis	
Sex	Age	Period	Sex and age of infected child
M*	5	12 months	F* 3 M* 2
M	10	15 months	3
F	10	6 months	M 12
M	11	12 months	M 5
M	4	2 months	M* 9
M*	3		
M*	6		
M*	9	16 months	M* 9 M 3

* Sleep together

a family, including even the females, become infected. We believe these were most likely strains of unusual infectivity.

In only 8 of the 257 families studied was there certain re-exposure of individuals recovered from tinea capitis pointing up the difficulty usually encountered when attempting to determine an immunological response under natural conditions. These patients either had been cured by one of the many nostrums prescribed in our clinic or had cleared spontaneously. TABLE 4 shows the conditions of re-exposure. None of them became infected a second time.

With the advent of griseofulvin an opportunity was afforded to search more thoroughly for evidence of immunity following infection. The first indication was the observation that some of our patients who were clinically cured and nonfluorescent retained viable organisms for some few months thereafter. Until very recently we had felt this represented loose spores surviving in the hair of the previously infected individuals. It was not inconceivable that fungus spores notorious for their survival properties might well remain for some months following only oral medication, especially since these patients

often practiced very poor hygiene and since the numbers of colonies observed in culture were so often very few in number. A description of these patients and the numbers of colonies found on each of the cultures taken at regular intervals following loss of fluorescence is shown in TABLE 5. We had believed failure to become reinfected after exposure to these residual fungi indicative of

TABLE 5

RESIDUAL FUNGI IN ORALLY TREATED PATIENTS WITH *TINEA CAPITIS* (*M. AUDOUINI*)

Patient No.	Griseofulvin dosage	Nonfluorescent since 1959	No. colonies*
1	1 gm Q3Dx28†	July	TNC 0 10 0 1
2	3 gm 1 dose	October	TNC 0 1 0 0
3	1 gm Q3Dx28	July	TNC 313 0 5 34 0
4	3 gm 1 dose	September	TNC 27 TNC 6
5	3 gm 1 dose	August	TNC 20 0 TNC 26 0

* Cultures collected at various times since loss of fluorescence

† Q3Dx28 every 3 days for 28 days

TNC Number of colonies too numerous to count

TABLE 6

RESISTANCE TO REINFECTION OF RECOVERED PATIENTS WITH NONINFLAMMATORY *TINEA CAPITIS* TREATED WITH GRISEOFULVIN

Family no.	Recovered griseofulvin		Re-exposure to fluorescent non-inflammatory tinea capitis
	Sex	Age	
1	M*	8	8 months to M*1 age 7
	M*	5	8 months to F*2 age 3
2	M*	6	6 months to F* age 3
3	M*	11	6 months to M age 10
4	M*	8	6 months to M* age 9 and M* age 4
5	M	5	6 months to F age 2 M age 3 and M* age 9
	M	5	
	M*	6	
	M*	7	
6	M*	9	6 months to M* age 7
7	M	9	M age 6
8	M*	7	M* age 5
9	M		6 months to M age 7
10	M*	7	M* age 9

Total 15

* Slept together 1 female M male

a degree of immunity following recovery from infection. However some doubt is cast on this reasoning by the recent observation of Rosenthal and his associates⁷ that the skin of guinea pigs may remain infected with *T. mentagrophytes* after griseofulvin treatment even after the hairs are rendered free of fungi. We are presently trying to determine whether these cultural isolations in clinically recovered patients represent surviving but not infecting spores or latent infections. If the latter is true the failure to become clinically

diseased again could not be considered as evidence of immunity. However, none of fifteen culturally as well as clinically cured patients thus far exposed to foci of infection have become infected a second time. In two instances we have isolated *M. audouinii* in small number from their scalps, but this is not surprising inasmuch as similar isolations have been made from their home environs and the observation merely supports the thesis that these patients were re-exposed. The conditions of these re-exposures described in TABLE 6 seemed as intense as could be devised short of deliberate reinoculation. Most of the foci for reinfection were males in age groups similar to those being exposed, thus presumably providing ample opportunity for vigorous contact. Also, most of those being exposed slept regularly with an infected individual. By coincidence family number 5 was the Green family shown in TABLE 3 as one of the few families infected with what is probably a strain of unusually high infective properties. Admittedly, a far larger number of individuals escaped first infection in our study of 257 families, casting some doubt on the failure of these 15 to become reinfected as being evidence of immunity. However, those escaping infection among the 257 families represented only a small percentage of the whole whereas the escape of the 15, even though a small group, was uniform. It is our opinion these individuals became resistant as a result of a previous infection. Whether this represents an immunity due to an as yet undetected antibody is yet to be resolved. However, it is not inconceivable that an infectious agent could induce a specific and protective cellular alteration. Finally, it is significant that griseofulvin therapy apparently did not block this mechanism.

References

- 1 DELAMATER E. D. 1938. Experimental studies with the dermatophytes. I. Primary disease in laboratory animals. *J. Invest. Dermatol.* **1**: 451-467.
- 2 DELAMATER E. D. & R. W. BENHAM. 1938. Experimental studies with the dermatophytes. II. Immunity and hypersensitivity produced in laboratory animals. *J. Invest. Dermatol.* **1**: 469-496.
- 3 HEINS F. & L. LEONARD. 1955. Experimental *Microsporum lanosum* infection in dogs, cats and rabbits. II. Studies on the course of reinfection. *J. Invest. Dermatol.* **24**: 589-594.
- 4 KEENEY E. L. & M. HILPERT. 1959. Immunization against superficial fungus infection. I. Studies on experimental animals. *J. Invest. Dermatol.* **32**: 7-13.
- 5 HILPERT M. & E. L. KEENEY. 1959. Immunization against superficial fungus infection. II. Studies on human volunteer subjects. *J. Invest. Dermatol.* **32**: 15-17.
- 6 BARLOW A. J. F. & F. W. CHATTARAY. 1958. The parasitism of the ringworm group of fungi. *N.M.J. Arch. Dermatol.* **77**: 399-405.
- 7 KLIGMAN A. M. 1952. The pathogenesis of tinea capitis due to *Microsporum audouinii* and *Microsporum canis*. I. Gross observations following the inoculation of humans. *J. Invest. Dermatol.* **18**: 231-246.
- 8 ROSENTHAL S. A. N. GOLDFARB & R. L. BAER. 1959. Therapeutic and preventive effects of griseofulvin in guinea pigs. *J. Invest. Dermatol.* **33**: 419-426.

CAPSULAR REACTIONS OF *CRYPTOCOCCUS NEOFORMANS**

E. Edward Evans

Department of Microbiology, University of Alabama Medical Center, Birmingham Ala

The work of several groups has established the fact that the capsules of *Cryptococcus neoformans*^{1, 2} and related species^{3, 4} are predominantly polysaccharide, however, much remains to be learned about the finer details of capsular structure, the relation of the capsule to other cellular components, its mechanism of synthesis, and its functions. The resolution of these problems undoubtedly will necessitate the use of considerable imagination plus a variety of chemical, immunological, and cytological methods.

One approach that has been particularly fruitful in studying the capsule in its normal hydrated state is the use of specific antibodies directed toward capsular components. An excellent example of the possibilities inherent in this approach is seen in the work of Tomcsik and his associates,^{5, 10} who have demonstrated a complex structure in the capsule of certain strains of *Bacillus megaterium* through the use of antibodies specific for a glutamyl polypeptide and for a polysaccharide.

The existence of antibodies against the capsule of *C. neoformans* was first demonstrated by Neill *et al.*¹ and, shortly thereafter, our work¹¹ disclosed that this species was antigenically heterogeneous due to differences in capsular polysaccharides of various strains. Although the reaction between antibody and capsule is similar to the "Quellung" reaction of pneumococcus, it is generally referred to as the "capsular reaction"¹⁰ (CR) since there is no swelling of the capsule when it reacts with antibody.^{12, 13} Our results agree with those of Tomcsik,¹⁰ who describes the reaction as "precipitation which renders the capsule visible, usually without changing its size and shape."

More recently we have described another capsular reaction in which the capsular outline of *C. neoformans* is revealed by a basic polysaccharide rather than specific antibody. This basic polysaccharide, which has been designated APS, is a soluble polygalactosamine isolated from *Asperigillus parasiticus* by Blumenthal and his associates¹⁴ and by Distler and Roseman.¹⁵ It contains both acetylated and free amino groups, and it is presumably due to the latter that it reacts with the acidic capsular polysaccharide of *C. neoformans*.¹⁵ Although the capsular reaction due to APS is less specific than that due to antibody, it is nevertheless important for the information it provides on the ability of the cryptococcal capsule to function as a polyvalent anion. The APS reaction appears to be similar in principle to the nonspecific reactions of proteins with microbial capsules (Tomcsik¹⁰), however, the APS molecule possesses fundamental structural differences from the proteins used by Tomcsik since it is a basic polysaccharide. The effective pH range of the APS reaction is also much wider than one finds with proteins, although Tomcsik found that lysozyme reacted weakly with cryptococcus between pH 2 and 5.

The present report summarizes our work on the APS reaction as well as some

* The work described in this paper was supported in part by Grant E 1066 from the National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.

Evans Capsular Reactions of *C. neoformans*

further observations on the reaction between the cryptococcal capsule and specific antibody

Methods

C. neoformans, strain 6 (Type A) and strain 15 (Type B) were used for these studies. Cultures were grown on neopeptone glucose broth enriched with thiamine¹³ or on the same medium solidified with 2 per cent (w/v) agar. In some experiments cells were harvested from peritoneal exudates of experimentally infected white mice. Preparation of polysaccharides,^{14,15} anti-serum^{11,16} and APS solutions¹⁶ has been described elsewhere. Quantitative precipitin determinations by micro Kjeldahl analysis of antibody nitrogen were performed by methods described in Kabat and Mayer⁷ and supernates from these precipitations were tested for residual antibody by determining the capsular reaction (CR) titer on each tube. CR titers with antibody or with APS were determined as outlined in earlier reports^{1,2}. (Cryptococcal cell suspensions used in the CR were centrifuged and rinsed 5 times before each experiment and standardized at 10^7 or 2×10^7 cells/ml).

For certain experiments, cryptococcal cells were fragmented by mixing a thick slurry of cells in saline with an equal volume of 0.2 mm glass beads and subjecting this mixture to high speed stirring in a Virtis 45 homogenizer. The sample-container was immersed in a melting ice bath and samples were removed after 5, 10-, 20-, and 30-min treatment at rheostat setting no. 60.

Results

If the CR with APS was conducted in saline solution or in 0.2 M phosphate buffer at a pH of 6 or 7, it resembled the antibody CR quite closely except that it was slightly less intense (FIGURE 1a and b). If the APS reaction was conducted in distilled water or at extremes of pH there was considerable shrinkage and distortion of the capsule (FIGURE 1c and d). As might be expected cells that have undergone a CR with APS also agglutinated. The CR is usually read after 30-min incubation at room temperature while agglutination is read after the tubes have been stored for an additional 18 hours at 0 to 4°C¹¹. In a strong agglutination the cells were firmly adherent to the test tube, but could be removed by scraping with a stirring rod. TABLE 1 shows that titers obtained in the agglutination test were not significantly higher than the CR. The 3 serologic types of *C. neoformans* could not be differentiated by the APS reaction.

Additional evidence that the APS reaction lacks the specificity of the antibody reaction was found in a study of precipitation reactions. If the soluble S polysaccharide of *C. neoformans* was mixed with AIS in 0.15 M NaCl precipitation resulted¹¹. This reaction was obtained not only with the three types of *C. neoformans* polysaccharide, but also with the capsular polysaccharides of pneumococcus Types 2 and 3, as well as with gum acacia. Since these polysaccharides all contain carboxyl groups, it seemed likely that precipitation was the result of combination between such groups and the free-amino groups of APS. Dextran which does not contain carboxyl groups failed to react while proteins such as rabbit serum and rabbit gamma globulin would precipitate

with APS or would block the CR between APS and cryptococcal cells (E. E. Evans, unpublished data)

The reaction between APS and the capsule of *C. neoformans* can occur within a wide pH range, however, the range may be more restricted with a single buffer system as shown in TABLE 2. For example, with citrate buffer the reaction is strong at pH 3 and 4, weaker at pH 5, and negative at pH 6, whereas




FIGURE 1 (a) The capsular reaction (CR) between APS and cryptococcal cells in 0.15 M sodium chloride solution. (b) The same cells shown in FIGURE 1a after antibody was applied to produce a specific CR. (c) The CR between APS and cryptococcal cells in distilled water. Note the shrinkage of the capsule in contrast to FIGURE 1a. (d) A group of cells from the same preparation shown in FIGURE 1c after the addition of antibody to produce a specific CR.

the reaction in phosphate buffer is strong at pH 5 and 6 weaker at pH 7 and negative at pH 8. This suggests that concentration of buffer ions other than the hydrogen ion is important.

Under certain conditions, the APS bond is quite stable and cryptococcal cells retain a visible APS CR even after repeated centrifuging and rinsing. TABLE 3 shows the effect of 5 rinses with APS free buffers on cells that have been treated with 50 μ g/ml of APS for 30 min at 3 different pH levels. With citrate buffer, pH 4, and phthalate buffer, pH 6 and APS bond survived at

TABLE 1
AGGLUTINATION AND CR TITERS OF *C. NEOFORMANS* PLUS APS IN 0.15 M
SODIUM CHLORIDE

React on	APS μ g/ml					
	25	12.5	6	3	1.5	0.75
CR	CR	(CR)	(CR)	-	-	-
Agglutination	+	+	+	±	±	-

Strength and variability of the capsular react on are indicated in decreasing order by the symbols CR (CR) (-)

TABLE 2
CR OF *C. NEOFORMANS* WITH APS IN VARIOUS BUFFER SYSTEMS

pH	Buffer (M/20)			
	Citrate	Phosphate	Veronal	Cysteine NaOH
3	CR			
4	CR			
5	(CR)			
6	-	CR		
7		CR		
8		(CR)		
9		-	CR	
10			CR	CR (CR)

See footnote to TABLE 1

least 5 rinses, but with HCl KCl buffer at pH 2 the CR disappeared during the first rinse. Incidentally, the reaction mixture designated Rinse II in the table did not reach the buffer pH of 2, but was approximately 2.3 to 2.4 and when the basic APS was removed during the first rinse with pH 2 buffer, the pH would be expected to decrease to approximately 2.0 at which point carboxyl groups are probably not dissociated. One may therefore view the extinction of the CR during the first rinse as a replacement of APS with hydrogen ion. That APS was actually replaced could be verified by taking the cells from the first pH 2 rinse and exposing them to citrate buffer at pH 4, a system in which a strong CR is obtained. When this was done no CR resulted, indicating that APS had been replaced. Such a result could have been due to loss of the capsule, but India ink disclosed that the capsule was still present, and a fresh

preparation of APS in pH 4 citrate buffer showed that it was still capable of reacting

Thus it was possible to reverse the APS reaction by replacing it with other cations. Of the 2 cations present in the pH 2 buffer, H^+ was much more effective in producing reversal since HCl could do so in a concentration of 0.02 M , while approximately 4 M KCl was required to cause extinction of the CR. It should be noted however that if KCl was added before APS was mixed with cells the reaction was inhibited by concentrations as low as 0.5 M .

TABLE 3
EFFECT OF REPEATED RINSING ON THE CR PRODUCED BY APS

Rinse No.	Buffer used for rinse		
	Phthalate pH 4	Citrate pH 4	HCl KCl pH 2
0*	CR*	CR*	CR*
1	(CR)	CR	—
2	(CR)	CR	—
3	(CR)	CR	—
4	(CR)	CR	—
5	(CR)	(CR)	—

* APS was added (50 μg /ml) only to Rinse 0

TABLE 4
INHIBITION OF THE CR BETWEEN *C. neoformans* (TYPE A) AND APS AFTER THE ADDITION OF DISSOLVED SA TO CELLS IN VARIOUS BUFFER SYSTEMS

Buffer (M/20)	SA added (μg /ml.)			
	0	10	100	1000
HCl KCl (pH 2)*	CR	CR	(CR)	—
Citrate (pH 4)	CR	CR	—	—
Phosphate (pH 6)	CR	CR	—	—
Veronal (pH 8)	CR	CR	—	—

* Final pH of reacting mixture was 2.3 to 2.4 cell concentration 5×10^6 /ml APS concentration 50 μg /ml

The APS reaction then may be visualized as a reaction between a polyvalent anion (the S polysaccharide of *C. neoformans*) and a polyvalent cation (the APS polysaccharide). It is important because it emphasizes the role of the acidic capsular polysaccharide in binding various ionized substances and it suggests that the capsule may play a role in cell permeability due to its anionic nature.

We do not yet have a complete picture of the chemical structure of the cryptococcal capsule however several laboratories have isolated the acidic S polysaccharide that reacts with APS. Drouhet and his associates² were the first to describe the hydrolytic products as xylose, mannose and glucuronic acid and our results with the S polysaccharide have confirmed this although a second polysaccharide is present in cultural supernates.³

Certain inhibition and absorption experiments provide some support for the hypothesis that the S polysaccharide is the major ingredient of the *Cryptococcus* capsule. If, in the CR with APS the S polysaccharide was mixed with a cell suspension before APS was added the dissolved S competed with the capsule for APS, and the extent of the inhibition by Type A polysaccharide (SA) can be seen in TABLE 4. Inhibition by an excess of SA was lightly less.

TABLE 5
CR ON SUPERNATES OF QUANTITATIVE PRECIPITATION DETERMINATION (TYPE B)

SB added (mg)	Antibody precipitated (mg)	Supernate test	
		PPV	CR titer
0.00	0.00	Excess Ab	40
0.05	0.19	Excess Ab	40
0.10	0.30	Excess Ab	20
0.30	0.46	No Ab or S	<8
0.60	0.54	Excess S	<8
1.00	0.59	Excess S	<8
1.25	0.60	Excess S	*

* Not tested

TABLE 6
INHIBITION OF CR BY MIXING S WITH CELL SUSPENSION BEFORE THE
ADDITION OF ANTIBODY

Ant serum	Cell type	S added		CR titer
		Type	mg./ml	
Type A	A	SA	0	40
			0.31	10
			0.63	0*
			1.25	0
Type B	B	SB	0	20
			0.31	10
			0.63	0
			1.25	0

* A titer of 0 indicates failure to react at 1:4 the lowest serum dilution possible. Final cell concentration 2.5×10^6 /ml.

effective with pH 2 buffer (final pH 2.3 to 2.4), otherwise complete inhibition was obtained with 100 μ g of SA per 5×10^6 cells per 50 μ g of APS. The fact that such inhibition can occur emphasizes the importance of rinsing encapsulated cells immediately prior to their use in an experiment. Since the A/S reaction is less specific than that due to antibody, more significance should be attached to the results presented in TABLES 5 and 6.

If the S polysaccharide is allowed to precipitate with antibody and the supernates from each tube are tested for reactivity in the capsular reaction, it is found that the capsular reaction titer diminishes as more antibody is removed until it becomes negative near the equivalence zone (TABLE 5). As

in the APS reaction inhibition of the specific capsular reaction can be observed by adding dissolved S to suspensions of cells before antibody is added showing that S competes with the capsule for the antibody (TABLE 6)

These data suggest that the S polysaccharide is the major component of the region near the capsular surface. Since antibody and APS appear to react only at the surface of the capsule we cannot rule out the possibility of other capsular components in a zone adjacent to the cell wall. Also the inhibition and absorption experiments would fail to reveal impurities that do not react with the antibody or APS. It should be recalled that extracellular starch⁶ can be synthesized by *C. neoformans* but that it appears only in growth media in which the pH drops below 5. Under the usual conditions of cultivation starch does not appear to be synthesized and thus it need not be considered as contributing to the structure of the capsule.

Cryptococcal cells growing in fluid cultures elaborate soluble capsular polysaccharide into the supernate while the culture is growing. When the cells are killed and rinsed they can be stored for prolonged periods in water or saline without loss of capsule and can be subjected to repeated alternate rinsing and centrifugation without apparent reduction in size of the capsule. In the absence of cytological evidence to the contrary it might seem that the outer layer of the capsule was covered by a membrane. That this is not the case may be seen in experiments in which cells were fragmented by bombardment with 0.2 mm glass beads in a high speed homogenizer. After 10 to 30 min of such treatment cells in various stages of fragmentation could be observed under the microscope. In FIGURE 2 is seen a typical group of cells after 10-min treatment. Antibody has been added to disclose the boundary of the capsule. It is apparent that even when the capsule and cell wall have been sliced through the capsule does not flow. This is evidence against a capsular membrane and it suggests that the capsule is a thick gel one that might even be called a tough gel since it can withstand considerable mechanical trauma.

At present it is not known whether the firmness of the capsule is due merely to concentration of the S polysaccharide or perhaps to some complex between the S polysaccharide and one or more other substances; however evidence has been obtained that the S polysaccharide alone can produce a firm gel when mixed with water. Artificial capsules have been prepared by dissolving the S polysaccharide in water or saline at concentrations of 10, 20, 40 and 80 mg/ml. In the case of the Type A preparation used (SA) the contents of each test tube above the 10 mg level set up as a firm gel. These gels could be rinsed 100 times with saline solution without dissolving although there was some degree of swelling. When washed gels of this type were overlaid with antibody a precipitate resulted but it was confined to a fine line at the interface. After the preparations were allowed to stand at room temperature additional precipitation occurred in the supernatant fluid but in no case did it extend into the gel. Similar results were obtained with APS. These experiments help to explain why the specific capsular reaction appears to produce only an interfacial line near the capsular surface for if the concentration of S polysaccharide in the intact capsule approached the concentration in our

artificial capsules, precipitation within the capsular substance out due to inhibition by the great excess of antigen material of antibody that might diffuse into the gel. This is in agreement with microscopic observations made on the CR of encapsulated (cryptococcal unpublished data)




FIGURE 2. A group of cryptococcal cells showing varying degrees of reaction. The cell wall and capsule following high speed stirring with 0.2 M glucose. The cells have been allowed to show the location of the capsular gel.

Summary and Conclusions

Some recent observations were presented on the capsular reactions (CR) of *C. neoformans* with specific antibody and with the polygalactosamine (APS) from *Aspergillus parasiticus*. Both varieties of the CR appeared to have some potential value as cytological tools. Under certain conditions the CR produced by APS resembled the CR produced by antibody but when the APS reaction occurred in distilled water or at extremes of pH considerable shrinkage and distortion of the capsule were observed. The APS reaction appeared to be a combination of a polyvalent cation (APS) with a polyvalent anion (cryptococcal polysaccharide). In contrast to the reaction between antibody and the capsule, the APS reaction appeared to be relatively non-specific since it occurred with all compounds tested that are known to possess carboxyl groups. Studies with APS suggested that the capsule of *Cryptococcus* as

well as other microbial capsules, might have a role in the binding of various substances that possess cationic groups. Because of its anionic nature and potential role in ion exchange processes, the capsule could exert some influence on permeability.

Inhibition and absorption data were compatible with the hypothesis that the S polysaccharide is the major ingredient of the *Cryptococcus* capsule. At present, however, one cannot exclude the possibility of other capsular ingredients in a zone adjacent to the cell wall or of substances that do not react with APS or antibody. Even if subsequent work should verify the fact that the S polysaccharide is the only "resident" ingredient of the capsule, it would seem not unlikely that various substances that possess cationic groups could be located "transiently" within the negatively charged capsule.

Experiments in which the cell was fragmented mechanically disclosed that the capsule was quite resistant to disintegration and that it appeared to be a firm gel. Gels with similar properties ('artificial capsules') could be made in the test tube by dissolving relatively high concentrations of type A polysaccharide (SA) in aqueous media. Such artificial capsules were also used to study the reaction of the capsular gel with antibody. As a result of such observations together with microscopic studies of the natural capsule (E. E. Evans, unpublished data), it is suggested that the CR produced by antibody is a thin line of precipitate formed at the interfacial gradient between the capsular gel and the surrounding fluid.

References

- 1 NEILL J M, C G CASTILLO, R H SMITH & C E LAPROS. 1949. *J Exptl Med* 89: 93.
- 2 DROUOT E, G SEGRETAIN & J P AUBERT. 1950. *Ann Inst Pasteur* 70: 891.
- 3 EVANS E L & J F KESSEL. 1951. *J Immunol* 67: 109.
- 4 EVANS E F & J W MEHL. 1951. *Science* 114: 10.
- 5 EVANS E E & R J THERIAULT. 1953. *J Bacteriol* 66: 571.
- 6 MAGER J. 1947. *Biochem. J* 41: 603.
- 7 EINSBINDER J M, R W BENJAMIN & C T NELSON. 1954. *J Invest Dermatol* 22: 279.
- 8 BEUTMANN W. 1958. *AMA Arch Microbiol* 111: 227.
- 9 TOMCSIK J. 1956. *Ann Rev Microbiol* 10: 213.
- 10 TOMCSIK J. 1956. *Bacterial Anatomy* 41. Cambridge Univ Press, Cambridge, England.
- 11 EVANS E F. 1950. *J Immunol* 64: 423.
- 12a EVANS E E, H P R SEELIGER, L KORNFIELD & C GARCIA. 1956. *Proc Soc Exptl Biol Med* 93: 257.
- 12b SEELIGER H P R. 1959. *Erg Mikrobiol* 32: 23.
- 13 BILMENTHAL H J, S T HOROWITZ, A HEMERLINE & S ROSEMAN. 1955. *Bacteriol Proc* 137.
- 14 DISTLER J & S ROSEMAN. 1958. *Bacteriol Proc* 107.
- 15 EVANS E E. 1959. *Proc Soc Exptl Biol Med* 101: 760.
- 16 EVANS E E, L J SORESENSEN & A W WALLS. 1953. *J Bacteriol* 66: 287.
- 17 KABAT E A & M M MAYER. 1948. *Experimental Immunochimistry*. Thomas, Springfield Ill.

ANTIGENS OF *BLASTOMYCES*

Stanley Marcus

Department of Bacteriology University of Utah College of Medicine Salt Lake City Utah

Gilbert A Hill

Latter Day Saints Hospital Salt Lake City Utah

Ralph A Knight

Veterans Administration Hospital Salt Lake City Utah

The material to be reported stems from interest in the hypothesis that agents more specific than those available might be prepared for use in skin and skin test reactions involving systemic mycotic pathogens. The importance of specificity of skin test reagents is of prime importance because of the demonstration that cross reactions may occur among individual antigens to histoplasmin, blastomycin, coccidioidin, and Emmonsin.

Martin has presented the results of wide ranging studies on various *Blastomyces dermatitidis* antigens.^{1,2} Soluble antigen obtained by sonic vibration of yeast phase cells of *B. dermatitidis*, yielded as satisfactory a complement fixation test antigen as entire yeast phase cells but had the advantages of solubility and ease of storage. A polysaccharide precipitated from yeast phase cell extract was found to be serologically active as well as capable of multiplying a limited degree of resistance to disease in mice. The crude extract has never been found to be of significant value as skin test antigens. We have further explored these areas and, in this report, present aspects of strain variation in *B. dermatitidis* and the comparison of serologic skin reactive and immunogenic properties of polysaccharides prepared from different strains of this organism.

Constancy of Virulence and Strain Variation in *B. dermatitidis*

Benham has stated³ "Pathogenicity [of *B. dermatitidis*] seems to be fixed in character, for, after years on artificial media this fungus will reproduce the disease in animals."

TABLE 1 gives typical results of mouse (albino *Mus musculus*) LD₅₀ determinations with 3 strains of *B. dermatitidis*.

Strain 410 originally isolated from surgically excised pulmonary tissue at Tulane University, New Orleans, La. and sent to us in 1952 by M. L. Pittman, has been employed extensively by our group. As noted in TABLE 1 the organism has maintained an intravenous LD₅₀ for 11 days, of about 200 population units.

The term "population unit" is defined as individual cells, budding cells, or clumps of cells, each counted as a unit. The organisms have been maintained on 10 to 15 per cent human blood agar slants, containing penicillin and streptomycin.

* Virulence referred to in this publication has made necessary a change of the name of the organism formerly known as *Haplosporangium parvum* to *Emmonsinia parva*. A second species described by Emmons and Johnson in this new genus is called *E. crescent*. The new nomenclature requires revision of the term employed for the filtrate antigen that should now be called Emmonsin rather than haplosporangan.

mycin, at 37° C. The strains were usually transferred at weekly intervals although occasionally as much as 4 weeks passed between transfers.

Inocula were prepared by harvesting the yeast phase growth from a 96 hour blood agar slant into broth. The broth suspension is filtered through sterile glass wool and a quantitatively diluted aliquot of the suspension is counted in a hemocytometer. This count is employed to make the estimate of the broth suspended population and of the dilutions designed to contain the numbers of population units to be injected. All injections have been made intravenously (IV) into a tail vein of albino *Mus musculus* obtained from local sources.

TABLE 1
WOLF LD₅₀ DETERMINATIONS WITH *B. DERMATITIDIS*

Strain and date of test	No. of organisms injected	Mortality ratio	LD ₅₀ (population units)
410 10/15/51	100	5/10	155 (77 to 310)*
	500	7/10	
	1000	9/10	
	2000	10/10	
2/19/52	10	0/8	285 (119 to 684)
	100	3/8	
	1000	5/8	
9/10/57	17	5/24	115 (32 to 406)
	170	9/18	
	1700	14/16	
380	10 ⁴	0/10	—
	10 ⁵	0/10	—
	10 ⁶	0/10	—
6052	10 ⁴	0/10	8.5 × 10 ⁵ (0.33 to 2.2 × 10 ⁶)
	10 ⁵	1/10	
	10 ⁶	4/10	

* Ninety five per cent confidence limits

The IV challenge with *B. dermatitidis* produces predominantly lung lesions from which the organisms are readily cultured.

The LD₅₀ value of about 200 population units for strain 410 was maintained over the 6-year period shown. This observation is similar to Benham's.⁹

Variation in virulence of strains is considered in the remainder of TABLE 1. Strain 380, also from the Tulane collection, was isolated from a fatal case of blastomycosis. This organism has been uniformly nonlethal in doses of 1 × 10⁶ population units. Strain 6052, received from Fimmers' collection, has maintained a 21-day LD₅₀ of approximately 10⁶ population units since 1955.

The statistical analyses have been carried out employing the methods of Wilcoxon and Litchfield.¹⁰

The discovery of variation in animal virulence of strains of *B. dermatitidis* is not unexpected; that is, virulence differences among strains of the same fungus organism have been reported by others. For example, Howell and Kippe¹¹

Marcus *et al* Antigens of *Blastomycosis*

and Drouhet and Schwarz¹² have reported virulence differences in // strains of *C. immitis*, and Salvin *et al*¹⁴ have shown differences for mice among strains of *C. albicans*.

It may be concluded that the three strains of *B. dermatitidis* he originally from human infections and maintained in yeast phase culture media for prolonged periods of time showed little variation although stable virulence characteristics for mice by the methods described. The three strains were found to be indistinguishable in either yeast or mycelial phase grossly and microscopically. That conflicting reports concerning effects observed in animals with *B. dermatitidis* could be due to differences in the virulence of the organism used rather than to the effect being measured.

Serologic Characteristics

Yeast phase cell free extracts were prepared from organism biotic containing blood agar plates and in broth. Both types were incubated for 3 to 7 days at 37° C. The agar grown organisms were to the broth suspensions, and all were killed by addition of 10 per cent final concentration, 24 hours at 37° C. The cells were then transferred by test of viability on agar. Each suspension as determined by test of viability on agar. Each suspension and then transferred to a heavy glass centrifuge bottle containing The bottle was placed on ball mill rollers and run at slow speed at 5° C. Cellular debris was centrifuged off at high speed and the supernate represented cell free extract (CFE).

Polysaccharides were extracted by the methods of Heidell¹⁵ modified by local circumstances¹⁶. This procedure gave good yields of saccharides from both yeast cell filtrate broths and CFE. A crude protein fraction was prepared by saturating CFE with ammonium sulfate. Larger yields of brownish to grey colored polysaccharide were obtained from yeast phase broths than from CFE. A statement by M. 1953 report¹⁷ is appropriate: "antigenically active polysaccharide on the surfaces of yeast phase cells of *B. dermatitidis* which diffuses rapidly into the surrounding fluid." For example per liter of original material was obtained 574 gm from broth versus 510 mg from CFE of *B. dermatitidis* strain 380. The control, that is, un inoculated but incubated broth yielded 80 mg of material. Seven day broth cultures of strain 410 yielded 147 gm/l and strain 6052 yielded 392 gm/l. Yields of similar nature and appearance have been obtained with 3 strains of *H. capsulatum* and 1 strain each of *Sporothrix schenckii* and *Coccidioides immitis*. The control material obtained was serologically inactive and yielded no skin test reactions in animals or in human volunteers injected with 100-µg amounts.

Attention has been given to some chemical characteristics of these polysaccharide substances. The hydrolyzed *H. capsulatum* and *B. dermatitidis* materials each contained an ascending migrating constituent in 1-dimensional paper chromatograms. These carbohydrates, when developed into ultraviolet light visible

mycin at 37° C. The strains were usually transferred at weekly intervals although occasionally as much as 4 weeks passed between transfers.

Inocula were prepared by harvesting the yeast phase growth from a 96-hour blood agar slant into broth. The broth suspension is filtered through sterile glass wool and a quantitatively diluted aliquot of the suspension is counted in a hemocytometer. This count is employed to make the estimate of the broth suspended population and of the dilutions designed to contain the numbers of population units to be injected. All injections have been made intravenously (I.V.) into a tail vein of albino *Mus musculus* obtained from local sources.

TABLE I
MOLT LD₅₀ DETERMINATIONS WITH *B. DERMATITIDIS*

Strain and date of test	No. of organisms injected	Mortality ratio	LD ₅₀ (population units)
410 10/15/51	100	5/10	155 (77 to 310)*
	500	7/10	
	1000	9/10	
	2000	10/10	
2/19/52	10	0/8	285 (119 to 684)
	100	3/8	
	1000	5/8	
9/10/57	17	3/24	115 (32 to 406)
	170	9/18	
	1700	14/16	
380	10 ⁴	0/10	—
	10	0/10	—
	10 ⁶	0/10	—
6052	10 ⁴	0/10	8.5 × 10 ⁴ (0.33 to 2.2 × 10 ⁵)
	10 ⁵	1/10	
	10 ⁶	4/10	

* Ninety five per cent confidence limits

The I.V. challenge with *B. dermatitidis* produces predominantly lung lesions from which the organisms are readily cultured.

The LD₅₀ value of about 200 population units for strain 410 was maintained over the 6-year period shown. This observation is similar to Benham's.⁹

Variation in virulence of strains is considered in the remainder of TABLE I. Strain 380 also from the Tulane collection was isolated from a fatal case of blastomycosis. This organism has been uniformly nonlethal in doses of 1 × 10⁶ population units. Strain 6052 received from Immons collection has maintained a 21 day LD₅₀ of approximately 10⁵ population units since 1955.

The statistical analyses have been carried out employing the methods of Wilcoxon and Litchfield.¹⁰

The discovery of variation in animal virulence of strains of *B. dermatitidis* is not unexpected; that is, virulence differences among strains of the same fungus organism have been reported by others. For example, Howell and Kippe.¹

and Drouhet and Schwarz¹² have reported virulence differences in *H. capsulatum*. Friedman *et al*¹³ have demonstrated virulence differences in strains of *C. immitis*, and Salvin *et al*¹⁴ have shown differences in virulence for mice among strains of *C. albicans*.

It may be concluded that the three strains of *B. dermatitidis* studied originally from human infections and maintained in yeast phase on rich culture media for prolonged periods of time showed individually but although stable virulence characteristics for mice by the method described. The three strains were found to be indistinguishable morphologically in either yeast or mycelial phase grossly and microscopically. It is that conflicting reports concerning effects observed in animal infection with *B. dermatitidis* could be due to differences in the virulence of the organism used rather than to the effect being measured.

Serologic Characteristics

Yeast phase cell free extracts were prepared from organism grown on biotic containing blood agar plates and in broth. Both types of cultures were incubated for 3 to 7 days at 37° C. The agar grown organisms were then suspended in the broth suspensions, and all were killed by addition of formalin to a 1 per cent final concentration, 24 hours at 37° C has accomplished this. The suspension was then centrifuged at 5000 rpm for 10 minutes and the supernatant as determined by test of virility on agar. Each suspension was then and then transferred to a heavy glass centrifuge bottle containing glass beads. The bottle was placed on ball mill rollers and run at slow speed for 48 hours at 5° C. Cellular debris was centrifuged off at high speed and the opalescent supernate represented cell free extract (CFE).

Polysaccharides were extracted by the methods of Heidelberg *et al*¹⁵ modified by local circumstances. This procedure gave good yields of polysaccharides from both yeast cell filtrate broths and CFE. A crude protein fraction was prepared by saturating CFE with ammonium sulfate.

Larger yields of brownish to grey colored polysaccharides were obtained from yeast phase broth filtrates than from CFE. A statement from Martin's 1953 report¹⁶ is appropriate: "antigenically active polysaccharide occurs on the surfaces of yeast phase cells of *B. dermatitidis* which diffuses rapidly into the surrounding fluid." For example per liter of original material we obtained 5.74 gm from broth versus 510 mg from CFE of *B. dermatitidis* strain 380. The control that is un inoculated but incubated broth yielded 80 mg of material. Seven-day broth cultures of strain 410 yielded 1.45 gm/l, and strain 6052 yielded 3.92 gm/l. Yields of similar nature and appearance have been obtained with 3 strains of *H. capsulatum* and 1 strain each of *Sporotrichum schenckii* and *Coccidioides immitis*. The control material obtained was serologically inactive and yielded no skin test reactions in animals or in 5 human volunteers injected with 100 µg amounts.

Attention has been given to some chemical characteristics of these polysaccharide substances.

The hydrolyzed *H. capsulatum* and *B. dermatitidis* materials each contained 1 ascending migrating constituent in 1 dimensional paper chromatograms. These carbohydrates, when developed into ultraviolet light visible spots were

in the same relative position as the control hexose (dextrose) spots. No pentose or disaccharide was detected. Protracted hydrolysis yielded 75 to 90 per cent reducing substances, hexoses measured 50 to 59 per cent. Iodine and biuret tests of solutions of the materials were negative, Molisch tests were positive. Small amounts of nitrogen were present in each preparation. A guess concerning structure of these polysaccharides is that they are largely or entirely hexose polymers. The nitrogen content may represent contamination or a structure containing an occasional hexosamine moiety.

Examination of the extracted polysaccharides by the Ouchterlony¹⁴ method of agar plate double diffusion has been carried out. Central wells contained rabbit antiserum of known specific reactivity, peripheral wells contained polysaccharides about 100 $\mu\text{g}/\text{ml}$, from *H. capsulatum*, *B. dermatitidis*, *C. immitis* and *Sp. schenckii*, also wells containing dextran and saline were filled as controls. The only reactions noted were with the homologous system in each case.

No opportunity has been available to carry out tests with this technique and sera from infected humans. Low titer complement fixing antibody from infected guinea pigs has been uniformly negative by the Ouchterlony procedure.

J. H. Schubert (personal communication) examined these polysaccharides at the Communicable Disease Center, Chamblee, Ga. and found that the *H. capsulatum* material is not comparable with antigen employed there with serum from proved cases of persons with histoplasmosis. *B. dermatitidis* antigen was comparable in concentrations of 100 $\mu\text{g}/\text{ml}$ and *C. immitis* in concentrations of 10,000 $\mu\text{g}/\text{ml}$. Positive human serum against *Sp. schenckii* was not available but employing rabbit antibody, Schubert found that 50 $\mu\text{g}/\text{ml}$ of polysaccharide reacted similarly to antigen employed by the CDC.

We have had the opportunity to examine the serum from an individual (M. W.) with active histoplasmosis who died in the hospital of complications of noninfectious disease. The serum yielded a titer of 1:16 to 1:32 with both CFE and *H. capsulatum* polysaccharide, 50 $\mu\text{g}/\text{ml}$, but no reactions with the other available antigens.

When mycelial filtrate antigens, that is, histoplasmin, blastomycin, and coccidioidin were examined by agar plate double diffusion against the rabbit CFE antisera, only one band of homologous precipitate was noted. Since the filtrates contain protein as well as polysaccharide, reasons for observing but one band are open to speculation and further investigation. The suggestion has been offered that analysis by Oudin procedure¹⁵ would yield more sensitive results.

Results obtained by complement fixation with rabbit antibody from animals immunized with CFE are shown in TABLES 2 and 3. The results of TABLE 2 were obtained with polysaccharide antigen, the result of TABLE 3 with CFE antigen. In each case the micro Kolmer complement fixation method was employed. It is apparent that cross reaction characterized these results. For example, anti *H. capsulatum* antiserum cross reacted to titer with *B. dermatitidis* polysaccharide. However, a degree of discrimination is apparent in these results: a 1:40 dilution of anti *H. capsulatum* antibody showed no reaction

in the same relative position as the control hexose (dextrose) spots. No pentose or disaccharide was detected. Protracted hydrolysis yielded 75 to 90 per cent reducing substances, hexoses measured 50 to 59 per cent. Iodine and biuret tests of solutions of the materials were negative, Molisch tests were positive. Small amounts of nitrogen were present in each preparation. A guess concerning structure of these polysaccharides is that they are largely or entirely hexose polymers. The nitrogen content may represent contamination or a structure containing an occasional hexosamine moiety.

Examination of the extracted polysaccharides by the Ouchterlony¹⁸ method of agar plate double diffusion has been carried out. Central wells contained rabbit anti-serum of known specific reactivity, peripheral wells contained polysaccharides about 100 $\mu\text{g}/\text{ml}$, from *H. capsulatum*, *B. dermatitidis*, *C. immitis*, and *Sp. schenckii*, also wells containing dextran and saline were filled as controls. The only reactions noted were with the homologous system in each case.

No opportunity has been available to carry out tests with this technique and sera from infected humans. Low titer complement fixing antibody from infected guinea pigs has been uniformly negative by the Ouchterlony procedure.

J. H. Schubert (personal communication) examined these polysaccharides at the Communicable Disease Center, Chamblee, Ga. and found that the *H. capsulatum* material is not comparable with antigen employed there with serum from proved cases of persons with histoplasmosis. *B. dermatitidis* antigen was comparable in concentrations of 100 $\mu\text{g}/\text{ml}$ and *C. immitis* in concentrations of 10,000 $\mu\text{g}/\text{ml}$. Positive human serum against *Sp. schenckii* was not available but, employing rabbit antibody, Schubert found that 50 $\mu\text{g}/\text{ml}$ of polysaccharide reacted similarly to antigen employed by the CDC.

We have had the opportunity to examine the serum from an individual (M. W.) with active histoplasmosis who died in the hospital of complications of noninfectious disease. The serum yielded a titer of 1:16 to 1:32 with both CFE and *H. capsulatum* polysaccharide, 50 $\mu\text{g}/\text{ml}$, but no reactions with the other available antigens.

When mycelial filtrate antigens, that is, histoplasmin, blastomycin and coccidioidin, were examined by agar plate double diffusion against the rabbit CFE anti-sera, only one band of homologous precipitate was noted. Since the filtrates contain protein as well as polysaccharide, reasons for observing but one band are open to speculation and further investigation. The suggestion is offered that analysis by Oudin procedure¹⁹ would yield more sensitive

results obtained by complement fixation with rabbit antibody from animals immunized with CFE. The results of TABLE 2 and 3. The results of TABLE 2 were obtained with polysaccharide antigen, the result of TABLE 3 with CFE antigen. In each case the micro Kolmer complement fixation method was employed. It is apparent that cross reaction characterized these results. For example, anti *H. capsulatum* anti-serum cross reacted to titer with *B. dermatitidis* polysaccharide. However, a degree of discrimination is apparent in these results, a 1:40 dilution of anti *H. capsulatum* antibody showed no reaction

TABLE III
COMPLEMENT FIXATION TITERS RABBIT ANTIBODY VERSUS POLYSACCHARIDE

Rabbit ant body dilutions	1	Polysaccharide antigen µg/ml									
		<i>H. capsulatus</i>					<i>B. dermatitidis</i>				
		100	50	25	12	0*	100	50	25	12	0
anti <i>H. capsulatus</i> (anti)	10	4	4	4	4	2	4	4	4	2	2
	20	4	4	4	3	0	4	3	3	0	0
	40	4	4	0	0	0	3	0	0	0	0
	80	0	0	0	0	0	1	0	0	0	0
	160	0	0	0	0	0	0	0	0	0	0
anti <i>B. dermatitidis</i> (anti)	10	4	4	4	4	2	4	4	4	2	2
	20	3	2	2	2	0	4	3	3	0	0
	40	1	0	0	0	0	3	0	0	0	0
	80	0	0	0	0	0	0	0	0	0	0
	160	0	0	0	0	0	0	0	0	0	0
anti <i>C. immitis</i> (anti)	10	4	4	4	4	3	4	4	4	2	2
	20	4	4	4	4	2	4	4	3	3	0
	40	1	1	1	1	0	3	3	0	0	0
	80	0	0	0	0	0	0	0	0	0	0
	160	0	0	0	0	0	0	0	0	0	0
anti <i>Sp. schenckii</i> (anti)	10	4	4	4	4	0	4	4	4	0	0
	20	2	2	2	2	0	4	4	3	0	0
	40	0	0	0	0	0	2	3	0	0	0
	80	0	0	0	0	0	0	0	0	0	0
	160	0	0	0	0	0	0	0	0	0	0

* Saline control, 0 no fixation, 4, complete fixation

in the same relative position as the control hexose (dextrose) spots. No pentose or disaccharide was detected. Protracted hydrolysis yielded 75 to 90 per cent reducing substances, hexoses measured 50 to 59 per cent. Iodine and biuret tests of solutions of the materials were negative, Molisch tests were positive. Small amounts of nitrogen were present in each preparation. A guess concerning structure of these polysaccharides is that they are largely or entirely hexose polymers. The nitrogen content may represent contamination or a structure containing an occasional hexosamine moiety.

Examination of the extracted polysaccharides by the Ouchterlony¹⁵ method of agar plate double diffusion has been carried out. Central wells contained rabbit antiserum of known specific reactivity. Peripheral wells contained polysaccharides about 100 $\mu\text{g}/\text{ml}$, from *H. capsulatum*, *B. dermatitidis*, *C. immitis*, and *Sp. schenckii*; also wells containing dextran and saline were filled as controls. The only reactions noted were with the homologous system in each case.

No opportunity has been available to carry out tests with this technique and sera from infected humans. Low titer complement fixing antibody from infected guinea pigs has been uniformly negative by the Ouchterlony procedure.

J. H. Schubert (personal communication) examined these polysaccharides at the Communicable Disease Center, Chamblee, Ga. and found that the *H. capsulatum* material is not comparable with antigen employed there with serum from proved cases of persons with histoplasmosis. *B. dermatitidis* antigen was comparable in concentrations of 100 $\mu\text{g}/\text{ml}$ and *C. immitis* in concentrations of 10,000 $\mu\text{g}/\text{ml}$. Positive human serum against *Sp. schenckii* was not available but, employing rabbit antibody, Schubert found that 50 $\mu\text{g}/\text{ml}$ of polysaccharide reacted similarly to antigen employed by the CDC.

We have had the opportunity to examine the serum from an individual (M. W.) with active histoplasmosis who died in the hospital of complications of noninfectious disease. The serum yielded a titer of 1:16 to 1:32 with both CFE and *H. capsulatum* polysaccharide, 50 $\mu\text{g}/\text{ml}$ but no reactions with the other available antigens.

When mycelial filtrate antigens that is histoplasmin, blastomycin and coccidioidin were examined by agar plate double diffusion against the rabbit CFE antisera, only one band of homologous precipitate was noted. Since the filtrates contain protein as well as polysaccharide, reasons for observing but one band are open to speculation and further investigation. The suggestion has been offered that analysis by Oudin procedure¹⁶ would yield more sensitive results.

Results obtained by complement fixation with rabbit antibody from animals immunized with CFE are shown in TABLES 2 and 3. The results of TABLE 2 were obtained with polysaccharide antigen, the result of TABLE 3 with CFE antigen. In each case the micro Kolmer complement fixation method was employed. It is apparent that cross reaction characterized these results. For example, anti *H. capsulatum* antiserum cross reacted to titer with *B. dermatitidis* polysaccharide. However, a degree of discrimination is apparent in these results: a 1:40 dilution of anti *H. capsulatum* antibody showed no reaction

with *C immitis* or *Sp schenku* polysaccharide in the 50 µg/ml range, although these are optimal concentrations for the homologous systems

It is observed by complement fixation that the polysaccharides are not significantly more specific than the CFE's. Although not tabulated, the crude protein preparations showed the least degree of specificity

No critical explanation is available to reconcile the apparent specificity of reactivity described for the agar plate double diffusion tests and the high degree of cross reactivity obtained with the same antibodies in complement fixation tests

The results suggest a greater degree of relationship among these dimorphic fungi and probably others, than is apparent from morphology

Skin Test Results

Results with the *B dermatitidis* and *H capsulatum* polysaccharide preparations injected into humans and infected guinea pigs have been reported¹⁷ Additional experiments were conducted in which each volunteer was injected with polysaccharide and filtrate antigens. The homologous polysaccharide preparations were indistinguishable in infected guinea pigs. For this reason as well as for convenience one polysaccharide preparation of each organism has been employed

The polysaccharide preparations were all employed in a concentration of 10 µg in 0.1 ml saline injected intradermally and read at 24, 48 and 72 hours. The maximum reaction was taken for the final result. In addition to the polysaccharides the volunteer group was injected with commercially available histoplasmin, blastomycin and coccidioidin as well as a saline control. In all therefore each individual received 8 injections, 4 on the volar surface of each forearm. The sites for injection were chosen at random but each individual received the 8 injections at the same site. In all 65 persons volunteered to be injected including the entire sophomore medical class and members of the staff of our different establishments. No reactions were noted with saline or with polysaccharides from *Sp schenku* or *B dermatitidis*. Commercial blastomycin yielded no reactions. Results previously reported^{17, 18} with *B dermatitidis* polysaccharide and blastomycin suggested somewhat greater sensitivity and lessened although not significantly so specificity of polysaccharide skin test material.

Five individuals reacted to both histoplasmin and polysaccharide but as has been noted showed no cross reaction with the *B dermatitidis* reagents. All 5 individuals had lived in the area of histoplasmosis endemicity in the middle western United States and in addition one had sustained a proved laboratory infection. This latter individual showed the greatest sensitivity among the reactors.

Five persons reacted to both coccidioidin and to *C immitis* polysaccharide. 3 of the reactions showed less than 5 mm of induration. All 5 persons had lived or spent time in the area of coccidioidomycosis endemicity. No significant difference was noted in reactions to filtrate and polysaccharide antigens.

It is apparent that these results do not resolve the problem of serologic and

TABLE 3
COMPLEMENT FIXATION TITERS RABBIT ANTIBODY VERSUS CFE

Rabbit and body dilutions	Cell free extract antigen diluted 1																			
	<i>H. capsulatum</i>					<i>B. dermatitidis</i>					<i>C. parvulus</i>					<i>Sp. schenckii</i>				
	30	40	50	100	0*	10	20	40	80	0	20	40	80	160	0	40	80	160	0	0
anti <i>H. capsulatum</i>	4	4	4	4	2	4	4	2	0	2	4	4	4	3	2	4	4	3	2	0
10	4	4	4	4	0	4	4	0	0	0	4	4	4	2	0	4	4	2	0	0
20	4	4	4	4	0	4	4	0	0	0	4	4	4	2	0	4	4	2	0	0
40	4	4	4	3	0	4	4	0	0	0	4	4	4	2	0	4	4	2	0	0
80	4	4	4	3	0	4	4	0	0	0	4	4	4	2	0	4	4	2	0	0
160	2	2	0	0	0	0	0	0	0	0	4	4	4	2	0	4	4	2	0	0
0*	0	0	0	0	0	0	0	0	0	0	4	4	4	2	0	4	4	2	0	0
anti <i>B. dermatitidis</i>	4	4	4	3	2	3	3	2	0	2	4	4	4	3	2	4	4	3	2	0
10	4	4	4	3	0	3	3	0	0	0	4	4	4	3	0	4	4	3	2	0
20	4	4	4	2	0	3	3	0	0	0	4	4	4	3	0	4	4	3	2	0
40	4	4	2	0	0	3	3	0	0	0	4	4	4	3	0	4	4	3	2	0
80	0	0	0	0	0	3	3	0	0	0	4	4	4	3	0	4	4	3	2	0
160	0	0	0	0	0	0	0	0	0	0	4	4	4	3	0	4	4	3	2	0
anti <i>C. parvulus</i>	4	4	4	3	2	4	4	1	0	3	4	4	4	3	2	4	4	3	2	0
10	4	4	4	3	0	4	4	1	0	0	4	4	4	3	0	4	4	3	2	0
20	4	4	4	2	0	4	4	1	0	0	4	4	4	3	0	4	4	3	2	0
40	4	4	4	2	0	4	4	1	0	0	4	4	4	3	0	4	4	3	2	0
80	4	4	4	2	0	4	4	1	0	0	4	4	4	3	0	4	4	3	2	0
160	0	0	0	0	0	0	0	0	0	0	4	4	4	3	0	4	4	3	2	0
anti <i>Sp. schenckii</i>	4	4	4	3	0	0	0	0	0	0	4	4	4	3	0	4	4	3	2	0
10	4	4	4	3	0	0	0	0	0	0	4	4	4	3	0	4	4	3	2	0
20	4	4	4	3	0	0	0	0	0	0	4	4	4	3	0	4	4	3	2	0
40	4	4	4	2	0	0	0	0	0	0	4	4	4	3	0	4	4	3	2	0
80	4	4	4	2	0	0	0	0	0	0	4	4	4	3	0	4	4	3	2	0
160	0	0	0	0	0	0	0	0	0	0	4	4	4	3	0	4	4	3	2	0

* Saline control, 0 no fixation, +, complete fixation

with *C immitis* or *Sp schenku* polysaccharide in the 50 μ g/ml range, although these are optimal concentrations for the homologous systems

It is observed by complement fixation that the polysaccharides are not significantly more specific than the CFE's. Although not tabulated, the crude protein preparations showed the least degree of specificity

No critical explanation is available to reconcile the apparent specificity of reactivity described for the agar plate double-diffusion tests and the high degree of cross reactivity obtained with the same antibodies in complement fixation tests

The results suggest a greater degree of relationship among these dimorphic fungi, and probably others, than is apparent from morphology

Skin Test Results

Results with the *B dermatitidis* and *H capsulatum* polysaccharide preparations injected into humans and infected guinea pigs have been reported¹⁷ Additional experiments were conducted in which each volunteer was injected with polysaccharide and filtrate antigens. The homologous polysaccharide preparations were indistinguishable in infected guinea pigs. For this reason, as well as for convenience, one polysaccharide preparation of each organism has been employed

The polysaccharide preparations were all employed in a concentration of 10 μ g in 0.1 ml saline injected intradermally and read at 24, 48, and 72 hours. The maximum reaction was taken for the final result. In addition to the polysaccharides, the volunteer group was injected with commercially available histoplasmin, blastomycin, and coccidioidin, as well as a saline control. In all, therefore, each individual received 8 injections, 4 on the volar surface of each forearm. The sites for injection were chosen at random, but each individual received the 8 injections at the same site. In all 65 persons volunteered to be injected, including the entire sophomore medical class and members of the staff of our different establishments. No reactions were noted with saline or with polysaccharides from *Sp schenku* or *B dermatitidis*, commercial blastomycin yielded no reactions. Results previously reported^{17, 18} with *B dermatitidis* polysaccharide and blastomycin suggested somewhat greater sensitivity and lessened, although not significantly so, specificity of polysaccharide skin test material

Five individuals reacted to both histoplasmin and polysaccharide but, as has been noted, showed no cross reaction with the *B dermatitidis* reagents. All 5 individuals had lived in the area of histoplasmosis endemicity in the middle western United States and, in addition, one had sustained a proved laboratory infection. This latter individual showed the greatest sensitivity among the reactors

Five persons reacted to both coccidioidin and to *C immitis* polysaccharide, 3 of the reactions showed less than 5 mm of induration. All 5 persons had lived or spent time in the area of coccidioidomycosis endemicity. No significant difference was noted in reactions to filtrate and polysaccharide antigens

It is apparent that these results do not resolve the problem of serologic and

skin reactivity of polysaccharide materials derived from *B dermatitidis* or other systemic mycotic pathogens

In addition to other reasons previously mentioned for which the problem deserves continued consideration are the reports that repeated histoplasmin skin tests may result in the appearance of false positive reactions.^{18,19} Although it appears that specific polysaccharide may be employed as an immunizing agent against histoplasmosis in mice,²⁰ the amounts employed for skin testing may be less than the amount necessary to induce skin reactivity in humans. If the opposite situation were to obtain, this would be good reason to abandon use of polysaccharide for skin tests.

In summary, data are presented to suggest that strains of *B dermatitidis* vary quantitatively in mouse virulence and that, serologically, skin reactive polysaccharides can be prepared readily in large quantities from yeast phase broth of both virulent and avirulent strains.

Acknowledgment

We are grateful for the effort and reports of J. H. Schubert, Microbiology Diagnostic Unit, Communicable Disease Center, Chamblee, Ga.

References

1. EMMONS C. W., B. J. OLSEN & W. W. ELDRIDGE. 1945. Studies of the role of fungi in pulmonary disease. I. Cross reactions of histoplasmin. Public Health Repts. U. S. 60: 383.
2. HOWELL A. JR. 1947. Studies of fungous antigens. I. Quantitative studies of cross reactions between histoplasmin and blastomycin in guinea pigs. Public Health Repts. U. S. 62: 631.
3. SMITH C. E., M. T. SAITO, R. R. BEARD, H. G. ROSENBERGER & E. G. WHITING. 1949. Histoplasmin sensitivity and coccidioidal infection. I. Occurrence of cross reactions. Am. J. Public Health 39: 722.
4. PALMER C. F., P. Q. EDWARDS & W. F. ALLFATHER. 1957. Characteristics of skin reactions to coccidioidin and histoplasmin with evidence of an unidentified source of sensitization. Am. J. Hyg. 66: 196.
5. PROCEEDINGS OF THE SIXTH ANNUAL MEETING. 1951. Intern. Northwestern Conf. on Diseases of Nature Communicable to Man. 104-108.
6. MARTIN D. S. 1950. Practical applications of immunologic principles in the diagnosis and treatment of fungous infections. Ann. N. Y. Acad. Sci. 50(10): 1376.
7. MARTIN D. S. 1953. Serologic studies on North American blastomycosis. J. Immunol. 71: 192.
8. MARTIN D. S. 1957. Evaluation of skin tests and serologic methods in fungous infections. J. Chronic Diseases. 6: 580.
9. BENHAM R. W. 1950. Cryptococcosis and blastomycosis. Ann. N. Y. Acad. Sci. 50(10): 1299.
10. WILCOXON F. & J. I. LITCHFIELD. 1949. A simplified method of evaluating dose effect experiments. J. Pharmacol. Exptl. Therapy 95: 99.
11. HOWELL A. JR. & G. F. KIPPE. 1950. Studies on experimental histoplasmosis. IV. A comparison of the virulence of five strains of *Histoplasma capsulatum* by intracerebral inoculation of male DBA line 1 mice. J. Lab. Clin. Med. 35: 547.
12. DROLLET E. & J. SCHWARTZ. 1956. Comparative study with 111 strains of histoplasmin. J. Lab. Clin. Med. 47: 128.
13. FRIEDMAN L. C., E. SMITH & L. E. GORDON. 1955. The assay of virulence of coccidioides in white mice. J. Infectious Diseases 97: 311.
14. SALVIN S. B., J. C. CORY & M. A. BENG. 1952. The enhancement of the virulence of *Candida albicans* in mice. J. Infectious Diseases 90: 177.
15. KNIGHT R. A. & S. MARCUS. 1958. Polysaccharide skin test antigens derived from *H. capsulatum* and *B. dermatitidis*. Am. Rev. Tuberc. and Pulmonary Disease 77: 983.
16. OUDIN J. 1952. Specific precipitation in gels and its application to immunochemical

- analysis *In* Methods in Medical Research 5: 335-378 Year Book Publ New York, N Y
- 17 KNIGHT, R A, S CORAY & S MARCUS 1959 *Histoplasma capsulatum* and *Blastomyces dermatitidis* polysaccharide skin tests on humans *Am Rev Respiratory Diseases* 80: 264.
- 18 PRIOR J A & S SASLOW. 1952 Effect of repeated histoplasmin skin tests on skin reactivity and colloidal agglutination *Am Rev Tuberc* 66: 588
- 19 SELLS, R D, J ROSE & J F BERK 1959 Altered skin reactivity induced by repeated histoplasmin skin tests *J Allergy* 30: 541
- 20 KNIGHT, R A G A HILL & S MARCUS 1959 Immunization of mice with polysaccharides of *Histoplasma capsulatum* *Proc Soc Exptl Biol Med* 100: 356

Part IV Therapy

EXPERIENCE WITH AMPHOTERICIN B

John H. Scabury and Harry E. Dascomb

Louisiana State University School of Medicine New Orleans, La.

Amphotericin is an antifungal antibiotic produced by a streptomycete. Its major antifungal activity *in vitro* is against those species having a yeastlike form in tissue. TABLE 1 presents the range of *in vitro* sensitivity of selected human pathogens. The values given are a composite of our own determinations and those in the literature.¹⁻³

We do sensitivity studies by incorporating the antifungal agent in melted Sabouraud's dextrose agar at pH 7. The dextrose agar has been accurately dispensed into 150 × 25 mm tubes prior to setting up the sensitivity studies. The agar in the tubes is then melted and kept fluid in a water bath. The desired amounts of antifungal agent are pipetted into the tubes of agar, well mixed and the tubes slanted and rapidly hardened in the refrigerator. The surface of the slants is inoculated with 0.1 ml of a fungus suspension calculated to contain 20 to 100 infective particles. Each series is set up in duplicate with duplicate controls. The slants are incubated at 27° C.

The inhibitory capacity of amphotericin B remains constant at room temperature for five days. After this there is fairly rapid deterioration. If easily recognized growth is not present in the control tubes by the fifth day the sensitivity studies will be inaccurate.

We believe that grading and comparison of growth are easier on solid media than in liquids. Furthermore, our experience leads us to believe that there is a closer correlation between therapeutic effectiveness and *in vitro* sensitivity in solid media.

Routes of Administration

The first clinical trials of amphotericin B were made with material for oral administration. Relatively large doses produced therapeutic effects in some patients. In others absorption of the antibiotic was entirely inadequate.

Oral amphotericin was replaced by a suspension of the antibiotic in saline for parenteral use. This material was insoluble, was difficult to administer intravenously but was effective. F. M. Squibb and Sons, New Brunswick, N. J., replaced this insoluble amphotericin B with a preparation that was combined with sodium deoxycholate, buffered with sodium phosphate and lyophilized. When water was added to this material a clear colloidal suspension was formed. This preparation is spoken of here as solubilized amphotericin B. We have represented it by the symbol S in our tables, whereas the insoluble suspension is designated by the symbol I.

In a previous report⁴ we discussed the administration of solubilized amphotericin by intramuscular, intravenous, intrathecal and aerosol routes. Bioassay and clinical observation suggested that the antibiotic was not absorbed from intramuscular sites. Subsequent observations substantiate this view.

Basic treatment is by the intravenous route. We begin with a dose of 0.25

mg/kg of body weight. The total dose for adults is increased by 5 mg every other day except in those patients with acute cryptococcal meningitis, for whom we increase dosage by 5 mg daily. The maintenance dose is determined by toxicity and side effects, but is never greater than 15 mg/kg. If side effects limit dosage to a level below 0.4 mg/kg of body weight, we either inject 25 mg of the sodium succinate ester of hydrocortisone intravenously at the time of starting the infusion or add it to the amphotericin glucose solution. This has reduced the severity of side effects. We routinely incorporate an antihistaminic in the infusion fluid.

The calculated dose of amphotericin may be variously diluted and infused over a wide range of time, according to individual experience and prejudice. We prefer to dilute the antibiotic with 500 ml of 5 per cent dextrose and administer it during a period of 2 or 3 hours. Infants may be given the calculated dose in 50 to 100 ml of diluent.

TABLE I
MINIMAL INHIBITORY CONCENTRATION OF AMPHOTERICIN B FOR SELECTED
PATHOGENIC FUNGI

Organism	Inhibitory range (μ g./ml.)
<i>Blastomyces dermatitidis</i>	0.05 to 0.5
<i>Candida albicans</i>	0.5 to 3.7
<i>Cladosporium trichoides</i>	1.0 (1 strain)
<i>Coccidioides immitis</i>	0.4 to 0.5
<i>Cryptococcus neoformans</i>	0.03 to 0.6
<i>Histoplasma capsulatum</i>	0.04 to 0.9
<i>Sporotrichum schenckii</i>	
Yeast phase	0.07 to 0.5
Mycelial phase	>40

Our assays have shown that solubilized amphotericin disappears from the blood stream rather rapidly during the first 2 postinfusion hours and at a much slower rate during the next 22. The 24-hour level usually has been between 0.5 and 1.0 mcg./ml. of serum following the intravenous administration of between 0.6 and 0.8 mg./kg. of body weight.⁴

Since blood levels are well maintained and the yeastlike fungi are slow dividers, many physicians choose to administer the antibiotic on alternate days. We believe, without proof, that daily treatment is more effective.

We previously reported⁴ that amphotericin B in its solubilized form is suitable for intrathecal administration. We dissolve the material in water for injection, U.S.P., so that 10 mg. of the antibiotic is contained in 0.5 ml. of water. Spinal fluid is withdrawn for laboratory studies, and 20 mg. of the sodium succinate ester of hydrocortisone is then injected through the spinal needle. A 5 cc. syringe containing 10 mg. of amphotericin in solution is connected to the spinal needle. The syringe is filled with spinal fluid and 1.0 ml. slowly reinjected. The syringe is refilled with spinal fluid and another 1.0 ml. is injected. The amphotericin is diluted by spinal fluid in this manner 4 or 5 times before completely emptying the syringe.

Whenever possible, we inject amphotericin intrathecally in the sitting position. Immediately following injection, the patient is asked to lie on his back for fifteen minutes, and then to assume the prone position. We restrict intrathecal injection to twice each week.

We have not detected amphotericin in the spinal fluid during the intravenous treatment of any patient whose spinal fluid protein was less than 75 mg per cent. We have reported that assayable amounts of the antibiotic diffuse into the spinal fluid when the protein level is high.⁴ Intrathecally injected amphotericin was not detected in the spinal fluid beyond 48 hours.

The relatively low concentrations of amphotericin in the spinal fluid of patients with central nervous system cryptococcosis undergoing treatment intravenously are apparently adequate for sterilization in patients with very susceptible organisms. The highest concentration found was 0.46 $\mu\text{g}/\text{ml}$ in a spinal fluid whose protein was 450 mg per cent. Multiple assays on 3 patients with cryptococcal meningitis indicated that one can anticipate concentrations of amphotericin between 0.17 and 0.27 $\mu\text{g}/\text{ml}$ if the spinal fluid protein is above 150 mg per cent and intravenous dosage is at least 0.33 mg of solubilized antibiotic per kilogram of body weight per day.

Since the *in vitro* sensitivity of the yeastlike fungi varies widely, we believe it desirable to give amphotericin intrathecally early in the treatment of mycotic meningitides. Winn⁵ believes this procedure should be followed in all cases of coccidioidal meningitis.

Both the insoluble suspension and the solubilized antibiotic were well tolerated when injected into abscesses, pyoarthroses, suppurated lymph nodes, areas of osteomyelitis and pleural empyema. Up to 30 mg of the solubilized antibiotic was required to sterilize a coccidioidal pyoarthrosis. This amount produced no side effects.

Results of Treatment

Patients 1 through 21 were the basis for a report given in June 1958.⁴ They have remained under observation and are included in the tables and text that follow, retaining the original numerical designation. Patients 22 and 23 were discussed in our previous report, but were not directly under our care and are omitted from the present report. Patients 16, 6 and 8 have been re-treated since our 1958 report. Of these, only patient 6 represents re-treatment for relapse. Patient 8 had received only intramuscular amphotericin when first reported. A second course of treatment was given to patient 16 subsequent to our first report. Original treatment had been interrupted because of azotemia, and the second course was administered only because of our conviction that the first course was inadequate for treatment of acute cryptococcal meningitis.

Patients 24 through 32 have been treated since June 1958. It is our policy to maintain follow-up observation of our patients at intervals no greater than 3 months during the first year and 6 months thereafter.

Toxicity and Side Effects

Intravenous administration of amphotericin B is accompanied by a high incidence of side effects and significant toxicity. The reactions noted by us in the treatment of 29 patients are listed in order of frequency in TABLE 2.

Reactive fever occurs during or following infusion in most patients. It is usually moderate and persists until maintenance dosage is reached. Continued daily administration of the same dose is accompanied by reduction or disappearance of reactive fever. We believe the pyrogenic activity of amphotericin B is in some way related to impurities rather than the antibiotic itself.

TABLE 2
TOXICITY AND SIDE EFFECTS OF INTRAVENOUS AMPHOTERICIN B

Type of reaction	Proportion of patients having reaction	Comment
Fever	27/29	One patient had fever once
Chills	25/29	One patient had single chill
Anorexia	16/29	Always at high dosage
Nitrogen retention	13/29	
Headache	12/29	During infusion at high dosage
Abdominal pain	10/29	Predominantly epigastric
Nausea	9/29	Unrelated to azotemia
Vomiting	6/29	
Phlebitis	4/29	
Melena	1/29	No ulcer demonstrated
Hemorrhagic gastroenteritis	1/29	At autopsy
Blurring of vision	1/29	
Exfoliative dermatitis	1/29	All in 1 infant at high dosage
Purpura		
Convulsions		
Death	1/29	
Muscular weakness		
Polymyositis		
Chest pain	1/29	Only with refrigerated infusion fluid
Bradycardia with dropped beats		
Palpitation		
Hematemesis	1/29	Asymptomatic when treatment discontinued
Probable duodenal ulcer		

This opinion is based on the repeated observation of rigors and moderate to severe fever when a preparation bearing a new lot number has been administered to patients who have achieved maintenance dosage.

Chills, fever, headache, and nausea are usually kept at a tolerable level by premedicating the patient with acetylsalicylic acid and incorporating an antihistaminic in the infusion fluid. If these measures fail, 25 mg of the sodium succinate ester of hydrocortisone given intravenously has been remarkably effective in our experience.

Anorexia has been a serious problem in three patients and a significant complaint in slightly more than one half of those treated intravenously. In only a few patients has this been accompanied by weight loss. Anorexia is usually lessened by hydrocortisone.

Abdominal pain during intravenous infusion has been frequent but rarely severe. The pain is predominantly epigastric, cramping in nature and is irregularly modified by anticholinergics and anti spasmodics. One patient in whom no peptic ulcer could be demonstrated, had abdominal pain and melena to a degree requiring transfusions. One patient died from acute staphylococcal pneumonia on the day following the last infusion of amphotericin. This patient had complained of severe epigastric pain following each infusion. Autopsy revealed a superficial hemorrhagic gastroenteritis that was quite similar to that described in dogs treated with intravenous amphotericin.⁶ However similar pathology may result from severe staphylococcal infection. A third patient with persistent epigastric pain had two small hematemeses. Gastrointestinal X rays showed a deformity of the duodenal bulb with probable ulceration. This patient had no previous history of gastrointestinal complaints and her symptoms disappeared promptly when amphotericin was discontinued.

Vomiting occurred infrequently in our experience. It became persistent in two patients who also had severe anorexia. One of these developed profound muscular weakness, albuminuria and polymyositis proved by biopsy. We initially suspected this to be due to hypersensitivity to amphotericin B. However hypokalemia was found and the patient's symptoms disappeared dramatically following infusions of potassium chloride solution. A patient currently under treatment, not included in TABLE 2, developed a similar picture. Weakness became so great that he could not raise his head from the pillow. Serum electrolytes were within normal range but the electrocardiogram was typical of hypokalemia. Intravenously administered potassium restored his muscular strength within a few hours.

Phlebitis has occurred infrequently in our patients in contrast to the high incidence observed by some other physicians. A needle left within the vein for many hours is a recognized cause of phlebitis. Acidic solutions may irritate veins. We have found that some commercially prepared 5 per cent glucose solutions have a pH of less than 5.0 at the time they are used for infusions. Our low incidence of phlebitis may be due in part to the relatively short duration of our infusions and in part to the use of 5 per cent glucose solutions near neutrality.

Azotemia has been the most important toxic manifestation of intravenous amphotericin B in so far as the regulation of dosage is concerned. In our experience decreased urea clearance was unaccompanied by albuminuria, cylindruria or abnormal microscopic hematuria in most patients. Azotemia did not develop in either patient 14 or patient 17 who received the largest doses of the solubilized antibiotic on a body weight basis.

Patient 32 developed nitrogen retention at a dosage of 0.26 mg/kg of body weight and his blood urea nitrogen remained above 30 mg per cent on a daily dose of 0.3 mg/kg of body weight. This patient had normal urinalysis and blood chemistries prior to treatment.

Patient 16 developed persistent azotemia on a daily dose of 0.7 mg of the solubilized antibiotic per kilogram of body weight during his first course of treatment. Treatment was discontinued due to azotemia. We attempted to

reinstitute intravenous therapy 2 months later. The fourth infusion contained 0.38 mg of amphotericin per kilogram of body weight and produced elevation of the blood urea nitrogen to 24 mg per cent. Intravenous amphotericin was discontinued. Sixteen months later his blood urea nitrogen was still 28 mg per cent, although his blood creatinine was only 1.31 mg per cent and his urinalysis normal. Other studies showed a urea clearance of 26.2 ml/min but a nonurea osmolar clearance that was within normal limits. This is the only patient in our group who has shown evidence of renal damage of a probably permanent type.

During treatment of our first 19 patients we reduced the daily dose of amphotericin whenever the blood urea nitrogen rose above 20 mg per cent. We have paid less attention to this toxic reaction in managing our last 10 patients. If nitrogen retention develops at a dose below 0.5 mg/kg of body weight per day we continue treatment at the same or a higher dosage so long as the blood urea nitrogen does not rise above 50 mg per cent.

Only 2 infants were among our patients. Patient 27 had severe rigors with concomitant cyanosis until maintenance dose was reached. The daily dose was increased rapidly due to the serious nature of his illness. The patient also had frequent vomiting. Patient 21 became cyanotic during severe rigors. The last two infusions were accompanied by brief convulsions. When exfoliative dermatitis and purpura appeared treatment was stopped. We believe this infant's death was in part due to amphotericin toxicity.

Some physicians have expressed the opinion during informal conferences that refrigeration of the amphotericin glucose solution prior to infusion reduces its toxicity and side effects. Refrigeration for 24, 48, and 72 hours has been suggested. We have attempted to evaluate this in patients who have developed azotemia or persistently troublesome side effects by changing from freshly prepared solutions to refrigerated ones. Treatment of 2 patients was initiated with refrigerated solutions and changed to freshly prepared ones when the same indications arose. All refrigerated solutions were brought to room temperature prior to infusion. We have been unable to detect any difference in the toxicity or acceptability of the 2 types of solutions.

Patient 28 developed a sharp left lateral chest pain that radiated subternally during infusion of refrigerated amphotericin solutions. Bradycardia and occasional dropped beats were present at such times. Minor alterations in the T waves of the electrocardiogram were present in precordial leads 4, 5, and 6. Both findings and complaints disappeared when a freshly prepared solution of amphotericin was substituted for refrigerated material.

Intrathecal amphotericin B has been free from serious toxic reactions when given in the manner and dosage previously described. Paresthesia developed regularly within a few minutes after intrathecal instillation. When the antibiotic was instilled in the sitting position these paresthesias were usually confined to the area below the waist. Transient paresis of one or both lower extremities has occurred on several occasions but has never persisted beyond 72 hours. Catheterization for urinary retention during the first 24 hours following intrathecal administration has been necessary on two occasions. Temporary mild relaxation of the anal sphincter occurred in one patient.

Patient 30 developed right sciatic pain in addition to mild paresthesia of the right leg following the tenth intrathecal dose. No further intrathecal treatments were given. Without suggestions or questioning this patient continued to complain of right sciatic pain during the first hour or two of each subsequent intravenous infusion of amphotericin. The pain did not persist between infusions. We were particularly interested in this phenomenon since it suggested that sufficient amphotericin was diffusing into the spinal fluid to produce pain in the distribution of the already damaged roots. The spinal fluid protein exceeded 300 mg per cent at the time.

Treatment of Blastomycosis

Seven patients with systemic blastomycosis have been treated with amphotericin B. The antibiotic was given initially by the intramuscular route to 2 patients. We observed no effect in one who had both cutaneous and pulmonary lesions. The second patient 8 is discussed later. The essential clinical data are in TABLE 3.

Intravenous amphotericin B produced prompt and unequivocal response in every patient. Patient 5 succumbed to a nosocomial staphylococcal pneumonia just prior to the planned termination of treatment. There was no histological or cultural evidence of persisting blastomycosis at autopsy. Patients 7, 9, 28, and 29 healed rapidly and have remained well.

Patient 6 had disease that recurred following each course of treatment with iodides, diamidines, oral amphotericin, and short courses of intravenous amphotericin B. In a previous report⁴ we stated that he healed completely following 90 daily infusions of amphotericin. However, relapse occurred 6 months later. The organism isolated during this exacerbation had the same *in vitro* sensitivity to amphotericin B as before. Retreatment was given daily for 130 days and then interrupted to start plastic reconstruction of his nose. The surgically removed tissue was negative histologically and culturally for *Blastomyces dermatitidis*. Two months later treatment was resumed for an additional 38 days, making a total of 168 days of treatment. The patient remained well during the subsequent 10 months.

Treatment of patient 8 is worthy of comment. This patient was transferred to us following diagnosis by resection of the upper lobe of the right lung. Forty-three daily intramuscular injections of amphotericin B were given prior to discharge. The disease became active 4 months later. Extensive cavitation in the remaining lobes of the right lung was present at readmission.

The initial infusions of amphotericin B were accompanied by unusually severe reactions despite a low dose of 10 mg. Various antiemetics and antispasmodics had little effect upon nausea and vomiting. Treatment on alternate days did not lessen the reactions. Azotemia developed and was accompanied by albuminuria. The spinal fluid protein was 76 mg per cent. When cutaneous hyperalgesia appeared followed by profound muscular weakness, hypersensitivity vasculitis was suspected. Amphotericin was discontinued after only 42 days of treatment.

Muscle biopsy demonstrated patchy areas of degeneration with adjacent

sarcolemmal proliferation Hypokalemia was found The patient's symptoms disappeared promptly after treatment with potassium intravenously She regained her weight and sense of well being after one month without any treatment Her sputum was negative for *B dermatitidis* by direct examination culture, and animal inoculation Nevertheless, it was decided that additional therapy was desirable

TABLE 3
TREATMENT OF BLASTOMYCOSIS WITH AMPHOTERICIN B*

Patient	Age (yr)	Clinical status before treatment	Duration of treatment, days	Average daily dosage mg/kg	Response and follow up
5	76	Disseminated moribund	26 I M 58 I V	1.0 (S) 0.65 (S)	None Promptly improved Death during R _x from staphylococcal pneumonia
6	46	Disseminated cachectic	6 I V 12 I V 8 I V 6 I V 90 I V	0.92 (I) 0.46 (I) 0.92 (I) 1.4 (I) 0.62 (S)	Good relapse Improved Improved Relapsed Healed relapsed 6 mo later
7	57	Disseminated cachectic	168 I V	0.52 (S)	Healed Well 10 mo p R _x
8	37	Involvement of mediastinum & questionably liver ambulatory Pneumonitis with cavitation & mediastinitis	78 I V 43 I M 46 I V	1.25 (I) 0.7 (S) 0.41 (S)	Healed Well 36 mo p R _x Progressive disease 4 mo p R _x R _x stopped due to toxicity Healed after diam. and surgery Well 3 mo p R _x
9	69	Disseminated severely ill	62 I V	0.43 (S)	Healed Well 28 mo p R _x
28	35	Good Involvement of bone & soft tissues	67 I V	0.54 (S)	Healed Well 5 mo p R _x
29	31	Good Pulmonary pharyngeal laryngeal involvement	90 I V	0.54 (S)	Healed Well 13 mo p R _x

* The following abbreviations are used in TABLES 3 to 6 inclusive: I M intramuscular; I V intravenous; I T 1 mg amphotericin B intrathecally; (I) suspension of insoluble amphotericin B; (S) solubilized amphotericin B; f after q every other day; R treatment.

It was necessary to interrupt treatment with intravenous hydroxystilbamidine on the fourteenth day due to the appearance of pneumococcal infection with bacteremia. After appropriate treatment for the pneumococcal infection hydroxystilbamidine was reconstituted daily for 1 month and on alternate days for an additional 6 weeks.

Although her sputum remained negative for *Blastomyces* it was decided to resect the remaining lobes of the right lung because of persistent cavitation. Mediastinal and hilar lymph nodes were greatly enlarged, but so matted they could not be removed safely. The lung contained abscesses with areas of necrosis and granulation tissue. Atypical foreign body giant cells were present.

but no fungi were seen by special staining. Cultures of the resected lung were negative for *B. dermatitidis*.

In summary, of the 7 patients treated intravenously with amphotericin B 5 were healed, 1 was mycologically negative at the time treatment was changed to hydroxystilbamidine, and 1 died from an unrelated cause.

Treatment of Cryptococcosis

Eight patients with central nervous system cryptococcosis are included in TABLE 4. Patients 10 and 15 should not be considered in evaluating the effectiveness of amphotericin B. Patient 10 was moribund at the time of admission and died during the fourth day of treatment. Patient 15 showed obvious regression of cutaneous lesions during 14 days of intravenous therapy. He refused further infusions, but did accept 26 days of oral medication during which the cutaneous lesions rapidly worsened. He died 6 months later.

Of the 6 patients who completed the planned course of treatment, none has relapsed. Three of these have been followed closely for more than 2 years. The spinal fluid of all 6 is sterile, acellular, and contains normal concentrations of dextrose and chloride. The protein is normal in patients 14 and 16 who received both intravenous and intrathecal treatment. Cultures of the spinal fluid of patient 13 were negative following 14 intrathecal injections of amphotericin given during the course of intramuscular treatment. After we had determined that intramuscular treatment was ineffectual the patient was recalled for intravenous treatment. The spinal fluid protein remains elevated in this patient. Patient 30 is still convalescing but the other 5 are pursuing their regular occupations or household duties without restriction or symptoms.

No spinal fluid specimen was positive culturally for *Cryptococcus neoformans* after the fourteenth day of treatment. Cryptococci could be found microscopically beyond this time in 2 patients. We tried unsuccessfully to prove their viability. The organisms were separated rapidly from the spinal fluid by centrifugation. Growth of *C. neoformans* was not found in either solid or liquid media even after weeks of incubation.

TABLE 4 shows that we have depended primarily on daily intravenous treatment. It was supplemented by intrathecal administration in 4 patients. Three of these had a cerebro-spinal fluid protein level below 100 mg per cent at the time treatment was started. The total duration of all treatment was 4 months or more in 5 of the 6 patients who completed their planned course of therapy.

Because of inability to demonstrate amphotericin B in the spinal fluid of intravenously treated patients whose spinal fluid proteins were below 78 mg per cent, we shall continue to use semiregular intrathecal antibiotic during the first months of treatment. We have no proof that diffusion of assayable amounts of amphotericin into spinal fluid is necessary for successful therapy. In addition, one might reasonably doubt that amphotericin instilled into the spinal fluid would diffuse into parenchymal cysts located at a distance from the ventricular system.

Relatively speaking we have had extensive experience with central nervous system cryptococcosis. Prior to the use of amphotericin, all of our patients

TABLE 4
TREATMENT OF CRYPTOCOCCOSIS WITH AMPHOTERICIN B*

Patient	Age yr	Clinical state before treatment	Involvement	Treatment	Average daily dose, mg/kg	Clinical response & follow up
10	67	Comatose moribund	CNS adrenals kidneys	4 IV 115 IV 96 IV 20 IV 88 IV 74 IV (q o d) 17 (14) 90 IV 17 (2) 56 IV 17 (11) 14 IV 26 oral	1.66 (1) 1.07 (1) 0.35 (S) 1.0 (1) 0.54 (S) 0.54 (S)	Died on 4th day of Rx Working full time Well 32 mo p Rx Full activity Well 30 mo p Rx
11	43	Semicomatose delirious poor				
12	52	Comatose poor	CNS			
13	63	Unlulutory good	CNS			
14	34	Good amulutory	Skin bones liver lungs spleen CNS	59 IV 17 (17) 51 V 120 IV 17 (10)	0.57 (S) 1.0 (S) 0.75 (1) 0.70 (S) 0.29 (S)	Well 20 mo p Rx Full activity Well 27 mo p Rx Improved during IV Rx rapid relapse during oral Rx Died 6 mo p Rx Attending college well 18 mo p 2nd Rx
15	72	Fair amulutory				
16	15	Acutely ill delirious	CNS			
30	51	Good let rle	CNS		0.45 (S)	Well 1 mo p Rx

* See TABLE 3 for key to abbreviations

died from their infection. Observation of patients treated with amphotericin B has been continued for a sufficient time to permit cautious enthusiasm.

We suspect that treatment of central nervous system cryptococcosis with amphotericin will follow the same errant pathway as the antimicrobial treatment of tuberculous meningitis. Because of the nature of the pathology produced by *Cryptococcus* in the central nervous system relapse may not occur for months or years after apparently successful treatment. This makes it difficult to determine the optimal duration of treatment. Infections of the meninges without deep seated parenchymal cysts may be cured by no more than two months of treatment. Four months of treatment may be inadequate for more deeply seated lesions.

Treatment of Histoplasmosis

We have completed the treatment of 8 patients with histoplasmosis. Seven of these exhibited clinical features that Furcolow⁷ associates with a guarded prognosis. The essential therapeutic data are in TABLE 5.

Patient 1 had primary disease of the type that is usually self limited. Illness was relatively prolonged and appeared unaltered by oral amphotericin. Patients 2 and 3 received oral amphotericin in addition to the intravenous medication. The orally administered antibiotic has been omitted from TABLE 5.

Patient 3 had chronic disseminated disease of the progressive type. Response to treatment was excellent and rapid. He remained well for 15 months at which time he developed a recurrent lesion of the maxillary alveolar ridge. Retreatment was terminated after 3 days due to the appearance of cyanosis and severe hypotension. Clinically the patient's death 24 hours later was ascribed to an anaphylactic reaction to amphotericin.

Autopsy revealed infarction of the distal ileum with perforation and generalized purulent peritonitis. This patient had experienced vascular occlusive episodes in the past without relation to amphotericin B therapy. Both adrenals were greatly enlarged. They contained both acute granulomatous lesions associated with *Histoplasma* and areas of caseation and fibrosis devoid of organisms. The granulomatous areas were culturally positive for *Histoplasma capsulatum*. Active histoplasmosis was found in the adrenals and gingival ulcer only. The autopsy studies supported our beliefs that *Histoplasma* persisted in the adrenals and that the initial course of treatment was inadequate.

Response of patient 27 is more difficult to interpret. This infant was desperately ill at the time of admission. He had suffered one month of persistent diarrhea, progressive anemia, chills and fever to 105° F daily. Cyanosis was observed during rigors. The liver and spleen were greatly enlarged and bilateral central pneumonitis was seen by X ray. *H. capsulatum* was seen in stained smears of bone marrow and recovered in culture. Intravenous treatment was given daily between September 19, 1958 and November 14, 1958. The prompt clinical response and the difficulties created by daily intravenous infusion of a small infant led us to treat him on alternate days between November 14, 1958 and February 6, 1959. At this time the chest X ray was normal. Physical examination revealed no enlargement of the liver or spleen and the patient was discharged.

One month later he contracted a middle ear infection with fever and anorexia. A pediatrician was consulted. In addition to the middle ear disease, he found enlargement of the liver and spleen. Aspiration of the bone marrow revealed intracellular *H. capsulatum* in the stained smear. Unfortunately the marrow was not cultured. The infant appeared to recover completely during a three and one half month's course of triple sulfonamides. The pediatrician considered him normal two months after treatment was stopped. The patient was lost to follow up.

TABLE 5
TREATMENT OF HISTOPLASMOSIS WITH AMPHOTERICIN B*

Patient	Age	Classification of disease	Duration of treatment days	Average daily dosage mg/kg	Response and follow up
1	7 yr	Moderately severe primary	164 oral	90	No definite change in course Recovered Well 29 mo p R _x
2	32 yr	Reinfection, moderate	15 IV 15 IV (q 3d)	1.25 (I) 1.25 (I)	Prompt improvement Prompt improvement
3	■ yr	Chronic progressive	86 IV 70 IV 8 IV	0.37 (S) 0.87 (I) 0.57 (S)	Healed Well 30 mo p R _x Prompt healing Relapse 15 mo p R _x
4	43 yr	Chronic progressive	79 IV	■ 63 (S)	Healed Well 23 mo p R _x
24	59 yr	Chronic progressive	91 IV	0.66 (S)	Healed Well 11 mo p R _x
■	64 yr	Chronic progressive	90 IV	0.58 (S)	Prompt improvement sputum conversion Well 2 mo p R _x MRD 112†
26	48 yr	Chronic progressive	61 IV	0.5 (S)	Healed Well 11 mo p R _x
27	11 mo	Progressive disseminated	57 IV 42 IV (q o d)	0.88 (S) 1.0 (S)	Dramatic response R _x in adequate apparent recovery after sulfonamide Well 10 mo p R _x

* See TABLE 3 for key to abbreviations

† MRD 112 is β -diethylaminoethyl fencholate

It is known that intracellular *H. capsulatum* may be seen in lesions from which they cannot be recovered culturally or by animal inoculation. Nevertheless, the clinical course of this infant suggests that histoplasmosis was still active after four and one half months of intravenous treatment.

Patients 24 and 26 had progressive ulcerative and granulomatous mucous membrane lesions with visceral dissemination. Healing was prompt, and both have remained well.

The type of histoplasmosis present in patients 4 and 25 is difficult to evaluate therapeutically without prolonged observation. These patients had chronic progressive pulmonary disease with extensive cavitation. The constitutional manifestations of disease subsided promptly during treatment with amphotericin, and *H. capsulatum* disappeared from the sputum. Chest X rays revealed clearing of the exudative disease but persistence of fibrosis and cavitation. The problem is similar to that in chronic cavitary tuberculosis.

The left upper lobe was resected from patient 4 at the termination of treatment with amphotericin. The wall of the cavity consisted of a thin layer of fibrous connective tissue without any evidence of inflammation in its wall or the adjacent lung. Granulomas within the lung were well encapsulated, showed caseation necrosis centrally, and were negative for *H. capsulatum* and mycobacteria by special stains. One half of one of the larger nodules was triturated. Portions of this material were sterile culturally and by animal inoculation.

Studies of the resected lobe indicate that the results of amphotericin treatment of this patient with chronic cavity histoplasmosis were similar to those achieved by isoniazid and para-aminosalicylic acid in some patients with chronic cavity tuberculosis. If amphotericin B can bring about the so called 'open negative' status (persistent cavitation with culturally negative sputum) in the majority of patients with chronic cavity histoplasmosis it will represent a major therapeutic advance. Many of these patients are not suitable for surgical treatment. As with isoniazid in relation to cavity tuberculosis the rate of relapse from the open negative state can be determined only when a statistically significant population has been followed for a minimum of three years.

In our experience the initial response of histoplasmosis to amphotericin B has been similar to that of tuberculosis when treated with either streptomycin or isoniazid alone. Microbial persistence and relapse have occurred. The sensitivity to amphotericin B of the *H. capsulatum* isolated from patient 3 at autopsy was the same as that determined from the pretreatment culture.

We believe that the optimal duration of treatment needs to be established and the possibilities of combined chemotherapy investigated. The latter consideration led us to treat patient 25 with amphotericin B intravenously and beta diethylaminoethyl fencholate orally. The oral drug has been tolerated well in large doses and *in vitro* studies have indicated that beta-diethyl aminoethyl fencholate has a mycostatic effect.

Treatment of Coccidioidomycosis

Our experience with coccidioidomycosis is too inadequate to be very meaningful. The two patients who have completed therapy are included in TABLE 6. Patient 17 had severely disseminated disease. Cutaneous anergy to coccidioidin was present throughout her illness and complement fixing antibodies against coccidioidin were present in serum diluted 1:256. The patient received more than 12 gm of the insoluble suspension of amphotericin intravenously and almost 7 gm of the solubilized antibiotic. She died from coccidioidomycosis during the course of treatment.

Patient 31 developed infiltration in her right lung some time between 1940 and 1944. She was discharged without diagnosis after 9 months in a sanatorium in 1944. Between 1946 and 1956 she had recurrent 'bronchitis' during which she would raise small amounts of blood flecked sputum. The area of disease in her right lung increased in early 1956 and new disease appeared in the left lung. Chemotherapy for tuberculosis was begun in 1956 and continued until 1959. The patient was hospitalized briefly in 1956 following an hemop-

TABLE 6
TREATMENT OF MISCELLANEOUS DEEP MYCOSES WITH AMPHOTERICIN B*

Patient	Age	Disease	Clinical status before treatment	Treatment days	Average daily dosage mg./kg	Response & follow up
17	35 yr	Coccidioidomycosis disseminated	Moribund	66 IV } 20 oral } 113 IV } 65 IV } 88 IV } 48 IV (q o d) Course 2†	3 0 (I) 242 0 1 5 (I) 0 6 (S) 0 43 (S) 0 43 (S)	Remarkable improvement, became ambulatory Progression of disease during lower dosage
31	45 yr	Coccidioidomycosis disseminated	Good	18 IV } 65 IV } 34 IV } 95 IV } 46 IV (q o d)	0 6 (S) 1 0 (S) 1 14 (S) 0 52 (S) 0 58 (S)	Temporary improvement, death
18	61 yr	Sporotrichosis disseminated	Cachectic severely im paired gain	58 IV	0 63 (S)	Sputum conversion and excellent serologic response Hydroxystybamidine concurrently Well 2 mo p R _x
19	30 yr	Sporotrichosis lympho cutaneous	Good	49 IV	0 42 (S)	Ifealed Normal gain Well 22 mo p R _x
32	22 yr	Sporotrichosis lympho cutaneous	Good	30 IV	0 30 (S)	Ifealed Well 20 mo p R _x
20	62 yr	Moniliasis (pyelone phritis)	Poor uremic	6 IV	0 25 (S)	Ifealed Well 11 mo p R _x
21	6 mo	Moniliasis	Poor congenital agam maglobulinemia	13 IV } 13 IV }	2 0 (I) 3 0 (I)	Became afebrile with negative blood and urine cultures Death from cardiac failure Healing of pulmonary and hepatic involve ment died

*See TABLE 3 for key to abbreviations

†Course 2 was separated from Course 1 by 38 days at home and treatment with intravenous calicium between September 3 and October 31 1957

tysis During this time numerous sputa and gastric washings were studied without finding any pathogenic organisms Skin tests with histoplasmin coccidioidin blastomycin and 1:100 old tuberculin were negative

This patient was rehospitalized in 1957 because of persistent cavitory disease A right upper lobectomy was performed A diagnosis of coccidioidomycosis was made from histopathological study of the resected lobe The coccidioidin skin test was again negative but complement fixing antibodies were present against coccidioidin in a titer of 1:64

Multiple areas of cavitation appeared in the right lower lobe during late 1958 and early 1959 The patient's sputum became positive for *Coccidioides immitis* and she was referred to us for treatment The coccidioidin complement fixation titer was 1:128 and the coccidioidin skin test was negative prior to treatment The patient received 3.775 gm of amphotericin B and 9.225 gm of hydroxystilbamidine intravenously Sputum conversion was obtained promptly and the complement fixation titer fell from 1:128 to 1:8 within 8 months The immediate response of this patient has been excellent but follow up is too brief to justify optimism

A patient with coccidioidal meningitis is currently under treatment The initial response has been excellent and intrathecal therapy well tolerated William A Winn⁶ has had significant experience with coccidioidomycosis and believes that many such patients can be successfully treated with amphotericin B properly administered

On the basis of our observations of patient 17, both during life and at autopsy we believe that amphotericin is unlikely to be successful in patients with severely disseminated coccidioidomycosis who have large visceral abscesses that are inaccessible to surgical drainage or repeated instillation of amphotericin

The course of patient 31 exemplifies the well recognized hazard of resection for pulmonary coccidioidomycosis New cavitory disease develops within the unresected lung with disturbing frequency It is desirable to perform necessary surgery for coccidioidomycosis during the course of intravenous treatment with amphotericin B Winn recommends 3 or 4 months of treatment⁶

Treatment of Sporotrichosis

One patient with disseminated sporotrichosis and 2 with lymphocutaneous disease have been treated with amphotericin B They are included in TABLE 6 All have healed without relapse to date Patient 18 with disseminated disease has been previously reported Two months of intravenous therapy seemed adequate to control his disease which involved the pharynx larynx lungs bones lymph nodes and cutaneous tissues Patient 32 was treated with relatively small doses of amphotericin for only 30 days Our purpose was to determine whether relapse would occur The patient has remained healed for 11 months

We do not recommend treatment of lymphocutaneous sporotrichosis with intravenous amphotericin This type of disease responds well to oral iodides in most instances Patients who are sensitive to iodides or who fail to respond well to the medication can be treated with hydroxystilbamidine or amphotericin We believe that hydroxystilbamidine is easier and safer to administer

Infiltration of the lesions of lymphocutaneous sporotrichosis with a solution of amphotericin B in procaine is entirely feasible. It would be interesting to combine a short course of oral iodides with locally injected amphotericin.

Treatment of Moniliasis

Neither of the two patients under our direct management for monilia had disease suitable for therapeutic evaluation. Patient 20 had cardiac renal disease, which was responsible for his death after only 6 days of treatment with intravenous amphotericin. Blood and urine cultures which had been positive for *Candida albicans*, became sterile during therapy. The patient became afebrile within 24 hours after the first infusion.

Patient 21 was an infant with congenital agammaglobulinemia who probably developed candidiasis as a complication of antibiotic treatment for staphylococcal infection. Treatment with amphotericin controlled his pulmonary moniliasis and sterilized his blood stream. Death was probably due in large part, to amphotericin. Cultures of the lung and multiple minute abscesses in the liver were negative at autopsy for *Candida*. It is not known whether the abscesses of the liver were produced by *Candida* or by the prior-existing staphylococcal disease.

Our experience permits no estimate of the value of amphotericin B for the treatment of systemic candidiasis. In the past we have observed several patients with positive blood and urine cultures for *C. albicans* during the course of prolonged therapy with broad spectrum antibiotics. Blood and urine cultures became negative, and the patients recovered after antibiotics were discontinued. No antifungals were given. We believe that this disease is difficult to evaluate therapeutically unless definite tissue invasion can be demonstrated.

Discussion and Summary

Amphotericin B is an initially effective antibiotic for the treatment of blastomycosis, cryptococcosis, histoplasmosis and sporotrichosis. Post treatment follow up has been long enough to indicate that the initial good results are maintained in a high percentage of those receiving intravenous treatment for two or more months. Amphotericin should be valuable in all fungus infections having a yeastlike tissue phase. We have had insufficient experience to form an opinion of its effects on systemic candidiasis and coccidioidomycosis.

In its present form, this antibiotic is suitable for intravenous, intrathecal, and local instillation. Intramuscular injection produces neither detectable blood levels nor healing of susceptible infections. Amphotericin B is poorly and irregularly absorbed from the alimentary tract.

We have treated 29 patients with amphotericin B by the intravenous route. There have been 2 relapses and 4 treatment failures. Two of the failures can be eliminated in an attempt to evaluate the efficacy of intravenous amphotericin. One of the failures died after only 4 infusions and the second refused intravenous therapy after the fourteenth day. Both had cryptococcosis with central nervous system involvement.

Analysis of the 2 real failures and the 2 relapses does not lead to any conclusions that, if heeded, might prevent future failure. Patient 17 and, perhaps,

patient 27 never achieved initial healing. Patient 17 responded dramatically during early daily treatment with the insoluble form of the antibiotic. The most obvious deterioration occurred during alternate day treatment with 0.43 mg of the solubilized antibiotic per kilogram of body weight. The second course of therapy was given daily with a dosage range between 0.6 and 1.14 mg/kg of body weight. The sensitivity of the infecting *C. immitis* was unchanged throughout treatment. The total duration of treatment was 16 months. The most obvious cause for failure of treatment was the presence of multiple large abscesses that were inaccessible to surgical drainage or direct instillation of amphotericin. These abscesses contained viable *C. immitis* and were the probable source for repeated hematogenous dissemination.

Patient 27, an infant, was treated for 57 days at a level of 0.88 mg/kg of body weight, and this was followed without interruption by 42 infusions on alternate days at a level of 1.0 mg/kg. *H. capsulatum* was seen in his bone marrow within a month after termination of treatment. One may suspect that either the total duration of treatment (four and one half months) was inadequate or that alternate-day treatment was the principal cause of failure. Both alternatives represent only the obvious and perhaps superficial possibilities.

Patients 3 and 6 relapsed. Patient 3 received the insoluble suspension of amphotericin for all but eight of his infusions. As we have previously reported, a variable amount of the insoluble suspension of amphotericin in the infusion fluid actually reached the patient's blood stream. The true daily dose was always conjectural. The total duration of intravenous therapy was only 78 days, which is probably inadequate for disseminated histoplasmosis.

Recurrence in patient 6 took place 8 months after 90 daily infusions at an average dose of 0.62 mg/kg of body weight. The infecting organism *B. dermatitidis* was inhibited completely by 0.06 μ g of amphotericin per ml of Sabouraud's dextrose agar. The sensitivity of the organism under the same conditions had not changed when it was redetermined during relapse. Serum assays of amphotericin following infusions of the average maintenance dose showed a level of 1.0 μ g/ml or higher during the first 4 hours after infusion and a level of 0.5 μ g/ml 24 hours after infusion. In our opinion this indicates adequate dosage. The fact that this patient's disease had reappeared many times after treatment with various drugs may be pertinent. However, his past history did not indicate unusual susceptibility to other infections. Retreatment for 168 days at a smaller daily dose has been successful to date.

We draw no specific conclusions from the small group of failures. It seems obvious that optimal dosage and duration of treatment for the various mycoses are still unknown. Comparison of our treatment protocols with those of others makes us believe that we are using a smaller daily dose for longer periods of time. We have made no conscious attempt to lower dosage, striving to achieve a range between 0.5 and 0.8 mg/kg of body weight of the solubilized suspension per day. That we have not always achieved this range is excellent evidence of the toxicity and side effects of the antibiotic.

Winn⁶ suggested that serologic changes during the treatment of coccidioidomycosis are useful not only for prognosis but as a guide to duration of therapy.

The serology of histoplasmosis is not on as firm a foundation. Nevertheless, if a high titer of complement fixing antibodies is present before treatment, we believe that a three- or fourfold decrease in titer is significant when properly determined. The complement fixing titer of the pretreatment serum and sera drawn at monthly intervals during treatment should be compared in simultaneous tests. The first and last sera drawn should be adequate in volume to serve as controls against subsequent sera and should always be run with them. This is a basic principle of serologic testing that is neglected frequently by physicians. There are no serologic tests for patients with cryptococcosis. Serologic methods now available are not helpful in North American blastomycosis or in those patients with histoplasmosis whose initial titers are low.

A pitfall of serial single complement fixation determinations is illustrated by the course of patient 25. Complement fixing antibodies against histoplasmin were present in his serum in a titer of 1:28 before treatment. Serologic study in the same laboratory three months later revealed a complete absence of complement fixing antibodies against both histoplasmin and yeast phase antigen. Blood drawn on the day following this negative report had a complement fixing titer of 1:64 against histoplasmin. If testing had been done on all 3 sera at the same time, such conflicting results would have been unlikely.

The toxicity of amphotericin may not be appreciated fully until many more patients have received it. Our experience indicates that the kidney is affected most frequently. Urea clearance may be reduced markedly. Azotemia usually disappears when treatment is stopped. Patient 16 however had a normal blood urea nitrogen and urinalysis prior to treatment but a diminished clearance and elevated blood urea nitrogen more than one year after the institution of therapy. This patient gave no history of previous renal disease. This cannot be eliminated definitely. More study of renal toxicity is

required. Amphotericin may produce a hemorrhagic enterocolitis in dogs and clinical signs and symptoms suggesting a similar persistent epigastric pain following infusion. At autopsy on the day following the last infusion, death was due to acute staphylococcal enteritis. This was attributed for the gastroenteritis. It has not been reported in many of our patients but this is more than could be accounted for by

hypokalemia during the course of therapy. In one of these patients revealed hypokalemia intravenously restored both the hypokalemia and the fever. The hypokalemia present during amphotericin but it could be accounted for by the hypokalemia present in both patients who received treatment or whose therapy was interrupted more severe renal toxicity in the initial course. We have

patient 27 never achieved initial healing. Patient 17 responded dramatically during early daily treatment with the insoluble form of the antibiotic. The most obvious deterioration occurred during alternate day treatment with 0.43 mg of the solubilized antibiotic per kilogram of body weight. The second course of therapy was given daily with a dosage range between 0.6 and 1.14 mg/kg of body weight. The sensitivity of the infecting *C. immittis* was unchanged throughout treatment. The total duration of treatment was 16 months. The most obvious cause for failure of treatment was the presence of multiple large abscesses that were inaccessible to surgical drainage or direct infiltration of amphotericin. These abscesses contained viable *C. immittis* and were the probable source for repeated hematogenous dissemination.

Patient 27, an infant, was treated for 57 days at a level of 0.88 mg/kg of body weight and this was followed without interruption by 42 infusions on alternate days at a level of 1.0 mg/kg. *H. capsulatum* was seen in his bone marrow within a month after termination of treatment. One may suspect that either the total duration of treatment (four and one half months) was inadequate or that alternate day treatment was the principal cause of failure. Both alternatives represent only the obvious and perhaps superficial possibilities.

Patients 3 and 6 relapsed. Patient 3 received the insoluble suspension of amphotericin for all but eight of his infusions. As we have previously reported, a variable amount of the insoluble suspension of amphotericin in the infusion fluid actually reached the patient's blood stream. The true daily dose was always conjectural. The total duration of intravenous therapy was only 78 days, which is probably inadequate for disseminated histoplasmosis.

Recurrence in patient 6 took place 6 months after 90 daily infusions at an average dose of 0.62 mg/kg of body weight. The infecting organism *B. dermatitidis* was inhibited completely by 0.06 μ g of amphotericin per ml of Sabouraud's dextrose agar. The sensitivity of the organism under the same conditions had not changed when it was redetermined during relapse. Serum assays of amphotericin following infusions of the average maintenance dose showed a level of 1.0 μ g/ml or higher during the first 4 hours after infusion and a level of 0.5 μ g/ml 24 hours after infusion. In our opinion this indicates adequate dosage. The fact that this patient's disease had reappeared many times after treatment with various drugs may be pertinent. However, his past history did not indicate unusual susceptibility to other infections. Re-treatment for 168 days at a smaller daily dose has been successful to date.

We draw no specific conclusions from the small group of failures. It seems obvious that optimal dosage and duration of treatment for the various mycoses are still unknown. Comparison of our treatment protocols with those of others makes us believe that we are using a smaller daily dose for longer periods of time. We have made no conscious attempt to lower dosage, striving to achieve a range between 0.5 and 0.8 mg/kg of body weight of the solubilized suspension per day. That we have not always achieved this range is excellent evidence of the toxicity and side effects of the antibiotic.

Winn⁸ suggested that serologic changes during the treatment of coccidioidomycosis are useful not only for prognosis but as a guide to duration of therapy.

The serology of histoplasmosis is not on as firm a foundation. Nevertheless, if a high titer of complement fixing antibodies is present before treatment we believe that a three- or fourfold decrease in titer is significant when properly determined. The complement fixing titer of the pretreatment serum and sera drawn at monthly intervals during treatment should be compared in simultaneous tests. The first and last sera drawn should be adequate in volume to serve as controls against subsequent sera and should always be run with them. This is a basic principle of serologic testing that is neglected frequently by physicians. There are no serologic tests for patients with cryptococcosis. Serologic methods now available are not helpful in North American blastomycosis or in those patients with histoplasmosis whose initial titers are low.

A pitfall of serial single complement fixation determinations is illustrated by the course of patient 25. Complement fixing antibodies against histoplasmin were present in his serum in a titer of 1:28 before treatment. Serologic study in the same laboratory three months later revealed a complete absence of complement fixing antibodies against both histoplasmin and yeast phase antigen. Blood drawn on the day following this negative report had a complement fixing titer of 1:64 against histoplasmin. If testing had been done on all 3 sera at the same time such conflicting results would have been unlikely.

The toxicity of amphotericin may not be appreciated fully until many more patients have received it. Our experience indicates that the kidney is affected most frequently. Urea clearance may be reduced markedly. Azotemia usually disappears when treatment is stopped. Patient 16 however had a normal blood urea nitrogen and urinalysis prior to treatment but a diminished urea clearance and elevated blood urea nitrogen more than one year after the termination of therapy. This patient gave no history of previous renal disease but this cannot be eliminated definitely. More study of renal toxicity is indicated.

Intravenous amphotericin may produce a hemorrhagic enterocolitis in dogs. Three of our patients have had clinical signs and symptoms suggesting a similar toxic effect. One patient with persistent epigastric pain following infusion had a hemorrhagic gastroenteritis at autopsy on the day following the last administration of amphotericin. Death was due to acute staphylococcal pneumonia and this may have accounted for the gastroenteritis.

A mild normochromic anemia developed in many of our patients but this was never significant clinically nor greater than could be accounted for by the underlying disease.

Two patients developed profound muscular weakness during the course of intravenous therapy. Biopsy of the muscle of one of these patients revealed the presence of myositis. Potassium salts given intravenously restored both patients to their previous level of muscular strength. The hypokalemia present may have been due to specific toxicity of amphotericin but it could be accounted for by the severe anorexia and vomiting present in both.

Some patients who were given a second course of treatment or whose therapy was interrupted for several weeks or more have experienced more severe reactions when treatment was resumed than during the initial course. We have

no proof that amphotericin B produced hypersensitivity in any of these patients. Until this possibility is better understood, we suggest that re treatment be approached with caution.

Side effects from intravenous amphotericin B are many. Fever, chills, and nausea are usually controllable by adjunctives. Acetylsalicylic acid and antihistaminics are used routinely. When side effects are severe or persistent, we believe that 25 mg of sodium succinate ester of hydrocortisone will reduce reactions considerably if injected at the time of starting the infusion or incorporated into the dextrose solution.

Local instillation of amphotericin B has been well tolerated. Dissolving the antibiotic in 1 per cent procaine made it suitable for local infiltration and injection into suppurated lymph nodes and pyoarthroses. No additive was necessary for intrapleural instillation.

References

- 1 GOLD, W. H. A. STOUT, J. F. PAGANO & H. DONOVICA. 1955-1956. Antifungal antibiotics produced by a streptomycete. I. *In vitro* studies. Antibiotics Annual 579. Medical Encyclopedia Inc. New York, N. Y.
- 2 LOURIA, D. B., N. FEDER & C. W. FEMONS. 1956-1957. Amphotericin B in experimental histoplasmosis and cryptococcosis. Antibiotics Annual 870. Medical Encyclopedia Inc. New York, N. Y.
- 3 HALDE, C. V., D. NEWCOMER, F. T. WRIGHT & T. H. STERNBERG. 1957. An evaluation of amphotericin B *in vitro* and *in vivo* in mice against *Coccidioides immitis* and *Candida albicans* and preliminary observations concerning the administration of amphotericin B to man. J. Invest. Dermatol. 28: 217.
- 4 SEABURY, J. H. & H. E. DASCOMB. 1958. Experience with amphotericin B for the treatment of systemic mycoses. A. M. A. Arch. Intern. Med. 102: 960.
- 5 WINN, W. A. 1959. The use of amphotericin B in the treatment of coccidioidal disease. Am. J. Med. 27: 617.
- 6 BARTNER, F. H., ZINNY, R. A., MOE, & J. S. KULESZA. 1957-1958. Studies on a new solubilized preparation of amphotericin B. Antibiotics Annual 53. Medical Encyclopedia Inc. New York, N. Y.
- 7 FLETCHELOW, M. I. 1956. The clinical diagnosis of histoplasmosis. Postgrad. Med. 20: 349.
- 8 LEUWIG, K. A., F. J. MURRAY, J. K. SMITH, C. R. THOMPSON & H. W. WERNER. 1954. Laboratory studies on β -d ethylaminoethyl fencholate, a new antifungal agent. Antibiotics & Chemotherapy 4: 56.

THE TREATMENT OF SYSTEMIC FUNGUS INFECTIONS WITH AMPHOTERICIN B*

Victor D. Newcomer, Thomas H. Sternberg, Edwin T. Wright, Ronald M.
Reisner, Earl G. McNall, Lloyd J. Sorensen

Department of Medicine, Division of Dermatology, University of California Medical Center and
the Medical Service, Veterans Administration Center, General Medical and Surgical Hospital,
Los Angeles, Calif.

Since its introduction four years ago by Gold *et al.*¹ amphotericin B† has received increasing clinical trial in the treatment of virtually all of the systemic mycoses that affect man. Much additional experience will be required before the ultimate value of amphotericin B can be determined, but accumulating clinical data suggest that to date it represents the most effective chemotherapeutic agent currently available for the treatment of these heretofore recalcitrant diseases. This paper deals with our clinical experience to date with amphotericin B in the treatment of systemic mycoses, particularly coccidioidomycosis.

Amphotericin B is isolated from a species of *Streptomyces*.¹ It is a member of a growing family of closely allied polyene antifungal agents which includes amphotericin A, trichomycin, rimocidin, nystatin, candicidin, ascocin, pimarin, and others. A tentative empirical formula, $C_{47}H_{71}NO_8$, has been assigned to it.² *In vitro*, amphotericin B inhibits a wide variety of pathogenic and nonpathogenic fungi in concentrations ranging from 0.5 µg/ml to 125 µg/ml.^{1,3} The growth of the majority of the organisms producing systemic mycoses is inhibited by amphotericin B in concentrations as low as 0.02 to 0.5 µg/ml.¹ These include *Blastomyces dermatitidis*, *Blastomyces brasiliensis*, *Candida albicans*, *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Coccidioides immitis*, and the yeast phase of *Sporotrichum schenckii*. Initial toxicity studies indicated that calculated therapeutic levels of the drug could be obtained without serious sequelae in several species of animals.¹ These studies were followed by others designed to evaluate the effectiveness of amphotericin B on experimentally produced fungus infections in animals. Amphotericin B has favorably influenced the course of such infections due to *C. albicans*, *C. neoformans*, *H. capsulatum*, *C. immitis*, *Rhizopus oryzae*, *Aspergillus fumigatus*, and some *Volvutella* species.⁴ Preliminary studies in man indicated that amphotericin B was in general poorly absorbed when given by mouth⁵ or intramuscularly. In addition, when the drug was given intramuscularly in therapeutic amounts, it proved too irritating for routine use.⁶ The currently available preparation of amphotericin B has been most usefully employed intravenously, although in certain instances it has been effective when given by other routes. The drug is highly insoluble in aqueous solutions, and the early intravenous preparations consisted of relatively coarse suspensions of the drug.⁷ The use of sodium deoxycholate, a solubilizing agent, has improved the intravenous preparation considerably, however, true solutions

* This paper was supported in part by a grant from the Squibb Institute for Medical Research, New Brunswick, N. J.

† Supplied by Squibb Institute for Medical Research, New Brunswick, N. J.

are still not produced but rather a colloidal dispersion of particles smaller than bacteria¹² The drug is diluted in 500 to 1000 cc of dextrose injection (5 per cent U S P) and administered intravenously over a 6 hour period The initial dose is usually in the range of 5 to 10 mg/day with daily increments of from 5 to 10 mg depending on the patient's tolerance for the drug Once a dosage level of from 0.7 to 1.4 mg/kg per day is reached (in the adult 50 to 100 mg) an attempt is made to sustain it Adjustments of the dosage including complete cessation of the drug for short periods of time administration on alternate days and return to lower dosage levels are employed as necessitated by the patient's reaction Dosages of more than 100 mg of amphotericin B intravenously per day have been tolerated by adults for short periods of time but in our experience toxic manifestations soon necessitate the reduction of this daily dosage

Material and Methods

To date we have treated with amphotericin B 30 patients with various systemic mycoses either under direct observation or in cooperation with other physicians in the community All patients were hospitalized and some or all of the following base line studies were obtained before instituting therapy complete blood count urinalysis liver function studies blood urea nitrogen serum creatinine chest films and other appropriate X rays fungus cultures serologic tests and spinal fluid examinations where applicable These studies were repeated at appropriate intervals during the course of therapy wherever possible Amphotericin B was administered in courses varying from 2 weeks to 5 months in duration The patients have been followed for periods up to 3 years TABLE 1 details our data regarding the patients treated to date TABLE 2 summarizes the results obtained in the treatment of these patients

Coccidioidomycosis

We have treated 18 patients with disseminated coccidioidomycosis Five of these had coccidioidal meningitis Two of these 5 were given amphotericin B intrathecally as well as intravenously One patient succumbed after 7 weeks of therapy All of the other patients have shown various degrees of clinical improvement with clearing of the sensorium disappearance of headaches improvement in the neurological findings and cessation of nausea and vomiting Two returned to gainful employment The spinal fluid findings of these latter patients improved but some laboratory abnormalities have ominously persisted in all including such findings as increased protein pleocytosis elevated pressure and persistent positive complement fixation tests for coccidioidomycosis Two patients have suffered clinical relapse after 7 and 21 months respectively One has been lost to follow up The remaining patient has become asymptomatic but has been followed for too short a period of time to determine his final outcome

The remaining 13 patients had involvement of bone skin lungs or combinations thereof Five of these demonstrated no improvement but of these 5 2 were inadequately treated in the light of our current knowledge 1 patient

receiving the drug intravenously for only 10 days the other solely by the oral route. Initially however the remaining patients demonstrated various degrees of improvement some to the point of being considered clinically free of the disease. Of this latter group of 8 patients 2 have relapsed 6 and 8 months respectively after discontinuing therapy and in several of the remaining 6 the complement fixation test has remained ominously elevated in spite of their asymptomatic clinical status.

Cryptococcal Meningitis

Five patients with cryptococcosis have received amphotericin B orally intravenously and intrathecally. Two patients succumbed 1 receiving amphotericin B orally only and the other receiving 1050 mg of amphotericin B intravenously over a 24-day period. The remaining 3 patients have shown moderate to marked clinical improvement. In 2 of these patients cultures of the spinal fluid are negative 18 months after discontinuation of therapy. One of these received amphotericin B intrathecally in a total dosage of 11.3 mg over a 1 month period. No abnormalities exist in the spinal fluid of these 2 patients at present and the third has been lost to follow up although her spinal fluid culture was negative at the time of her last visit.

North American Blastomycosis

Our experience with North American blastomycosis has been limited to the treatment of one patient with genitourinary and cutaneous involvement. This patient was given amphotericin B intravenously over a 22 day period a total dosage of 880 mg. This was followed by complete healing of the cutaneous lesions and the disappearance of *B. dermatitidis* from the urine. No evidence of recurrence was present 18 months after discontinuing therapy.

Aspergillosis

Two patients with pulmonary aspergillosis have been treated. One a 23½ year old white male with hypergammaglobulinemia improved after receiving 470 mg of amphotericin B intravenously over a 3 month period and 1 remained unchanged after receiving 624.4 mg of amphotericin B over a 15-day period. In the latter patient therapy was discontinued because of phlebitis at the site of infusion.

Candidiasis

Two patients with candidiasis have been treated. One patient with ocular involvement with *Candida parakrusei* following a corneal transplant demonstrated a complete clearing of his infection following topical and intravenous administration of amphotericin B but subsequently lost the eye following failure of the corneal graft to take. The other patient had had a chronic generalized infection due to *C. albicans* extensively involving the oral mucosa, vaginal mucosa and 7 fingernails. She had resisted all previous forms of therapy including numerous topical agents and prolonged courses of orally administered nystatin, pimafucan, trichomycin, amphotericin A and a mixture of amphotericin A and B. She received 2 courses of amphotericin B intra

TABLE 1
SYSTEMIC MYCOSES TREATED WITH AMPHOTERICIN B

Patient age race sex	Diagnosis	Skin test	Complement fixation	Precipitation	Dosage of amphotericin B	Duration of time
1 T L., 48, WM	Coccidioidal meningitis	Negative 1:100	Serum 1+ 1:16 spinal fluid 1+ 1:8	Negative	10 to 50 mg IV every day 50 mg IV every day Avg 25 to 45 mg IV daily Intrathecal avg 0.5 to 0.9 mg q o d	2 weeks 6 weeks 79 days 33 days
2 W R., 29, WM	Disseminated coccidioidomycosis with cutaneous lesions and meningitis	Negative 1:100	Serum 1+ 1:16 spinal fluid 1+ 1:2	Negative	50 mg IV, every day 0.1 to 1 mg intrathecally twice weekly	10 weeks 7 weeks
3 C S., 26, WM	Coccidioidal meningitis	Negative 1:100	Serum 3+ 1:16	Negative	5 to 40 mg IV every day Suspension 1.5 mg/kg every day	5 months 7 weeks
4 R B., 26, WM	Coccidioidal meningitis	Negative 1:100	Serum 2+ 1:8	Negative		
5 S C., 27, Armenian, M	Coccidioidal meningitis	Negative 1:100	Serum 2+ 1:16, spinal fluid 4+ 1:4	Negative		
Patient	Total dosage	Results	Toxicity	Remarks		
1 T L., 48, WM	2440 mg	Complement fixation tests of spinal fluid after 8 wks treatment 1+ 1:16, afebrile mentally alert, discharged from hospital Skin test—Neg, C F serum 1:32, serum meningismus and headache Return of spinal fluid pressure to normal Some improvement in laboratory findings, spinal fluid protein, cells and pressure decreased, over all condition unchanged	Chills, fever, increase in BUN, and drop in hematocrit from 47 to 35	Seven months after treatment relapsed, but lost to follow up		
2 W R., 29, WM	1505 mg 7 25 mg		Fever, chills, malaise BUN increased from 15.8 to 31.5, intrathecal administration produced transient paresthesias and low back pain Vomiting following IV administration (vomiting also part of clinical picture prior to treatment)	Spinal fluid protein (360) (131) cell and sugar—(36) have remained abnormal Still being treated		
3 C S., 26 WM	3500 mg 9 5 mg			Transferred to USVA Hospital in Houston, Texas, further contact lost		

4 R II WM	6200 mg	Clinically well skin test 1+1 III	Malaise tremor and back pain	Returned to gainful employment. Then 1 year 9 months later developed ver- tigo and ataxia. Cell count in spinal fluid—134 WBC protein 210 mg % given amphotericin II 0.2-0.8 intrathecally q d. Developed pel- vic girdle pain and (?) arachnoiditis drug was therefore discontinued C.F. 2 years after treatment serum 1:8 CSF 1:4. Continues to have ataxia and failing to right
5 S C Am Indian M	4100 mg	Expired	Drug levels	
Patient			Drug levels	
1 T I 48 WM				
2 W R 29 WM				
3 C S 26 WM				
4 R R III WM				
5 S C 27 Am Indian M				
Patient age race sex	Diagnosis	Skin test	Complement fixation	Precipitation
6 D C 44 WM	Possible coccidioidal meningitis	2+ 1 100	Serum 1+ 1 16 spinal fluid negative	Negative
7 A L 12 Mex can F	Coccidioidal granuloma of radial head and left metatarsal area	—	Serum 1+ 1 256	Negative
8 G F 6 Mex can J	Possible coccidioidal granuloma left ankle	Positive 1 100	Serum 2+ 1 4	Negative
9 D B 5 NM	Disseminated coccidioidomycosis	Negative	Positive 1 128	Negative
10 L T 53 NM	Disseminated coccidioidomycosis with peripheral granuloma	Positive 1 100	1 128	Negative
11 R D 33 NM	Coccidioidomycosis with granuloma of neck	4+ positive 1 100	Serum 4+ 1 32	4+ 1 10
12 J M 24 Mex can M	Disseminated coccidioidomycosis	Positive 1 100	Serum 1 1024	Negative
13 S D 36 NM	Disseminated coccidioidomycosis with destruction of several carpal bones	Positive 1 1000	Serum 3+ 1 128	Negative

TABLE 1—Continued

Patient	Dosage of amphotericin B	Duration of time	Total dosage	Results	Remarks	Drug levels
6 D C, 44 WM 7 A L, 12 Mexi can F	50 mg IV every day 50 mg IV every day	2 months 3 weeks	3000 mg 1050 mg	Remission of symptoms of headache and vomiting Healing of sinus tract of foot improvement in sinus tract of arm No improvement	Patient had had bilateral upper lobectomies for pulmonary coccidioidomycosis and subsequently developed headache and morning vomiting with elevated spinal fluid pressure, increased protein, and cells cultures complement fixation, and precipitin tests of spinal fluid all negative, patient has been asymptomatic for approximately 10 months since discharge from hospital	—
8 G F, 6, Mexi can F	15 mg IV (1 mg/kg) every day	10 days	150 mg			
9 D B, 5 WM	15 mg q o d IV 20 mg q o d IV	2½ months 1½ months	500 mg	Partial clearing of chest X ray improved sense of well being		
10 L T, 53, WM	5 to 40 mg IV daily 20 mg IV on average 3X/week	9 days 4 months	1025 mg	Decreased size of peripheral granulomata C F unchanged		
11 R D, 33 WM	50 mg IV every day or every other day	2 months	2250 mg	Clearing of lung fields cessation of cough, afebrile, increased weight and strength no adenopathy, granuloma of neck healed		
12 J M, 24, Mexi can M	5 to 40 mg IV daily 10 to 30 mg on average q o d	8 days 36 days	510 mg	Much improved feeling of strength and well being C F decreased to 1.8 Weight gain of 2.5 kg	Diagnosis of coccidioidomycosis not confirmed by culture	—
13 S D, 36, WM	25 to 140 mg IV every day	4 months	5450 mg	Complement fixation dropped to 3+ 1.32, little clinical change		
6 D C, 44 WM	Increase of BUN nausea					
7 A L, 12 Mexi can F	Nausea vomiting fever					
8 G F, 6 Mexi can F	Chills fever, nausea					
9 D B, 5 WM 10 L T, 53 WM	Chills fever, nausea BUN increased from 14 to 33					
					Hb rose from 11.6 to 15.4	

Patient		Dose of amphotericin B	Durat on of time	Total dosage	Results
14 J H 46 WM	50 mg IV every day	3 months	4550 mg	C I dropped to 2+ 1 16 precipitant dropped to 0 afebrile no clinical evidence of recurrence complete healing of skin lesions lung infiltrate unchanged now working	
15 C B 55 WM	50 mg IV every day	25 days	1250 mg	C I 2+ 1 16 regression of lung lesions clinically well and returned to work	
16 B A 23 WM	5 to 15 gm /OS every day	3 1/4 months	1050 gm	No change	

Patient age race sex		Diagnosis	Skin test	Complement fixation	Precipitation
14 J H 46 WM	15 C B 55 WM	Disseminated coccidioidomycosis with skin lesions	Negative 1 100	Serum 2+ 1 32	4+ 1 40
16 B A 23 WM	17 F J C 40 WM	Disseminated coccidioidomycosis with coccidioid lymphadenitis	Negative 1 100	Serum 1+ 1 4	4+ undiluted
17 F J C 40 WM	18 A S 26 NM	Disseminated coccidioidomycosis and pleurocutaneous fistula	Negative 1 100	Serum 2+ 1 256	Negative
19 R M 21 1/2 WM	20 R T 57 WM	Disseminated coccidioidomycosis with bone and skin involvement	Positive 1 100	Serum 2+ 1 32	—
21 F K 29 WM	22 R L 48 WM	Pulmonary aspergillosis with mass in neck and draining thoracic sinus	Negative	2/22 1 2048 5/1 1 16000 6/6 1 4096 7/10 1 8192	—
23 T H 29 WM		Pulmonary aspergillosis	—	—	—
		Candidiasis oral—2 years nasals and vagina—6 months	—	—	—
		Candida paratuberculosis infection of eye after corneal transplant	—	—	—
		Cryptococcal meningitis	—	—	—

Complement fixation rose to serum 2+ 1 256 6 months after cessation of treatment developed recurrence of granuloma of neck		Returned to gainful employment	Hematocrit fell from 51 to 45 BUN rose from 19 to 44 later dropped to 10 while still on drug recently treated with intra arterial perfusion of amphotericin B Results pending
Nausea vomiting fever BUN increased from 6 to 26			
Nausea vomiting fever BUN increased from 15.5 to 34 Occasional low grade fever			

TABLE 1—Continued

Patient	Dosage of amphotericin B	Duration of time	Total dosage	Results
17 E J C, 40, WM	5 to 50 mg IV every day 45 to 60 mg IV every day	10 days 26 days	1650 mg	Marked reduction of swelling dorsum right hand and scrotal nodules, symptomatically improved complement fixation unchanged, returned to work
18 A S, 26 NM	5 to 50 mg IV every day 50 mg IV every day	8 days 3½ months	5350 mg	Gained 25 lb (131 to 156), increased appetite, strength, elevated hemoglobin from 8 to 13.6 gm. Healing of abscesses low back and closure sinus tract from low back to left femoral head area
19 R R, 21½ WM	1 to 10 mg/kg IV every day 1 gm/OS every day	3 months 3 months	470 mg 93 gm	Partial healing of draining sinus of chest partial clearing of lung in filtrate general clinical improvement
20 R T, 57 WM	50 mg IV every day 50 mg IV daily	9 days 6 days	324.4 mg 300 mg	Therapy discontinued because of phlebitis no improvement at that time
21 E K, 29, WF	5 to 50 mg IV q d 20 mg IV q d 5 to 50 mg IV daily 25 mg IV q d	5 days 16 days 8 days 8 days	265 mg 190 mg	Vaginal and mucous membrane lesions cleared Nails greatly improved Striking clinical improvement
22 R E, 48, WM	5 to 10% solution topically 30 to 80 mg IV every day	26 days 7 days	410 mg	Candida infection cleared
23 T H, 29, WF	0.25 mg/kg IV every day 0.50 mg/kg IV every day 0.75 mg/kg IV every day 1.00 mg/kg IV every day	5 days 5 days 3 days 8 days	840 mg	Spinal fluid cultures became negative March 26, drug started April 13, returned home, clinically fairly well
Patient	Toxicity	Remarks	Drug levels	
14 J H, 46, WM	Nausea for first 10 doses, none thereafter, mild persistence of backache, fever, and vomiting for first 13 doses, none thereafter	No rise in BUN prophylactic aspirin and antihistamines did not prevent fever with drug administration	—	
15 C B, 55, WM	Nausea, vomiting and fever	BUN rose from 15 to 28 One year later still well, working and active	Serum 3.65 mg/ml, urine 50 mg/ml	
16 B A, 23, WM	None observed	Refused IV medication	Serum 0.0 mg/ml	
17 E J C, 40, WM	Hemoglobin dropped from 14 to 11.1 gm	Has remained clinically well to date and returned to work Recurrence of lesion dorsum right hand C T dropped to 1.8	—	

Patient	Sex	Age	Race	Patient age here sex	Diagnosis	Results
11	S	26	WM			
19	R	R	21 ²	WM	Excellent clinical improvement despite poor serologic response. Clinically well working last C F 10/58 1:1024 Patient had hypergammaglobulinemia and history of many previous infections	Serum 0.53 to 1.82 μ g/ml, spinal fluid 0.00 μ g/ml, urine 1.05 to 1.41 μ g/ml
20	R	T	57	WM	Current status unknown	
21	E	A	29	WF	5 months after therapy developed recurrent paronychia and was re-treated	
22	R	I	48	WM	Graft-slogued and eye lost	
23	T	I	29	WF	Wale on drug had 4 grand mal seizures and became semicomatose now home and clinically well lost to follow up	Serum 0 μ g/ml, spinal fluid 0
24	M	S	30	WF	Cryptococcal meningitis	
25	L	R	58	WM	Cryptococcal meningitis	
26	W	M	42	WM	Cryptococcal meningitis	
27	J	P	23	WM	Cryptococcal meningitis	
28	T	M	50	WM	Mycetoma (Madura foot) due to <i>Monosporium apiospermum</i>	
29	W	S	62	WM	North American blastomycosis	
30	J	Q		Mexican F	Sporotrichosis	
Patient age here sex					Diagnosis	
					Results	
					Total doses	
					Duration of 1 mg	
					Dose of amphotericin B	
					Results	
24	M	S	30	WF	10 to 16 gm /O5 every day	Expired
25	I	R	58	WM	15 to 40 mg IV every day	Expired
26	W	M	42	WM	50 mg IV every day	Clinically well with disappearance of headache and clearing of sensorium
27	J	P	23	WM	5 to 50 mg IV every day	Dramatic clinical improvement, spinal fluid cultures negative at one month post treatment
27	J	P	23	WM	50 mg IV every day	
27	J	P	23	WM	5 to 40 mg IV every day	
27	J	P	23	WM	50 mg IV every day	
27	J	P	23	WM	0.1 to 1 mg intrathecally every other day	
28	T	M	50	WM	5 to 50 mg IV every day	Decreased drainage from nodules on foot, otherwise no change
28	T	M	50	WM	50 mg IV every day	

TABLE 1—Continued

Patient	Dosage of amphotericin B	Duration of time	Total dosage	Results
29 W S, 62, WM	12.5 to 40 mg IV every day	4 days	1270 mg	Cutaneous lesions healed epididymitis cleared, urine culture for <i>B dermatitidis</i> negative 11 weeks post treatment Complete clinical cure
30 J Q, 58, Mexican F	50 to 75 mg IV every day 600 to 3000 mg /OS every day 5 mg /day IV	18 days 57 days 2 days	147.6 gm 10 mg	
Patient	Toxicity			
24 M S, 30, WF 25 L R, 58, WM	None Chills, fever, nausea, vomiting			Underlying pathology of multiple myeloma preceded onset of cryptococcal meningitis, course complicated by a <i>Proteus mirabilis</i> septicemia Before: Spinal fluid cells, 1,100, protein 1+, Pandy, sugar, low; pressure, 400 11 months after discontinuing therapy, patient is clinically well and spinal fluid has been completely normal for 4 months. 11 months after discontinuing treatment patient remains well clinically and by laboratory tests with regard to his meningitis. No significant improvement, given intra arterial amphotericin B, awaiting results Therapy stopped because of localized phlebitis, 1 yr later—remains clinically well, skin and urine cultures negative Follow up of patient 13 months later shows patient clinically well
26 W. M, 42, WM	BUN rose from 16 to 28 mg per cent, chills, fever from 100 to 102° F, hemoglobin dropped from 18 to 10 gm			
27 J P, 23, NM	Nausea, chills, vomiting, fever			
28 T M, 50, WM	Nausea vomiting, chills, fever, BUN rose to 42.8 mg per cent			
29 W S, 62, WM	Chills nausea, fever, vomiting, hemoglobin dropped from 15.5 to 13, creatine rose from 1.2 to 2.3			
30 J Q, 58, Mexican F	Intravenous amphotericin B produced fever, chills headache, nausea, malaise			

venously 265 mg over a 21-day period and, 5 months later, 190 mg over a 13-day period. During the first course of treatment all infected nails were avulsed. The oral and vaginal lesions improved rapidly, and all nails appeared to be returning normally. However, 5 nails subsequently developed evidence of infection and, 5 months later, these infected nails were again avulsed and the patient received a second course of amphotericin B. Again, all nails appeared to be returning normally, however, 2 nails have recently become infected.

Mycetoma

A single patient with far advanced mycetoma (Madura foot) due to *Monosporium apiospermum* was treated over a 20 day period with intravenous amphotericin B, with essentially no improvement.

TABLE 2
SUMMARY OF RESULTS OF PATIENTS TREATED WITH AMPHOTERICIN B

	Total	Improved	Improved then relapsed	Unchanged
Disseminated coccidioidomycosis	18	7	4	7
Meningitis	5	1	2	2
Bone skin lung	13	6	2	5
Cryptococcal meningitis	5	3	—	2*
Pulmonary aspergillosis	2	1	—	1
Candidiasis	2	2	—	—
Mycetoma due to <i>Monosporium apiospermum</i>	1	—	—	1
North American blastomycosis	1	1	—	1
Sporotrichosis	1	1*	—	—
Total	30	15	4	11

* One patient treated with oral amphotericin B only.

Sporotrichosis

One patient with the localized lymphangitic type of sporotrichosis involving the hand, forearm, and arm with multiple ulcerating lesions was treated with oral amphotericin A and B in essentially equal parts of each to a total dose of 147.6 gm over a 57 day period. This was followed by complete resolution of all lesions. Thirteen months after discontinuation of therapy the patient remains clinically well.

Discussion

It should be stressed at the outset that the evaluation of a fungicide on the course of the systemic mycoses in man is extremely difficult because of many factors: the small number of patients available, the reluctance on the part of the clinician to withhold a potentially effective medication to form ideally matched control groups, the difficulty in obtaining unbiased observations, the lack of knowledge concerning many facets of the natural course of the systemic mycoses and, finally, the inevitable loss of patients from prolonged follow up.

since adequate follow-up periods must be measured in years before preliminary opinions can be substantiated. Realizing these shortcomings, we nevertheless feel that there is still considerable value in presenting our clinical experience to date, even though many of our conclusions must be of a tentative nature.

Our clinical experience with amphotericin B has been primarily with the treatment of disseminated coccidioidomycosis.¹² Amphotericin B, when given intravenously, appears definitely to influence favorably the course of this disease in some cases, so that a patient with progressive disseminated coccidioidomycosis, shortly after the inception of treatment, may develop an improved feeling of well being, increased appetite, weight gain, desquescence, and healing of cutaneous, osseous, and pulmonary lesions, and eventually appear clinically well. This has occurred particularly following the initial treatment of that group of patients having disseminated disease with skin and soft tissue or lung involvement, or both. Of the 13 patients treated to date, 6 have improved and remained symptom free for periods as long as 3 years. Two of the 5 who did not improve received grossly inadequate treatment according to our present concepts. The remaining 5 patients either did not respond or have relapsed following cessation of therapy. Again it should be stressed that those patients who are at present clinically well have not been followed long enough for final evaluation, moreover, we have no comparable control group upon which to interpret these seemingly favorable results.

Although coccidioidal meningitis thus far has been consistently fatal with patients generally succumbing within a period of 2 years, some of the more chronic forms have persisted for 10 years and longer. This has tended to make the evaluation of any form of therapy extremely difficult in this particular complication of coccidioidomycosis.

The ultimate value of amphotericin B in preventing meningeal involvement, which is the major cause of death in Caucasians with disseminated disease and which, in some series of disseminated coccidioidomycosis, occurs with a frequency of 25 per cent, is unknown at this time. Evidence to date suggests that amphotericin B can produce remissions and perhaps prolong life in the patient with coccidioidal meningitis. The ultimate rate of actual cure of patients with coccidioidal meningitis is, however, undetermined at this time.

Improvement occurred in 3 of our 5 patients with coccidioidal meningitis, in 2 instances to the point where the patient was relatively symptom free and was able to return to gainful employment. However, abnormalities persisted in the spinal fluid in all of these instances. The significance of this has become more ominous since 2 of these 3 have already developed clinical relapse. These results are not as favorable as those reported recently by Winn,¹⁴ who has detailed the treatment of 6 patients with meningitis due to *C. immitis*. Excellent results were obtained in 3 of the 6 patients, these patients becoming clinically asymptomatic and their spinal fluid abnormalities returning completely to normal. Some of these have been followed for periods as long as 18 months. Winn stresses the simultaneous intrathecal and intravenous administration of amphotericin B. The value of the intrathecal use of amphotericin B is still open to question, even though the drug is known to be poorly transported across the blood brain barrier into the spinal fluid.^{15, 16} Apparently quanti-

tics reach the infected portions of the meninges at a level sufficient to produce clinical remissions in some instances of meningitis due to *C. neoformans*, *C. immitis* and *B. dermatitidis*.^{11,12} Because of the serious nature of the disease, the value of the intrathecal use of amphotericin B, it seems desirable concurrently to treat such patients both intravenously and intrathecally. The drug is at present recommended for intrathecal administration in dosages not to exceed 1 mg every other day in the adult. This dosage is attained by starting with 0.1 mg and slowly increasing to the maximum depending upon the patient's reactions. It is dissolved in 2 to 3 cc of distilled water or spinal fluid. A total dose of 44-42 mg has been given in 2 courses over a period of 23-24 days,¹⁴ however the development of arachnoiditis in this patient interfered with its regular use.

The exact optimal dosage for the treatment of coccidioidomycosis is undetermined and the length of treatment still depends upon the clinical status of the patient. At present a dosage range of 2000 to 4000 mg daily for 2 to 4 weeks and in some cases for 6 to 8 weeks is recommended.

The exact optimal dosage for the treatment of coccidioidomycosis is still undetermined and the length of treatment still depends on evaluation of the clinical status of the patient. At present however it appears to be in the range of 2000 to 4000 mg although some patients have responded to lower doses and in some instances have required up to 10 000 mg total dosage. The ideal goal that should be sought is complete disappearance of all clinical evidence of disease with the regaining of the laboratory findings to normal former weight. Furthermore reversion of the patient's sense of well-being and including sedimentation rate hemoglobin complement fixation test for coccidioidomycosis and skin test for coccidioidomycosis is highly desirable but in our experience it has not been generally attainable particularly in respect to complement fixation tests for coccidioidomycosis. Laboratory evidence of kidney damage may necessitate the temporary cessation of amphotericin B therapy but to date it has not posed a serious problem in the over all use of the drug except insofar as it limits the total amount of amphotericin B that can be administered in a specific period of time. Sclerosis of the superficial veins has occurred in some instances to such a degree as to be a serious handicap to the continued administration of amphotericin B.

In the untreated patient with coccidioidomycosis the properly performed skin test and complement fixation tests at intervals of about one month have permitted one to make a more accurate prognosis than by relying on the clinical observations.² For example a highly positive skin test and a negative complement fixation test indicate an excellent prognosis and a negative reaction to a skin test and a high titer response to the complement fixation test suggest with dissemination.

These tests in patients receiving treatment with amphotericin B suggested the patient's changing status at a sufficient interval to permit continuation of therapy. The skin test to coccidioidomycosis may also be used to determine the development of arachnoiditis in this patient interfere

In the untreated patient with coccidioidomycosis the properly performed test and complement fixation tests at intervals of about one month have permitted one to make a more accurate prognosis than by relying on the clinical observations. For example a highly positive skin test and a negative complement fixation test indicate an excellent prognosis and a negative reaction to a skin test and a high titer response to the complement fixation test suggest death by dissemination.

These tests in patients receiving treatment with amphotericin B have not reflected the patient's changing status at a sufficient rate of speed to act as guides to therapy. The skin test to coccidioidin may remain negative throughout the course of therapy or may revert to low positivity in both instances the patients may appear clinically cured. The complement fixation test for coccidioidomycosis may decrease greatly over several months, decrease moderately in titer may then return to the previous status may remain essentially the same or may increase temporarily while clinically the patient during this same period may become asymptomatic may show no improvement or may

become clinically asymptomatic but later develop local recurrence of the disease.

Which trend in the laboratory and skin tests and their combinations may indicate biological or clinical cure or on the other hand impending relapse and thus indicate the need for retreatment before clinical manifestations become apparent are questions that still await clarification. At present the criteria for re-treatment are based primarily on the development of clinical symptomatology. Evidence in the literature suggests that *C. immitis* can develop a significant degree of resistance to amphotericin B *in vitro*.²¹ This possibility however has not been encountered at a clinical level to date.

Finally it should be stressed that amphotericin B supplements but does not supplant those measures that are referred to as supportive. These include bed rest, a high protein, high vitamin, high caloric diet, excellent nursing care and drainage of the subcutaneous abscesses and other surgical procedures where indicated. Many instances of cures attributed to promising fungicidal agents may be attributed in retrospect to the intensified application of these measures by the interested investigator.

Amphotericin B appears to be the most effective chemotherapeutic agent available for the treatment of coccidioidomycosis. Its exact status in this respect however is still to be determined. It appears capable in some instances of arresting the progress of disseminated disease, eliminating all clinical symptoms and even reversing laboratory evidence of dissemination. The exact rate of relapse is unknown but probably will increase as longer periods of observation are attained. The drug appears to produce remissions in patients with coccidioidal meningitis but here again the percentage of patients who ultimately will be cured appears extremely small.

Amphotericin B may prove to be more effective in the prevention of dissemination than in its treatment but this point needs documentation. Until more definite knowledge is available it seems desirable to treat a variety of clinical situations in which dissemination is a likely possibility and is known to occur with a high frequency. This includes patients with severe primary coccidioidomycosis that does not show evidence of improvement within a few weeks of conservative management or who demonstrate a weak or negative skin test coupled with a rising complement fixation titer, the primary pulmonary complex in the Negro, Filipino and Mexican, primary coccidioidomycosis in the pregnant woman, the diabetic, the patient with a lymphoma, a patient who is receiving corticosteroids or in other clinical conditions where the host defense mechanisms are basically impaired and finally as coverage for surgical procedures involving diseased tissues.^{22, 23}

Our experience with the other systemic mycoses has been more limited. The one patient with North American blastomycosis promptly and rapidly improved following the administration of a comparatively small quantity of amphotericin B. This provides additional support to the tentative conclusion that amphotericin B appears to be of considerable value for the treatment of this disease entity.^{24, 25}

No spinal fluid abnormalities have persisted in the three patients with cryptococcal meningitis who achieved clinical cure; thus their prognosis appears

favorable, but further follow up will be necessary to determine their ultimate outcome. These findings are similar to those of many other investigators.¹⁶⁻²⁰ Assessment of the ultimate curative value of amphotericin B for cryptococcal meningitis must, however, await longer follow up periods.

Two patients with pulmonary aspergillosis have been treated with amphotericin B. One, a 2½ year-old Caucasian boy, showed partial resolution of his pulmonary lesions and disappearance of the organisms from exudates of a draining thoracic sinus. The other patient was unable to complete an adequate course of therapy because of severe phlebitis at the sites of infusion. No conclusions can be drawn from this limited experience except that the drug is worthy of further clinical evaluation in this disease.

Amphotericin B appears to offer promise for the treatment of several recalcitrant forms of candidiasis. The one patient who had extensive infection due to *C. albicans* involving the oral and vaginal mucous membranes and severe deformities of seven fingernails who had resisted all forms of topical and oral therapy, promptly responded to amphotericin B given intravenously. A recurrence involving two nails, however, developed following two courses of therapy. The second patient achieved rapid sterilization of an ocular infection due to *C. parapsilosis*. The rapid response of a variety of candidal infections to relatively small doses of amphotericin B suggests that this drug has great potential value in the management of many heretofore chronic, recalcitrant, and occasionally fatal candidal infections.²¹⁻²³

One patient with primary cutaneous sporotrichosis with numerous ulcerative granulomatous lesions extending up to the forearm and upper arm responded to amphotericin B administered orally. Although potassium iodide remains the drug of choice for the treatment of this disease, amphotericin B may be of considerable value in the treatment of such cases when the organism does not respond to adequate doses of iodine or the patient has become intolerant to the administration of iodine.

We have had no experience in the treatment of histoplasmosis or South American blastomycosis or chromoblastomycosis. The current literature indicates that the drug is of extreme value for the treatment of several types of histoplasmosis^{24-30, 32} and South American blastomycosis³³⁻³⁵ particularly in those instances where the organism has become resistant to sulfonamide therapy. Chromoblastomycosis has been cured by local injections^{36, 37} and by tattooing³⁸ the material into the lesion.

Route of Administration

The intravenous route presently appears to be the most satisfactory method of administering amphotericin B. It must be stressed that the initial dose should be in the range of 5 to 10 mg per day. The dosage may then be increased by increments of 5 to 10 mg depending upon the reactions of the patient. With the initial infusion some patients will develop fever, shaking chills, anorexia, nausea, vomiting, chest pain, and anxiety, with or without headaches. If these symptoms become severe the administration should be discontinued until the following day and again started at essentially the same dosage as otherwise patients may progress to seizures and shocklike states.

In general patients tend to develop a tolerance to subsequent administrations including the addition of small increments of the drug.

It is preferable to administer the drug over a 4 to 6 hour period. Although the drug may be given over a shorter period of time this procedure is not without risk. The inadvertent administration of 20 mg. of the drug over a 60-min. period was followed by grand mal convulsions, ventricular fibrillation and cardiac arrest that fortunately responded to a sharp blow on the chest.¹¹

Chronic cumulative toxicity of the drug developing after prolonged administration is manifested by the development of increasing malaise, nausea, vomiting and anorexia for increasing lengths of time following each administration of amphotericin B. When these symptoms interfere with the nutrition of the patient to such a degree that it becomes apparent that he is not consuming an adequate daily diet the drug should be discontinued temporarily and reinstituted at a lower level either daily or on alternate days depending on the patient's subsequent response.

At essentially this same time or even shortly before the clinical evidence of chronic toxicity occurs, laboratory studies have demonstrated kidney damage as shown by consistent elevation of the blood urea nitrogen and creatinine levels.

Until a better understanding of the nature of the kidney damage produced by the administration of amphotericin B is forthcoming it has been our policy to interrupt therapy until the blood urea nitrogen and creatinine have returned to normal. These laboratory abnormalities in our experience to date invariably have returned to their pretreatment levels following cessation of therapy. This however has not always been the case (W. A. Winn personal communication). The need for clarification of the damage if any to the kidney of either a temporary or permanent nature becomes of additional importance as accumulated experience suggests that several of the deep mycoses may require repeated courses of amphotericin B to maintain the patient symptom free. A battery of kidney function tests was performed in two of our patients in an effort to elucidate the nature of the kidney lesions. These indicated an associated decreased rate of glomerular filtration and a decreased renal plasma flow.

An annoying complication and occasionally a limiting factor in the continued administration of amphotericin B is the development of phlebitis at the site of infusion. It is therefore important if a prolonged course is contemplated to utilize the most distal vein first using a small needle and a slow rate of infusion. We have had no experience with the addition of heparin to the infusion in an effort to prevent phlebitis.^{12,13} Other manifestations of toxicity reported in the literature include transitory vestibular disturbances, flushing, sweating, fatigue, drowsiness,¹⁴ hypokalemia in one patient,¹⁵ generalized pain, weight loss, a drop of the platelet count to 20,000 and anaphylactoid shock.¹⁶ In three of our patients we have noted a persistent drop in the hematocrit ranging from 6 to 10 U. It is recommended that appropriate hematological and renal function studies be done periodically on all patients receiving prolonged therapy with amphotericin B.

Conclusions

Thirty patients with a variety of systemic mycoses have been treated, including coccidioidomycosis, cryptococcosis, North American blastomycosis, candidiasis, aspergillosis sporotrichosis, and mycetoma. From our experience, as well as from that reported in the literature, amphotericin B appears to be of significant value in the treatment of coccidioidomycosis, cryptococcosis, North and South American blastomycosis histoplasmosis sporotrichosis candidiasis and chromoblastomycosis. Its exact therapeutic status awaits further detailed clinical experience.

The drug is most effectively given intravenously in dosages of 0.7 to 1.4 mg/kg daily or on alternate days. The high incidence of acute and chronic toxicity associated with the administration of the drug makes close medical supervision mandatory.

In general total effective dosage depends on the nature of the infecting agent and the clinical status of the patient. The optimum total dosage appears to be in the range of 2000 to 4000 mg for the treatment of coccidioidomycosis in the adult.

The most common manifestations of toxicity have included anorexia nausea vomiting anxiety chest pain rising blood urea nitrogen and a fall in hematocrit. Generally these symptoms have disappeared upon temporary cessation of therapy.

References

1. GOLD W, H A STOLT J S PAGANO & R DUVORICK 1956 Amphotericins A and B Antifungal Antibiotic Reduced by a Streptomycin. *Antibiotics Annual 1955-1956* 579-586.
2. DITCHER J D M D YORVO J H SHERMAN W HIBBIS & D J WALTERS 1957 Chemical Studies of Amphotericin B. I. Preparation of the Hydrogenation Product and Isolation of Mycosamine and Acetolysis Products. *Antibiotics Annual 1956-1957* 866-869.
3. STERNBERG T H F T WRIGHT & M OLTRA 1956 A New Antifungal Antibiotic Amphotericin B. *Antibiotics Annual 1955-1956* 566-573.
4. STEINBERG B A W I JAMBOR & L O SCUDAM 1956 Amphotericins A and B Two New Antifungal Antibiotics Possessing High Activity Against Deep Seated and Superficial Mycoses. *Antibiotics Annual 1955-1956* 574-578.
5. HALDE C V D NEWCOMER F T WRIGHT & T H STERNBERG 1957 An evaluation of amphotericin B in rat and in mice against *Coccidioides immitis* and *Candida albicans* and preliminary observations concerning the administration of amphotericin in man. *J Invest Dermatol* 28: 211.
6. LORRIA D V A FADER & C W FUMON 1955 Histoplasmosis and Cryptococcosis. *Antibiotics Annual 1954-1955* 80-877.
7. BALM G L J SCHWARZ & C J K WANG 1958 Treatment of experimental histoplasmosis with amphotericin B. *Arch Intern Med* 101: 84.
8. BALM G L H KIBELL & J SCHWARZ 1957 Treatment of Experimental Histoplasmosis in Animals. *Antibiotics Annual 1956-1957* 878-882.
9. CHICK F W J EVANS & R D BAAR 1958 The inhibitory effect of amphotericin B on localized *Rhizopus oryzae* infection (mucormycosis) utilizing the pneumodermis pouch of the rat. *Antibiotics (chemotherapy)* 8: 506-510.
10. FOSTER B T F ALPERT M I LITTMAN & I WILSON 1959 Some intracutaneous and conjunctival effects of amphotericin B in man and in the rat. *Med cal Encyclo* 60: 555-564.

- 11 EVANS J H & R B BAKER 1959 Treatment of experimental aspergillosis with amphotericin B. *Antibiotics & Chemotherapy* 3(4) 209-213
- 12 NEWCOMER V D T H STERNBERG L T WRIGHT & R M REISNER 1959 Current status of amphotericin B in the treatment of the systemic fungus infections. *J Chronic Diseases* 9(4) 354-374
- 13 BARTNER T H ZINNES K A MOY & J S ALLESZA 1958 Studies on a New Solubilized Preparation of Amphotericin B. *Antibiotics Annual 1957 1958* 53-58. *Medical Encyclopedia* New York N Y
- 14 WINN W A 1959 The use of amphotericin B in the treatment of coccidioidal disease. *Am J Med* 27(4) 617-635
- 15 LOURIA D B 1958 Some aspects of the absorption distribution and excretion of amphotericin B in man. *Antibiotic Med Clin Therapy* 5 295
- 16 LITTMAN M L 1959 Cryptococcus (Torulosis) current concepts and therapy. *Am J Med* 27(6) 96
- 17 RUBIN H & M L FURCOLOW 1958 Promising results in cryptococcal meningitis. *Neurology* 8(8) 590-595
- 18 SMITH G W 1958 The treatment of torula meningo encephalitis with amphotericin B. *J Neurosurg* 18(5) 572-575
- 19 MARTIN W J D R NICHOLS & H J SVEN 1959 Cryptococcosis further observations and experiences with amphotericin B. *A M A Arch Internal Med* 104 4-14
- 20 SEABURY J H & H F DASCOMB 1958 Experience with amphotericin B for the treatment of systemic mycoses. *A M A Arch Internal Med* 102 960-976
- 21 CARMODY E J W TAPPEN 1959 Blastomycosis meningitis report of a case successfully treated with amphotericin B. *Ann Intern Med* 51(4) 780-791
- 22 LEWIS G M M HOPPER J W WILSON & O ILIARRETT 1958 An Introduction to Medical Mycology. Yearbook Publ. New York N Y
- 23 SØRENSEN I J E G McNALL & T H STERNBERG 1959 The Development of Strains of *Candida albicans* and *Coccidioides immitis* Which are Resistant to Amphotericin B. *Antibiotics Annual 1958-1959* 920-923. *Medical Encyclopedia* New York N Y
- 24 NEWCOMER V D 1959 Coccidioidomycosis Current Therapy 423-424. Saunders Philadelphia Pa
- 25 HARRELL R E & A C CURTIS 1957 The treatment of North American blastomycosis with amphotericin B. *A M A Arch Dermatol* 76 561
- 26 HARRELL F K 1958 The treatment of North American Blastomycosis treatment with amphotericin B. *Am Trudeau Soc Meeting May 1959* *Am Rev Tuberc Pulmonary Diseases* 78 312
- 27 SAROT I & M L LITTMAN & M M CERRUTH 1959 Intrathoracic injection of amphotericin B in the treatment of monilial Empyema. *Seaside Hosp Bull* 18(3) 96-100
- 28 OWILVER D A & E M BRICKER 1959 *Candida albicans* peritonitis successfully treated with amphotericin B. *New Engl J Med* 260 488-489
- 29 CHILDS A J 1959 Further clinical trials of amphotericin with a report of the treatment of a probable case of generalized moniliasis. *Scot Med J* 4 80-83
- 30 LITZ J P D V LOURIA N FEDER C W EMMONS & N B MCCULLOUGH 1958 A Report of Clinical Studies on the Use of Amphotericin in Patients with Systemic Fungal Diseases. *Antibiotics Annual 1957 1958* 65-70. *Medical Encyclopedia* New York N Y
- 31 VOGEL R A & J C CRITCHER 1958 Studies on the dosage and excretion of amphotericin B in patients with systemic mycoses. *Antibiotic Med Clin Therapy* 5 501
- 32 LEHAN P H J L YATES C A BRASHERM H W LARSH & M L FURCOLOW 1957 Experiences with the therapy of sixty cases of deep mycotic infections. *Diseases of the Chest* 32 597
- 33 RUBIN H P H LEHAN & M L FURCOLOW 1957 Severe nonfatal histoplasmosis Report of a typical case with comments on therapy. *New Engl J Med* 257 599
- 34 MILLER J M M GINSBERG H R JOHNSON & A BOGOSIAN 1958 The treatment of histoplasmosis with amphotericin B (fungizone). *Antibiotic Med Clin Therapy* 5(10) 593-597
- 35 GREENDYKE R M & M L KALTREIDER 1959 Chronic histoplasmosis Report of a patient successfully treated with amphotericin B. *Am J Med* 27(1) 135-138
- 36 BELCHER C D & L P LANG 1959 Histoplasmosis treated with amphotericin B A case report. *Del State Med J* 31 59-63
- 37 LITTLE J J BRUCE H ANDREWS A CRAWFORD & G MCKINLEY 1959 Treatment of disseminated infantile histoplasmosis with amphotericin B. *Pediatrics* 24 1-6

- 38 LACAZ C DA S & S SAMPAIO 1958 Tratamento da Blastomicose Sul Americana com anfotericina B Resulta los preliminares Rev paulista Med 62 343
- 39 VERNESI R F MELLO F J ALMEIDA G DEL NEGRO S A P SAMPAIO J M FERREIRA & D A MEIRA 1959 Resultados Terapeuticos Obtidos com o Emprego da Anfotericina B em Formas Superficiais e Profundas da Blastomicose sul Rev Hosp Clin 14 231-244
- 40 DA SILVA J C P J SEGAL S A P SAMPAIO & A C M CASTRO 1959 Forma Linfatico Tegumentar da Blastomicose Sul Americana Complicada com Disseminacao Hematogenica do Paracoccidioides brasiliensis Consideracoes em Torno da Blastomicose sul Americana O Hospital 66 115-139
- 41 MIRANDA J L & J M FILHO 1959 Chromoblastomycosis treated with local infiltration of amphotericin B solution J Am Med Assoc 171 1961 1963
- 42 COSTELLO M J C P DEFEQ JR & M L LITTMAN 1959 Chromoblastomycosis treated by vibrapuncture injection of amphotericin B Am Med Assoc Arch Dermatol 80 286-287
- 43 DEFEQ C P & L C HARRER 1959 Chromoblastomycosis treated with local infiltration of amphotericin B solution J Am Med Assoc 171 1961 1963
- 44 DERRBS V J L FRIEDMAN & J D KRACHULA 1959 Chromoblastomycosis treated by vibrapuncture injection of amphotericin B Am Med Assoc Arch Dermatol 80 286-287
- 45 LITTMAN M L 1957 Preliminary Observations on the Intravenous Use of Amphotericin B and Antifungal Antibiotic in the Therapy of Acute and Chronic Coccidioidomycosis Conf on Coccidioidomycosis L S Dept Health Ed and Welfare & Ariz State Health Dept 86-95 Feb 11 13 Phoenix Ariz

Discussion of the Paper

Comment May I add a brief summary of my own experience with the treatment of the deep mycoses with amphotericin B I have had the opportunity to treat successfully two cases of South American blastomycosis and one case of Madura foot produced by Madurella with bone involvement

One case of South American blastomycosis had secondary cutaneous lesions produced by hematogenous dissemination of the parasite and the other case presented pulmonary infection with secondary manifestation in the left eye

Both cases had been unsuccessfully treated previously with sulfonamides drugs that usually clear up the lesions of South American blastomycosis

The patient with Madura foot had had this condition for more than fifteen years and had been treated with different types of chemotherapy He was subjected simultaneously to a conservative surgical treatment removing the bone fragments and to amphotericin B injected intravenously

These 3 patients healed within a period of 2 to 3 months and did not show any relapses in the follow up of 1 1/2 years All of them presented some degree of side effects but only one presented toxic manifestation which obliged us to interrupt the treatment for 3 day

One more case of South American blastomycosis was treated successfully in Argentina and four cases were treated with the same results in São Paulo Brazil

Two cases of chromoblastomycosis healed by means of amphotericin B injected locally have been reported from Bellevue Hospital New York N Y I suggest the same type of treatment for rhinopodisma which is also a localized deep mycosis


THE TREATMENT OF SYSTEMIC MYCOSES WITH ORALLY ADMINISTERED PIMARICIN: PRELIMINARY REPORT*

Victor D. Newcomer, Thomas H. Sternberg, Edwin T. Wright,
Ronald M. Reissner, Earl G. McNall, Lloyd J. Sorensen

Department of Medicine Division of Dermatology University of California Medical Center
and the Medical Service Veterans Administration Center General Medical and Surgical
Hospital Los Angeles Calif

Pimaricin is a new crystalline antifungal antibiotic derived from *Sireptomycetes natalensis* originally isolated from a soil sample obtained near Pietermaritzburg Natal Union of South Africa. Its chemical and physical properties have been characterized by Struyk *et al*¹ and by Dekker and Ark². It is a tetraene antibiotic and is related to but not identical with rimocidin, antimycin, nystatin and chromin. These tetraenes are members of a larger group of antibiotics the majority of which possess fungicidal activity and include such compounds as amphotericin, trichomycin, ascocin and candicidin.

An empirical formula of $C_{40-42}H_{70-80}O_{13}$ was assigned early to pimaricin¹. More recently, however, Patrick *et al*³ have elucidated the structural formula of pimaricin⁴ (see formula below), the first of the many polyene antifungal antibiotics to have its structure so determined.



It is insoluble in water but suspensions may be sterilized for 20 min. at 110° C. with only a moderate reduction in potency. The ultraviolet absorption spectra of pimaricin show considerable similarity to the absorption spectra of both nystatin and amphotericin but pimaricin can be distinguished readily from these antibiotics by paper chromatography.

The effect of pimaricin is primarily fungicidal and it possesses no significant bactericidal activity. *In vitro* it inhibits a wide variety of pathogenic and nonpathogenic fungi in concentrations of from 1 to 10 µg/ml¹. The minimum concentrations of pimaricin found in our laboratory to inhibit *in vitro* growth of some of these fungi are summarized in TABLE 1.

Experimentally induced resistance to amphotericin B has been produced in *Candida albicans* and *C. immitis* but these same organisms showed no in

* This study was supported in part by a grant from the New Drug Institute, New York, which also supplied the pimaricin as 200 mg enteric coated tablets of the sodium salt of pimaricin.

creased cross resistance to pimaricin.⁴ Oral toxicity studies in rats demonstrated that 50 to 70 mg of pimaricin per kilogram could be administered daily for periods of 5 to 10 weeks with no adverse effects; however, doses of 500 mg/kg produced diarrhea, serious growth inhibition, and a 30 per cent mortality within a 2 week period.

The acute intraperitoneal toxicity of pimaricin was found to be only one tenth that of nystatin, but its oral toxicity was found to be two to three times greater in rats, mice, and guinea pigs. It was hypothesized that perhaps pimaricin was better absorbed from the gastrointestinal tract.¹

To date, amphotericin B has proved to be the most effective fungicidal agent available for the treatment of coccidioidomycosis, North American blastomycosis, cryptococcosis, and histoplasmosis. The fact that the intravenous route of administration has been the only satisfactory means of administering the

TABLE I
INHIBITION OF VARIOUS FUNGI BY PIMARICIN

Fungus	Minimum inhibitory concentration (µg/ml)
<i>Mucor</i> sp.	2.5-5
<i>Microsporum canis</i>	2.5-5
<i>Candida albicans</i>	2.5
<i>Cryptococcus neoformans</i>	3
<i>Trichophyton mentagrophytes</i>	10
<i>Exidia</i> sp.	3.5-5
<i>Blasium dermatitidis</i>	1
<i>Histoplasma capsulatum</i>	2.5
<i>Sporobolus schenckii</i>	more than 1000
<i>Aspergillus fumigatus</i>	10

drug except in specialized situations together with the high incidence of acute and chronic toxic reactions presents serious drawbacks to its use. Accordingly, an antifungal antibiotic effective by the oral or intramuscular route would be of considerable advantage in the treatment of the systemic mycoses. The response of a patient with disseminated coccidioidomycosis (case 2, TABLE 2) to the use of orally administered pimaricin in preliminary evaluation of its effect on the flora of the G.I. tract also suggested that enough of this compound might be absorbed via this route to be useful in the treatment of the systemic mycoses. This led to consideration of the possibility of utilizing pimaricin as a potential oral agent for the treatment of systemic fungal infections in man.

This paper presents our findings in ten patients with various mycoses who received pimaricin orally.

Materials and Methods

The drug was administered orally in the form of enteric-coated tablets of the sodium salt of pimaricin. The dosage varied in the adults from 200 to 1000 mg daily depending upon the patient's tolerance to the drug. Among the patients treated to date were 7 with disseminated coccidioidomycosis, 2 with

TABLE 2
SUMMARY OF RESULTS OF TREATMENT OF VARIOUS MYCOSES WITH PIMARICIN

Patient, age, race, sex	Disease	Dosage (mg./day)	Duration (days)	Total dose	Result	Toxicity	Comments
1 J M 34 Mexican M	Disseminated coccidioidomycosis	200	24	4800 mg	No change	Anorexia nausea vomiting	Blood urea nitrogen hematocrit complement fixation test for coccidioidomycosis unchanged Complement fixation test for coccidioidomycosis dropped from 1:2048 to 1:64 Five months after discontinuation of therapy the patient relapsed Despite healing of granuloma regional lymph node remains enlarged and soft Drug discontinued because of toxicity
2 R D 34 NM	Disseminated coccidioidomycosis	200-1000	154	111 2 mg	Complete healing of granuloma of neck 2 months after instituting therapy with pimarinin	Mild diarrhea, nausea vomiting	
3 A S, 28, NM	Disseminated coccidioidomycosis	400	180	72 gm	Healing of granuloma of neck, partial regression of regional node No change	Could not exceed 400 mg daily without severe diarrhea, vomiting severe anorexia	
4 B A 26 WM	Disseminated coccidioidomycosis	50-250	13	2 6 gm	No change	Anorexia nausea diarrhea and at lower dosage levels flatulence Occasional loose stools	Drug discontinued because of toxicity
5 S D 36 NM	Disseminated coccidioidomycosis	50-600	64	28 3 gm	Showed initial apparent healing by X ray of osteomyelitis of wrist but subsequently relapsed despite continued therapy No change		Patient received intramuscularly 0.25 mg of pimarinin in 0.5 cc of saline This produced marked induration and pain
6 R B 35 WM	Coccidioidal meningitis	300-1000	130	96 6 gm	No change	Nausea and diarrhea at doses greater than 800 mg daily Mild anorexia and loose stools	None
7 G S, 67, WM	Disseminated coccidioidomycosis	300-1000	104	89 4 gm	No change		During the therapy the hemoglobin dropped from 15.7 to 13.1 gm

8 T M 52 W M	Vijcetoma due to <i>Monosporium apio- spermum</i>	200-800	01	28 2 gm	No change	Nausea and vomiting at doses greater than 600 mg daily, flatulence and mild anorexia at doses less than 600 mg / day None	None
9 D C 31½ W F	Disseminated muco-cutane- ous candidi- asis	25-75	70	36 75 gm	Early apparent improve- ment with partial re- gression of muco cuta- neous lesions and ap- parent replacement of 2 infected nails by new normal nails No change	None	Too early to determine effect of drug
10 T N 29, W F	Disseminated muco-cutane- ous candidi- asis	400	20	8 gm	No change	Severe diarrhea	Drug discontinued because of toxicity

disseminated mucocutaneous candidiasis and 1 with a mycetoma due to *Monoascus apiospermum*. The maximum daily dose was determined by the development of clinical evidence of intolerance. Courses have varied in duration from 13 days to 334 days.

Appropriate laboratory studies including fungal cultures, complete blood counts, urinalysis, blood urea nitrogen, liver function tests, roentgenological examinations of the chest and other structures, skin tests, and complement fixation tests for coccidioidomycosis were obtained prior to the initiation of therapy and at appropriate intervals during the course of therapy.

Results

TABLE 2 summarizes the results of the treatment of these patients with orally administered pimaricin. Improvement with the concomitant administration of pimaricin occurred in only one patient whose case history is detailed below.

Case 2 R D 32-year-old male Negro with disseminated coccidioidomycosis previously treated with amphotericin B with apparent cure suffered a relapse manifested by a granulomatous lesion on the right side of the neck. The patient was given pimaricin in doses ranging from 200 to 1000 mg per day for a period of 154 days to a total dose of 111.2 gm. During this time his albumin globulin ratio reverted toward normal, changing from 2.9/0.0 to 3.4/4.2. His hemoglobin dropped from 12.0 to 7.4 but it was subsequently discovered that the patient had bleeding hemorrhoids and with their control and iron therapy the patient's hemoglobin returned to normal while he was still receiving pimaricin. The white count, platelets, and reticulocytes as well as the BUN and creatinine remained unchanged. No evidence of any abnormalities occurred in the urine. During this time, however, his complement fixation titer for coccidioidomycosis dropped from 1:2048 to 1:64. The patient experienced mild diarrhea which became more severe together with nausea and vomiting during the first 2 days of treatment. These symptoms disappeared upon temporary discontinuance of the drug and thereafter the only side effect was mild diarrhea as long as the dosage of the drug was maintained below 800 mg daily. Nausea, anorexia, and moderately severe diarrhea occurred consistently when the daily dose of the drug was increased to more than 800 mg. Two months following the institution of therapy the granuloma was completely healed. However 5 months following discontinuance of therapy evidence of a granuloma occurred in the same area. Therapy with pimaricin was reinstituted with a daily dose of 400 mg. This was continued for a period of 6 months and resulted in complete healing of the granuloma of the neck but only partial regression of a nearby enlarged regional lymph node. The total dose that this patient received with no evidence of laboratory or serious clinical toxicity was 183.2 gm.

In addition, two other patients (cases 5 and 9, TABLE 2) showed some improvement during treatment.

Case 5 S D 36-year-old male Negro with disseminated coccidioidomycosis manifested by a coccidioidal osteomyelitis of the right wrist demonstrated apparent early healing and union of a previously chronic nonunion of the wrist but subsequently relapsed despite continued treatment.

Case 9 D C, a 31½ year old white female with disseminated mucocutaneous candidiasis, showed early evidence of improvement, with partial clearing of facial and mucosal lesions and apparent healing of two fingernails. However, the duration of therapy and observation has been too short to allow any conclusions to be drawn at this time.

Toxicity

No laboratory evidence of toxicity was observed in any of these patients. Clinical evidence of toxicity consisted of varying degrees of anorexia, nausea, vomiting, flatulence and diarrhea. These signs were of such severity as to be the major limiting factor in ascertaining total daily dosage that could be administered. This was especially true in those instances where maintenance of adequate nutrition was essential to the patient's welfare.

In an effort to explore the possibility of administering pimaricin intramuscularly, 0.25 mg in 0.5 cc of saline was injected into the buttocks of patient 5, resulting in a painful tumescence at the site.

Discussion

The oral administration of the currently available preparations of pimaricin in dosages acceptable to the patient appeared to have little influence on the clinical course of several varieties of mycoses. The one apparently good result concomitant with the administration of pimaricin occurred in a patient with disseminated coccidioidomycosis, a disease characterized by the occasional occurrence of spontaneous remissions. The therapeutic value of pimaricin in this patient must be interpreted with considerable reservation, especially in view of the fact that the other six patients with coccidioidomycosis who were treated in this series demonstrated no improvement.

The major limiting factor in the oral administration of pimaricin has been the nausea, vomiting, and diarrhea that have developed regularly when dosages in the range of 600 mg to 1000 mg per day in the adult have been reached. Thus far we have been unable to ascertain whether this represents direct local action on the gastrointestinal tract or central toxicity following absorption. Although several antinauseant and antiemetic drugs were administered during therapy, no consistent beneficial effect was obtained.

The administration of pimaricin intramuscularly in a dose 0.25 mg in 0.5 cc of saline was followed by an extremely tender tumescence indicating that this route of administration would not provide a means by which therapeutic amounts of the drug could be routinely administered. Preliminary studies are now in progress to evaluate the intravenous route of administration.

Summary

Pimaricin was administered orally to ten patients with a variety of systemic mycoses, including patients with disseminated coccidioidomycosis, disseminated mucocutaneous candidiasis and a mycetoma due to *Monosporium apii* *spermum*. Nausea, vomiting and diarrhea limited the use of this drug in the adult to dosage levels of 600 to 1000 mg per day.

One patient with disseminated coccidioidomycosis improved significantly during this therapy, but this must be interpreted with a great deal of reservation.

Tentatively in its present form and in doses acceptable to the patient pimarcin does not offer promise as an effective oral antifungal agent for the treatment of systemic mycoses.

References

- 1 STRUHL A P I HOEFLE G DROST J M WAISWISZ T VAN ECK & J C HODGERHEIDE 1958 Pimaricin a new antifungal. *In* Antibiotics Ann 880-885 Medical Encyclopedia New York N Y
- 2 DEBAER J & P A IRE 1959 Protection of antibiotic pimaricin from oxidation and ultraviolet light by chlorophyllin and other compounds. *Antibiotics and Chemotherapy* 9(6) 327-333
- 3 PATRICK J B R P WILLIAMS C F WOLF & J S WEBB 1958 Pimaricin I Oxidation and hydrolysis products. *J Am Chem Soc* 80(24) 6688-6689
- 4 PATRICK J B R P WILLIAMS & J S WEBB 1958 Pimaricin II The structure of pimaricin. *J Am Chem Soc* 80(24) 6688-6689
- 5 SORENSEN I J J McNALL G FARL & T H STERNBERG 1958-1959 The development of strains of *Candida albicans* and *Coccidioides immitis* which are resistant to amphotericin B. *In* Antibiotics Ann 920-923 Medical Encyclopedia New York N Y

GRISEOFULVIN

Frank J. Roth Jr

Departments of Microbiology and Dermatology, University of Miami School of Medicine
Coral Gables, Fla

The antifungal antibiotic griseofulvin represents a major advance in the treatment of superficial fungus infections due to dermatophytes. It is a highly distinctive agent among the antibiotics in that it specifically localizes and concentrates in the keratinized cells of the skin, hair, and nails. Dermatophytes parasitizing these structures are inhibited in further growth and penetration and are subsequently removed by desquamation or are replaced by tissues free of infection. This new mechanism of chemotherapy may provide a basic rationale for designing methods of treatment for other microbial diseases of these tissues.

Griseofulvin is a metabolic product of several species of the genus *Penicillium*. It was first isolated from homogenized mycelium of *P. griseofulvum* by Oxford *et al.* in 1939¹. The failure of the compound to demonstrate activity against bacteria resulted in no further study of its properties by those investigators. Brian and his co-workers in 1947² recovered a metabolite from cultures of *P. janczewskii* that produced hyphal abnormalities in the fungus *Botrytis allii*. This compound was termed the "curling factor" and a year later Grove and McGowan³ showed it to be identical with griseofulvin. The chemical structure of the antibiotic was established by Grove *et al.*⁴. The compound is a white, bitter, neutral, thermostable substance chemically designated as 7-chloro-2,4,6-trimethoxy-6-methyl-paro/benzofuran 2(3H)-1-(2-cyclohexene)-3,4'-dione. It is weakly soluble in water (0.001 per cent) but soluble in ethanol, methanol (0.1 per cent) and dimethylformamide (12.0 per cent). Its thermostability is attested to by the fact that it remains fully potent in the dry state for at least 2 years at a temperature of 35° C and can be autoclaved at neutrality for 30 min or more without loss of activity. The systemic anti-mycotic activity of griseofulvin in plants was shown by Brian and co-workers in 1951⁵. The compound has been widely used in agriculture to control and treat *Botrytis* infection of lettuce and *Alternaria* blight of tomatoes.

The first report of the value of griseofulvin administered by the oral route for the treatment of experimental dermatophyte infections of animals was made by Gentles in 1958⁶. Guinea pigs infected with *Microsporum canis* were cured with an oral dose of 60 mg/kg of the antibiotic. The drug was administered 10 days after infection and marked clinical improvement was noted within 4 days of therapy. At the eighth day of treatment the hair follicles were largely free of invading fungal structures and the hair formed during the treatment period was completely resistant to invasion by the dermatophyte. Similar success was observed when the animals were experimentally infected with *Trichophyton mentagrophytes*. The preliminary findings of Gentles were confirmed by Martin⁷ who demonstrated that experimental dermatomycoses in guinea pigs can be controlled by oral doses of 25 to 100 mg/kg of griseofulvin. Topical application of 1 per cent griseofulvin ointment inhibited the development of skin lesions when applied on the fourth day after infection. Topical

griseofulvin in the treatment of tinea capitis and other dermatophytoses in children proved ineffective in studies by Peterkin⁸ and Pardo Costello.⁹ More recently Goldman *et al*¹⁰ report that a lotion containing 1.5 per cent griseofulvin with surfactants, stabilizer and urea in glyceride oil proved to be highly effective in clearing affected areas in patients with tinea capitis, tinea corporis, tinea cruris and tinea pedis. In a recent study Gentles¹ reported that 8 daily doses of 15 mg/kg halted the progress of infection; however, reinfection from fungal elements in the distal portions of the hair occurred after cessation of treatment.

Orally administered griseofulvin was employed successfully by Lauder and O'Sullivan² to treat *T. verrucosum* infections in cattle. Kaplan¹¹ treated cats spontaneously infected with *M. canis* at a daily dosage level of 40 to 60 mg/kg. Clinical cures were obtained in all animals within a maximum of 5 weeks of therapy. Inasmuch as cats constitute the major source of human infections by the species *canis*, griseofulvin can be used to control this animal reservoir.

The presence of active griseofulvin in the hair of guinea pigs given an oral dose of 30 mg/kg for 23 days has been reported by Gentles and his co-workers.¹⁴ The hair contained approximately 6 µg of the antibiotic per gram of hair. Since half of the griseofulvin was extracted from the hair by cold water and the remainder by hot methanol, these workers concluded that the antibiotic is not chemically bound to the keratin but occurs mainly as a simple deposit. The transport of the antibiotic depot outward by subsequent hair growth blocks further invasion by the fungus, and the parasite is eventually eliminated by removal or loss of the infected portion of the hair.

With the publication of Gentles' initial work demonstrating the effectiveness of griseofulvin in the treatment of experimental dermatomycoses in animals, a number of clinical groups began administering the drug to infected human beings. These studies were undertaken nearly simultaneously in the fall of 1958 by three widely separated teams: Williams group¹⁵ in London, England; Blank and Roth⁶ in Miami, Fla., and Riehl⁷ in Vienna, Austria. Their highly encouraging reports, as well as those from others, initiated world-wide interest in the new antibiotic and prompted many clinical and laboratory investigations. Numerous reports of further successes with the drug began to appear in diverse publications, and the present medical literature attests to the great interest in griseofulvin. Information on the clinical and laboratory aspects of griseofulvin therapy accumulated so rapidly as to make possible the International Symposium on Griseofulvin held by the University of Miami, Miami, Fla., in October of 1959, approximately one year after the first reports of its efficacy in the treatment of dermatomycoses in human beings.

At the present time griseofulvin has emerged as the treatment of choice in tinea corporis due to *T. rubrum*, tinea capitis due to *M. audouinii* and *T. tonsurans* and other species, tinea cruris with *Ep. dermatophyton floccosum*, as well as dermatophytoses due to less common species. Chronic cases of tinea pedis due to *T. mentagrophytes* have responded less successfully and represent the most resistant infections in therapy. The antibiotic is still in the assessment stage and more information must be obtained before the drug can be evaluated fully.

The dosage of griseofulvin currently recommended for adults is 1.0 gm. per day. The duration of therapy is related to the site and nature of the infection.

Lesions confined to the skin, exclusive of those occurring on the palms or soles, require 3 to 5 weeks of daily doses of griseofulvin. Due to the greater thickness of the stratum corneum on the palms and soles, a longer term of treatment is necessary. It would appear that clinical and mycologic cures can be anticipated after 6 to 8 weeks of griseofulvin therapy. However, resistant cases may require longer periods of treatment, higher dosage levels, and concomitant topical therapeutic measures. Hair and nail infections must be treated until normal structures have replaced the infected ones, or diseased portions can be removed or cut away. A number of excellent studies dealing with the clinical aspects of griseofulvin therapy have been published.^{18 19 20 21}

The widespread oral administration of griseofulvin has shown it to be a drug of remarkably low toxicity. There have been no reports of significant toxic manifestations. An occasional patient reports mild gastrointestinal upset, diarrhea, and headaches. Drug rashes, of vesicular, urticarial, and maculopapular forms have been seen. Cross sensitivity with penicillin has not yet been recorded even in patients with known penicillin sensitivity. Griseofulvin therapy has not been shown to affect the trichophyton skin test reaction except to reduce the symptoms associated with a strong positive reaction. No abnormalities of liver function, kidney function or blood chemistry have been observed.¹⁸ The marrow and peripheral blood counts have shown no deviations that could be attributed to griseofulvin.¹⁹ Paget and Walpole²⁰ reported that the intravenous and intraperitoneal administration of the antibiotic to animals in doses in excess of 50 times that employed in man inhibits mitosis of actively dividing cells, especially in spermatogenesis. For this reason periodic sperm counts have been carried out on patients receiving griseofulvin. Blank and Roth¹⁹ conducted sperm studies on 15 patients in their series and none showed significant depression or deviations from the normal. In a more elaborate study of the effect of griseofulvin on spermatogenesis and semen quality, MacLeod²¹ observed no adverse effects in 22 normal subjects on a daily dose of 20 gm for 6 months. The semen was examined at weekly intervals and included in the study were sperm counts, motility studies and examinations of sperm morphology. In addition testicular biopsies were taken from 8 men after 12 weeks of treatment.

Development of strains of dermatophytes resistant to griseofulvin *in vitro* has been reported by Robinson *et al*.²² In this study the fungi were transferred successively on solid media containing increasing concentrations of the antibiotic to a maximum of 15 $\mu\text{g/ml}$. Strains of *T. mentagrophytes*, *M. canis*, and *M. audouinii* developed marked resistance to the drug. Concomitant changes in colonial characteristics and microscopic morphology were associated with the increased tolerance to griseofulvin. Lytton and his co-workers²³ also have reported success in inducing *in vitro* resistance to griseofulvin in dermatophytes. Of the species studied, strains of *M. canis* were found to develop the highest degree of tolerance. The mechanism of resistance appears to be founded in the production of fungal enzymes which reduce griseofulvin to a biologically less active compound.

As yet, no isolation of a resistant strain from patients undergoing griseofulvin therapy has been reported. Infection of animals with experimentally produced resistant strains of dermatophytes has not been shown to be

recalcitrant to griseofulvin therapy.²⁵ A limited number of cases of dermatomycoses that failed to respond to the recommended dosages of the antibiotic has been observed. Of the fungi isolated from these cases none tested has been shown to be more resistant than the pretherapy isolate or other representatives of the species. It is postulated that these therapeutic failures find their origin in inadequate absorption of the antibiotic, inadequate dosage levels, or failure of the drug to be incorporated into the keratinized tissue elements.

The incorporation of griseofulvin into a medium in which a dermatophyte is growing produces abnormalities in the resultant mycelium. Concentrations of the antibiotic as low as 0.05 $\mu\text{g}/\text{ml}$ cause excessive production of lateral branches and clubbing of the advancing hyphal tips. At higher concentrations (0.1 to 0.3 $\mu\text{g}/\text{ml}$) the cytoplasm becomes highly vacuolated and large lipid droplets make their appearance. The mycelium develops contortions, curls, and swelling, and numerous septa form. A progressive inhibition in the rate of linear growth is observed as the concentration of griseofulvin is increased until further extension of the peripheral hyphae is halted.

The effects of griseofulvin on the internal structure of dermatophytes, as revealed by electron microscopy, have been studied by Blank *et al.*²⁶ The antibiotic produces drastic changes in the organization of the cytoplasm and many of the intracytoplasmic structures observed in normal cells are apparently destroyed. The complex membranous organization of the endoplasmic reticulum is disrupted and the mitochondria largely disappear. Large spherical osmophilic lipid bodies appear and replace much of the cytoplasmic content. The cells of the mycelium are greatly enlarged and balloon-like swellings are common. In these areas the cell wall is greatly thickened and in places may be three to four times normal thickness. The disruption in the internal organization of the cells by griseofulvin would indicate that the effect of the antibiotic is more fundamental than mere interference with synthesis of the chitin component of the cell wall, as had been suggested by earlier workers.²⁷

In a study of the *in vitro* spectrum of activity of griseofulvin Roth *et al.*²⁸ observed that the 13 recognized species of dermatophytes all demonstrated a high degree of sensitivity to the antibiotic. The minimal inhibitory concentrations of the drug after 72 hours of incubation ranged from 0.18 $\mu\text{g}/\text{ml}$ in the case of *T. rubrum* to 0.42 $\mu\text{g}/\text{ml}$ for *M. audouinii*. The effect of the antibiotic on these fungi is limited to fungistasis regardless of the concentration of griseofulvin in the medium. Pellets of dermatophytes can withstand 30 days of contact with 30 $\mu\text{g}/\text{ml}$ of griseofulvin in liquid medium without loss of viability. Etiological agents of cryptococcosis, sporotrichosis, chromomycosis, nocardiosis, blastomycosis, geotrichosis, histoplasmosis, and coccidioidomycosis were insensitive to high concentrations (25 $\mu\text{g}/\text{ml}$) of the antibiotic at both 28° C and 37° C. The growth of the yeast *Candida albicans* was neither inhibited nor enhanced by griseofulvin and the intraperitoneal injection into white mice of the yeast in combination with the antibiotic had no potentiative effect on its pathogenicity such as is observed when tetracyclines are so employed. Griseofulvin in high concentration did not affect the growth of a select group of 18 species of pathogenic bacteria. Similarly, 40 species of nonpathogenic ascosporogenous yeasts and imperfect yeasts and yeastlike fungi were completely resistant to a high concentration of the antibiotic.

Emmons¹⁰ tested the effect of griseofulvin on mice experimentally infected with the agents of histoplasmosis, blastomycosis, cryptococcosis, and coccidioidomycosis. The antibiotic was administered orally, intraperitoneally, and intravenously in daily doses of up to 30 mg per mouse. In no case did the treatment eliminate the infection or extend the survival times of the infected mice. Latap¹¹ recently reported the efficacy of griseofulvin therapy in human cases of sporotrichosis and mycetomas due to *Nocardia brasiliensis*. The antibiotic was administered orally in daily doses of from 1 to 2 gm. per day. Favorable responses, even to clinical cures, were observed in these mycotic diseases in spite of the lack of *in vitro* sensitivity of the etiological agents to griseofulvin. No evidence of improvement was noted in cases of chromomycosis similarly treated.

The presence of griseofulvin in human stratum corneum and its rate of transport through the epidermis has been demonstrated by Roth and Blank.¹² A direct *in vivo* bio-assay procedure was employed in which macroconidia of *M. gypseum* were applied to the skin of the inner surface of the forearm in micro-slide ring cultures. The presence of the antibiotic in the stratum corneum was established by the induction of morphologic abnormalities in the emerging germ tubes of the spores. Griseofulvin does not inhibit germination of the macroconidia but results in the clubbing, contortion and branching of the primary hyphal elements. The progress of griseofulvin through the thickness of the stratum corneum was determined by stripping off the cornified cellular elements to the desired depth with multiple applications of pressure sensitive tape. The antibiotic was detected at the junction of the stratum corneum and stratum mucosum in from 48 to 72 hours after onset of therapy. In subjects receiving 1 gm. of griseofulvin daily the drug had been transported through the 20 per cent level of the stratum corneum in from 7 to 12 days and attained the midpoint in from 11 to 19 days. The time required for the transport of the antibiotic to the various levels of the epidermis was directly correlated to the thickness of the horny layer of the subject. Utilizing this bio-assay technique, no unequivocal evidence of the presence of active griseofulvin at the surface of the intact skin was obtained even though some subjects were on therapy for as long as 7 weeks.

In spite of its limited solubility in water the antibiotic is quickly absorbed from the gastrointestinal tract. Employing spectrophotofluorometric assay techniques, Child and Tomich¹³ showed that peak blood levels occurred 4 hours after a single oral dose of griseofulvin. The compound was concentrated in the skin, liver, fat and skeletal muscle. In man and rat, the half life of the antibiotic during the decay period was approximately 6 hours. Sixteen per cent of an oral dose was excreted in the feces and less than 1 per cent was detected in the urine in the 24 hours following administration. Experiments in which rat tissue slices were employed showed that griseofulvin was rapidly destroyed by the liver but was not inactivated by the spleen, lung or kidney. As yet little is known of the mechanisms by which griseofulvin inhibits the growth of sensitive fungi. Roth and his co-workers¹⁴ conducted preliminary studies on the effect of the antibiotic on the respiration of *T. rubrum*. Utilizing Warburg manometric determinations, these investigators showed that griseofulvin had no effect on the cytoplasmic energy centers of the fungal cell. They

have postulated that, if energy mechanisms are influenced by the drug, it must be at a superficial locus such as the cell wall area. Recent studies by McNall¹² have shown that the inhibitory effect of griseofulvin is based, at least in part, on an interference in the synthesis of fungal nucleic acids. The antibiotic within the cell competes with purine nucleotides essential for elaboration of nucleic acids. The competitive inhibitory action is not complete, and the effect of the drug can be reduced or reversed by normal metabolites. Griseofulvin thus retards the metabolic activities of the fungus and curtails growth to a degree sufficient to permit the host to eliminate the arrested organism by exfoliation of the stratum corneum.

The availability of a highly efficacious and specific chemotherapeutic agent for the treatment of dermatophytoses imposes a greater responsibility on both the clinician and the medical mycologist. Since clinical manifestations of candidiasis, psoriasis, bacterial infections, alopecias, and other dermatologic disorders often closely resemble those of the superficial mycoses, it is mandatory that competent mycologic studies be performed. Consideration of the prolonged course of griseofulvin therapy frequently required in onychomycosis and other chronic tinea makes definitive laboratory studies of paramount importance. In the final analysis, the only criterion that can determine the required dosage levels and duration of treatment with griseofulvin and the final attainment of a biological cure are the laboratory findings obtained by the medical mycologist.

References

- 1 OXFORD A E H KAISTRICK & P SIMONART 1939 Studies of the biochemistry of microorganisms. LX Griseofulvin $C_{17}H_{12}O_6Cl$ metabolic product of *Penicillium griseofulvum* Diercks. *Biochem J* 33: 240.
- 2 BRIAN F W J J CURTIS & H J ISFARMING 1946 Biological assay production and isolation of curling factor. *Trans Brit Mycol Soc* 29: 173.
- 3 GROVE J I & J C MCGOWAN 1947 Identity of griseofulvin and curling factor. *Nature* 160: 574.
- 4 GROVE J F D ISMAIL J MACMILLAN T P C MULHOLLAND & M A T ROGERS 1951 The structure of griseofulvin. *Chem & Ind* 11: 219.
- 5 BRIAN F W J M WRIGHT J STUBBS & A M WAY 1951 Antibiotics as systemic fungicides. *Nature* 167: 347.
- 6 GENTLES J C 1958 Experimental ringworm in guinea pigs: oral treatment with griseofulvin. *Nature* 182: 476.
- 7 MARTIN A R 1958 Systemic treatment of dermatophytoses. *Vet Record* 70: 1232.
- 8 PETTERKIN G A G 1958 Diagnosis and treatment of tinea pedis. *Practitioner* 180: 543.
- 9 PARDO-COSTELLO A 1959 Bol Soc Cuban dermatol y sifilografia. 11: 1.
- 10 GOLDMAN L J SCHWARTZ R H PRESTON A BEYER & J LOOTZENHISER 1960 Current status of griseofulvin. *J Am Med Assoc* 172: 532.
- 11 GENTLES J C 1959 The treatment of ringworm with griseofulvin. *Brit J Dermatol* 71: 427.
- 12 FAUDER J M & J G O'SULLIVAN 1958 Ringworm in cattle. Prevention and treatment with griseofulvin. *Vet Record* 70: 949.
- 13 KAPLAN W Therapy of spontaneous ringworm in cats with orally administered griseofulvin. *AMA Arch Dermatol*. In press.
- 14 GENTLES J C M J BARNES & K H JAMES 1959 Presence of griseofulvin in hair of guinea pigs after oral administration. *Nature* 183: 256.
- 15 WILLIAMS D I R H MARTIN & I SARLANY 1958 Oral treatment of ringworm with griseofulvin. *Lancet* 2: 1212.
- 16 BLANK H & F J ROTH JR 1959 The treatment of dermatomycoses with orally administered griseofulvin. *AMA Arch Dermatol* 79: 259.
- 17 RIEHL G 1959 Peroral wirkendes Antimykoticum. *Hautarzt* 10: 136.

- 18 BLANK H, J G SMITH JR & F J ROTH JR 1959 Griseofulvin for the systemic treatment of dermatomycoses J Am Med Assoc 171 2168
- 19 KIRA J & L AJELLO 1959 Use of griseofulvin in the therapy of tinea capitis in children AMA Arch Dermatol 80 259
- 20 ROBINSON H M R C V ROBINSON F BERESTON I MANCHEY & F A BELL 1960 Griseofulvin clinical and experimental studies AMA Arch Dermatol 81 66
- 21 PRAZZA G J S FERGLSON J F COMPTON & B S McNEILL Treatment of tinea pedis with griseofulvin AMA Arch Dermatol In press
- 22 PAGET G E & A L WALPOLE 1958 Some cytologic effects of griseofulvin Nature 181 1320
- 23 MACLEOD J Griseofulvin and human spermatogenesis AMA Arch Dermatol In press
- 24 VITTOLO R S C A H CAMPBELL, F J NAPIER & D A L SEILFEL Mycological aspects of action of griseofulvin against dermatophytes AMA Arch Dermatol In press
- 25 ROSENTHAL S A Studies of the development of resistance to griseofulvin by dermatophytes AMA Arch Dermatol In press
- 26 BLANK H D TAPLIN & F J ROTH JR Electron microscope observations of the effects of griseofulvin on dermatophytes AMA Arch Dermatol In press
- 27 BRIAN I W 1949 Studies of the biological activity of griseofulvin Ann Botany 13 59
- 28 ROTH F J JR B SALLMAN & H BLANK 1959 In vitro studies of the antifungal antibiotic griseofulvin J Invest Dermatol 33 403
- 29 EMMONS C W Failure of griseofulvin to control experimental systemic mycoses in mice AMA Arch Dermatol In press
- 30 LAYAPIN B Griseofulvin in the treatment of some deep mycoses AMA Arch Dermatol In press
- 31 ROTH F J JR & H BLANK The bioassay of griseofulvin in human stratum corneum AMA Arch Dermatol In press
- 32 CHILD A J & F G TOMICH Distribution studies with griseofulvin in animals and man AMA Arch Dermatol In press
- 33 McVALL, L G Biochemical studies on the metabolism of griseofulvin AMA Arch Dermatol In press

GRISEOFULVIN IN DEEP MYCOSES

A. González Ochoa

Instituto de Salubridad y Enfermedades Tropicales Mexico City D. F. Mexico

During the recent symposium on griseofulvin held in Miami, Fla. in October 1959,¹ the agreement was reached that this antibiotic is useful only in dermatophytoses or mycoses caused by dermatophytes, a fact that had been foreseen from its fungistatic spectrum. It was also the consensus that the antibiotic is almost atoxic, and that it does not produce resistance *in vivo*.

Among the points on which a difference of opinion did exist is that of griseofulvin's activity in deep mycoses.^{1,2} The experiences of Emmons³ on the failure of griseofulvin in the experimental infections of mice by *Histoplasma capsulatum*, *Cryptococcus neoformans*, *Coccidioides immitis*, and *Blastomyces dermatitidis* were in accordance with the results *in vitro*. Notwithstanding this definite information my associates and I treated some patients with deep mycoses using griseofulvin and taking into account the fact that there have been previous experiences in microbiology where there is a lack of parallelism between results *in vitro* (or even in experimental infection) and clinical results.

The patients with deep mycoses subjected to treatment with griseofulvin were four with actinomycotic mycetoma from *Nocardia brasiliensis*, one with severe primary pulmonary histoplasmosis, two with chromoblastomycosis, and two with sporotrichosis. Except in treating sporotrichosis, griseofulvin failed as a therapeutic agent in all of these patients. The data from these observations constitute the material of this report.

Actinomycotic Mycetoma

In all 4 adult patients mycetoma was due to *N. brasiliensis* and was localized in the lower extremity. The duration of the infections varied, the extremes being a case that lasted 6 months, in which only the soft tissues were affected and another that had resisted all treatment for 8 years, this case involved in sections of bones of the leg and pelvis, and also of the urinary bladder. Griseofulvin was given to all 4 patients, the daily dose of 1 gm. being divided into 4 administrations. This treatment was usually maintained for 2 months and then suspended for lack of noticeable improvement.

Chromoblastomycosis

Two of these patients were adults, both infected by *Hormodendrum pedrosoi*, the first had a foot infection that had lasted 4 years, the second suffered in infection of the foot and leg with a 6-year long evolution. The latter patient had undergone surgical removal of diseased skin with the consequent skin grafts but the verrucous lesions reappeared in 3 places with abundant parasites. Since the administration of griseofulvin did not improve the clinical picture it was suspended after the usual 2 months.

Histoplasmosis

A young Swiss stayed in México, D. F., for a few months then visited a cave near the city of Orizaba in the state of Veracruz. Twelve days later he

presented fever and severe dyspnea, X rays showed abundant nodular infiltrates in both lungs, precipitin test with histoplasmin was positive at 1:32 dilution, and *H. capsulatum* was observed in sputum and was later isolated by culture. A slight improvement that lasted for 12 days was observed after 1 month of development, then fever and dyspnea increased, and X rays showed confluence of the nodules, especially in both bases. This was probably due to the previous administration of ACTH in order to decrease the temperature. Under these circumstances treatment with griseofulvin was started at 2 gm/day in 4 administrations. The patient's condition deteriorated and, after 35 days, treatment was suspended, he died 10 days later.

Sporotrichosis

We treated an outbreak of sporotrichosis in 3 patients exposed to the same focus of infection at the same time. The father, 32 years old, and the mother, 24 years old, presented lymphangitic type sporotrichosis with gummatous development⁴ on the right arm (figures 1a and b), the child, 8 months old, presented a fixed type sporotrichosis with a verrucous clinical form¹ on the left temporal region (figure 1c). After 2 months of clinical course the 3 patients were treated as follows: the father with potassium iodide, beginning with 0.50 gm and increasing the same amount per day until the daily dose was 4 gm. This dosage was continued over a period of 3 months. Both mother and son were subjected to treatment with griseofulvin. None of them received 1 gm and the son 250 mg daily divided in 4 administrations for a period of 3 months. The results in all 3 cases were amazingly similar. Only the patients presented any noticeable change after 2 weeks of treatment. One month later a 30 per cent improvement was observed in all three. After 2 months the clinical improvement was estimated at 70 per cent. The patients were considered cured 3 months later and therapy was suspended. Only patients continued under observation for 5 months after treatment was suspended and no relapse was observed. The antibiotic produced no side effects. The interest of this report lies perhaps in the fact that in sporotrichosis the same phenomenon is observed in relation to griseofulvin as to potassium iodide: that is, there is no parallelism between its action *in vitro* and its effect *in vivo*; this is true to such an extent that a 10 per cent concentration does not inhibit the growth of the organism⁴ and the substance does not prevent experimental sporotrichosis.⁴ Consequently, there is still no convincing explanation for the action of potassium iodide and griseofulvin in infections by *Sporotrichum schenckii*. Since cutaneous sporotrichosis has a specific treatment in potassium iodide for obvious reasons, griseofulvin would in no way be a substitute for it but knowledge of its usefulness in cutaneous sporotrichosis authorizes its use in visceral forms, as in pulmonary sporotrichosis in which potassium iodide does not achieve a cure. It is also possible that synergism may exist when both substances are used.

Summary

Observations are presented on the results of treatment with griseofulvin in 4 patients with actinomycosis mycetozoi from *A. brasiliensis*, 2 cases of chromo-



FIGURE 1

blastomycosis 1 case of severe primary pulmonary histoplasmosis and 2 cases of sporotrichosis. With the exception of sporotrichosis griseofulvin failed as a therapeutic agent in all of these patients.

The 2 cases of sporotrichosis described in this study involved an outbreak in 3 patients a father a mother, and their son. The father was treated with potassium iodide the mother and son with griseofulvin. The beneficial results with griseofulvin were identical to those obtained with potassium iodide given to the father as control. Complete cure was obtained in the same length of time with both medications 3 months of treatment for each patient. The cases continued to be under observation for 5 months after treatment was suspended and no relapse was observed. The antibiotic produced no collateral effects.

References

- 1 IARDO CASTELLÓ V. 1959 Paper presented at the Symposium on griseofulvin and dermatomycoses Univ. of Miami October 26 and 27 Miami Fla.
- 2 LATAPI F. *Ibid*
- 3 JIMMONS W. C. *Ibid*
- 4 GONZÁLEZ OCHOA V. 1955 The status of fungus diseases in Mexico. In Therapy of Fungus Diseases 66-72 H Sternberg and D Newcomer Ed Little Brown Boston Mass.
- 5 NORDÉN A. 1951 Sporotrichosis Clinical and laboratory features and a serologic study in experimental animals and humans. Acta Pathol Microbiol Scand (Suppl) 97.
- 6 DAVIS D. J. 1916 The effect of potassium iodide on experimental sporotrichosis. J Infectious Diseases 111 124.

NYSTATIN

Elizabeth L. Hazen and Rachel Brown

Division of Laboratories and Research New York State Department of Health Albany N. Y.

Nystatin is a polyene antibiotic of broad antifungal spectrum produced by *Streptomyces noursei*.¹ The antibiotic possesses certain unique chemical and biological properties that have given it a distinctive place among antifungal agents of importance, and also certain undesirable characteristics that have restricted its potential usefulness. In this paper we discuss some of the important chemical properties, the mode of action, development of resistance, the practical applications in the laboratory, and the use in therapy and prophylaxis of fungus diseases.

Physical and Chemical Properties

The more significant physical and chemical properties of nystatin are briefly presented as a basis for better understanding of the antibiotic. One of the outstanding characteristics is its slight solubility. Except at acid or alkaline reactions, nystatin is almost insoluble in water, but it is somewhat more soluble in the lower aliphatic alcohols, especially if water is present, and it is highly soluble in solvents such as propylene glycol, Δ, Δ -dimethylformamide, or dimethylsulfoxide.

Although nystatin was the first of the so called polyene antibiotics to be reported,² its chemical structure has not been completely elucidated. It is known to have both a conjugated diene and a conjugated tetraene moiety in the molecule.³ Of considerable interest in the chemistry was the identification of the aminomethyldeoxyribose, mycosamine,⁴ which was also identified in pimaricin,⁵ another tetraene, and in amphotericin B, a heptaene. The infrared spectrum indicates the presence of carboxyl and lactone structures. Because of the extensive unsaturation of the molecule, nystatin is unstable and hence readily inactivated. Crystalline material, however, has been stored at refrigerator temperature for 8 years without appreciable loss of activity, and aqueous suspensions were stored at -25°C for 18 mo without deterioration. At room temperature both alcohol solutions and aqueous suspensions gradually lose potency.

Mode of Action

Since nystatin is representative of a group of antibiotics specifically effective against fungi, its mode of action is naturally under study by several investigators, and some of their findings will be reviewed briefly. Lampen and his co-workers⁶⁻⁸ have observed the conditions under which this antibiotic is taken up by sensitive microorganisms and have demonstrated that resistant strains of *Candida* absorb less than do sensitive strains. Since the methyl ester and the Δ acetyl derivatives, which are not inhibitory to fungi, are not absorbed to any significant extent, these authors postulate that the ionic species $\text{HOOC} - \text{NH}_3^{+}$ in the molecule is responsible for the absorption by the cell. Working with bakers' yeast exposed to nystatin, Lampen and his asso-

rates observed an increase in the production of tri-phosphate, pyruvate, and malate and a marked reduction in activity of the following enzymes, aldolase, glyceraldehyde phosphate dehydrogenase, and phosphoglycerate kinase. They conclude that this effect on enzymes may be due to proteolytic turnover released under the influence of the antibiotic. Horvath *et al.*¹ further more observed that nystatin in less than fungistatic concentrations inhibited the production of amylase by *Penicillium chrysogenum*.

In the light of possible released proteolytic activities it is interesting to note the following random observations with *Histoplasma capsulatum*¹⁰. The yeastlike cells that normally, upon treatment with concentrated hydrochloric acid, yield soluble diuretic positive fractions active in the fixation of complement, failed to do so if first exposed to nystatin. Thus, there apparently was alteration in the protein components as evidenced by lack of serologic activity. This treatment resulted in shrunken cells, accompanied by a decrease in the volume of packed cells.

While Harman and Masterson¹¹ conclude that nystatin acts on several stages of glucose metabolism by *Candida albicans* and also depresses glucose uptake by alteration of cell permeability, Lampen *et al.*¹² found that glucose is still able to cross the cell wall of *Saccharomyces cerevisiae* rendered incapable of utilizing glucose by exposure to the antibiotic. Osteux and his co-workers¹³ observed increased amounts of radioactive P, mainly as orthophosphate in the medium used to suspend labeled *C. albicans* cells following the addition of nystatin and interpreted this to mean selective modification of cell membrane permeability. Bradley¹⁴ reports that the inhibition of the assimilation of glucose by *C. stellatoidea* exposed to this agent is not primarily an effect on permeability. He found cell wall development and protein synthesis unaltered and inhibition of glucose fermentation accompanied by altered phosphite metabolism and reversible by phosphate. Studies with the electron microscope destroying the cell walls. Ribereau-Layton and his co-workers¹⁵ found that induced to Blank¹⁶ that nystatin induced cytotoxicity of *C. albicans* cells without inhibiting the cell walls. Ribereau-Layton and his co-workers¹⁷ found that the respiratory, and especially the fermentative, activities of *Saccharomyces ellipsoidea* were inhibited by the antibiotic more strongly at pH 3.8 than at pH 7.0 when activity at neutrality. Small amounts enhanced fermentation to such some of these physiological, metabolic and biochemical responses to nystatin are not shown by bacteria or the occasional fungi that are resistant to the action of the antibiotic. The effect may be considered as peculiar to the genus and even to the species.

Development of Resistance

The possibility that resistant microorganisms may develop during therapy with nystatin has concerned many investigators. Several^{18, 19} of these researchers have reported that recent isolates of various species of *Candida* are sensitive to small amounts of antibiotic while Roda *et al.*²⁰ found that 36 of 79 strains of *C. krusei* were not inhibited in dilutions, although other species were. *C. albicans* isolates obtained before and after treatment have shown the same degree of sensitivity.^{18, 20, 21} Moreover, relapses following the cessation of treatment for moniliasis apparently have not been due to the presence of

resistant microorganisms. *In vitro* experiments⁷⁻¹¹ have demonstrated that a low grade resistance of *Candida* strains may be induced, although inconsistently. The mutants resistant to nystatin were also resistant to amphotericin B¹ or to sodium arsenate¹¹ and vice versa. A significant observation was made by Manning and Robertson²⁰ when treating a case of pulmonary aspergillosis. No resistant strain emerged after 38 days of nystatin therapy but the isolated *Aspergillus fumigatus* developed *in vitro* resistance in the laboratory. It is thus obvious that the acquisition of resistance *in vitro* is not the reflection of any *in vivo* pattern and that therapy with this antibiotic is to date uncomplicated by the appearance of resistant pathogenic fungi.

Laboratory Applications

In the laboratory, nystatin has found extensive applications²¹⁻²³ for the control of yeast and mold contamination in bacteriological media in samples of biological materials of human and animal origin from which the isolation of pathogens is to be attempted, and especially in tissue culture techniques. Effective concentrations are not inhibitory to growing viruses and not toxic for various lines of cells from human, murine, rabbit, porcine, bovine, feline, chick and monkey sources.

Therapy and Prophylaxis

The therapeutic and prophylactic applications of nystatin stem from its *in vitro* antifungal properties. It possesses strong activity against a wide variety of pathogenic and nonpathogenic yeasts and, to a somewhat lesser degree filamentous fungi. Animals infected experimentally with lethal doses of *Cryptococcus neoformans*, the yeastlike forms of *Blastomyces dermatitidis*, *H. capsulatum* and *C. albicans* received marked protection from nystatin injected subcutaneously.²⁴ No detectable cumulative systemic toxic effects resulted from repeated subcutaneous doses. At the site of injection there were induration and necrosis that healed spontaneously. Significant blood levels following subcutaneous injections of single doses of 100 mg/kg, were demonstrated in the mouse.

These potentialities of nystatin as a therapeutic agent, suggested by its effectiveness in animals have not been entirely realized in man since the antibiotic displays toxic properties and is poorly absorbed from the gastrointestinal tract. The toxic effects depend upon the route of administration. Applied topically orally or by inhalations or instillations in the form of an aerosol nystatin is remarkably free of harmful reactions. Few allergic effects or cases of contact dermatitis have been reported.²⁵ Newcomer and his associates²⁶ observed no side reactions other than transitory nausea and diarrhea when oral treatment was prolonged for 6 months and doses reached as high as 12 gm daily. Parenteral injections however, were shown in early clinical investigations to induce undesirable reactions. Given intravenously, it caused sclerosing of the veins, the initial injections being accompanied by shaking chills, fever, and malaise, intramuscular injections were followed by severe pain and tenderness at the site of injection. The unsuitability of the parenteral routes of administration and poor absorption from the gastrointes-

anal tract have curtailed its usefulness in therapy of the deep mycoses and the dermatophytoses as well.

However nystatin has proved remarkably effective in diseases where immediate direct contact between fungus incitant and antibiotic could be accomplished by topical application or administration inhaled or local injection. Favorable reports on the effectiveness of treatment of the various clinical forms of moniliasis (candidiasis) in infants, children, and adults are to be found in increasing number in the medical literature. Only a few of the more recent papers will be cited since many earlier ones were previously reviewed.

Infections in infants involving the oral cavity as gastrointestinal as urinary and respiratory as tracts intertriginous folds as genitocrural region as or cutaneous tissues have responded well as a whole often dramatically without significant side effects. Response to retreatment was usually prompt in instances of relapse in a few patients there was no response to nystatin. Korinn and Taschdjian¹¹ reported 11 infants cured after 1 course of therapy. 7 relapsed but responded promptly to retreatment and 2 improved but were not cured after 5 to 7 days when they were lost to observation. In addition Pohowalla and his associates¹² found that 75 per cent of 28 infants with oral moniliasis three fourths with complications of monilial diarrhea, were clinically cured by oral nystatin by the seventh day and 60 per cent were culturally negative. Seven of 13 suffering from dehydration died. These authors warned that dehydration in babies with thrush carries a high mortality. Huang and High¹³ found the antibiotic ineffective in 7 of 41 infants and children treated for oral moniliasis. 7 of these 7 were in a group of chronically ill older infants and children and premature infants many of whom were being treated with other antimicrobial agents. Gratifying results with combined oral and topical applications in 40 of 46 infants with eruptions of the genital area were reported by Robinson.¹⁴ Dobias¹⁵ found that 4 infants with candida in the stool and oral and cutaneous moniliasis when treated with oral nystatin experienced complete disappearance of a diarrhea due probably to gastrointestinal moniliasis. Symptoms of vulvovaginitis in a 2 month-old girl disappeared after 5 days of oral nystatin and an infant with cutaneous moniliasis dyspepsia, cyanosis and a rash evidence of pulmonary infiltration was cured of her respiratory symptoms after 3 days of oral nystatin alone. DeChre and his associates¹⁶ also found nystatin a favorable therapeutic agent in candida infections of the intestinal mucous membrane cutaneous abscesses and infections of the urinary tract.

Nystatin has also proved efficacious in moniliasis of children and adults although in some instances a long period of treatment may have been required. It well is Strauch and Levine¹⁷ and Grupper¹⁸ had remarkable success with nystatin in infections of the mucous membrane skin and nail and observed no harmful effects due to this antibiotic. Grupper pointed out the necessity of debulking infected foci at the base of the nail in chronic infections so that the antifungal agent could penetrate below the deeper layers of keratin where candida is localized and he advised to others have the concurrent use of topical and oral treatment. Wright and his associates¹⁹ treated effectively

122 infections of the mucous membranes and cutaneous tissues with nystatin. Five patients in whom the results were only fair had severe systemic illness or were receiving prolonged steroid or antibiotic therapy. These investigators stated that the clinical effectiveness was influenced by the type of vehicle in which nystatin was placed. For example, when it was used in ointment form to treat infections of the intertriginous areas the results were poor in contrast to rapid healing of the lesions when the drug was in solution. Dobias³⁶ has similarly warned against the use of any ointment on moist lesions.

Sahni³⁷ effectively treated a pulmonary moniliasis of an eight year-old child with potassium iodide and with nystatin both orally and by inhalation. He stated that it would be difficult to judge the relative roles played by the nystatin and the potassium iodide but added that the duration of active therapy required was shorter than that reported when the iodide was used alone. Mc Kendrick and Medlock³⁸ successfully employed inhalations of the antibiotic in aerosol in pulmonary moniliasis complicating fulminating influenzal pneumonia. Stewart³⁹ found nystatin to be an agent of very definite importance in the treatment of pharyngorespiratory mycotic infections. He emphasized however that any assessment of the efficacy of nystatin against such infections must be based upon a critical realization of the superficial nature and tendency to spontaneous amelioration of many monilial lesions. Robinson⁴⁰ found that the oral administration of large doses was effective in the treatment of a patient with cutaneous and urinary tract infections. Employing oral nystatin Barrett and his associates⁴¹ failed to prevent a fatal outcome of systemic moniliasis complicating pancreatitis with pancreatic abscess. The patient had received broad spectrum antibiotics over a long term. They suggest that the concurrent use of a fungicidal agent be considered when broad spectrum antibiotics are used in large doses for long periods of time. Vanbreuseghem and Eyckmans⁴² met with no success in the use of very large oral doses of nystatin in a patient with chronic moniliasis of long duration in whom local treatment with antiseptics and antifungals as well as actinotherapy had failed.

Raffe⁴³ employing intraperitoneal and intramuscular routes of injection of nystatin dissolved in propyl alcohol effectively treated a case of systemic moniliasis including granulomatous lesions of spleen and liver associated with prolonged use of broad spectrum antibiotics. Duncan⁴⁴ using silver reported prompt success in the treatment of a cutaneous moniliasis of the axilla resulting from the daily use of a deodorant ointment containing antibiotic.

Nystatin should find its greatest usefulness in monilial vulvovaginitis particularly in pregnant women. Reports⁴⁵⁻⁴⁷ of excellent results are frequent in the current literature indicating this antibiotic to be the therapy of choice for this annoying and common infection. Relief of symptoms is usually prompt and without evidence of toxicity.

On the controversial subject of the prophylactic use of nystatin Welch⁴⁸ after consideration of the conditions under which moniliasis is most likely to develop concluded that logically the antibiotic should be administered prophylactically whenever high doses of the broad spectrum antibiotics and/or the concurrent use of cortisone and related compounds are required for debilitated patients, diabetics and infants (particularly premature). Such situations

are frequently faced in the antibiotic treatment of bacterial endocarditis and meningitis, or for the prevention of rheumatic recurrences and in the treatment of leukemia with steroids.

As a prophylactic agent nystatin should find its greatest usefulness in the prevention of neonatal thrush, with its serious consequences.¹⁰ As early as 1938 Woodruff and Hechtline¹¹ showed that the incidence of thrush in the newborn has a direct relationship to the presence of fungi in the generative tract of the mother. This they found to be as high as 29 per cent in the third trimester of pregnancy and considerably higher in the lower economic groups. B. Dobias (personal communication) recommends a careful mycologic examination of the vagina of every pregnant woman, and the use of nystatin therapy in every patient in whom *C. albicans* is found. Pitt and Shant¹² have stated that the protection of an infant against exposure to a potentially dangerous *C. albicans* infection demands the prompt and effective treatment of every pregnant patient with vaginal moniliasis, they recommend prophylactic use of nystatin during the last week or 10 days of pregnancy as a justifiable and desirable measure in these women. Harter and his associates¹³ endeavoring to eliminate thrush in the newborn nurseries found that of 714 infants treated with nystatin not 1 developed thrush during its hospital stay and only 3 developed it within 1 week after discharge. In the control group of 728 untreated infants 18 developed thrush in the hospital and 13 in their first week at home. These investigators concluded that thrush can be eliminated completely from hospital nurseries by the simple harmless and inexpensive procedure of instilling nystatin solution into the mouths of newborn babies.

Other mycotic infections in which nystatin therapy appears to offer promise are aspergillosis of lungs, eye and external ear and accessible lesions of histoplasmosis.

Riddle¹⁴ reported early that inhalation of nystatin in suspension was effective in removing *A. fumigatus* from bronchial secretions. Manning and Robertson¹⁵ successfully treated a secondary infection due to *A. fumigatus* in a long-standing pyopneumothorax. The fungus was isolated in pure culture on 3 occasions from the sputum and once from the intrapleural cavity before treatment was begun. Nystatin was introduced in aqueous suspension by intrapleural instillations at first on successive and later on alternate days for 39 days. No side effects were noted. The authors thought it probable that *A. fumigatus* established itself in the pyopneumothorax as a result of treatment with a broad spectrum antibiotic over a period of 16 days. Gero and Zuck¹⁶ reported success in the treatment of a pulmonary aspergillosis by introduction of nystatin in aerosol containing 10,000 to 300,000 units by inhalation of the patient had improved. At the end of 4 weeks the general condition of the patient had improved. Prior to treatment sputum and chest films and the culture produced *A. fumigatus*. Mungaiara and Liebm¹⁷ reported that nystatin exerted a beneficial

effect in the treatment of a case of hypopyon keratitis caused by *A. fumigatus* they employed oral doses in conjunction with instillations of an aqueous suspension into the conjunctival sac

By injection of nystatin directly into oral *Histoplasma* lesions, Plotnick and Cerriti²³ brought about complete disappearance of the localized disease process. *H. capsulatum* was found in histological sections of biopsy of the lesion and was isolated from the specimen before treatment

Summary

Nystatin is a valuable therapeutic and prophylactic agent for the many clinical forms of moniliasis and has been shown to be efficacious in the treatment of pulmonary aspergillosis

This antibiotic has a broad antifungal activity, its chemical properties are unusual. It is not known to induce *in vitro* resistance, and it has been shown to induce only a low grade resistance *in vitro*. It lacks oral and topical toxicity

References

- HAZEN F L & BROWN 1951 Fungicilin, an antifolate produced by a soil actinomycete. *Proc Soc Exptl Biol Med* 76 93-97
- HAZEN F L & BROWN 1950 Two antifungal agents produced by a soil actinomycete. *Science* 112 423 (Soc Proc)
- DUTCHER J D D R WALTERS & O P WINTERSTEINER 1953 Studies of the chemical properties and structure of nystatin (Mycostatin). In *Therapy of Fungal Diseases*. An International Symposium 168-175. T H Sternberg & A D Newcomer Eds. Little Brown Boston Mass
- WALTERS D R J D DUTCHER & O WINTERSTEINER 1957 The structure of mycosamine. *J Am Chem Soc* 79 5076-5077
- PATRICK J B & J WILLIAMS C E WOLF & J S WEBB 1948 Imaricin. I. Oxidation and hydrolysis products. *J Am Chem Soc* 80 6688-6689
- LAMPEN J O I R MORGAN & SLOCUM & P ARON 1959 Absorption of nystatin by microorganisms. *J Bacteriol* 78 282-289
- LAMPEN J O & P ARON 1959 Significance of nystatin uptake for its antifungal action. *Proc Soc Exptl Biol Med* 101 792-797
- SCHOLZ R H SCHMITZ T BLICHER & J O LAMPEN 1959 Über die Wirkung von Nystatin auf Bäckerhefe. *Bochem Z* 331 71-80
- HORVÁTH I & A SZENTIRMAI 1959 Inhibitory effect of fungistatic antibiotics on the production of amylase by *Penicillium chrysogenum*. *Nature* 184 57-58
- BROWN H I I HAZEN & C H GREENE 1953 Fungal antigens for complement fixation tests. *Histoplasma capsulatum*. Ann Rept Div Lab & Research N Y State Dept of Health Albany N Y 45-47
- HARMAN J W & J G MASTERSON 1957 The mechanism of nystatin action. *Irish J Med Sci* Sixth series 378 249-253
- LAMPEN J O I R MORGAN & A SLOCUM 1957 Effect of nystatin on the utilization of substrates by yeast and other fungi. *J Bacteriol* 74 297-302
- OSTEUX H TRAN VAN KY & J BIGGET 1953 Contribution à l'étude du mode d'action de la nystatine sur *Candida albicans*. *Compt rend acad sci* 247 2475-2477
- BRADLEY S G 1958 Interactions between phosphate and nystatin in *Candida stellatoidea*. *Proc Soc Exptl Biol Med* 98 786-789
- BRADLEY S G 1958 Effect of nystatin on *Candida stellatoidea*. *Antibiotics & Chemotherapy* 8 282-286
- BLANK H 1957 Antifungal antibiotics in clinical medicine. *AMA Arch Dermatol* 75 184-192
- RIBÉREAU GAYON J E PEYNAUD S LAFOURCADE & M LAFON 1958 Mode d'action des antibiotiques antifongiques sur les levures. *Bull soc chim biol* 40 189-201
- DROUHET E 1955 Action de la nystatine (fungicide) *in vitro* et *in vivo* sur *Candida albicans* et autres champignons levuriformes. *Ann inst Pasteur* 88 298-314
- DROUHET E 1957 Pathology diagnosis and treatment of moniliasis. *Irish J Med Sci* Sixth series 378 241-249
- HUANG N N N KENDALL A J LAMBERTI & R H HIGH 1955-1956 Effects of

- nystatin on oral moniliasis in infants. *Antibiotics Annual* - 711-719. H. Welch & F. Marti Ibañez Eds. Medical Encyclopedia. New York N.Y.
21. JENNISON R. H. & P. STEINOV. 1957. Sensitivity of *Candida* strains to nystatin. *J. Clin. Pathol.* 10: 219-221.
 22. IUTZ A. O. GROOTEN & M. A. WITZ. 1957. Étude sur des champignons levures du genre *Candida*—leur fréquence—l'action de la mycostatine et de la trichomycine. *Rev. Immunol.* 21: 237-259.
 23. STEWART G. T. 1956. Laboratory and clinical studies with nystatin in post-antibiotic mycotic infections. *Brit. Med. J.* 1: 658-660.
 24. TYBIAKINA A. L. S. M. CHAYAROVSKAYA & E. K. BEREZINA. 1958. An experimental study of the antifungal effect of nystatin. *Antibiotics (Moscow)* 3: 40-45.
 25. SARACENI G. 1959. Attività micostatica *in vitro* della nistatina della tricomucina e della diclorossichinolina. *Boll. Ist. Sieroterap. Milan* 38: 342-346.
 26. RODA A. P., S. A. AGUIRRE & G. S. VIJAYO. 1957. Incidence of the species *Candida* from different sources and their sensitivity to mycostatin. *J. Philippine Med. Assoc.* 33: 251-255.
 27. STOUT H. A. & J. F. PAGANO. 1955-1956. Resistance studies with nystatin. *Antibiotics Annual* 704-710. H. Welch & F. Marti Ibañez Eds. Medical Encyclopedia. New York N.Y.
 28. LITTMAN M. L., M. A. ISANO & R. M. LANCASTER. 1957-1958. Induced resistance of *Candida* species to nystatin and amphotericin B. *Antibiotics Annual* 981-987. H. Welch & F. Marti Ibañez Eds. Medical Encyclopedia. New York N.Y.
 29. FORNI P. V. 1958. Resistenza acquisita della *Candida albicans* ad alcuni antibiotici. *Giorn. Bacteriol. e Immunol.* 61: 149-153.
 30. MANNING L. H. & L. ROBERTSON. 1959. A case of aspergillosis treated with nystatin. *Brit. Med. J.* 1: 345-346.
 31. RAPP F. 1955. Studies of diagnostic procedures and reagents. Nystatin in tissue cultures. *Ann. Rept. Div. Lab. & Research N.Y. State Dept. of Health Albany, N.Y.* 47.
 32. MCLIMANS W. F. C., BONGHOL E. V. DAVIS & G. RAKE. 1955-1956. Nystatin an antibiotic useful for the control of fungal and yeast contaminants in tissue culture. *Antibiotics Annual* 690-696. H. Welch & F. Marti Ibañez Eds. Medical Encyclopedia. New York N.Y.
 33. HILL I. 1956. The effect of nystatin on experimental candidiasis in tissue culture. *J. Invest. Dermatol.* 27: 25-29.
 34. McALLISTER R. M. & I. L. CORRIELL. 1956. Cultivation of human epithelial cells in tissue culture. *Proc. Soc. Exptl. Biol. Med.* 91: 349-394.
 35. PERLMAN D. N., A. GUYFRE, I. W. JACKSON & F. F. GIARDINELLO. 1959. Effects of antibiotics on multiplication of L cells in suspension culture. *Proc. Soc. Exptl. Biol. Med.* 102: 290-292.
 36. MYCOSTATIN SOLID NYSTATIN. Describing the usefulness of Mycostatin an antibiotic derived from *Streptomyces noursei* for suppressing the growth of yeast and mold selectively in tissue culture media. A Squibb Service to Science, October 1959.
 37. WIGMORE J. O. & W. M. HENDERSON. 1955. Control of yeast contamination by Mycostatin in cultures of the virus of foot and mouth disease. *Nature* 176: 516.
 38. BOMHARDT H. 1956. Versuche mit Mycostatin zur Unterdrückung des Wachstums von Schimmelpilzen beim kulturellen Brucellennachweis aus Milchproben. *Z. Hyg.* 143: 429-431.
 39. CARRIER L. J., KOLY & A. SLIRE. 1957. Effets d'un antibiotique sélectif pour l'inhibition des Brucella en produits contaminés. *Ann. Inst. Pasteur* 93: 131-135.
 40. BROWN K. & J. I. HAZEN. 1957. Present knowledge of nystatin an antifungal antibiotic. *Trans. N.Y. Acad. Sci. Ser. II* 19: 447-446.
 41. SIMIANCO S. A. M. C. FERNANDEZ, I. O. CAMPOS M. ORTIZ & A. JACALNE. 1957. Cutaneous candidiasis (a clinical and therapeutic study). *J. Philippine Med. Assoc.* 33: 257-260.
 42. NEWCOMER V. D., I. T. WRIGHT, T. H. STERNBERG, J. H. GRAHAM, R. H. WYER & R. O. GERSBERG. 1955-1956. Evaluation of nystatin in the treatment of candidomycosis in man. A preliminary report. *Antibiotics Annual* 831-836. H. Welch & F. Marti Ibañez Eds. Medical Encyclopedia. New York N.Y.
 43. CHAHAM H. S. 1959. Oral thrush in infancy treated with nystatin. *Lancet* 2: 600-601.
 44. KOZINS I. J. & C. L. TASCHOUJAN. 1957-1958. Oral thrush treated with hyoglycyl nystatin. *Antibiotics Annual* 75-79. H. Welch & F. Marti Ibañez Eds. Medical Encyclopedia. New York N.Y.

45. POHOWALLA J N M M ARORA & B N SINGH 1957 Nystatin in treatment of oral moniliasis *Indian J Med Sci* 11 15-18
46. HLANC N N & R H HIGH 1957 Treatment of oral moniliasis in infants and children Squibb Inst Med Research Monographs on Therapy 2 60-66
47. DEBRÉ R P MOZZICONACCI E DROLHET, V DROLHET & A HOPPELER 1955 Les infections à *Candida* chez le nourrisson *Ann paediat (Basel)* 184 129-164
48. DROLHET I 1955 Therapeutic activity of nystatin in *Candida* infections *In Therapy of Fungus Diseases. An International Symposium* - 211-218 T H Sternberg & V D Newcomer Eds Little, Brown Boston Mass
49. DOBIAS H 1957 Treatment of cutaneous moniliasis in pediatrics with nystatin Squibb Inst Med Research Monographs on Therapy 2 47-54
50. BECAMANA A J & J F NAVARRO 1955 Pneumonia complicating oral thrush treated with mycostatin a new antifungal antibiotic *J Pediat* 46 587-591
51. ROBINSON K C V 1957 Cutaneous moniliasis in infants *J Pediat* 50 721-723
52. HOWELL C M Jr 1958 Cutaneous candidiasis treated with nystatin (Mycostatin) *N Carolina Med J* 110 449-452
53. STRATCH J H & H IRVINE 1958 Moniliasis treatment with nystatin powder *Texas State J Med* 54 488-490
54. GRUFFYR C 1957 Le traitement des moniliasis cutanées *Sem. hôp Paris* 33 2048-2057
55. WRIGHT T J H GRAHAM & T H STERNBERG 1957 Treatment of moniliasis with nystatin *J Am Med Assoc* 163 92-94
56. DOBIAS H 1957 Moniliasis in pediatrics *A M A J Diseases Children* 111 234-251
57. SAHNI P S 1957 Pulmonary moniliasis *J Pediat* 50 484-486
58. MCKENDRICK G D W & J M MEDLOCK 1958 Pulmonary moniliasis treated with nystatin aerosol *Lancet* 1 621-622
59. ROBINSON K C V 1955 Systemic moniliasis treated with mycostatin *Case reports J Invest Dermatol* 24 375
60. BARRETT B W VOLWILER W M M AIRBY & C R JONES 1957 Fatal systemic moniliasis following pancreatitis *A M A Arch Internal Med* 111 209-213
61. VANDRENGHEM R & R FICKMANS 1956 Moniliasis chronique résistante à la nystatin *Arch Belg Dermatol et Syph* 12 323-326
62. LAFFR E A 1958 Superinfection and systemic moniliasis *Can Med Assoc J* 78 944-946
63. DUNCAN A G 1957 Cutaneous moniliasis Report of a case occurring in normal skin following an antibiotic treatment *A M A Arch Dermatol* 76 434-436
64. CARLSON J J 1958 Nystatin in the office treatment of vaginal moniliasis *N Y State J Med* 58 1688-1690
65. PACE H R & S I SCHWARTZ 1957 The changing incidence of monilial (*Candida albicans*) vaginitis Squibb Inst Med Research Monographs on Therapy 2 29-37
66. WRIGHT E T V D NEWCOMER C HALDE & T H STERNBERG 1957 The use of nystatin for the treatment of candidiasis of the skin and mucous membranes Squibb Inst Med Research Monographs on Therapy 2 12-15
67. JILLSON O F & J M LYLE 1956 Yeast vulvovaginitis Its successful treatment with nystatin (Mycostatin) *A M A Arch Dermatol* 74 489-492
68. WELCH H 1956 The place of nystatin in chemotherapy *Antibiotic Med* 2 79-82
69. WAGNER J M & I KRESSEL 1958 Complications of *Candida albicans* infection in infancy *Brit Med J* 2 362-366
70. WOODRUFF P W & H C HESSELYNE 1938 Relationship of oral thrush to vaginal mycosis and the incidence of each *Am J Obstet Gynecol* 36 467-471
71. HARRIS L J H G PRITZGER B LASAL V EISEN J W STEINER & I SHACK 1958 The effect of nystatin (Mycostatin) on neonatal candidiasis (thrush) A method of eradicating thrush from hospital nurseries *Can Med Assoc J* 79 891-896
72. RIDDELL R W 1956 Fungous diseases of Britain *Brit Med J* 2 783-786
73. GFRÓ S & J SZÉKELY 1958 Pulmonary aspergilliosis treated with aerosol *Lancet* 1 1229-1230
74. MANGIARACINE A B & S D LIESMAN 1957 Fungus keratitis (*Aspergillus fumigatus*) Treatment with nystatin (Mycostatin) *A M A Arch Ophthalmol* 58 692-698
75. PLOTNICK H & S CERRI 1957 Treatment of oral histoplasmosis by local inject on with nystatin *J Am Med Assoc* 165 346-347

TENNECETIN

Alton I. Welch

College of Medicine University of Cincinnati Cincinnati Ohio

Tennecetin an antifungal antibiotic was isolated by Burns and Holtman¹ from strains of *Streptomyces chaltanoogensis* obtained from Tennessee soil

Characteristics of the Organism

One of the most prominent characteristics of the organism is its ability to produce a deep yellow-orange pigment in most media. On solid media the pigment diffuses into the agar. The vegetative mycelium of the organism itself is of orange yellow color.

Sporulation occurs only on certain media for example Carvajal's oatmeal agar. Microscopically spores are found in chains at the ends of coiled sporophores. Other characteristics are gelatin is rapidly liquefied starch is hydrolyzed milk is coagulated and peptonized hydrogen sulfide is not produced growth without sporulation occurs at 37° C. but not at 45° C. growth is inhibited in media containing 3 per cent sodium chloride and a yellow ring often appears at the surface of limus milk tubes but a true pellicle has not been observed on any liquid medium.

It was not possible to identify this organism with any of the previously described species of *Streptomyces*.

Production and Recovery of Tennecetin

For production in quantity a shaken broth culture of the organism is inoculated into fermenters equipped with mechanical agitators filled with GPY media¹ and aerated with oxygen during the fermentation period at temperatures of 25 to 28° C.

Unlike most other polyenes tennecetin occurs almost entirely in the culture liquid. For this reason the mycelia are filtered off before extracting the antibiotic. Extraction is accomplished with n-butanol followed by concentration of the butanol extract *in vacuo* and precipitation of the active material by addition of four volumes of anhydrous ether.

The product resulting from this procedure is a yellow amorphous powder containing up to 100 U. of tennecetin activity per mg. of dried powder.¹

Assay of Tennecetin

A quantitative microbiological assay method has been developed for measuring the amount of tennecetin in crude broth extracts and dried powder. This is the paper disc agar diffusion method using *Saccharomyces carlsbergensis* as the test organism. This assay method gives a straight line response with a good slope over a tenfold range in concentration when plotted on semilogarithmic paper.

Using this method an arbitrary unit of tennecetin has been defined as that amount of antibiotic which when contained in 10 ml. of broth or diluent will give a 20 mm. zone (diameter) of inhibition against the test strain of *S. carlsbergensis*.

bergensis (Strain K 20) when tested in accordance with the conditions prescribed for the standard assay method¹

Chemical and Physical Properties of Tennecetin

Tennecetin is soluble in water, methanol, 95 per cent ethanol, propylene glycol, pyridine, formamide, dimethylsulfoxide, ethyl stearate, and *n* butanol. It is insoluble in chloroform, ethyl acetate, amyl acetate, ether, acetone, tetrahydrofuran, butyl stearate, methyl linoleate, and petroleum ether. Aqueous solutions of the antibiotic have an alkaline reaction¹ (see also F. S. Barr, personal communication).

Solutions of tennecetin kept in the refrigerator have retained full activity for more than 1 month. At pH 7.0 solutions of the antibiotic have retained full activity following treatment at 100° C for 20 min. Stability is markedly decreased at pH 4.0 and pH 10.0. Solutions of tennecetin are quite insensitive to visible light.¹

All active preparations of tennecetin have exhibited a characteristic ultra violet absorption spectrum with a slight shoulder at 270 to 280 $m\mu$, and peaks at 288-300 to 302 and 315 to 318 $m\mu$.¹ Such an absorption spectrum is characteristic of polyene compounds in general and tetraenes in particular.¹

When compared with the published spectra of other tetraenes, the infrared absorption of tennecetin shows several variations in the major and minor absorption bands of all indicating that they are not identical compounds.¹

Paper chromatography of tennecetin showed R_f value of 0.33 (as compared to R_f of 0.38 for Rimocidin sulfate and R_f of 0.22 for nystatin).¹

Biological Properties of Tennecetin

Tennecetin has been found to be markedly fungistatic or fungicidal, or both, to yeasts and filamentous fungi *in vitro*. More than eighty different species of microorganisms were tested for their susceptibility to the action of tennecetin. Thus far, no yeast or mold has been found that has not been inhibited by this antibiotic, although certain of the human dermatophytes have required somewhat higher *in vitro* concentrations to demonstrate the inhibitory effect. Most bacteria appear to be resistant to the action of tennecetin.¹ TABLE 1 lists some of the species that have been tested for *in vitro* sensitivity to tennecetin by cross streak agar diffusion technique.¹

TABLE 2 shows the amounts of tennecetin required, in units, for inhibition of some of the strains tested by Burns and Holman.¹

TABLE 3 shows the results of similar tests done in the Laboratory of Mycology, College of Medicine, University of Cincinnati (J. Schwartz, personal communication).

No growth of any of the organisms tested occurred in the media containing the various concentrations of tennecetin employed.

Toxicological Studies

The acute and chronic toxicity of tennecetin for 6 species of laboratory animals has been reported by Barr.² The agent was found to be toxic when

Welsh Tenneccetin

TABLE I

SENSITIVITY OF MICROORGANISMS TO TENNECCETIN BY CROSS STREAK AGAR
DIFFUSION TECHNIQUE

Organisms inhibited

Penicillium sp
Aspergillus sp
Aspergillus niger
Ascidia spinosa
Mucor sp
Syncephalastrum racemosum
Cunninghamella sp
Thamnidium elegans
Circinella tenuella
Emicillium curenium
Aspergillus candidum
Aspergillus glaucus
Aspergillus fumigatus
Aspergillus clavatus
Aspergillus ochraceus
Paecilomyces sp
Sporulicopsis sp
Fusarium gramineum
Fusarium sp
Penicillium canescens
Blastomyces dermatitidis (yeast phase)
Blastomyces dermatitidis (mycelium phase)
Sporothrix schenckii
Trichophyton mentagrophytes
Microsporum gypseum
Microsporum audouinii

Corynebacterium sp
Corynebacterium diphtheriae
Pseudomonas tabaci
Candida albicans
Candida krusei
Candida parakrusei
Candida stellatoidea
Geotrichum sp
Cryptococcus neoformans
Torulopsis sp
Rhodotorula sp
Saccharomyces cerevisiae
Saccharomyces carlsbergensis
Saccharomyces fragilis
Hansenula anomala
Hansenula moravica
Hansenula silvestris
Pichia membranifaciens
Schizosaccharomyces sp
Trigonopsis variabilis
Myoderma sp
Debaryomyces globosus
Sporobolomyces salmoniculus
Zygosaccharomyces lusitana
Candida tropicalis

Organisms slightly or questionably inhibited

O. spora lactis
Staphylococcus aureus
Staphylococcus sp

Sarcina lutea
Corynebacterium sp
Mycobacterium sp (ATCC 60+)

Organisms not inhibited

Escherichia coli
Serratia sp
Salmonella typhosa
Paraclostridium sp
Pseudomonas fragilis
Pseudomonas fluorescens
Alcaligenes viscolactis
Pseudomonas aeruginosa
Salmonella enteritidis
Bacterium cadaveris

Bacillus cereus
Bacillus subtilis
Bacillus pumilus
Yersinia enterocolitica
Yersinia pseudotuberculosis
Mycobacterium avium
Streptomyces sp
Clostridium sp
Clostridium botulinum
Micromonospora sp

used by injection by the intravenous intramuscular intraperitoneal and subcutaneous routes. The acute LD₅₀ by the oral route was not reached when doses 10 times the toxic intravenous dose were used.
 Chronic toxicity studies done on several groups of animals with doses of 100, 200 and 250 L of tennecetin daily by the oral route for periods as long as

6 months showed no toxicity during the studies. At the end of the studies only 2 animals when sacrificed, revealed pathological changes in the vital organs. One rat after receiving daily dosages of 100 mg of tennecetin orally

TABLE 2
CONCENTRATION OF TENNECETIN REQUIRED TO INHIBIT GROWTH OF CERTAIN FUNGI *IN VITRO**

Organism	Tennecetin U/ml medium			
	0.5	0.25	0.05	None
<i>Sporotrichum schenckii</i>	0	4	4	4
<i>Cryptococcus neoformans</i>	0	4	4	4
<i>Candida albicans</i>	0	0	4	4
<i>Candida parakrusei</i>	0	0	4	4
<i>Debaryomyces glabrous</i>	0	4	4	4
<i>Saccharomyces cerevisiae</i>	0	0	4	4
<i>Geotrichum candidum</i>	0	4	4	4
<i>Saccharomyces carlsbergensis</i>	0	2	4	4
<i>Mescheria boydii</i>	0	0	4	4
<i>Trichophyton rubrum</i>	0	0	4	4
<i>Microsporum audouinii</i>	0	3	3	4
<i>Blastomyces dermatitidis</i> (yeast phase)	0	0	4	4
<i>Blastomyces dermatitidis</i> (mycelial phase)	0	0	2	2
<i>Coccidioides immitis</i>	0	0	1	2

* Tennecetin was dissolved in Sabouraud's dextrose agar. Numerals in table refer to extent of growth judged by arbitrary scale between 0 and 4 (0 indicates no growth; 4 indicates heavy growth).

TABLE 3
CONCENTRATIONS OF TENNECETIN REQUIRED TO INHIBIT GROWTH OF CERTAIN FUNGI *IN VITRO*

Strains	Controls	Tennecetin mg./ml.* medium†					
		5	2.5	1.25	0.62	0.31	0.16
<i>Penicillium</i> sp.	+	—	—	—	—	—	—
<i>Candida albicans</i> strain 7	+	—	—	—	—	—	—
<i>Aspergillus</i> sp.	+	—	—	—	—	—	—
<i>Histoplasma capsulatum</i>	+	—	—	—	—	—	—
<i>Trichophyton mentagrophytes</i>	+	—	—	—	—	—	—
<i>Cryptococcus neoformans</i>	+	—	—	—	—	—	—

* 1 mg = 15.8 U tennecetin

† Sabouraud's dextrose agar

for 6 months had a hemorrhage in one lung. This hemorrhage was thought to be due to bacterial infection since it was confined to one lobe of one lung. One cat, receiving daily oral doses of 250 U of tennecetin for 6 months when sacrificed, had an abnormal deposit of fat in the liver. It was not possible to stain (J. Shapiro, personal communication).

Systemic in Viro Studies

The use of tenucetin by parenteral routes is apparently not practicable, since toxic levels are at or below therapeutic levels (F S Barr, personal communication)

Tenucetin was given intravenously to rats, 100 U/kg of body weight. Blood was withdrawn and assayed. When the blood was centrifuged and the serum assayed no tenucetin activity could be detected. However, when the red blood cells were hydrolyzed, the tenucetin activity reappeared.

Blood samples withdrawn one hour later were treated in the same manner, but no tenucetin activity was found. The urine collected for the same period did not display any antibiotic activity. These tests seem to indicate that the tenucetin was either broken down or deposited in some tissue (F S Barr, personal communication).

Tenucetin has been tested for toxicity by the oral route in laboratory animals and in human beings. The results of these tests indicate the antibiotic is of low toxicity when so employed (F S Barr personal communication).

Topical in Viro Studies Reported by Others

V J Durbin (personal communication to the S F Massengill Co) treated 23 patients who had tinea capitis and 12 who had tinea corporis and cruris. A summary of his report follows.

Tinea capitis	Cases	Cures	Treatment (in months)	
			1	2
<i>M. audouinii</i>	16	6	14	3
<i>T. tonsurans</i>	6	1	5	1
kerion	1	1	1	

Four of the 6 cures in *M. audouinii* infections occurred in patients treated for 2 months. The only cure in the *T. tonsurans* group was obtained after 2 months of treatment.

Tinea corporis and Tinea cruris	Cases	Cures	Treatment (in months)	
			1	2
<i>T. rubrum</i>	10	11	9	1
<i>T. tonsurans</i>	1	1	1	
Erythrasma	1	1	1	

I can say only that treatment in this group of cases was of too short duration to expect reasonably satisfactory response and does not represent adequate appraisal of this antibiotic agent in this group of patients. Additionally, the 10 U/gm ointment was used in all but 2 cases (in these the 500-U ointment was used).

R M Metcalfe (personal communication to the S E Massengill Co) reported on the use of tennecetin ointment (350 U/gm) in 7 patients as follows

Diagnosis	Result	Duration
Tinea corporis	Good	5 days
Tinea corporis	Good	10 days
Tinea corporis	Excellent	7 days
Tinea pedis	Excellent	7 days
Tinea pedis	Good	14 days
Tinea cruris	Fair	10 days
Onychomycosis	Poor	2 to 3 months

In summary this investigator reports excellent results in 2 good results in 3 and improvement in the fifth patient with dermatomycoses of the glabrous skin. There was no response in the patient with onychomycosis. In this group treatment was carried out for only short intervals.

L Goldman (personal communication) reported on the use of tennecetin ointment (500 U/gm) in 17 patients. Six had tinea pedis (3 proved by culture to be due to *T. mentagrophytes*), 1 had tinea corporis (proved by culture to be due to *T. gypsum*), 2 had tinea cruris, 3 had tinea versicolor, and 5 had moniliasis of the glabrous skin (proved by culture). Of the tinea pedis group 1 patient had an excellent result and 2 had fair results. One of the remaining 3 flared and the other 2 had poor response to the agent after 3 to 8 weeks of treatment. The patient who had tinea corporis did not respond after 3 weeks of treatment. One of the patients who had tinea cruris cleared the other flared after 3 weeks of treatment. The 3 patients who had tinea versicolor all cleared in 1 to 3 weeks while using tennecetin ointment but all relapsed when this agent was discontinued. Only 1 of the 5 patients with moniliasis had a satisfactory response after use of the antibiotic for from 3 to 8 weeks. In this group the treatment interval was short.

R Greenblatt (personal communication to the S E Massengill Co) reported on 9 patients who had vaginal moniliasis (all proved by culture). Seven patients cleared completely and had 3 negative cultures 3 weeks after treatment was discontinued. These patients were treated for 12 to 24 days. Two patients each treated for 12 days had positive cultures after 3 weeks although they had some amelioration of symptoms and marked relief of pruritus. One tennecetin suppository (400 U) was inserted into the vagina nightly. In this group of patients 77.7 per cent responded to this tennecetin preparation.

T C Todd (personal communication to the S E Massengill Co) treated 19 patients with moniliasis involving the vulva (all proved by culture) with tennecetin vaginal jelly (400 U/gm) one half to 1 applicatorfull in the vagina once or twice daily or one tennecetin suppository (400 U) in the vagina daily. He reported good response in 9 patients, improvement in 9 patients and a poor result in 1 patient.

F H Payne (personal communication to the S E Massengill Co) treated 6 patients who had moniliasis with tennecetin vaginal suppositories (400 U) for from 11 to 24 days. The diagnosis was " " in all

patients before treatment. Three patients had excellent results, 2 good results, and 1 a poor result. All but 1 had negative smears after treatment.

H. L. Riva and R. E. Staats (personal communication to the Massengill Co.) treated 10 patients who had moniliasis and 13 who had trichomoniasis of the vagina. They prescribed the insertion into the vagina of 1 tenneccetin (400 U) vaginal suppository twice daily. The night insertion was preceded by a vinegar douche. Eight of the patients who had moniliasis became asymptomatic and had negative smears after treatment. The other 2 patients of this group became asymptomatic, but continued to have positive smears. Eight of the patients who had trichomoniasis became asymptomatic following treatment, but in only 2 was negative microscopic evidence of trichomonal infection obtained. The remaining 5 patients who had trichomoniasis were unimproved symptomatically and continued to have microscopic evidence of trichomoniasis after treatment.

TABLE 4
DERMATOPHYTES TREATED

Diagnosis	No. cases
<i>Tinea pedis</i>	84
<i>Tinea mani</i>	25
<i>Tinea corporis</i>	48
<i>Tinea capitis</i>	30
<i>Tinea cruris</i>	23
<i>Tinea versicolor</i>	8
Onychomycosis	21
<i>Blastomycetia interdigitalis</i>	6
Total	245

Topical in Vivo Studies Conducted in Our Office

We attempted on evaluation of the therapeutic efficiency of tenneccetin broad spectrum antifungal antibiotic when applied topically for the treatment of selected dermatoses.

All patients (drawn from private practice) were instructed to apply the ointment to a small area, watch for and report any untoward reaction such as increased irritation, erythema, extension of eruption, and the like, before application was made to large areas. If untoward reaction did occur, patients were instructed to stop use immediately and return for observation. Applications of ointments were prescribed from 1 to 3 (occasionally 4) times daily. Usually ointments were applied twice daily. Frequency of application depended upon the condition. All patients were observed at weekly intervals. This report is based on a study period of approximately 23 months.

In the early part of the study concentrations of tenneccetin of 70 and 140 U/gm were employed; later concentrations of tenneccetin 200 and 350 U/gm were used. Finally, in the last few months formulation of tenneccetin ointment studied contained 500 U/gm. As the study progressed the concentration of tenneccetin in the ointment base was gradually increased as it became apparent that the early weaker concentrations did not give clinical results consistent

with *in vitro* studies. As the concentration of tennecetin in the ointment base was increased, the response index was increased. The tennecetin was incorpo-

TABLE 5
MONILIASIS TREATED

Location	No. cases
Vulva	17
Mouth	10
Commissures	2
Paronychia	5
Nail	1
Total	35

TABLE 6
DURATION TREATMENT IN MONTHS

1-3	4-5	6-12
170	77	33

TABLE 7
PATIENTS TREATED WITH 500 U TENNECETIN OINTMENT

Diagnosis	No. cases
Tinea pedis	17
Tinea manuum	4
Tinea corporis	10
Tinea capitis	10
Tinea cruris	8
Tinea versicolor	6
Blastomycetia interdigitalis	4
Moniliasis	8
Total	67

TABLE 8
RESULTS WITH 500 U TENNECETIN OINTMENT

	No. cases	Per cent
Excellent	30	44.7
Good	16	23.5
Fair	11	16.4
Poor	10	14.9

rated in an ointment base consisting of beeswax, white petrolatum, and liquid petrolatum.

Tennecetin ointments of various concentrations were used topically in 280 patients. It seems irrelevant to record here the results of studies with the

weaker concentrations of tennecetin ointment, therefore, only the results with the 500 U/gm ointment are tabulated hereafter

Diagnoses in all cases were confirmed by KOH preparation, or culture, or both. TABLE 4 demonstrates the various types of dermatophytoses and the number of cases treated with the several concentrations of tennecetin ointment. These dermatoses had persisted in these patients for from 1 month to 20 years.

TABLE 5 illustrates the location of involvement and the number of cases of moniliasis treated with the several concentrations of tennecetin formulation.

TABLE 6 indicates the duration of treatment in months.

TABLE 7 depicts the various types of conditions and the number of cases treated with the 500 U/gm tennecetin ointment.

TABLE 8 records the clinical results obtained with the 500 U tennecetin formulation in 67 patients.

TABLE 9 lists the reactions observed in the 290 patients studied employing the various concentrations of tennecetin in either ointment or jelly base. Sensitization was not observed.

TABLE 9
REACTIONS OBSERVED IN 290 PATIENTS

Irritating	6
Desquamating fissuring	2
Burning	2
Sensitizing	0
Total	10

Discussion of Therapeutic Results

It is now apparent that a concentration of at least 500 U of tennecetin per gm of ointment base is requisite for reasonable therapeutic response in the topical therapy of the various superficial fungal infections studied, and in moniliasis.

The response with the 500 U tennecetin formulation was considered excellent in 44.7 per cent of the cases studied and good in an additional 23.5 per cent. This appears to be a reasonable therapeutic response index.

Of the 290 patients studied only 10 showed reaction of any type. Six demonstrated irritation. 5 of these had tinea cruris with superimposed contact factors. One had tinea corporis on the flexor surface of the left forearm that was already eczematized from previous medication. Two patients desquamated (in spite of the lubricating nature of the ointment base) to the point of fissuring. Two reported a burning sensation with each application of the ointment lasting for such long intervals that it was necessary to discontinue the ointment. Objectively these 2 patients did not show irritation or eczematization.

Patients with tinea versicolor responded regularly to treatment with the 500 U/gm tennecetin ointment. However, relapses were fairly regular when treatment was discontinued after clinical and laboratory data were negative. This appeared to be definitely due to reinfection from contaminated fomites. In 5 patients who have after clearing continued to use the tennecetin 500

U/gm ointment weekly, as a preventive measure, there has been no recurrence in the 6 months this procedure has been employed

As was to be expected, in moniliasis of the female genitalia, it was necessary to eradicate vaginal moniliasis, if present, by use of tennecetin jelly or suppositories in order to obviate recurrence on the mucosal and cutaneous parts of the genitalia and adjacent areas. Patients with moniliasis experienced an early relief of pruritus followed by desquamation of the pseudomembrane on mucosal surfaces and scaling on cutaneous surfaces.

Patients who had onychomycosis or moniliasis of the nails failed to respond even to prolonged use of the tennecetin ointments in the concentrations employed.

Summary

The general characteristics of *S. chaltanoogensis* and the antibiotic—designated as tennecetin, a tetraene—derived from it, have been summarized. The chemical, physical, and biological properties, toxicological data, *in vitro* sensitivity data, and available systemic *in vivo* studies of tennecetin have been partially reviewed. Clinical studies with topical tennecetin ointment, vaginal jelly, and vaginal suppositories conducted by others and those done personally have been presented.

Conclusions

To date, results of studies of the broad spectrum, antifungal antibiotic tennecetin for the topical treatment of superficial fungal infections appear encouraging.

It is my opinion that a better therapeutic response index might be obtained if the tennecetin were used in formulations employing a vanishing lotion or ointment base, or both. Such formulations should allow better penetration of the agent into the tissues.

If formulations can be developed that will allow this agent to exert its full antifungal activity when employed topically, it should eventuate as a very effective agent for the topical therapy of superficial fungal infections.

References

1. BURNS J & F. HOLTMAN. 1959. Tennecetin: a new antifungal antibiotic. General characteristics. *Antibiotics & Chemotherapy* 9: 398-405.
2. OROSHNIK W, I. G. Vining, A. D. MEBANE & W. A. TASSER. 1955. Polyene antibiotics. *Science* 121: 147.
3. BARR I. S. 1959. Tennecetin: a new antifungal antibiotic. Toxicological Studies. *Antibiotics & Chemotherapy* 9: 406-408.

ANALYSIS OF AMPHOTERICIN TREATMENT FAILURES IN SYSTEMIC FUNGAL DISEASE

John P. Utz and Vincent T. Andriole

National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md

Administered intravenously, amphotericin has been an effective treatment in a number of patients with cryptococcosis, histoplasmosis, coccidioidomycosis, and blastomycosis.¹⁻⁴ In addition, isolated cases of aspergillosis,⁵ sporotrichosis,⁶ and *Candida* infections of the peritoneum⁷ and pleural cavity⁸ have been treated successfully by intravenous or local (intraperitoneal or intrathoracic) therapy. Such success is a significant advance in the treatment of these diseases.

At the National Institutes of Health, we have studied 40 patients with 41 culturally confirmed systemic fungal infections treated intravenously with amphotericin. The results of this treatment are shown in TABLE 1. The details of treatment have been described previously in most cases,⁹⁻¹¹ and the patient numbers refer to these and forthcoming reports. The success achieved in treatment of 20 of these infections has led to the present analysis of the 20 infections that represent treatment failures (the remaining patient is currently on therapy). It becomes apparent that a number of factors played a part in these failures.

Early Discontinuation of Treatment

Patient 11 has had known pulmonary blastomycosis since March 1955. In May 1957 she received amphotericin over a period of 11 days, but discontinued treatment after a total dose of only 110 mg. She is asymptomatic, but sputum cultures have been persistently positive except for 2 months immediately following treatment.

Patient 6, with known cryptococcal meningitis since January 1956, received amphotericin in July 1957 for 13 days in total dosage of 223 mg and then broke off treatment.

Such obvious causes for treatment failure are worthy of mention only to emphasize the fact that the side effects of intravenous therapy (chills, fever, nausea, vomiting, anorexia) may be more distressing to a patient than the symptoms of his disease.

Advanced Disease

In contrast to the acute disease encountered with most bacterial and viral infections, systemic fungal diseases are generally chronic. In a few instances, however, the total course of fungal illness may be a matter of a month or less, leaving little time for treatment after diagnosis has been made.

Patient 3, a 6-month old infant with extensive disseminated histoplasmosis, lived only 24 days after hospitalization and only 7 days after institution of intravenous therapy with a total dose of 30 mg of amphotericin.

Patient 34 had had correction of a mitral valve insufficiency by open heart surgery on November 6, 1958. On return admission for postoperative evalua-

U/gm ointment weekly, as a preventive measure, there has been no recurrence in the 6 months this procedure has been employed

As was to be expected, in moniliasis of the female genitalia, it was necessary to eradicate vaginal moniliasis, if present, by use of tennecetin jelly or suppositories in order to obviate recurrence on the mucosal and cutaneous parts of the genitalia and adjacent areas. Patients with moniliasis experienced an early relief of pruritus followed by desquamation of the pseudomembrane on mucosal surfaces and scaling on cutaneous surfaces.

Patients who had onychomycosis or moniliasis of the nails failed to respond even to prolonged use of the tennecetin ointments in the concentrations employed.

Summary

The general characteristics of *S. chaltanoogensis* and the antibiotic—designated as tennecetin, a tetraene—derived from it, have been summarized. The chemical, physical, and biological properties, toxicological data, *in vitro* sensitivity data, and available systemic *in vivo* studies of tennecetin have been partially reviewed. Clinical studies with topical tennecetin ointment, vaginal jelly, and vaginal suppositories conducted by others and those done personally have been presented.

Conclusions

To date, results of studies of the broad spectrum, antifungal antibiotic tennecetin for the topical treatment of superficial fungal infections appear encouraging.

It is my opinion that a better therapeutic response index might be obtained if the tennecetin were used in formulations employing a vanishing lotion or ointment base, or both. Such formulations should allow better penetration of the agent into the tissues.

If formulations can be developed that will allow this agent to exert its full antifungal activity when employed topically, it should eventuate as a very effective agent for the topical therapy of superficial fungal infections.

References

1. BURNS J & F. HOLTMAN. 1959. Tennecetin, a new antifungal antibiotic. General characteristics. *Antibiotics & Chemotherapy* 9: 399-403.
2. OROSHNIK W, L. G. VIVING, A. D. MFSANF & W. A. TABER. 1955. Polyene antibiotics. *Science* 121: 147.
3. BARR F. S. 1959. Tennecetin, a new antifungal antibiotic. *Toxicological Studies*. *Antibiotics & Chemotherapy* 9: 406-408.

ANALYSIS OF AMPHOTERICIN TREATMENT FAILURES IN SYSTEMIC FUNGAL DISEASE

John P. Utz and Vincent T. Andriole

National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md

Administered intravenously, amphotericin has been an effective treatment in a number of patients with cryptococcosis, histoplasmosis, coccidioidomycosis, and blastomycosis.¹⁻⁴ In addition, isolated cases of aspergillosis,⁵ sporotrichosis,¹ and *Candida* infections of the peritoneum⁷ and pleural cavity⁸ have been treated successfully by intravenous or local (intraperitoneal or intrathoracic) therapy. Such success is a significant advance in the treatment of these diseases.

At the National Institutes of Health, we have studied 40 patients with 41 culturally confirmed systemic fungal infections treated intravenously with amphotericin. The results of this treatment are shown in TABLE 1. The details of treatment have been described previously in most cases,^{4,9} and the patient numbers refer to these and forthcoming reports. The success achieved in treatment of 20 of these infections has led to the present analysis of the 20 infections that represent treatment failures (the remaining patient is currently on therapy). It becomes apparent that a number of factors played a part in these failures.

Early Discontinuation of Treatment

Patient 11 has had known pulmonary blastomycosis since March 1955. In May 1957 she received amphotericin over a period of 11 days, but discontinued treatment after a total dose of only 110 mg. She is asymptomatic, but sputum cultures have been persistently positive except for 2 months immediately following treatment.

Patient 6, with known cryptococcal meningitis since January 1956, received amphotericin in July 1957 for 13 days in total dosage of 223 mg and then broke off treatment.

Such obvious causes for treatment failure are worthy of mention only to emphasize the fact that the side effects of intravenous therapy (chills, fever, nausea, vomiting, anorexia) may be more distressing to a patient than the symptoms of his disease.

Advanced Disease

In contrast to the acute disease encountered with most bacterial and viral infections, systemic fungal diseases are generally chronic. In a few instances, however, the total course of fungal illness may be a matter of a month or less, leaving little time for treatment after diagnosis has been made.

Patient 3, a 6-month old infant with extensive disseminated histoplasmosis, lived only 24 days after hospitalization and only 7 days after institution of intravenous therapy with a total dose of 30 mg of amphotericin.

Patient 34 had had correction of a mitral valve insufficiency by open heart surgery on November 6, 1958. On return admission for postoperative evalua-

U/gm ointment weekly, as a preventive measure, there has been no recurrence in the 6 months this procedure has been employed

As was to be expected, in moniliasis of the female genitalia, it was necessary to eradicate vaginal moniliasis, if present, by use of tennecetin jelly or suppositories in order to obviate recurrence on the mucosal and cutaneous parts of the genitalia and adjacent areas. Patients with moniliasis experienced an early relief of pruritus followed by desquamation of the pseudomembrane on mucosal surfaces and scaling on cutaneous surfaces.

Patients who had onychomycosis or moniliasis of the nails failed to respond even to prolonged use of the tennecetin ointments in the concentrations employed.

Summary

The general characteristics of *S. challanoogensis* and the antibiotic—designated as tennecetin, a tetraene—derived from it, have been summarized. The chemical, physical and biological properties, toxicological data, *in vitro* sensitivity data, and available systemic *in vivo* studies of tennecetin have been partially reviewed. Clinical studies with topical tennecetin ointment, vaginal jelly, and vaginal suppositories conducted by others and those done personally have been presented.

Conclusions

To date, results of studies of the broad spectrum, antifungal antibiotic tennecetin for the topical treatment of superficial fungal infections appear encouraging.

It is my opinion that a better therapeutic response index might be obtained if the tennecetin were used in formulations employing a vanishing lotion or ointment base, or both. Such formulations should allow better penetration of the agent into the tissues.

If formulations can be developed that will allow this agent to exert its full antifungal activity when employed topically, it should eventuate as a very effective agent for the topical therapy of superficial fungal infections.

References

1. BURNS J & F. HOLTMAN. 1959. Tennecetin, a new antifungal antibiotic. General characteristics. *Antibiotics & Chemotherapy* 3: 398-405.
2. OROSHNIK W. I., G. VINEY, A. D. MESSINE & W. A. TABER. 1955. Polyene antibiotics. *Science* 121: 147.
3. BARR F. S. 1959. Tennecetin, a new antifungal antibiotic. *Toxicological Studies*. *Antibiotics & Chemotherapy* 3: 406-408.

ANALYSIS OF AMPHOTERICIN TREATMENT FAILURES IN SYSTEMIC FUNGAL DISEASE

John P. Utz and Vincent T. Andriole

National Institute of Allergy and Infectious Diseases Public Health Service, Bethesda Md

Administered intravenously, amphotericin has been an effective treatment in a number of patients with cryptococcosis, histoplasmosis, coccidioidomycosis, and blastomycosis.¹⁻⁴ In addition, isolated cases of aspergillosis,⁵ sporotrichosis,⁶ and *Candida* infections of the peritoneum⁷ and pleural cavity⁸ have been treated successfully by intravenous or local (intraperitoneal or intrathoracic) therapy. Such success is a significant advance in the treatment of these diseases.

At the National Institutes of Health, we have studied 40 patients with 41 culturally confirmed systemic fungal infections treated intravenously with amphotericin. The results of this treatment are shown in TABLE 1. The details of treatment have been described previously in most cases,⁹⁻¹² and the patient numbers refer to these and forthcoming reports. The success achieved in treatment of 20 of these infections has led to the present analysis of the 20 infections that represent treatment failures (the remaining patient is currently on therapy). It becomes apparent that a number of factors played a part in these failures.

Early Discontinuation of Treatment

Patient 11 has had known pulmonary blastomycosis since March 1955. In May 1957 she received amphotericin over a period of 11 days, but discontinued treatment after a total dose of only 110 mg. She is asymptomatic, but sputum cultures have been persistently positive except for 2 months immediately following treatment.

Patient 6, with known cryptococcal meningitis since January 1956, received amphotericin in July 1957 for 13 days in total dosage of 223 mg and then broke off treatment.

Such obvious causes for treatment failure are worthy of mention only to emphasize the fact that the side effects of intravenous therapy (chills, fever, nausea, vomiting, anorexia) may be more distressing to a patient than the symptoms of his disease.

Advanced Disease

In contrast to the acute disease encountered with most bacterial and viral infections, systemic fungal diseases are generally chronic. In a few instances, however, the total course of fungal illness may be a matter of a month or less, leaving little time for treatment after diagnosis has been made.

Patient 3, a 6-month-old infant with extensive disseminated histoplasmosis, lived only 24 days after hospitalization and only 7 days after institution of intravenous therapy with a total dose of 30 mg. of amphotericin.

Patient 34 had had correction of a mitral valve insufficiency by open heart surgery on November 6, 1958. On return admission for postoperative evalua-

tion, February 18, 1959, she gave a history of intermittent fever and increased dyspnea of about 3 weeks' duration. Six blood cultures on February 18, 19, and 20 were positive for *Candida guilliermondii*. On February 21 amphotericin treatment was instituted, but on February 24 the patient expired after receiving only 140 mg of drug. The fulminating course of disease in this patient precluded a long course of therapy, although we have not found amphotericin effective in other cases of *Candida endocarditis*.

Patient 17 with cryptococcal meningitis survived for only 27 days after onset of disease and died after receiving only 621 mg of amphotericin.

Insufficient Amount of Drug

Patient 33, a 23 year old Negro man, while in the Air Force and stationed in Arizona as a construction worker, had a pulmonary disease diagnosed as coccidioidomycosis from which he slowly improved. However, his chest film,

TABLE 1
TREATMENT WITH AMPHOTERICIN INTRAVENOUSLY AND INTRATHECALLY

Disease	Apparent recovery	Improved	On treatment	Relapse	Unchanged	Dead	Total
Histoplasmosis	4*	3	0	1	0	2	10
Cryptococcosis	4	3*	0	1	1	3	12
Blastomycosis	4*	0	0	1	1	0	6
Coccidioidomycosis	0	1	1	1	2	1	6
Candidiasis	1	0	0	0	0	5	6
Maduramycosis	0	0	0	0	1	0	1
Totals	13	7	1	4	5	11	41†
					20		

* One patient dead of other cause.

† Dual infection (cryptococcosis and maduramycosis) in one patient.

at time of discharge, September 1957, showed a 2 cm nodular density at the superior pole of the right hilus. In November 1958 he began to have headache and, following studies that indicated possible posterior fossal tumor, underwent craniotomy. A multilobed cystic mass containing pus was removed from the right vermis of the cerebellum. Cultures of this, cerebrospinal fluid, and sputum were positive for *Coccidioides*. Cultures became negative, and there was clinical improvement during a 4-week course of treatment with 800 mg of amphotericin. The patient was discharged April 15, 1959, but was readmitted May 15 with lymphocytic meningitis due to *Coccidioides*. He expired June 4 after unsuccessful therapy with another antifungal drug. Although, as will be observed later, success with amphotericin in coccidioidomycosis is limited in retrospect it seems that this patient received less than optimal dosage.

Although amphotericin treatment of blastomycosis has been generally successful, patient 19 relapsed 8 months after a 3 month course of 2298 mg of amphotericin. His infection had been severe, with osteomyelitis of lumbar spines 1, 2, 3, 4 and psoas abscess. No pulmonary lesion had been seen on chest film, but sputum specimens had been culturally positive. He responded

well to surgical drainage of the psoas abscess and the amphotericin treatment, but then relapsed. The possibility that treatment failure was related to insufficient total dosage is suggested by the successful treatment of patient 12 who had equivalent, if not more extensive, disease and who responded without relapse to a course of treatment over a 7-month period with a dosage (5185 mg) more than twice that of patient 19.

Patient 63 is of especial interest because he had unusual skin manifestations of cryptococcal infection but normal cerebrospinal fluid at the time of his initial hospitalization.¹⁰ From September 3 to October 6, 1956, 1 gm. of amphotericin was given, and on rehospitalization, December 5 to December 24, 1956, an additional course of 880 mg was given. A third course of treatment (430 mg) was administered from July 5, 1957 to January 1, 1958, following which the skin lesions healed and the patient returned to work. On August 18, 1959, he was readmitted, and for the first time symptoms, cerebrospinal fluid findings, and cultures indicated cryptococcal meningitis. He was restarted on amphotericin treatment, transferred to the Clinical Center, and treated over a 2 month period with 3140 mg of drug. Normal cerebrospinal fluid findings were present at end of therapy, November 10, 1959.

Death From Associated Disease

Patient 27 had had disseminated histoplasmosis dating to November 1957. At the time of admission October 22, 1958, he had positive cultures of blood, bone marrow, urine and oral ulcer. Despite this severe disease, he seemed to be making a satisfactory recovery with negative cultures after 2 weeks' treatment with 460 mg of amphotericin. Despite normal steroid values in blood and urine, adrenal insufficiency had been suspected on the basis of hypotension, hyponatremia, and hyperkalemia, and the patient had been on 10 mg. of hydrocortisol daily. On December 3 the patient developed acute pyelonephritis, subsequently shown to be due to staphylococcus, which seemed to respond to penicillin, tetracycline, and steroids (increased to 50 mg./day). On December 10 he suddenly developed signs of pneumonia and died within 24 hours despite additional antistaphylococcal therapy. Autopsy revealed staphylococcal bronchopneumonia and caseous lesions of the adrenal glands. Cultures of urine, blood, ascitic fluid, spleen, kidneys, liver, lungs, alveolar ridge and lymph nodes were negative for *Histoplasma*. However, cultures of both adrenal glands were positive. In this case treatment failure seems to be the direct result of staphylococcal pneumonia occurring in a patient recovering from, but with crucial residual adrenal disease due to, *Histoplasma*.

Patient 44 similarly seemed to be responding to a course of 457 mg of amphotericin for cryptococcal meningitis. Fever persisted, however, and he died suddenly of *Pseudomonas septicemia*.

Relapse with Pregnancy

Patient 21, a 25 year old Negro woman, had known coccidioidomycosis since July 1957, manifested by subcutaneous abscesses of the left shoulder, supraclavicular fossa, groin, thoracic paravertebral area, and thigh, septic arthritis of the right metacarpophalangeal joint and left knee, osteomyelitis of the thoracic spines 10, 11, 12, pubis, left fifth proximal phalanx, clavicle, sternum, and tibia,

neumonic infiltrate of the right upper lobe, and empyema. Cultures of multiple sites were positive for *Coccidioides*. After many surgical incisions with drainage and a 6 months' course of amphotericin treatment (7300 mg total) ending March 2, 1959, she seemed to improve. In June 1959 at a return visit remarkable clinical improvement had continued and cultures of gastric acid—the only readily available specimen—were negative. Subsequent to this she became pregnant (last menstrual period late June 1959) and in September 1959 noted onset of a subcutaneous paravertebral mass from which, on hospitalization in November 1959, *Coccidioides* was again cultured. Pregnancy has been known for some time to have a deleterious effect on the course of coccidioidomycosis, and this patient represents relapse after prior treatment and improvement.

Relapse Associated with Steroid Treatment

A 62 year-old farmer (patient 28) in July 1958 developed an illness characterized by fever, fatigue, mental changes, and a lymphocytic meningitis. He was admitted to the Clinical Center in December 1958, and *Histoplasma capsulatum* was isolated from multiple cerebrospinal fluid specimens. Cultures became negative, and the patient showed marked improvement after 2621 mg amphotericin treatment administered from December 30, 1958 to March 31, 1959. Hospitalization was complicated by concomitant diabetes mellitus, pyelonephritis, thrombophlebitis, pulmonary embolus, and uveitis. For the latter, the patient received local therapy with atropine and cortisol beginning May 12, 1959. Uveitis did not improve, however, and on June 11, 1959, systemic therapy with prednisone was begun in dose of 30 mg/day. Clinical relapse of histoplasmosis began about June 29, and cerebrospinal fluid cultures were positive July 5. Following treatment with 2589 mg additional amphotericin ending September 24, the patient made an apparent recovery and was discharged October 29.

Essentially Resistant Disease

Of all fungal diseases treated with amphotericin in this series, the most resistant as a group have been fixed *Candida* infections. Four cases of endocarditis and 1 case of *Candida meningitis* have failed to respond to treatment, and all patients have perished from their disease.

One of these 5, patient 34, has already been discussed.

It is of particular interest that only 2 (patients 23 and 45) of these 4 remaining patients were infected with an organism that *in vitro* was resistant to a level of drug greater than that found with "sensitive" strains of fungi or greater than level of amphotericin achievable in serum of treated patients. Patient 23 received 831 mg of amphotericin during a 4 week course of treatment and patient 45 1644 mg during a 9 week course.

The remaining 2 patients (22 and 24) received 2136 mg during a 48 week period and 2370 mg during a 5 month period, respectively. Serum levels were reached in excess of (by factors of 4 and 7 times) the *in vitro* sensitivity (0.04 and 0.07 $\mu\text{g}/\text{ml}$) of the infecting strains. In all 4 patients, however, blood or cerebrospinal fluid cultures remained positive during life and at autopsy. In the 4 cases of endocarditis, 3 had large vegetations on valves and endocardium.

measuring, in 2 cases, (patient 23) 8 cm and (patient 45) 2 cm. The size of these vegetations suggests that organisms were multiplying in depths of fibrin that may not have been penetrated by the antibiotic. This plausible explanation of persistence of organisms would not seem to account, however, for the large colony counts circulating in the blood stream, apparently not suppressed or killed by serum antimicrobial levels.

Multiple infection by 2 fungal agents was seen in patient 31, who had cryptococcal meningitis and a *Madurella* cellulitis of the left leg. Amphotericin in total dose of 1551 mg intravenously and 9.5 mg intrathecally during a 7 week period was sufficient to convert cerebrospinal fluid cultures to negative and produce marked improvement in cerebrospinal fluid findings. No appreciable change was observed, however, in the cultures or appearance of the lesion due to *Madurella*.

Patient 30 had meningitis due to a strain of *Cryptococcus* resistant *in vitro* to 2 to 4 times the amount of amphotericin that suppressed strains from other patients. He died of his disease despite over 3800 mg of amphotericin intravenously and 15 mg intrathecally (0.5 mg, 2 to 3 times a week) over a 4 month period.

Indeterminate Factors

Factors are not known that may have played a part in treatment failures in 2 cases (patients 14 and 69) who had pulmonary coccidioidomycosis. Large total dosages of drug (2600 and 3525 mg) were administered for long periods (11 weeks and 4 months, respectively), and in patient 14 a good serum level was proved on at least 1 occasion. Steroids or other disease did not play a part and the sensitivities of the organisms were not determined.

These 2 patients, as well as the 6 who had 'essentially resistant disease' (see above) compose that group (8 of 40 patients, 20 per cent) who failed completely to respond to otherwise adequate amounts of drug given for a significant period of time.

Summary

Unprecedented success has been achieved with amphotericin treatment of many cases of blastomycosis, histoplasmosis, cryptococcosis, coccidioidomycosis, and in isolated cases of aspergillosis, sporotrichosis, and some types of *Candida* infections. This success suggested an evaluation of 20 amphotericin treatment failures in the 41 infections (40 patients) studied at the Clinical Center of the National Institutes of Health. Factors that seemed important in these failures included early discontinuation of treatment, advanced disease, insufficient amount of drug, death from associated disease, relapse with pregnancy, relapse associated with steroid treatment, essentially resistant infection, and indeterminate factors.

Acknowledgment

We acknowledge the technical assistance of Margaret A. Huber.

References

1. SEABURY, J. H. & H. E. DASCOMB. 1958. Experience with amphotericin B for the treatment of systemic mycoses. *A.M.A. Arch. Intern. Med.* 102: 960.

- 2 RUBIN H & M L FURCOLOW 1958 Promising results in cryptococcal meningitis *Neurology* 8 590
- 3 NEWCOMER V D T H STERNBERG F T WRIGHT & R M REISNER 1959 Current status of amphotericin B in the treatment of systemic fungus infections *J Chronic Diseases* 9 353
- 4 WINN W A 1959 The use of amphotericin B in the treatment of coccidioidal disease *Am J Med* 27 647
- 5 HARRFELL I R & A C CLAYIS 1959 North American blastomycosis *Am J Med* 27 750
- 6 UTZ J P & A TREGGER 1959 The current status of chemotherapy of systemic fungal disease *Ann Intern Med* 51 1220
- 7 QUWILER D A & I M BRICHER 1959 *Candida albicans* peritonitis successfully treated with amphotericin B *New Engl J Med* 260 488
- 8 SAROT I A M L LITMAN & M M CERRITI 1959 Intrathoracic injection of amphotericin B in the treatment of monilial empyema *Sea View Hosp Bull* 3 93
- 9 UTZ J P A TREGGER A B MCCULLOUGH & C W EMMONS 1959 Amphotericin B Intravenous use in twenty-one patients with systemic fungal diseases 65 *Antibiotics Annual 1958-1959 Medical Encyclopedia New York N Y*
- 10 CROUNSF R G & A B LERNER 1958 Cryptococcosis case with unusual skin lesions and favorable response to amphotericin therapy *AMA Arch Dermatol* 77 210

MONOGRAPHIC PUBLICATIONS OF THE NEW YORK ACADEMY OF SCIENCES

(MUSEUM OF NATURAL HISTORY, 1817-1876)

(1) The **ANNALS** (octavo series) established in 1823, contain the scientific contributions and reports of researches, together with the records of meetings of the Academy. The articles that comprise each volume are printed separately, each in its own cover, and are distributed immediately upon publication. The prices of the separate articles depend upon their length and the number of illustrations, and may be ascertained upon application to the Executive Director of the Academy.

Current numbers of the **ANNALS** are sent free to all Members of the Academy desiring them.

(2) The **SPECIAL PUBLICATIONS**, established in 1939, are issued at irregular intervals as clothbound volumes. The price of each volume will be advertised at time of issue.

(3) The **MEMOIRS** (quarto series), established in 1893, are issued at irregular intervals. It is intended that each volume shall be devoted to monographs relating to some particular department of science. Volume I, Part 1 is devoted to Astronomical Memoirs. Volume II to Zoological Memoirs. No more parts of the Memoirs have been published to date. The price is one dollar per part.

(4) The **SCIENTIFIC SURVEY OF PORTO RICO AND THE VIRGIN ISLANDS** (octavo series), established in 1919, gives the detailed reports of the anthropological, botanical, geological, paleontological, zoological, and meteorological surveys of these islands.

Subscriptions and inquiries concerning current and back numbers of any of the publications of the Academy should be addressed to

EXECUTIVE DIRECTOR

*The New York Academy of Sciences
2 East Sixty-third Street
New York 21, N. Y.*